---
document_datetime: 2023-09-21 22:22:31
document_pages: 183
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/trecondi-h-c-004751-ii-0014-epar-assessment-report-variation_en.pdf
document_name: trecondi-h-c-004751-ii-0014-epar-assessment-report-variation_en.pdf
version: success
processing_time: 253.2958703
conversion_datetime: 2025-12-31 03:45:50.653137
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

26 January 2023 EMA/CHMP/117245/2023 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Trecondi

International non-proprietary name: treosulfan

Procedure No. EMEA/H/C/004751/II/0014

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                 | ..............................................9                                                          |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................9 |                                                                                                          |
| 1.2. Steps taken for the assessment of the product.......................................................10                |                                                                                                          |
| 2. Scientific discussion                                                                                                   | ..............................................................................11                         |
| 2.1. Introduction.......................................................................................................11 |                                                                                                          |
| 2.1.1. Problem statement                                                                                                   | ..........................................................................................11             |
| 2.1.2. About the product............................................................................................12     |                                                                                                          |
| 2.1.3. The development programme/ compliance with CHMP guidance/ scientific advice                                         | ....13                                                                                                   |
| 2.1.4. General comments on compliance with GLP,                                                                            | GCP.................................................15                                                   |
| 2.2. Non-clinical aspects                                                                                                  | ............................................................................................16           |
| 2.2.1. Introduction....................................................................................................16  |                                                                                                          |
| 2.2.2. Pharmacology                                                                                                        | .................................................................................................18      |
| 2.2.3. Pharmacokinetics.............................................................................................25     |                                                                                                          |
| 2.2.4. Toxicology                                                                                                          | ......................................................................................................28 |
| 2.2.5. Ecotoxicity/environmental risk assessment                                                                           | .........................................................35                                              |
| 2.2.6. Discussion on non-clinical aspects......................................................................36          |                                                                                                          |
| 2.2.7. Conclusion on the non-clinical aspects................................................................38            |                                                                                                          |
| 2.3. Clinical aspects                                                                                                      | ..................................................................................................38     |
| 2.3.1. Introduction....................................................................................................38  |                                                                                                          |
| 2.3.2. Pharmacokinetics.............................................................................................43     |                                                                                                          |
| 2.3.3. Pharmacodynamics..........................................................................................53        |                                                                                                          |
| 2.3.4. PK/PD modelling..............................................................................................54     |                                                                                                          |
| 2.3.5. Discussion on clinical pharmacology...................................................................58            |                                                                                                          |
| 2.3.6. Conclusions on clinical pharmacology.................................................................61             |                                                                                                          |
| 2.4. Clinical efficacy                                                                                                     | ..................................................................................................61     |
| 2.4.1. Dose response studies......................................................................................61       |                                                                                                          |
| 2.4.2. Main studies                                                                                                        | ...................................................................................................62    |
| 2.4.3. Discussion on clinical efficacy..........................................................................           | 121                                                                                                      |
| 2.4.4. Conclusions on the clinical efficacy...................................................................             | 124                                                                                                      |
| 2.5. Clinical safety                                                                                                       | .................................................................................................. 125   |
| 2.5.1. Discussion on clinical safety ............................................................................          | 163                                                                                                      |
| 2.5.2. Conclusions on clinical safety ..........................................................................           | 166                                                                                                      |
| 2.5.3. PSUR cycle                                                                                                          | ................................................................................................... 166  |
| 2.6. Risk management plan......................................................................................            | 166                                                                                                      |
| 2.7. Update of the Product information ......................................................................              | 168                                                                                                      |
| 2.7.1. User consultation...........................................................................................        | 168                                                                                                      |
| 3. Benefit-Risk Balance............................................................................169                     |                                                                                                          |
| 3.1. Therapeutic Context .........................................................................................         | 169                                                                                                      |
| 3.1.1. Disease or condition.......................................................................................         | 169                                                                                                      |
| 3.1.2. Available therapies and unmet medical                                                                               | need..................................................... 169                                            |
| 3.1.3. Main clinical studies                                                                                               | ....................................................................................... 170              |
| 3.2. Favourable effects ............................................................................................       | 171                                                                                                      |
| 3.3. Uncertainties and limitations about favourable effects...........................................                     | 172                                                                                                      |

<div style=\"page-break-after: always\"></div>

3.4. Unfavourable effects  .........................................................................................  172

3.5. Uncertainties and limitations about unfavourable effects ....................................... 174

3.6. Effects Table  ....................................................................................................  175

3.7. Benefit-risk assessment and discussion  ............................................................... 180

3.7.1. Importance of favourable and unfavourable effects  ............................................ 180

3.7.2. Balance of benefits and risks  ...........................................................................  181

3.7.3. Additional considerations on the benefit-risk balance ......................................... 181

3.8. Conclusions .....................................................................................................  182

4. Recommendations ...............................................................................  182

5. EPAR changes  ......................................................................................  183

<div style=\"page-break-after: always\"></div>

## List of abbreviations

µl

Microliter

ADME

Absorption, distribution, metabolism and excretion

AE

Adverse event

aGVHD

Acute graft versus host disease

AIC

Akaike information criterion

ALAT

Alanine aminotransferase

ALL

Acute lymphoblastic leukaemia

alloHSCT

Allogeneic Haematopoietic Stem Cell Transplantation

ALT

Alanine aminotransferase

AML

acute myeloid leukaemia

ANC

Absolute neutrophil count

AP

Alkaline phosphatase

AR

Adverse reaction

AST

Aspartate aminotransferase

ATLL

Adult T-cell leukaemia/lymphoma

AUC

Area under the curve or area under the plasma concentration time curve

AUC ∞

Area under the concentration time curve from time zero to infinity

b.w.

Body weight

BBB

Blood-brain barrier

BCRP

Breast cancer resistance protein

BD

1,3-butadiene

BIC

Bayesian information criterion

BM

Bone marrow

BMSC

Bone marrow stromal cell

BMT

Bone marrow transplantation

BSA

Body surface area

BSEP

Bile salt export pump

BU

Busulfan

CAFC

Cobblestone area forming cell

CCG

Creatinine clearance or glomerular filtration rate

CD

Cluster of differentiation

CDER

Center for Drug Evaluation and Research

CHMP

Committee for Human Medicinal Products

CI

Confidence interval

CIOMS

Council for International Organisations of Medical Sciences

CiPA

Comprehensive comprehensive in vitro proarrhythmia assay

CL

Total clearance

CLL

Chronic lymphocytic leukaemia

Cmax

Maximum plasma concentration

CNS

Central nervous system

CR

Complete remission

CRF

Case report form

CRFS

Chronic GvHD-free and relapse / progression-free survival

CRO

Contract Research Organisation

CRP

C-reactive protein

<div style=\"page-break-after: always\"></div>

| CSF          | Cerebrospinal fluid                                                                                                        |
|--------------|----------------------------------------------------------------------------------------------------------------------------|
| CSR          | Clinical study report                                                                                                      |
| CTCAE        | Common Terminology Criteria for Adverse Events                                                                             |
| CTD          | Common technical document                                                                                                  |
| CTP          | Clinical Trial Protocol                                                                                                    |
| CTR          | Clinical trial report                                                                                                      |
| CY           | Cyclophosphamide                                                                                                           |
| CYP          | Cytochrome                                                                                                                 |
| DDI          | Drug drug interactions                                                                                                     |
| DEB          | (2S,3S)-1,2:3,4-diepoxybutane                                                                                              |
| DLI          | Donor-lymphocyte infusion                                                                                                  |
| DMC          | Data Monitoring Committee                                                                                                  |
| DNA          | Deoxyribonucleic acid                                                                                                      |
| EBD, EBDM    | (2S,3S)-1,2-epoxybutane-3,4-diol-4-methane-sulfonate or 3,4-epoxy-1,2-butanediol, the monoepoxide metabolite of treosulfan |
| EBMT         | European Group for Blood and Marrow Transplantation                                                                        |
| EBV          | Epstein-Barr virus                                                                                                         |
| ECG          | Electrocardiogram                                                                                                          |
| ED X         | Effective dose in X% of animals                                                                                            |
| EFS          | Event-free survival                                                                                                        |
| ELISA        | Enzyme-linked immunosorbent assay                                                                                          |
| EMA          | European Medicines Agency                                                                                                  |
| EoT          | End of Trial                                                                                                               |
| ESI          | Electrospray ionisation                                                                                                    |
|              | set                                                                                                                        |
| FAS          | Full analysis                                                                                                              |
| FLU          | Fludarabine                                                                                                                |
| FPD GC       | Field potential duration Gas chromatography                                                                                |
|              | Glomerular filtration                                                                                                      |
| GFR          | rate                                                                                                                       |
| GGT          | Gamma glutamyl transferase                                                                                                 |
| GI 50        | Drug concentration capable of 50% growth inhibition chromatography                                                         |
| GLC          | Gas-liquid                                                                                                                 |
| GMP          | Good Manufacturing Practice                                                                                                |
| GOF          | Goodness-of-fit                                                                                                            |
| GOT          | Serum glutamic oxaloacetic transaminase                                                                                    |
| GRFS         | GvHD-free and relapse / progression-free survival                                                                          |
| GSH          | Glutathione Glutathione S-transferase                                                                                      |
| GST          | Graft- versus -host disease                                                                                                |
| GvHD or GVHD |                                                                                                                            |
| HCT          | Haematopoietic cell                                                                                                        |
| hERG         | transplantation Human ether à go go related gene                                                                           |
| HIV          | Human immunodeficiency virus                                                                                               |
| HLA          | Human leucocyte antigen                                                                                                    |

<div style=\"page-break-after: always\"></div>

| HPLC     | High-performance liquid chromatography                                                                                |
|----------|-----------------------------------------------------------------------------------------------------------------------|
| HSCT     | Haematopoietic stem cell transplantation                                                                              |
| HSOS     | Hepatic sinusoidal obstruction syndrome                                                                               |
| hu-Alb   | Human albumin                                                                                                         |
| i.p., IP | Intraperitoneal(ly)                                                                                                   |
| i.v., IV | Intravenous(ly)                                                                                                       |
| IARC     | International Agency for Research on Cancer                                                                           |
| IC 50    | Half maximal (50%) inhibitory concentration                                                                           |
| ICH      | International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use |
| IEC      | Independent Ethics Committee                                                                                          |
| IFN      | Interferon                                                                                                            |
| IgG, IgM | Immunoglobulin G, immunoglobulin M                                                                                    |
| IL       | Interleukin                                                                                                           |
| INN      | International Non-proprietary Name                                                                                    |
| IP       | Investigational product                                                                                               |
| IRB      | Institutional Review Board                                                                                            |
| ISS      | Integrated Summary of Safety                                                                                          |
| IUPAC    | International Union of Pure and Applied Chemistry                                                                     |
| JMML     | Juvenile myelomonocytic leukaemias                                                                                    |
| KCl      | Potassium chloride                                                                                                    |
| K e/p    | RBC/plasma coefficient                                                                                                |
| kg       | Kilogram                                                                                                              |
| K M      | Michaelis constant                                                                                                    |
| KPS      | Karnofsky Performance Score, syn.: Karnofsky Performance Status, Karnofsky Index                                      |
| LC       | Liquid chromatography                                                                                                 |
| LC-MS/MS | Liquid chromatography-tandem mass spectrometry                                                                        |
| LC X     | Lowest concentration of drug observed to kill X %of cells                                                             |
| LDH      | Lactate dehydrogenase                                                                                                 |
| LD X     | Lethal dose to X %of animals                                                                                          |
| LEO      | LEO Pharmaceutical Products, Denmark                                                                                  |
| LLN      | Lower limit of normal                                                                                                 |
| LLOQ     | Lower limit of quantitation                                                                                           |
| LPS      | Lansky Performance Score                                                                                              |
| LSC      | Liquid scintillation counting                                                                                         |
| LVEF     | Left ventricular ejection fraction                                                                                    |
| MATE     | Multidrug and toxin extrusion                                                                                         |
| MDS      | Myelodysplastic syndrome                                                                                              |
| MFD      | Matched family donor                                                                                                  |
| mg       | Milligram                                                                                                             |
| MHC      | Major histocompatibility complex                                                                                      |
| min      | Minute                                                                                                                |
| mM       | Millimolar                                                                                                            |
| MRD      | Matched related donor                                                                                                 |
| mRNA     | Messenger RNA                                                                                                         |
| MS       | Mass spectrometry                                                                                                     |
| MSD      | Matched sibling donor                                                                                                 |

MTD

Maximum tolerated dose

MTT

3-(4,5-dimethyl-2-tetrazolyl)-2,5-diphenyl-2H tetrazolium-bromide

MUD

Matched unrelated donor

NaCl

Sodium chloride

NADPH

Nicotinamide adenine dinucleotide phosphate

NaOH

Sodium hydroxide

NCI

U.S. National Cancer Institute

NHL

Non-Hodgkin's lymphoma

NK cells

Natural killer cells

NMR

Nuclear magnetic resonance

NOAEL

No observed adverse effect level

NOEL

No observed effect level

NRM

Non-relapse mortality

OAT

Organic anion transporter

OATP

Organic-anion-transporting polypeptide

OCT

Organic cation transporter

OECD

Organisation for Economic Co-operation and Development

OFV

Objective function value

OS

Overall survival

OS

Overall survival

p.o., PO

Per oral, orally

PB

Peripheral blood

PBMCs

Peripheral blood mononuclear cells

PBPK

Physiologically-based pharmacokinetikpharmacokinetic

PCR

Polymerase chain reaction

PCT

Procalcitonin

PDCO

Paediatric Committee

PDIP

Protocol Deviation Identification Plan

PFS

Progression-free survival

pH

Negative logarithm of H +  concentration

PIL

Product Information Leaflet

PIP

Paediatric Investigation Plan

PK

Pharmacokinetic

PLT

Platelets

PMN

Polymorphonuclear neutrophilic leucocytes, neutrophils

PND

postnatal day

PopPK

Population pharmacokinetics

PT

Preferred Term

Q1

25%-percentile (first quartile)

Q3

75%-percentile (third quartile)

QA

Quality assurance

RAEB

Refractory anaemia with excess blasts

RBC

Red blood cells

RFS

Relapse-free survival

RNA

Ribonucleic acid

RP HPLC

Reverse phase HPLC

RT

Room temperature

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| S,S-DEB      | (2S,3S)-1,2:3,4-diepoxybutane                                                                                   |
|--------------|-----------------------------------------------------------------------------------------------------------------|
| S,S-EBDM     | (2S,3S)-1,2-epoxybutane-3,4-diol-4-methanesulfonate                                                             |
| s.c., SC     | Subcutaneous(ly)                                                                                                |
| s.d.         | standard deviation                                                                                              |
| SAE          | Serious adverse event                                                                                           |
| SAP          | Statistical Analysis Plan                                                                                       |
| SAR          | Serious adverse reaction                                                                                        |
| SB           | Serious breaches                                                                                                |
| SCD          | Sickle cell disease                                                                                             |
| SCID         | Severe combined immunodeficient                                                                                 |
| SCT          | Stem cell transplantation                                                                                       |
| SD           | Standard deviation                                                                                              |
| SmPC         | Summary of Product Characteristics                                                                              |
| SOC          | System Organ Class                                                                                              |
| SOP          | Standard operating procedure                                                                                    |
| SUSAR        | Suspected unexpected serious adverse reaction                                                                   |
| t ½          | Plasma elimination half-life                                                                                    |
| TBI          | Total body irradiation                                                                                          |
| TEAE         | Treatment-emergent adverse event                                                                                |
| TESAE        | Treatment-emergent serious adverse event                                                                        |
| t max        | Time to reach C max                                                                                             |
| TMF          | Trial Master File                                                                                               |
| TNF          | Tumour necrosis factor                                                                                          |
| TREO         | Treosulfan                                                                                                      |
| TRM          | Transplantation-related mortality                                                                               |
| TRM          | Transplant-related mortality                                                                                    |
| TTCB         | Conditioning regimen, comprising donor specific transfusion, treosulfan and cyclophosphamide injections and BMT |
| ULN          | Upper limit of normal                                                                                           |
| USA          | United States of America                                                                                        |
| versus, vs . | As the alternative to or in contrast with                                                                       |
| V max        | Maximum reaction rate, described in the Michaelis-Menton kinetics                                               |
| VPC          | Visual predictive checks                                                                                        |
| WBC          | White blood cells, leucocytes                                                                                   |
| WHO          | World Health Organisation                                                                                       |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, medac Gesellschaft fur klinische Spezialpraparate mbH submitted to the European Medicines Agency on 7 March 2022 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include additional non-malignant transplant indications (non-malignant diseases in the paediatric population) for Trecondi 1 g/5 g powder for solution for infusion based on final 12-months follow-up results of study MC-FludT.16/NM; a randomised phase II interventional study aimed to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with non-malignant diseases.

Further, the MAH proposes to amend an existing warning on skin toxicity based on new literature data. Moreover, the MAH proposes to introduce a slightly modified dosing regimen according to the patient's body surface based on long-term follow-up data of paediatric study MC-FludT.17/M, a Phase II trial to describe the safety and efficacy of Treosulfan based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haematological malignancies, as well as a final analysis of the population pharmacokinetics of treosulfan in paediatric patients. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.0 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information relating to orphan designation

Trecondi, was designated as an orphan medicinal product EU/3/04/186 on 23 February 2004 in the following indication: Conditioning treatment prior to haematopoietic progenitor cell transplantation.

At the time of the granting of the Marketing Authoirisation, the Commission decided that on the basis of the COMP's final opinion Trecondi no longer met the criteria for designation (established in Article 3 of Regulation No 141/2000) and that, therefore, it could not be designated as an orphan medicinal product. However, following the judgement of the General Court of 23-Sep-2020 the orphan designation was reestablished by the Commission Implementing Decision C(2020)8389 (final), dated 24-Nov-2020.

## Information on paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  EMA  Decision P/0346/2020 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP was completed.

<div style=\"page-break-after: always\"></div>

The PDCO issued an opinion on compliance for the PIP P/0346/2020.

## Information relating to orphan market exclusivity

The  orphan  market  exclusivity  for  \"Conditioning  treatment  prior  to  haematopoietic  progenitor  cell transplantation\"  (based  on  designation  EU/3/04/186)  started  on  24  Jun  2019.  This  orphan  market exclusivity will expire on 24 Jun 2029.

There is no authorised orphan medicinal product for a condition related to the proposed indication.

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Protocol assistance

The MAH did not seek Protocol Assistance at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

| Rapporteur: Co-Rapporteur:                           | Fátima Ventura   | <N/A>   |                  |
|------------------------------------------------------|------------------|---------|------------------|
| Timetable                                            |                  |         | Actual dates     |
| Submission date                                      |                  |         | 7 March 2022     |
| Start of procedure:                                  |                  |         | 23 April 2022    |
| CHMP Rapporteur Assessment Report                    |                  |         | 29 June 2022     |
| PRAC members comments                                |                  |         | 29 June 2022     |
| Updated PRAC Rapporteur Assessment Report            |                  |         | 30 June 2022     |
| PRAC Outcome                                         |                  |         | 7 July 2022      |
| CHMP members                                         | comments         |         | 11 July 2022     |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report |                  |         | 14 July 2022     |
| Request for supplementary information (RSI)          |                  |         | 21 July 2022     |
| CHMP Rapporteur Assessment Report                    |                  |         | 11 October 2022  |
| PRAC Rapporteur Assessment Report                    |                  |         | 14 October 2022  |
| PRAC Outcome                                         |                  |         | 27 October 2022  |
| CHMP members comments                                |                  |         | 28 October 2022  |
| Updated CHMP Rapporteur Assessment Report            |                  |         | 3 November 2022  |
| Request for supplementary information (RSI)          |                  |         | 10 November 2022 |

<div style=\"page-break-after: always\"></div>

| Timetable                                 | Actual dates     |
|-------------------------------------------|------------------|
| CHMP Rapporteur Assessment Report         | 22 December 2022 |
| PRAC members comments                     | N/A              |
| CHMP members comments                     | 16 January 2023  |
| Updated CHMP Rapporteur Assessment Report | 19 January 2023  |
| CHMP Opinion                              | 26 January 2023  |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

The MAH is now requesting an extension of the indication to include additional non-malignant transplant indications ( non-malignant diseases in the paediatric population based on final 12-months follow-up results of study MC-FludT.16/NM .

## State the claimed the therapeutic indication

Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases and in paediatric patients older than one month with malignant and non-malignant diseases.

## Epidemiology

According to the Worldwide Network of Blood and Marrow Transplantation (WBMT), 82 718 HSCTs were conducted worldwide by 1 662 teams from 86 countries in 2016. Of those transplants, on average 53.5% are autologous and 46.5% are allogeneic; 45.2% occur in Europe, 24.4% in North America, 22.7% in the  South  East  Asia/Western  Pacific  Region,  5.1%  in  Latin-America  and  2.7%  in  the  African/East Mediterranean Region. Absolute numbers of alloHSCTs had increased from 20 333 in 2006 to 38 425 in 2016.

In 2019, there were 5 189 paediatric patients &lt; 18 years of age receiving HSCT in Europe, 3 990 received an allogeneic and 1 199 an autologous HSCT [Passweg 2021].

Change in HSCT numbers is different for each indication with novel indications emerging. The number of alloHSCTs continues to increase annually, and reductions in organ damage, infection, and severe acute graft versus host disease (aGvHD) seem to be contributing to improved outcomes.

<div style=\"page-break-after: always\"></div>

## Biologic features, Aetiology and pathogenesis

The use of the product reflects the current clinical practice of transplantation in the European Union.

## Clinical presentation

In paediatric patients, alloHSCT has become a therapeutic option with curative potential for treatment of otherwise incurable hematological malignancies and non-malignant diseases, e.g., immunodeficiencies,  haemoglobinopathies  (Hb-pathies),  bone  marrow  failure  (BMF)  syndromes,  or metabolic diseases.

In non-malignant diseases such as primary immunodeficiencies (PIDs) alloHSCT has become increasingly successful.

## Management

Patients undergoing an alloHSCT are prepared with chemotherapy alone or chemotherapy combined with radiotherapy, the so-called conditioning or preparative regimen, with three aims: to reduce the tumour burden when the disease is neoplastic, to eliminate the self-renewing capacity of the patient's own haematopoiesis, and to suppress the recipient's immune system in order to allow engraftment of donor stem cells.  Exceptions  to  this  rule  are  infants  with  severe  combined  immune  deficiency  (SCID)  and patients with severe aplastic anaemia (SAA) with an identical twin donor who may be grafted without conditioning.

The purine analogue fludarabine (FLU) has been widely incorporated into such regimens. It is highly immunosuppressive, producing profound lymphopenia, which has been shown to facilitate allogeneic stem cell engraftment. It has the additional advantages of having anti-tumour activity in haematologic malignancies and a low non-haematologic toxicity profile

Efficacy, safety and PK of treosulfan-based conditioning regimens in paediatric subjects prior to alloHSCT have already been demonstrated in several published studies. It has been shown that treosulfan is highly effective enabling sustained engraftment without increasing the risk for severe acute or chronic graftversus-host disease (aGvHD / cGvHD). Considering that most children and adolescents with malignancies or non-malignant diseases have either been heavily pre-treated or have already undergone a previous HSCT,  the  toxicity  profile  is  obviously  low  compared  with  either  TBI  containing  regimens  or  other myeloablative  treatments  (e.g.,  busulfan,  cyclophosphamide,  etoposide  or  melphalan).  However, children &gt; 4 years of age undergoing alloHSCT for acute lymphoblastic leukaemia should preferentially be conditioned with TBI-based regimens. Results of the medac-sponsored phase 2 trial MC-FludT.17/M in 70 children with malignant transplantation indications support this observation.

## 2.1.2. About the product

Treosulfan, a prodrug of a bifunctional alkylating agent and a broad antineoplastic and potent antileukemic medicine fulfils the criteria for a perfect cytotoxic agent for conditioning regimens: sufficient stem cell toxicity (with respect to primitive as well as committed stem cells) and immunosuppression, to enable rapid and stable engraftment, low organ toxicity, especially with respect to the liver, kidneys, lung,  and  the  nervous  system,  sufficient  cytotoxicity  to  guarantee  an  effective  treatment  of  the underlying  hematological  malignancy,  and  predictive  pharmacokinetics  (IV  administration,  linear pharmacokinetics,  low inter-individual variability, no enzyme-dependent drug activation).

<div style=\"page-break-after: always\"></div>

Under physiological conditions (pH 7.4, temperature 37°C) the pharmacologically inactive treosulfan converts spontaneously (non-enzymatically) into a reactive monoepoxide intermediate and finally to Ldiepoxybutan. These epoxides are able to react with neutrophilic centres of biological molecules like proteins  or  DNA  and  are  considered  to  be  responsible  for  the  antineoplastic  activity  via  secondary biological mechanisms.

Due to its pronounced toxicity against committed and primitive hematopoietic stem cells as well as its proven immunosuppressive and haematotoxic characteristics, treosulfan is currently developed as an alternative conditioning agent to busulfan or TBI.

Based  on  the  given  clinical  experience  in  adults,  treosulfan  has  been  widely  used  as  therapeutic alternative in paediatric HSCT conditioning regimens in the past years.

Patients, who undergo HSCT for non-malignant diseases, especially immunodeficiencies and metabolic diseases, are mostly infants, toddlers, and small children. The patterns of acute and especially late effects are different compared to adult transplantation patients and demand special attention. Mental development, growth and hormonal disorders, fertility, and risk of secondary cancer (particularly after TBI) are of special interest and are followed-up by national and international registries (e.g., within EBMT). Since the first successful allogeneic HSCT, more than 50,000 paediatric patients have undergone this procedure in Europe, and more than 2500 children are transplanted annually in Europe.

The MAH is now requesting an extension of the indication to include additional non-malignant transplant indications (non-malignant diseases in the paediatric population based on final 12-months follow-up results of study MC-FludT.16/NM.

Further, the MAH proposes to amend an existing warning on skin toxicity based on new literature data and to introduce a slightly modified dosing regimen according to the patient's body surface based on long-term follow-up data of paediatric study MC-FludT.17/M in paediatric patients with haematological malignancies, as well as a final analysis of the population pharmacokinetics of treosulfan in paediatric patients.

## 2.1.3. The development programme/ compliance with CHMP guidance/ scientific advice

Treosulfan  in  combination  with  fludarabine  is  indicated  as  part  of  conditioning  treatment  prior  to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and nonmalignant diseases, and in paediatric patients older than one month with malignant diseases.

The following relevant guidelines were followed:

- Evaluation of Anticancer Medicinal Products in Man (CPMP/EWP/205/95 Rev. 3)
- Appendix  1  to  the  Guideline  on  the  Evaluation  of  Anticancer  Medicinal  Products  in  Man (CHMP/EWP/267575/06)
- Addendum on Paediatric Oncology (CPMP/EWP/569/02)
- ICH E11 Clinical investigation of medicinal products in the paediatric population (CPMP/ICH/2711/99)
- Guideline on clinical trials in small populations (CHMP/EWP/83561/05)
- Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population (EMEA/CHMP/EWP/147013/2004/Corr)

## Treosulfan based conditioning in adult patients:

Three medac sponsored Phase 1 / 2 trials investigated the conditioning regimen treosulfan / fludarabine in  adult  subjects.  Efficacy  and  safety  parameters  of  treosulfan-based  conditioning  were  analysed  in

<div style=\"page-break-after: always\"></div>

subjects  with  advanced  haematological  malignancies  prior  to  alloHSCT.  Furthermore,  a  prospective, comparative pivotal Phase 3 clinical trial (medac protocol code MC-FludT.14/L ) in adult acute myeloid leukaemia  and  myeloid  dysplastic  syndrome  (MDS)  subjects,  who  were  non-eligible  for  standard busulfan-  or  TBI-based  myeloablative  conditioning,  started  in  Nov-2008.  After  dose-  and  regimenadjustment  for  treosulfan  to  10  g/m²  on  day  -4,  -3,  -2,  the  trial  restarted  in  June  2013  and  was completed in Jan-2018. The trial demonstrated statistically significant non-inferiority regarding eventfree survival (EFS) as well as improved overall survival (OS) and non-relapse mortality (NRM) in favour of treosulfan.

## Treosulfan based conditioning in paediatric patients:

As a requirement within the paediatric investigational plan (PIP; PIP number EMEA-000883- PIP01-10, decision number P/122/2011) for treosulfan and subsequent modifications, the paediatric committee of EMA (PDCO) requested  medac  to  conduct  a  retrospective  evaluation  (meta-analysis)  on  safety  and efficacy data of treosulfan-based conditioning in paediatric subjects registered within the EBMT database. Within this registry study, data of 521 allogeneic and 83 autologous paediatric subjects transplanted between Jan-2005 and Jul-2010 were evaluated.

The median treosulfan dose administered for alloHSCT was in total 42 g/m 2  within 3 consecutive days. Treatment was effective and well tolerated in children of all age groups with malignant as well as nonmalignant diseases. The dose of treosulfan was without significant impact on all analysed safety and efficacy parameters. In addition, medac was requested within the PIP to conduct 2 transplantation trials in paediatric subjects, one in subjects with malignant diseases ( MC-FludT.17/M ) and another trial in subjects with non-malignant diseases ( MC-FludT.16/NM ).

The MC-FludT.17/M trial started on 21-Nov-2014 and was completed on 30-Sep-2019 (last subject completed longer term follow-up).

In  non-malignant  disorders  with  a  high  risk  of  graft  rejection,  intensified  regimens  with  additional thiotepa combined with either treosulfan / fludarabine or busulfan / fludarabine are recommended by EBMT / ESID guidelines to ensure engraftment.

In  order  to  evaluate  the  current  clinical  practice  of  the  use  of  thiotepa  in  combination  with  either treosulfan / fludarabine-based or busulfan / fludarabine-based conditioning  regimens,  another retrospective analysis of the EBMT database in children with non-malignant diseases, who underwent allogeneic HSCT between the years 2010 and 2014 was performed. A large variety of non-malignant diseases comprising data from 2187 patients were included in the EBMT registry analysis. In total, 895 out of the 2187 patients received a preparative regimen consisting of treosulfan / fludarabine either in combination  with  thiotepa  (473  patients)  or  without  thiotepa  (422  patients).  Thiotepa  was  most frequently added in Hb-pathies (374 out of 590 patients), affecting about half of the patients treated with treosulfan / fludarabine or busulfan / fludarabine. The number of patients who received thiotepa in addition to treosulfan / fludarabine increased significantly from 44% (66 out of 149 patients) in the year 2010 to 65% of patients (140 out of 217 patients) in the year 2014. Several retrospective studies covering  the  years  2009  to  2015  also  indicate  the  more  frequent  use  of  thiotepa  in  treosulfan  / fludarabine-based conditioning regimens in paediatric patients with nonmalignant diseases. Depending on the underlying disease, thiotepa was administered in up to 74% of patients.

The more frequent use of thiotepa reflects the current clinical practice of most transplantation centres in the European Union. The trial, MC-FludT.16/NM , was designed based on the modified PIP number EMEA-000883-PIP01-10-M01, decision number P/0104/2013. As the initial trial design did not reflect the more frequent use of thiotepa, but required the vast majority of subjects (at least 85 out of 100 subjects) to be treated without additional thiotepa, a PIP modification was submitted to the PDCO of EMA in Nov2016 in order to permit the additional use of thiotepa in all qualified subjects at the discretion of the

<div style=\"page-break-after: always\"></div>

Investigator. The PIP modification number EMEA-000883-PIP01-10-M03 was approved by the PDCO of EMA  on  17-Mar-2017  (Decision  number  P/0059/2017).  Details  of  trial  design  and  conduct  were predefined by the PDCO. The most recent CTP version complies with the most recent PIP modification (EMEA-000883-PIP01-10-M05; Decision number P/0346/2020).

MC-FludT.16/NM: Clinical phase II trial to compare safety and efficacy of treosulfan-based conditioning therapy with busulfan-based conditioning therapy in children of different age groups with non-malignant diseases  requiring  myeloablative  conditioning  treatment  prior  to  alloHSCT.  To  describe  the  TREO compared to the conventional dose BU (control), each product was administered as part of a standardised FLU-containing conditioning regimen and also contributed to a pharmacokinetic model.

Analysis of treosulfan and monoepoxide plasma levels in a subgroup of subjects allocated to the test arm of the trial contributes to a separately reported population PK evaluation for treosulfan.

The clinical trial report (CTR) focusses mainly on the complete and final 12-month data, but also contains longer-term follow-up data that were available by data cut-off on 07-Jun-2021.

MC-FludT.17/M : Clinical phase II trial to describe the safety and efficacy of TREO-based conditioning therapy prior to alloHSCT in paediatric patients with haematological malignancies; To describe the safety and  efficacy  of  TREO  as  part  of  a  standardised  FLU-containing  conditioning  and  to  contribute  to  a pharmacokinetic model.

The  final  analysis  of MC-FludT.14/L Trial  II  has  confirmed  the  non-inferiority  of  TREO-based conditioning compared to reduced-intensity conditioning therapy based on intravenous BU. Additionally, superiority of TREO versus BU could now be shown with the final data set.

Longer-term follow-up data will be collected until the last recruited subject has completed visit Month 36 and presented in an updated version of the CTR expected in 2023. Joint PK and Pop-PK evaluations of treosulfan and monoepoxide drug concentration measurements of both trials MCFludT. 16/NM and MC-FludT.17/M were reported by Venn Life Sciences.

Furthermore, both paediatric studies have been completed. Final CSRs are now available, with 3-year follow-up survival data for study MC-FludT.17/M and 1-year follow-up data for study 16/NM.

Moreover, the PopPK model for TREO was updated and the BSA-adapted dose regimen of TREO in paediatric patients slightly modified.

## 2.1.4. General comments on compliance with GLP, GCP

## GLP

Most of the early study results on treosulfan are available as brief summaries of LEO contracted studies conducted in the 1970s and 1980s to support the use of treosulfan in clinical trials and application for marketing authorisation as an anti-cancer agent. The corresponding data as well as other supportive information is also published in the literature. Accordingly, the historical information of the nonclinical dossier regarding study design and reporting of results does not comply with current regulatory quality standards like Good Laboratory Practice (GLP) and guidelines for e.g. the conduct of safety studies (OECD and ICH guidelines). However, the studies were generally carried out state of the art at the time of performance and were accepted by the European authorities. Other, more recently conducted nonclinical studies (e.g. a 4-week subchronic toxicity and toxicokinetic study in adult rats as well as a toxicity study in juvenile rats) are in full compliance with GLP regulations.

## GCP

<div style=\"page-break-after: always\"></div>

All 7 clinical studies submitted by medac have been designed, conducted, and analysed according to the principles of Good Clinical Practice.

## 2.2. Non-clinical aspects

## 2.2.1. Introduction

The investigational drug substance, treosulfan, was already registered in the 70ies and 80ies of the last century  by  LEO  Pharmaceutical  Products  in  Denmark  (LEO)  for  the  chemotherapeutic  treatment  of patients with  ovarian cancer  in several European  countries.  Pharmacological  and  toxicological characteristics of treosulfan were initially assessed by the U.S. National Cancer Institute (NCI) under the compound identifier NSC-39069.

In 1990 medac GmbH took over the product with all legal rights and obligations. Later on, chemistry, manufacturing and control data, as well as new nonclinical and clinical data have been generated by medac to support the clinical development of a treosulfan-based conditioning therapy prior to autologous or allogeneic haematopoietic stem cell transplantation (HSCT).

The early nonclinical development of treosulfan as an anti-cancer agent started in the 1960s in the research laboratories of LEO. By order of LEO, treosulfan (NSC-39069) was extensively tested in vitro and in vivo by the Cancer Chemotherapy National Service Center in collaboration with the NCI. The corresponding  study  reports  were  compiled  by  LEO  within  a  nonclinical  dossier  for  application  of marketing authorisation of treosulfan for treatment of ovarian cancer in several European countries (LEO, 1978b). The nonclinical study results of NSC-39069 and various other structures were published as special issue of Cancer Chemotherapy Reports (Schmidt et al., 1965).

Later  on,  an  extensive  nonclinical  programme  was  performed  to  evaluate  the  pharmacodynamics, pharmacokinetics and the toxicological properties of treosulfan. In some studies, other alkylating agents, including busulfan, or reactive metabolites of treosulfan were applied for comparison and elucidation of mechanistic aspects.

Most of the early study results on treosulfan are available as brief summaries of LEO contracted studies conducted in the 1970s and 1980s to support the use of treosulfan in clinical trials and application for marketing authorisation as an anti-cancer agent. The corresponding data as well as other supportive information is also published in the literature.

Accordingly, the historical information of the nonclinical dossier regarding study design and reporting of results does not comply with current regulatory quality standards like Good Laboratory Practice (GLP) and guidelines for e.g. the conduct of safety studies (OECD and ICH guidelines). However, the studies were generally carried out state of the art at the time of performance and were accepted by the European authorities.

Other, more recently conducted nonclinical studies (e.g. a 4-week subchronic toxicity and toxicokinetic study in adult rats as well as a toxicity study in juvenile rats) are in full compliance with GLP regulations. The most recent 4-week toxicity study in rats also used the new lyophilised drug product formulation and  covers,  therefore,  the  only  three  days  treatment  period  recommended  for  clinical  use  in  the indication  of  conditioning  prior  to  HSCT.  In  view  of  the  alkylating  properties  and  the  toxicological characteristics of treosulfan as well as the clinical use for life-threatening conditions indicated for HSCT,

<div style=\"page-break-after: always\"></div>

further  specific  toxicological  qualification  procedures,  in  particular  regarding  potential  genotoxic properties of impurities, metabolites and decomposition products, are deemed not necessary. Moreover, its established clinical use in Europe for decades and the corresponding pharmacovigilance information is in line with the overall conclusions from the nonclinical safety studies drawn by the MAH.

In  June  2019,  the  European  Commission  approved  treosulfan  for  marketing  authorisation  with  the following label: 'Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases, and in paediatric patients older than one month with malignant diseases' (see SmPC TRECONDI®).

Meanwhile, medac also established a new production processes and a lyophilized formulation of the drug product.

Treosulfan  is  a  prodrug.  The  parent  compound  is  water  soluble  and  converts  under  physiological conditions by non-enzymatic intra-molecular substitution into a reactive monoepoxide intermediate (S,SEBDM) and subsequently to diepoxybutane (S,S-DEB) (Figure 2.4-4). The reactive intermediates alkylate DNA and create interstrand cross-links. Alkylation also affects other biological molecules and structures, involved  in  various  physiological  functions  and  thus  contributes  to  the  stem  cell  toxicity  as  well  as generally broad cytotoxicity of treosulfan.

li

Figure 2.4-1: Conversion of treosulfan to biologically active epoxides ( Glowka et al., 2012)

<!-- image -->

The two hydroxyl groups in position 2 and 3 of the treosulfan molecule are responsible for significant differences  between  treosulfan  and  busulfan  (1,4-butanediol-dimethylsulfonate),  which  is  currently approved  for  conditioning  treatment  prior  to  HSCT.  These  differences  include  physico-chemical, pharmacological, pharmacokinetic and toxicological characteristics.

<div style=\"page-break-after: always\"></div>

The  directly  alkylating  agent  busulfan  was  used  as  positive  control  treatment  in  a  number  of pharmacological and toxicological tests and demonstrated a higher potential to induce hepatotoxicity, lung toxicity, CNS toxicity and effects on fertility than treosulfan.

Due to its long-established clinical use for treatment of European patients with ovarian cancer and the well-known clinical as well as nonclinical safety profile, pharmacokinetics and efficacy, treosulfan was more recently evaluated in high-dose treatment regimens with subsequent autologous HSCT. The proven haematopoietic stem cell toxicity against both, primitive and committed haematopoietic stem cells, as well as its immunosuppressive and haematotoxic characteristics, qualify treosulfan in particular as a developmental candidate for conditioning treatment of adult and paediatric patients with malignant as well as non-malignant diseases indicated for allogeneic HSCT.

For conditioning treatment, preferentially the combination of treosulfan with fludarabine (for pretransplant immunosuppression) is applied. The drug product is used for intravenous infusion after dissolution in 20 mL (1.0 g strength) or 100 mL (5.0 g strength) 0.45% sterile saline. A single daily dose of 10 g/m² to 14 g/m 2  body surface area of treosulfan is to be administered on 3 consecutive days.

The MAH is now requesting an extension of the indication to include additional non-malignant transplant indications ( non-malignant diseases in the paediatric population based on final 12-months follow-up results of study MC-FludT.16/NM .

Further, the MAH proposes to amend an existing warning on skin toxicity based on new literature data and to introduce a slightly modified dosing regimen according to the patient's body surface based on long-term follow-up data of paediatric study MC-FludT.17/M in paediatric patients with haematological malignancies, as well as a final analysis of the population pharmacokinetics of treosulfan in paediatric patients.

## 2.2.2. Pharmacology

## Introduction

An overview of relevant studies to evaluate the pharmacodynamic profile of treosulfan is shown:

## Table 1: Overview of pharmacodynamic studies

<div style=\"page-break-after: always\"></div>

| Type of Study                                                                                                      | Test System                                                          | Admini- stration   | Reference                             |
|--------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|--------------------|---------------------------------------|
| PRIMARY PHARMACODYNAMICS Mechanism of action (cytotoxicity)                                                        |                                                                      |                    |                                       |
| Interaction of treosulfan andepoxides with DNA                                                                     | IsolatedDNA andhuman chronicinvitro myelogenous leukaemic K562 cells |                    | Hartley et al., 1999                  |
| Interaction ofEBDM andDEBwith DNA                                                                                  | Isolated calf thymus DNA                                             | in vitro           | Romanski et al.,2019                  |
| Interactions ofDEBstereoisomerswith DNA                                                                            | Xenopusborealisplasmids                                              | in vitro           | Millard et al.,2006                   |
| Interactions ofDEBwithDNA and proteins                                                                             | Nuclear extractsfrom human cervical carcinoma (HeLa) cells           | in vitro           | Michaelson-Richie et al., 2010        |
| Interactions of DEBwith DNA                                                                                        | Human fibrosarcoma (HT1080) cells                                    | in vitro           | Gherezghiher et al.,2013              |
| Chemosensitivity of humanbone marrow stromal cells                                                                 | Bone marrowstromal cells line HS-5 and primary cells                 | in vitro           | Schmidmaier et al.,2006               |
| Myeloablative and immunosuppressiveeffects                                                                         |                                                                      |                    |                                       |
| Sensitivityofmurinebonemarrow towardsbusulfanand treosulfaninvitro and invivo                                      | Murinebone marrow cells                                              |                    | in vitro, i.p. Westerhof et al., 2000 |
| Sensitivity of treosulfan compared to busulfan against leukaemia and different myeloid leukaemia cells cells types | Primary lymphoblastic and                                            | in vitro, ex vivo  | Munkelt et al. 2008                   |
| Sensitivityofmurinebonemarrow towardssingledose andfractionated treosulfancompared tobusulfaninvitro and invivo    | Murinebone marrow cells                                              | in vitro, ip.      | Ploemacher [report], 2000             |
| Single and fractionated treosulfan treatmenton thefemoral CAFCcontent                                              | Mouse                                                                | i.p.               | Ploemacher [report]., 2003            |
| Induction of donor-specific tolerance for Mouse skin grafts acrossfull MHC barriers                                |                                                                      | in vitro, i.v.     | van Pel.,et al., 2003                 |
| Induction of specific skin graft tolerance Mouse across haploidentical MHC barriers                                |                                                                      |                    | in vitro,i.v.van Pel et al.,2004      |
| Nonmyeloablative conditioning in a murine sickle cell disease model                                                | Mouse                                                                | i.p.               | Devadasan et al.,2018                 |

Type of Study

Test System

Myeloablative and immunosuppressive

Mouse properties of treosulfan in mice

Immunosuppressive activity of low-dose Mouse treosulfan in mice

Use of high-dose treosulfan orbusulfan to prepare recipients for allogeneic BMT

inmice

Permanent acceptance of skin grafts afterlow-dosetreosulfan andBMTin

mice

Anti-tumoureffects(haematologicalmalignancies)

Efficacy against fresh human tumour cells

Cytotoxic effects of treosulfan and busulfan against paediatric leukaemic

cells

Cytotoxicity on paediatric tumou cells

Cell deathin myeloma cells

Treosulfan-induced apoptosis, chemosensivity tests

Apoptosis induction by treosulfan and other cytotoxic agents

Drug-resistanceprofile of treosulfan

Antileukaemicactivity of treosulfan in xenografted humanALL

Antileukaemic activity of treosulfan in xennograftedDunningleukaemia

Several tumour types (ALL,

ATLL, AML, MDS, NHL)

Primary lymphoblastic and myeloid leukaemia cells

leukaemia celllines

NCI-H929 and U266 cell lines frompatients

U937,THP-1,HL-60,TUR, and primary AML cells from patients

PBMCs from patients with CLL

ALLsamples,paediatric patients

Mouse

Rats

Admini- stration

i.p.

i.p.

i.p.

i.p.

in vitro in vitro, ex

vivo in vitro

in vitro in vitro

in vitro in vitro

i.p.

i.p., p.o.

Reference

Sjoo et al., 2006

Melchers et al., 2000

BioTransplant, 2000

Andersson et al.,2003

Bath Analytical,1994

Munkeltet al.,2008

Lanvers-Kaminsky et al.,

2006

Meinhardt et al., 2003

Schmidmaier et al.,2004

Ristovska et al., 2009

Pogorzala et al.,2015

Fichtner et al., 2003

Jones et al.,1960, Schmidt et al., 1965

Mouse

Mouse

<div style=\"page-break-after: always\"></div>

| SECONDARY PHARMACODYNAMICS                                                                                  |                                                     | in vitro Peter et al., 2015   |                            |
|-------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|-------------------------------|----------------------------|
| Treosulfan impedes the migration of immunocompetent cells                                                   | Human venous blood                                  |                               |                            |
|                                                                                                             |                                                     | in vitro                      | Kopadze et al., 2007       |
| Invitrosensitivityof human ovarian tumours                                                                  | Human ovarian tumours                               | in vitro                      | Wilson and Neal, 1981      |
| Efficacyoftreosulfan againstfresh human tumour cellsin vitro                                                | Human tumour cells                                  | in vitro                      | Bath Analytical, 1994      |
| Sensitisation of glioma cells to treosulfan                                                                 | Humanglioma cells                                   | in vitro                      | Reber et al., 1998         |
| Hyperthermia enhanced chemosensitivityofhumanmalignant glioma cells                                         | Human glioma cells                                  | in vitro                      | Hermisson and Weller. 2000 |
| Potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in oa u pue o                      | Human glioma cells, and rats                        | in vitro, i.p.                | Wick et al.,2002           |
| Ex vivo chemosensitivity profile of choroidal melanoma                                                      | Human primary uveal melanoma specimens              | exvivo                        | Myatt et al., 1997         |
| Ex vivo chemosensitivity assessment of choroidal melanoma                                                   | Human primary uveal melanoma specimens              | ex vivo                       | Saakyan et al.,2020        |
| Ex vivo sensitivity of choroidal melanomabycombination oftreosulfan withgemcitabine or cytosine arabinoside | Human primary uveal melanoma specimens              | exvivo                        | Neale et al., 1999         |
| Treosulfan for malignant melanoma in oai u pue o.                                                           | Melanoma cell lines,andhuman primary melanoma cells | in vitro and ex vivo          | Neuber et al., 1999        |
| Chemosensitivitytestinginmalignant melanoma                                                                 | Humanmetastaticmelanoma tissue specimens            | ex vivo                       | Ugurel et al., 2003        |
| Invitro andinvivoactivityoftreosulfan towards human renal-cell carcinoma                                    | 1Renal tumourcells,andmouse                         | in vitro.,i.v.                | Kopf-Maier,1998            |
| Cytotoxic effect of treosulfan on spheroids from primary cell cultures of kidneycellcarcinomas              | Primary renal cell carcinoma cells.                 | ex vivo                       | Kugler et al., 1998        |

<div style=\"page-break-after: always\"></div>

| Antitumour activityof treosulfanin human lung carcinomas                                                                        | Mouse                                                                                            | i.p.              | Kopf-Maier and SaB, 1996    |
|---------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-------------------|-----------------------------|
| Treosulfan demonstrate potent activity inEwing'ssarcoma                                                                         | Mouse                                                                                            | i.p.              | Werner et al., 2008         |
| Effects of treosulfan in several xennografted tumours                                                                           | Mouse and Rats                                                                                   | i.p., p.o.        | White,1962                  |
| SAFETYPHARMACOLOGY                                                                                                              |                                                                                                  |                   |                             |
| Electrophysiological examination on the HEK 293 cells hERG-mediated potassium current                                           |                                                                                                  | in vitro          | B'SYS,2017                  |
| Effect on hERG, hNav1.5, hCav1.2, hKir2.1 and hKCNQ1/minK cardiacion channels                                                   | HEK293 cells (partly transfected / recombinant), CHO-K1 cell line                                | in vitro          | CYP1269R11-R12,2020         |
| Effect on beat period and field potential duration (FPD) in cardiomyocytes                                                      | fCDI hiPSC-derived cardiomyocytes                                                                | in vitro          | CYP1269R10,2020             |
| Effects onsmoothmuscle                                                                                                          | Guinea pig intestine, cat trachea                                                                | in vitro          | LEO,1978b                   |
| Effects on central nervous system, cardiovascularfunction,gastric secretion, blood                                              | Mouse, rat, dog, monkey                                                                          |                   | p.o., i.p., i.v. LEO, 1978b |
| PHARMACODYNAMICDRUG INTERACTIONS                                                                                                |                                                                                                  |                   |                             |
| Synergistic effects against leukaemia cells after combination with fludarabine                                                  | Primary lymphoblastic and myeloid leukaemia cells                                                | in vitro, ex vivo | Munkelt et al., 2008        |
| Interactionofradiation andtreosulfan                                                                                            | AML-and MDS-derived myeloid cell lines and primary marrow cells from patients and healthy donors | in vitro          | Zang et al., 2015           |
| Improved immune reconstitution after cytostatic conditioning with treosulfan/ fludarabine combination                           | Mouse                                                                                            | i.p.              | Bouazzaoui et al., 2014     |
| Addition of treosulfan to a nonmyeloab-Mouse lative conditioningregimen                                                         |                                                                                                  | i.p.              | Ploemacher et al., 2004b    |
| Induction of tolerance across fully mismatched barriers by a nonmyeloablative treatment excluding antibodies of irradiation use | Mouse                                                                                            | i.p.              | Stephan et al., 2006        |
| Influenceoftimeintervalbetweenthe lasttreosulfaninjectionandtotalbody inradiation ontoxicityin rats                             | Rat                                                                                              | i.p.              | Sender et al., 2009         |

Abbreviations: p.o.: oral; i.p.: intraperitoneal; i.v.: intravenous

## Primary pharmacodynamic studies

Primary pharmacodynamic properties of treosulfan comprehend cytotoxicity, the main mechanism of action, myeloablative and immunosuppressive  effects, and anti-tumour effects with focus on haematological malignancies considered relevant for the proposed use as conditioning treatment prior to HSCT.

In treosulfan-treated cells of the human chronic myelogenous leukemic cell line K562, DNA cross-links formed slowly, while incubation with preformed epoxides showed faster and more efficient cross-linking. Alkylation in plasmid DNA occurred at guanine bases with sequence selectivity similar to other alkylating agents such as the nitrogen mustards (Hartley et al., 1999).

DEB  formed  DNA-protein  cross-links  between  cysteine  thiols  within  proteins  and  the  N-7  guanine positions  within  DNA  (Michaelson-Richie  et  al.,  2010).  DEB-mediated  DNA-protein  cross-linking  was investigated in human fibrosarcoma (HT1080) cells. Over 150 proteins including histones, high mobility group proteins, transcription factors, splicing factors, and tubulins were found among those covalently cross-linked to chromosomal DNA in the presence of DEB. A large portion of the cross-linked proteins are known factors involved in DNA binding, transcriptional regulation, cell signalling, DNA repair, and DNA damage response (Gherezghiher et al., 2013).

<div style=\"page-break-after: always\"></div>

While  alkylating  agents  (melphalan,  treosulfan)  and  doxorubicin  demonstrated  marked  cytotoxicity, nucleotide  analogs  (gemcitabine,  cytarabine)  induced  only  limited  apoptosis  in  human  bone  marrow stromal cells (Schmidmaier et al., 2006).

Cytotoxicity of treosulfan and busulfan was evaluated in vitro in two human leukaemia cell lines and revealed a consistently higher cytotoxic potential than busulfan (Lanvers-Kaminsky et al., 2006). ALL samples of paediatric origin were tested for ex vivo chemosensitivity to various cytotoxic drugs. Their combined drug resistance profile was analysed. Lymphoblasts from patients who experienced multiple relapses  were  comparably  resistant  to  daunorubicin,  doxorubicin,  cyclophosphamide,  ifosfamide, busulfan, treosulfan, fludarabine, clofarabine, and bortezomib (Pogorzala et al., 2015).

Compared  with  other  dimethanesulfonate  compounds  (related  to  busulfan),  treosulfan  exhibited comparably high in vitro activity, but relatively low activity in vivo (in case of only one single dose treatment) in terms of their toxicity to different haematopoietic stem cell subsets (Westerhof et al., 2000). Treosulfan was more active against 20 leukemic cell specimens of paediatric origin and against 3 leukaemia-derived cell lines than busulfan. Beyond that, purified haematopoietic CD34+ stem cells were most sensitive  against  treosulfan,  followed  by  CD56+CD3-  NK  and  CD3+T  cells.  In  the  lymphocyte subsets, treosulfan was threefold and in stem cells 20fold more effective than busulfan (Munkelt et al., 2008).

Using  dose  fractionation  and  repeated  administrations  of  treosulfan,  profound  stem  cell  depleting properties in all stem cell subsets were shown in vitro and in vivo. This is in contrast to busulfan, which is predominantly toxic for long-term repopulating stem cells which might explain its low immunosuppressive potential (Ploemacher [report], 2000; Ploemacher [report], 2003).

Conditioning with non-myeloablative doses of treosulfan, followed by transplantation with syngeneic bone marrow (BM) donor cells, permitted long-term mixed-donor chimerism in a murine model of sickle cell disease. The induced level of chimerism correlated with improvement in sickle cell disease (SCD) related haematologic parameters, normalisation of urine osmolality, and improvement in liver and spleen pathology (Devadasan et al., 2018).

Myeloablative and immunosuppressive properties of treosulfan were investigated in mice treated with treosulfan,  cyclophosphamide, or busulfan at sublethal doses that maintained survival without bone marrow support. Treosulfan and busulfan induced a high and persisting degree of myeloablation, as compared  with  cyclophosphamide. Moreover, treosulfan was  more  effective than busulfan or cyclophosphamide  in  depletion  of  splenic  B  and  T  cells.  Treatment  with  treosulfan  induced  only interleukin-2 production in spleen cells of mice for a short time only and had no significant effect on synthesis of tumour necrosis factor-alpha and/or interferon-gamma as compared with either busulfan or cyclophosphamide (Sjöö et al., 2006).

The immunosuppressive activity of treosulfan was investigated using human peripheral blood B and T lymphocytes  and  mice  immunized  with  keyhole  limpet  haemocyanin.  Low  dose  treosulfan  induced suppression of the early immune response, probably including the proliferation/differentiation of cells repopulating lymphoid organs and influenced the balance of regulatory T cell subpopulations (Melchers et al., 2000).

Fractionated high-dose treosulfan or busulfan treatment was investigated in mice to prepare recipients for allogeneic bone marrow transplantation. In addition, treosulfan and busulfan treatment regimens including concomitant treatment with anti-T cell antibodies and/or cyclophosphamide were assessed for induction of donor-type chimerism and tolerance to subsequent donor skin grafts after H-2 incompatible allogeneic HSCT (van Pel et al., 2003, 2004). Concomitant treatment of the stem cell depleting agent (busulfan or treosulfan) with T cell depletion with anti-CD4 and anti-CD8 monoclonal antibodies appeared to be important for achieving immune tolerance and induction of high levels of donor-type chimerism.

<div style=\"page-break-after: always\"></div>

Cyclophosphamide was, however, effective in enhancing low levels of donor chimerism produced by treosulfan-based conditioning regimen (BioTransplant, 2000).

Permanent acceptance of donor-type skin grafts and rejection of 'third party' skin grafts after low dose treosulfan-based conditioning and allogeneic HSCT was demonstrated in mice and confirmed functional aspects of the established donor-related immune system (Andersson et al.,2003).

Anti-haematological  malignancies  effects  of  Treosulfan  were  tested  in  vitro  by  differential  staining cytotoxicity assays against 55 tissue specimens from patients with acute lymphoblastic leukaemia (ALL), adult T-cell leukaemia/lymphoma (ATLL), acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS), and non-Hodgkin's lymphoma (NHL). Treosulfan induced dose-dependent cell death resulting in LC90 values of 2 to 512 μg/mL (Bath Analytical, 1994). Treosulfan was also more active than busulfan against leukaemic cells isolated from 20 paediatric ALL patients as well as against three leukaemiaderived cell lines with increasing IC50 values from initial diagnosis (chemotherapy naive specimens) to relapse (pretreated specimens; Munkelt et al., 2008). Treosulfan treatment of the myeloma cell lines NCI-H929 and U266 led to apoptosis in both cell lines in a dose- and time-dependent manner (Meinhardt et al., 2003).

Chemosensitivity tests were performed in AML cell lines and primary cells isolated from patients. All cell types displayed dose-dependent sensitivity to treosulfan (Schmidmaier et al.,2004). In peripheral blood mononuclear  cells  (PBMCs)  from  patients  with  chronic  lymphocytic  leukaemia  (CLL)  treosulfan,  4hydroperoxy-cyclophosphamide, fludarabine or cytarabine, but not busulfan, were effective inducers of apoptosis. Cell death was induced via caspase-activation (Ristovska et al., 2009).

The in vivo antileukaemic activity of treosulfan was compared with the activity of equitoxic doses of cyclophosphamide or busulfan using human ALL cells established in a xenotransplant mouse model in immunocompromised animals. Treosulfan was more effective with regard to the numbers of complete ALL regressions and the number of cured animals (Fichtner et al., 2003). In Fisher rats with Dunning leukaemia the chemotherapeutic activity of treosulfan was very much greater than that of busulfan, and was fully equivalent to the effect of 6-mercaptopurine (Jones et al., 1960; Schmidt et al., 1965).

## Secondary pharmacodynamic studies

Secondary pharmacology studies included effects of treosulfan on erythrocytes, on the migration of immunocompetent blood cells, and against solid tumour types.

Exposure of human erythrocytes to treosulfan in vitro significantly stimulated suicidal erythrocyte death (eryptosis),  at  least  in  part  by  inducing  oxidative  stress  and  stimulating  Ca2+  entry.  This  effect presumably contributes to the anaemia observed after treosulfan treatment in the animal studies (Peter et al., 2015).

Treatment  of  PBMCs  of  healthy  donors  with  treosulfan  significantly  inhibited  the  migration  of immunocompetent mononuclear cells across a fibronectin layer. The effect was observed in T cells (CD4+ and CD8+ cells) as well as in CD14+ monocytes to a similar extent (Kopadze et al., 2007).

Apart from activity against haematological malignancies, treosulfan also exhibits a broad anti-tumour activity against numerous solid tumour types as demonstrated against human tumour xenografts in rats and mice, human tumour biopsies, and tumour cell lines.

Treosulfan was consistently more cytotoxic (at lower IC90 values) than busulfan when evaluated in vitro on  four  human  Ewing  tumour,  four  human  neuroblastoma,  and  two  human  osteosarcoma  cell  lines (Lanvers-Kaminsky et al., 2006).

<div style=\"page-break-after: always\"></div>

## Safety pharmacology programme

The effect  of  treosulfan  on  vital  organ  functions  (cardiovascular  system,  respiratory  system,  central nervous  system)  as  well  as  on  supplemental  organ  functions  (gastro-intestinal  tract,  blood)  was investigated in vitro and in vivo. The historical studies (White, 1962; LEO, 1978b) provided no evidence of adverse effects regarding (maximum doses tested are given in brackets):

- Cardiovascular system: blood pressure in rats (40 mg/kg i.v.), blood pressure and ECG in dogs (200 mg/kg i.v.);

- Central nervous system: general behaviour of mice (300 mg/kg i.p.), dogs (222 mg/kg i.v and monkey (222 mg/kg i.v.) anticonvulsive and analgesic effects in mice (100 mg/kg and 50 mg/kg i.p.);

- Respiratory system: isolated tracheal muscle preparations of the cat (2 x 10-5 g/mL);

- Gastro-intestinal tract: gastric secretion in rats (50 mg/kg p.o.), isolated small intestine preparations of the guinea pig (10-5 g/mL).

- Local anaesthetic effects: mice (tail, injection of 0.05 mL of a 2% treosulfan solution).

A recently conducted in vitro hERG K+ channel assay exhibited no potential for an arrhythmogenic effect at  a  treosulfan  c oncentration  of  1000  μM  (B'SYS,  2017),  which  corresponds  approximately  to  the clinically relevant Cmax of 300 μg/ml in adult patient treated with 10 g/m 2  BSA (Hilger et al., 1998). Up to a fivetime higher treosulfan concentration (5000 μM) was assessed on an array of key cardiac ion channels proposed by CiPA, in particular hERG, hNav1.5 (both peak and late), hCav1.2, hKir2.1, and hKCNQ1/minK ion channels. In these assays, the % inhibitions at the highest concentration tested were &lt; 50%.

In cardiomyocytes, only the treosulfan top concentration of 5000 μM caused a transient increase in the beat period as well as a nominal shortening of the field potential duration (FPD), while the sodium channel endpoints were not affected at any of the concentrations tested in this assay. The change in the beat period at 5000 μM treosulfan may result from the instability of the test compound and the given closed cell culture system (CYP1269 R10, 2020).

## Pharmacodynamic drug interactions

The combination of treosulfan with fludarabine resulted in a synergistic cytotoxic effect against human leukaemic cells isolated from 20 paediatric patients (Munkelt et al., 2008). Conditioning treatment with treosulfan/fludarabine or busulfan/fludarabine resulted in decreased severity of acute graft versus host disease  (aGvHD)  compared  to  total  body  irradiation  (TBI).  Moreover,  treosulfan/fludarabine  was associated with improved immune reconstitution despite early gastro-intestinal or cutaneous toxicity (Bouazzaoui et al., 2014).

AML- or MDS-derived myeloid cell lines as well as primary marrow cells from patients with MDS and healthy donors were exposed to treosulfan, radiation or both, and the extent of apoptosis was assessed. In vitro pre-exposure to treosulfan did not clearly enhance radiation induced cell death (Zang et al., 2015).

The  combination  of  treosulfan  with  TBI  prior  to  bone  marrow  transplantation  in  rats  showed  that treosulfan possesses certain characteristics of a radio-sensitiser in vivo (Sender et al., 2009). Results of low-dose treosulfan added to an immune-suppressive regimen consisting of T cell depleting antibodies, fludarabine,  and  thymic  irradiation  indicate  that  low-dose  treosulfan  may  be  considered  as  a  useful component  of  a  truly  nonmyeloablative  conditioning  protocol  in  providing  for  sustained  mixed

<div style=\"page-break-after: always\"></div>

haematopoietic  chimerism  of  donor  type  and,  consequently,  in  establishing  a  platform  for  adoptive immunotherapy as well as donor-derived organ transplantation (Ploemacher et al., 2004b).

Permanent mixed chimerism and donor-specific tolerance was achieved in mice conditioned, prior to donor mouse muscle precursor cell transplantation, with a treosulfan treatment combined with a single cyclophosphamide dose, and finally a donor bone marrow transplantation (Stephan et al., 2006).

Profound stem cell toxic, myeloablative and immunosuppressive effects were demonstrated in various in vitro and in vivo models employing treosulfan alone or in combination with other clinically established conditioning  components.  The  strong  anti-leukemic  activity  of  treosulfan  potentially  reduces  posttransplant relapse of underlying malignancies in a clinical setting of allogeneic HSCT.

## 2.2.3. Pharmacokinetics

An overview of relevant studies conducted to evaluate the absorption, distribution, metabolism, and excretion (ADME) of treosulfan is shown:

<div style=\"page-break-after: always\"></div>

Table 2.4-2: Overview of ADME and in vitro pharmacokinetic studies

| Type of Study                                                                                                     | Test System                                                            | Admini- stration   | Reference                                |
|-------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|--------------------|------------------------------------------|
| Absorption /Bioavailability                                                                                       |                                                                        |                    |                                          |
| Plasma levels after single dose                                                                                   | Dog                                                                    | i.v., p.o.         | LEO, 1978a                               |
| Absorption in a single rat after a single dose                                                                    | Rat                                                                    | i.v.               | MDC/01, 2004                             |
| Plasma levels after single dose                                                                                   | Mouse                                                                  | i.p.               | Werner et al., 2008                      |
| Plasma levels after repeated dose                                                                                 | Juvenile rat                                                           | i.v.               | LPT26054,2011                            |
| Plasma levels after repeated dose                                                                                 | Rat                                                                    | i.v.               | LPT 37259,2020                           |
| Plasma levels of treosulfan and its transformation products after single dose                                     | Juvenile and young adult rat                                           | i.v.               | LPT 27700,2014                           |
| Plasma levels of treosulfan and its transformation products after single dose                                     | Rabbit                                                                 | i.v.               | Romanski et al., 2016                    |
| Distribution                                                                                                      |                                                                        |                    |                                          |
| Plasma protein binding of treosulfan and epoxide metabolites                                                      | Rat and human blood samples                                            | in vitro           | Glowka et al., 2012 Romanskiet al.,2015a |
| Red blood cell/plasma partition coefficient                                                                       | Rat                                                                    | i.p.               | Romanski et al., 2018                    |
| Tissue distribution                                                                                               | Rat                                                                    | i.v.               | MDC/01, 2004                             |
| Transport of treosulfan across blood-brain barrier                                                                | In vitro                                                               | n.a.               | Linz et al., 2015                        |
| Blood-brain barrier penetration of treosulfan and its transformation products after single dose                   | Rat, juvenile and young adult                                          | i.v.               | LPT27700,2014 Romanski et al., 2015a     |
| Determination of treosulfan andits monoepoxide in plasma, liver, lungs, kidneys, muscle, and brain                | Rat                                                                    | i.p.               | Romanski et al.,2017b                    |
| Disposition of treosulfan and its monoepoxide in plasma, bone marrow, liver, lungs, brain, and quadriceps femoris | Rat                                                                    | i.p..              | Romanski et al., 2017c                   |
| Metabolism                                                                                                        |                                                                        |                    |                                          |
| Glutathione conjugation of treosulfan                                                                             | Human liver cytosol                                                    | in vitro           | Romanski and Glowka,2019                 |
| Glutathione conjugation of DEB                                                                                    | Liver and lung cytosol  in vitro of mouse and rat, human liver cytosol |                    | Boogaard et al., 1996                    |
| Role of hydrolysis in detoxification of DEB                                                                       | Liver and lung microsomes ofmouse, rat, and human                      | in vitro           | Boogaard and Bond, 1996                  |

<div style=\"page-break-after: always\"></div>

| Transformation of treosulfan toDEB (dependence on pH and temperature)                                                             | Aqueous solution, human plasma          | in vitro   | Feit, 1997             |
|-----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|------------|------------------------|
| Activation of treosulfan at pH 7.4 and 37°C accompanied by hydrolysis of the active epoxides                                      | Aqueous solutions/ buffer               | in vitro   | Romanski et al., 2015b |
| Metabolism of treosulfan and its transformation products after single dose                                                        | Rabbit                                  | i.v.       | Romanski et al., 2016  |
| Kinetic and mechanistic study of the pH- dependent epoxidation of treosulfan including the reaction inhibition in a borate buffer | Aqueous solutions/ buffer               | in vitro   | Romanski et al.,2017a  |
| Distribution of treosulfan and its monoepoxide in, bone marrow, liver, lungs, brain, and muscle                                   | Rat                                     | i.p.       | Romanski et al., 2017c |
| Excretion                                                                                                                         |                                         |            |                        |
| Excretion into urine                                                                                                              | Rat                                     | i.p.       | Romanski et al., 2017c |
| Excretion into urine                                                                                                              | Dog                                     | i.v., p.o. | LEO,1978a              |
| Excretion into faeces, urine and expired air                                                                                      | Rat                                     | i.v.       | MDC/01,2004            |
| PharmacokineticDrugInteractions                                                                                                   |                                         |            |                        |
| CYP inhibitory potential                                                                                                          | human liver micro- somes                | in vitro   | MDC/02,2003            |
| Microsomal metabolic stability with CYP reaction phenotyping of treosulfan                                                        | human liver microsomes                  | in vitro   | CYP1269R13,2021        |
| CYP time dependent inhibition (IC50 shift) potential of treosuflan                                                                | human liver microsomes                  | in vitro   | CYP1269R9,2018a        |
| Inhibitory potential of treosulfan on human transporters                                                                          | cell test systems and membrane vesicles | in vitro   | CYP1269R9,2018b        |
| CYP induction potential of treosulfan                                                                                             | human hepatocytes                       | in vitro   | CYP1269R9,2018c        |
| CYP3A1, CYP3A2, CYP2C6 and CYP2C11 mRNA expression and activity                                                                   | Rat liver tissue                        | ex vivo    | 2019MED001,2020        |

Abbreviations: i.p.: intraperitoneal; i.v.: intravenous; p.o.: oral

Various bioanalytical procedures were validated and applied to detect concentrations of treosulfan and related epoxides in plasma, urine and tissues of different species.

Treosulfan and its alkylating metabolites were rapidly transformed, partly metabolised and excreted if not bound to biological macromolecules. Treosulfan as well as the epoxides distribute well into the bone marrow, reaching 70-80% of plasma concentration. Accordingly, it is observed a preferred exposure of the target tissue facilitating the intended action of conditioning treatment, namely myeloablation as well as immunosuppression of recipients of HSCT. There is no indication for accumulation in blood or tissues after repeated exposure.

In contrast to busulfan, treosulfan has a very low potential to cross the blood-brain-barrier which is in line with the clinical experience that anti-convulsive co-medication is not necessary for treosulfan based conditioning treatment.

In  opposition  to  gender,  age  does  influence  the  pharmacokinetic  parameters  of  treosulfan  and  its monoepoxide  transformation  product  as  demonstrated  in  experiments  in  juvenile  rats.  Half-life  of treosulfan in plasma of juvenile rats was somewhat longer than in young adults and accordingly, a higher exposure  can  be  expected  in  juvenile  animals.  This  observation  does  also  fit  to  clinical  PK  data  in paediatric  patients  and  is  reflected  in  a  population  pharmacokinetic  modelling.  The  low  SS-EBDM exposure of liver, lungs and brain, may contribute to comparably low toxicity of treosulfan with regard to vital organ functions of experimental animals.

<div style=\"page-break-after: always\"></div>

As treosulfan does not undergo either relevant spontaneous or GST-medicated conjugation with GSH, the interactions with other GSH-conjugated drugs or competition are not expected. However, metabolic phenotyping identified treosulfan as a weak substrate of CYP2D6, and in vitro and ex vivo studies as well as PBBK modelling of clinical data did not exclude a potential low to moderate risk for DDIs between treosulfan and CYP3A4 and CYP2C19 substrates.

## 2.2.4. Toxicology

An overview of toxicological studies considered for the nonclinical safety assessment of treosulfan is provided.

<div style=\"page-break-after: always\"></div>

Table 2.4-3: Toxicology Programme

| Study type and duration                        | Administration              | Species                                  | Compound administered           | Reference                                                                                                             |
|------------------------------------------------|-----------------------------|------------------------------------------|---------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Single-dose toxicity                           | p.o., s.c., i.v. p.o., i.p. | Mouse Rat                                | treosulfan, busulfan treosulfan | LEO, 1978b                                                                                                            |
| Repeat-dose toxicity                           |                             |                                          |                                 |                                                                                                                       |
| 5 days                                         | p.o., i.p.                  | Rat                                      | treosulfan                      | White,1962,LEO, 1978b                                                                                                 |
| 26 days in juvenile animals *                  | i.v.                        | Rat                                      | treosulfan                      | LPT 26054,2011                                                                                                        |
| 28 days *                                      | i.v.                        | Rat                                      | trosulfan                       | LPT37259,2020                                                                                                         |
| 14 to 17 days                                  | p.o., i.p.                  | Dog, monkey                              | treosulfan                      | LEO, 1978b                                                                                                            |
| 4 weeks                                        | i.p.                        | Mouse, rat                               | DEB                             | Doerr et al., 1996                                                                                                    |
| 7 months                                       | p.o.                        | Rat                                      | treosulfan, busulfan            | LEO,1978b                                                                                                             |
| Genotoxicity                                   |                             |                                          |                                 |                                                                                                                       |
| Interaction with DNA                           | in vitro                    | isolated DNA or fragments                | treosulfan, metabolites         | Gherezghiher et al. 2013;Hartley et al., 1999;Michaelson-Richie et al., 2010; Millard et al., 2006; Park et al., 2005 |
| Mutagenicity in bacteria                       | in vitro                    | S. typhi- murium strains, E. coli strain | treosulfan, metabolites         | Abu-Shakra et al., 2000. Zeiger and Pagano, 1989. Provivo38665,2022                                                   |
| Mutagenicity in mammalian cell systems         | in vitro                    | Chinese hamster ovary cells              | treosulfan, DEB                 | Zhu and Zeiger, 1993                                                                                                  |
| Increase of sister chromatide exchanges *      | in vitro                    | Human lymphocytes                        | treosulfan                      | Clare et al., 1982                                                                                                    |
| Clastogenic activity (chromosomal aberrations) | in vitro                    | Human lymphocytes                        | treosulfan                      | Provivo 38666,2022                                                                                                    |
| Micronucleus test                              | i.p.                        | Mouse                                    | treosulfan, DEB                 | Adler et al., 1997; Shelby et al., 1989                                                                               |

<div style=\"page-break-after: always\"></div>

| Carcinogenicity No studies performed                  |                           |            |                      |                   |
|-------------------------------------------------------|---------------------------|------------|----------------------|-------------------|
| Reproductive and develop- mental toxicity             |                           |            |                      |                   |
| Effects on male and female fertility                  | p.o., i.p.                | Mouse, rat | treosulfan, DEB      | LEO, 1978b        |
| Study on gonadal and ovarial toxicity                 | i.p.                      | Mouse      | treosulfan, busulfan | Levi et al., 2018 |
| Subchronic (26 days) toxi- city in juvenile animals * | i.v.                      | Rat        | treosulfan           | LPT26054,2011     |
| Effects on spermatogenesis                            | i.p.                      | Mouse      | DEB                  | Spano et al.,1996 |
| Local tolerance                                       |                           |            |                      |                   |
| Effects of local administration (ear)                 | intraarterial, perivenous | Rabbit     | treosulfan           | LEO, 1985         |
| Other Toxicity not applicable                         |                           |            |                      |                   |
| Toxicokinetics                                        |                           |            |                      |                   |
| Subchronic (26 days) toxi- city in juvenile animals * | i.v.                      | Rat        | treosulfan           | LPT26054,2011     |
| Subchrnic toxicity, 28 days *                         | i.v.                      | Rat        | trosulfan            | LPT 37259,2020    |

Abbreviations: p.o.: oral; i.p.: intraperitoneal; i.v.: intravenous; s.c.: subcutaneous; DEB: 1,2:3,4-diepoxybutane

## Single dose toxicity

Treosulfan  demonstrated  low  acute  toxicity  when  administered  intravenously  (i.v.),  orally  (p.o.)  or subcutaneously (s.c.) to mice and rats. No lethality was induced in mice following an i.v. injection of up to 3500 mg/kg of treosulfan (LEO, 1978b). A comparison of the p.o. and s.c. LD50 values of treosulfan (&gt; 3500 mg/kg) and busulfan (240 and 200 mg/kg, respectively) substantiates that treosulfan exhibits a considerably lower acute toxicity. Death of rats used in acute toxicity tests occurred within 4 to 6 days after dosing. Details on symptoms or pathological findings were not reported (LEO, 1978b).

## Repeat dose toxicity

Repeat-dose toxicity studies for treosulfan with intravenous administration, the intended clinical route, were performed in rats, dogs and monkeys, while limited information on tolerability in mice can be deduced from the primary pharmacology programme.

Dose-dependent haematological changes were observed after repeated i.v., i.p. or p.o. administration in mice, rats, dogs, and monkeys. These effects are generally expected for alkylating agents (White, 1962; LEO, 1978b; LPT 26054, 2011; LPT 37259, 2020).

Within historical toxicity studies, with lethality reporting only, treosulfan was administered i.p. once daily over 5 days to rats of two different strains. In Holtzman rats, the highest non-lethal dose was 1113 mg/kg, in Fischer rats 278 mg/kg. The LD50 were calculated with approximately 1364 and 696 mg/kg, respectively (LEO, 1978b).

Results of a more recent GLP-compliant study on tolerability of subchronic daily intravenous treosulfan administrations in juvenile rats starting on PND 10 are summarised. The 26-day treatment period was

<div style=\"page-break-after: always\"></div>

followed by a post-treatment observation / recovery period of 5 weeks. A complete reversibility was noted for all systemic changes observed during the treatment period for female rats. Only a slight delay of the physical development of the high dosed juvenile male rats (100 mg treosulfan/kg b.w./day) was noted (LPT 26054, 2011).

Within a recently conducted GLP compliant 4-week subchronic toxicity study, rats were treated with 10, 50, and 150 mg treosulfan. Haematological changes, related to the pharmacodynamic properties of the cytostatic drug treosulfan were observed starting at the low dose levels of 10 mg/kg b.w./day. At the end of the treatment period, a high number of erythrocytes and/or a high haemoglobin concentration were analysed in the urine of male animals treated.

Animals in high dose groups (150 mg treosulfan/kg b.w./day) presented additional signs of systemic toxicity like decreased body weights and decreased absolute and relative spleen and thymus weights. The weight decrease of the spleen correlated to a lymphoid atrophy. No histopathological correlate was found for the thymus weight decrease. The histopathological examination revealed test item related lymphohistiocytic infiltration in the skeletal muscle starting at 10 mg treosulfan/kg b.w./day, urothelial hypertrophy with atypical cells in the urinary bladder starting at 50 mg/kg b.w./day; increased fatty bone marrow and decreased red bone marrow; lymphoid atrophy of the spleen and decreased incidence of lymphoid hyperplasia of lymph nodes at 150 mg/kg b.w./day.

All changes noted for the clinical chemistry parameters and the organ weights had completely subsided at the end of the 2 week treatment-free recovery period. The body weights of the high dosed animals were still slightly reduced but revealed a tendency towards normalisation.

Changes in haematological parameters were still noted and urinalysis still revealed a high number of erythrocytes  and/or  a  high  haemoglobin  concentration  in  the  urine  of  the  male  animals  at  the intermediate and high dose levels. Histopathology still revealed a lymphohistiocytic infiltration in the skeletal muscle starting at 10 mg/kg b.w./day and urothelial hypertrophy with atypical cells in the urinary bladder at 50 and 150 mg/kg b.w./day. The changes in the bone marrow, spleen and lymph nodes were reversible at the end of the 2 week treatment-free recovery period. In addition, a necrosis of myofibers in the skeletal muscle was noted at the end of the recovery period.

Considering the afore mentioned findings, the no observed effect level (NOEL) was below 10 mg/kg b.w./day.

In a historical chronic toxicity study in Leo Wistar rats, treosulfan (5 and 50 mg/kg/day) or busulfan (1 mg/kg/day) were administered orally by gavage 6 days per week over 7 months. Treatment resulted in reduced body weight in the high-dose treosulfan group. Body weights and the number of neutrophilic granulocytes in peripheral blood were reduced in the busulfan group.

Findings regarding organ weights, gross pathology or histopathology revealed effects on the male and female  reproductive  organs  (gonads  and  ovaries)  in  all  treatment  groups.  No  abnormalities  were observed for liver, kidney, lung, heart, spleen, adrenals and prostate or uterus compared to controls. Overall,  toxicity  was  less  pronounced in treosulfan-treated  compared  to  busulfan-treated  rats.  A  No Observed Adverse Effect Level (NOAEL) was not established for both compounds in this study. Treatment was tolerated without lethality (LEO, 1978b).

Limited information on tolerability in mice can be deduced from the primary pharmacology programme. Tolerability in Beagle dogs was investigated following daily i.v. (56, 111, 222 or 445 mg/kg) or p.o. (56, 111, 222, 445, 890 or 1779 mg/kg) administrations of treosulfan for 5 to 19 consecutive days. The duration of treatment was dependent on survival. All three animals dosed i.v. with 222 or 445 mg/kg/day developed general signs of systemic intolerance, described as CNS-depression, malaise, weight loss, anorexia,  and  collapse  of  peripheral  circulation,  leading  to  death  on  Day  11  or  Day  12.  The

<div style=\"page-break-after: always\"></div>

haematopoietic system was affected at all dose levels as evidenced by leukopenia, neutropenia, and bone marrow depression. Reticulocytopenia, thrombocytopenia and lymphopenia were observed at the dose 111 mg/kg/day or higher. Post-mortal findings included decreased cellularity of bone marrow and signs of hyperaemia starting at 56 mg/kg/day. Animals dosed with 222 mg/kg/day or higher showed severe haemorrhagic lesions in several organs and atrophy of the spleen (LEO, 1978b). A NOAEL was not established in the dog studies. The maximum tolerated dose (MTD) based on lethality was 111 mg/kg/day for i.v. (LEO, 1978b).

Rhesus monkeys received treosulfan i.v. (56, 111, 222 or 445 mg/kg) or p.o. (56, 111, 222, 445, 890 or  1779  mg/kg)  once  daily  for  6  to  19  consecutive  days.  Duration  of  treatment  was  dependent  on survival.  Starting  at  222  mg/kg/day  of  i.v.  treatment,  the  monkeys  showed  signs  of  intolerability including a symptom described as CNS-depression, malaise, emesis, severe diarrhoea, anorexia, and collapse of peripheral circulation. These animals died on Day 8 to Day 13. Monkeys in all dose groups developed reticulocytopenia, leukopenia, and bone marrow depression. Weight loss and lymphopenia were observed in all animals starting at 111 mg/kg. Haemoconcentration was seen after 222 and 445 mg/kg/day. At necropsy, decrease in cellularity of bone marrow (all groups), atrophy of spleen and lymph  nodes  (at  111  mg/kg/day  and  above),  and  haemorrhagic  lesions,  especially  in  the  gastrointestinal tract, were noted (LEO, 1978b). Monkeys dosed with 111 or 222 mg/kg/day were sacrificed in moribund condition on Days 18 and 13, respectively. Monkeys dosed with 445 mg/kg/day or higher died on Days 6 to 10. Animals in all dose groups developed reticulocytopenia, leukopenia, lymphopenia, and bone marrow depression. At 222 mg/kg/day or higher, haemoconcentration was noted. Higher doses induced atrophy of lymph nodes and haemorrhages in the adrenal cortex, bladder mucosa and lung (LEO, 1978b).

A NOAEL was not established in the monkey studies. The MTD based on lethality was 111 mg/kg/day for the i.v. route (LEO, 1978b).

## Genotoxicity

Transformation of treosulfan to the reactive epoxides EBDM and DEB is a prerequisite for the genotoxic properties of treosulfan. Due to the presence of two versus one nucleophilic centres, reactions of DEB with DNA is much more efficient compared to EBDM (Gherezghiher et al., 2013; Hartley et al., 1999; Michaelson-Richie et al., 2010; Millard et al., 2006; Park et al., 2005).

Treosulfan up to the 3160 μg per plate was tested with and without metabolic activation in the Ames reverse mutation test, using four Salmonella typhimurium strains TA98, TA100, TA1535 and TA1537 and in  one Escherichia  coli strain  WP2  uvrA.  Treosulfan  caused  with  and  without  metabolic  activation  a concentration-related base-pair substitution mutagenic effect in the S. typhimurium strains TA100 and TA1535 (Provivo 38665, 2022). These results are supported by literature, where, treosulfan and DEB showed a pH-dependent spectrum of mutagenic responses in the Ames test ( S. typhimurium strains TA100, TA102, TA1535, TA7004, TA7005; Abu-Shakra et al., 2000; Zeiger and Pagano, 1989). Both compounds were mutagenic at the gpt locus in Chinese hamster ovary cells (Zhu and Zeiger, 1993).

A  potential  to  induce  sister  chromatid  exchanges  in  human  lymphocytes  was  demonstrated  with treosulfan in vitro (Clare et al., 1982).

In an in vitro cytogenetic study using human lymphocyte cultures treosulfan tested up to 50 μg/ml revealed mutagenic properties with respect to chromosomal or chromatid damage in the absence as well as presence of metabolic activation (Provivo 38666, 2022). The results are in accordance with literature data, where induction of micronuclei or chromosomal aberrations in bone marrow cells of mice was shown for treosulfan doses of 250 to 1000 mg/kg administered i.p. Similarily, DEB gave a positive

<div style=\"page-break-after: always\"></div>

response in the bone marrow micronucleus test and dominant lethal test (effect on implantation rate) in mice treated i.p. with of 36 mg/kg (Adler et al., 1997; Shelby et al., 1989).

## Carcinogenicity

According to the ICH S9 and ICH S1A guidelines unequivocally genotoxic compounds implying a hazard to humans are not to be subjected to long-term carcinogenicity studies (ICH guidelines). Therefore, specific carcinogenicity studies in animals were not performed with treosulfan.

## Reproduction toxicity

According to the ICH guideline S9 on nonclinical evaluation for anticancer pharmaceuticals, reproductive and developmental toxicity studies are not considered essential for pharmaceuticals that are genotoxic, target rapidly dividing cells in general toxicity studies (e.g., crypt cells, bone marrow), or in case they belong  to  a  class  that  has  been  well  characterized  as  causing  developmental  toxicity.  All  of  these conditions apply to treosulfan. Therefore, no dedicated reproductive and developmental toxicity studies for treosulfan addressing the fertility, early embryonic or embryo-fetal, pre- and postnatal development including maternal function were conducted.

Nevertheless, subchronic toxicity of treosulfan was investigated in juvenile and young adult rats. The effect of intravenously administered treosulfan on development of juvenile rats was investigated in a more recent GLP-compliant subchronic study with juvenile Sprague-Dawley rats. Ten animals per sex were treated i.v. with daily doses of 10, 50 or 100 mg/kg of treosulfan from PND 10 to 35. Body weights of  high-dose  males  and  females  were  markedly  reduced.  Haematological  changes  included  reduced numbers of leucocytes and neutrophile granulocytes in all dose groups. Urinalysis, ophthalmological examination,  auditory  examination,  and  macroscopic  post  mortem  findings  revealed  no  effects attributable to treosulfan treatment. Relative to body weight, weights of gonads, prostate, spleen, and thymus were reduced in high dosed rats and a slightly delayed time-point of vaginal opening was noted for the high dosed female animals. After a 5-week post-treatment observation period, only a slightly decreased body weight and the correlating reduced organ weights in high dosed males indicated a slight delay of physical development. Ten of 60 satellite animals of a 250 mg/kg/day dose group dedicated for pharmacokinetic investigations died prematurely on PND 19 to 30. The cause of death was not further examined. Most likely, a combined effect of treosulfan toxicity and weakening by frequent blood drawings resulted in a moribund state of the young adult rats (LPT 26054, 2011).

Studies with the transformation product DEB in mice and rats confirmed the potential of treosulfan to affect uterine-ovarian development and implantation as well as sperm development.

In pregnant rats, DEB reduced foetal growth and viability and induced implantation losses and foetal resorption  (Chi  et  al.,  2002;  Doerr  et  al.,  1996;  Marchetti  and  Wyrobek,  2008).  DEB  also  induced depletion  of  spermatids,  reduction  of  the  secondary  spermatocyte  layers,  and  altered  chromatin packaging in sperms of mice treated with a single i.p. dose of up to 78 mg/kg and followed up for up to 4 weeks (Spanò et al., 1996).

In another study with i.p. doses of up to 85 mg/kg on Day 1, 3, and 5, DEB induced signs of male reproductive toxicity including abnormal forms of sperms, reduced sperm motility, and accumulation of testicular cells in the G2/M phase. In a mouse premeiotic spermatocyte-derived cell line, DEB induced signs of genotoxic effects after incubation with 100 to 500 μM DEB (Dong et al., 2015).

Considering the substance class as well as the mode of action, treosulfan must be assumed a drug possessing all aspects of reproductive and developmental toxicity.

<div style=\"page-break-after: always\"></div>

## Toxicokinetic data

Three dedicated GLP compliant toxicokinetic studies in rats were performed using i.v. administration of treosulfan. One study was conducted as part of a 4-week toxicity study in adult rats (LPT 37259, 2020), a  second  one  in  juvenile  rats  treated  from  PND  10  to  35  (LPT  26054,  2011).  The  third  study  was performed as single-dose toxicity study in juvenile and young adult rats (LPT 27700, 2014). For results of  toxicokinetic  evaluations  of  treosulfan  after  single  dose  and  repeat-dose  treatment  refer  to  CTD Section 2.4.4 and 2.6.5.3.2 and 2.6.5.4. These data reveal a linear dose relationship with AUC in adult rats.  Accordingly,  toxicity  findings  including  laboratory  and  histopathological  changes  are  exposure related.

## Local tolerance

Intraarterial  or  perivenous  administration of a clinical-grade formulation of treosulfan to the ears of rabbits  were  tolerated  without  signs  of  local  lesions.  No  remarkable  local  findings  were  reported regarding the injection sites in the animal studies with i.v. or i.p. administration (LEO, 1985).

## Other toxicity studies

## Photosafety

No  nonclinical  photosafety  studies  were  performed  because  treosulfan  exhibits  no  significant  light absorption at wave lengths in the range of 290 nm to 700 nm.

## Antigenicity

Antigenicity has not been described for treosulfan.

## Immunogenicity

No formal non-clinical immunogenicity studies have been conducted.

## Dependence

Dependence on treosulfan has not been studied, and there is no evidence of treosulfan dependence. But given the indications for treatment with treosulfan as conditioning regimen prior to HSCT, the mode of action and the adverse drug reactions of treosulfan, dependence and abuse can be ruled out.

## Studies on Metabolites

Studies with the treosulfan metabolite DEB confirmed the expected cytotoxicity and genotoxicity in vitro and  in  vivo.  Furthermore,  effects  of  DEB  on  male  and  female  reproductive  organs  and  functions corroborate that the alkylating activity of the treosulfan related epoxides are responsible for both the pharmacodynamic activity and toxicities including mutagenicity, carcinogenicity and reproductive and developmental toxicity.

## Maximum Tolerated Doses (MTD) and Systemic Exposure in Animals versus Humans

The  maximum  tolerated  dose  (MTD)  regarding  severe  toxicity  including  lethality  after  single  dose treosulfan  administration  in  mouse  and  rats  was  about  10,000  and  15,000  mg/m 2 ,  respectively. Repeated,  subchronic  intravenous  administration  to  rats  was  tested  up  to  a  maximum  dose  of  150 mg/kg/day, corresponding to 900 mg/m 2 /day, only. In dogs and monkeys 111 mg/kg/day were tolerated when treated i.v. over a period of 10 to 14 and 8 to 19 days. In the Table below 2.4-4, the corresponding

<div style=\"page-break-after: always\"></div>

animal doses in terms of mg/m 2  body surface area (BSA) are compared with the MTD in adult patients of 12.5 mg/m 2  (single dose without subsequent HSCT; refer to Harstrick et al., 1996). For conversion of dose in mg/kg body weight to dose in mg/m 2  body surface area standard factors according to FDA guidance were used (FDA, 2005).

Apparently much higher doses are tolerated by humans than by animal species. However, in case the treosulfan  MTD  of  47  g/m²  of  human  exposure  is  considered  with  subsequent  HSCT  the  ratio  MTD animal/human is about 0.2.

Table 2.4-4: Comparison of the Maximum Tolerated Dose (MTD) for treosulfan in toxicology studies and in humans

| Species and exposureconditions                      | MTD (mg/kg/day)   | MTD (mg/m²/day) a   | MTD animal/ human   |
|-----------------------------------------------------|-------------------|---------------------|---------------------|
| Mouse Leo strain II (single dose, i.v., p.o.,s.c )a | >3.500            | > 10,500            | 0.84                |
| Mouse Charles River CDI (single dose, p.o.) b       | 3,360 d           | 10,080 d            | 0.81                |
| Mouse Charles River CDI (single dose, i.v.)         | >2,500            | >7,500              | 0.60                |
| Rat Wistar (single dose p.o.)*                      | 2575 d            | 15,450 d            | 1.24                |
| Rat Wistar (single dose i.p.)*                      | 2860 d            | 17,160 d            | 1.37                |
| Rat Holzman (5 days, i.p.)                          | 1113 /1364 d      | 6,678 / 8,184 d     | 0.53 /0.65          |
| Rat Fischer (5 days, i.p.)                          | 278 / 696 d       | 1668 / 4,176 d.     | 0.13/ 0.33          |
| Rat (28 days, i.v.)                                 | 150 e             | :006                | 0.07                |
| Dog (10-14 days, i.v. bolus)                        | 111               | 2220                | 0.18                |
| Monkey (8-19 days, i.v. bolus)                      | 111               | 1332                | 0.17                |
| Human (adult, single dose, i.v. 2 h infusion) f     |                   | 12500               |                     |
| Mouse (single dose, i.p., prior to HSCT) 8          | 3000              | 9,000               | 0.19                |
| Mouse (3 days, i.p., prior to HSCT) 8               | 2500              | 7,500               | 0.16                |
| Human (adult, single dose, i.v., prior to HSCT) h   |                   | 47000               |                     |

The maximum tolerated single dose of i.v. applied treosulfan in humans is 12.5 g/m 2 . When overcoming this pronounced haematotoxicity of higher doses by HSCT, the treosulfan dose can be increased 4- to 5-fold to a MTD of 47 g/m2. Considering the proposed indication of treosulfan 'conditioning prior to HSCT' which is characterised by the administration of an otherwise lethal treosulfan dose, the assessment of a usual safety margin might be somewhat misleading.

## 2.2.5. Ecotoxicity/environmental risk assessment

An ERA report was prepared in accordance with the Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use, EMEA/CHMP/SWP/4447/00 corr 2, 2006 and Questions and answers document on the Guideline, EMA/CHMP/SWP/44609/2010 Rev.1, 2016.

A Phase I ERA has been provided for the extension of indication to include additional non-malignant transplant indications (non-malignant diseases in the paediatric population) for Trecondi 1 g/5 g powder for solution for infusion.

1.  The  Phase  I  of  the  environmental  risk  assessment  requires  the  calculation  of  the  predicted environmental concentration of treosulfan in surface water. For PEC calculation, the MAH referred to

<div style=\"page-break-after: always\"></div>

the formulas given in the guidelines EMEA/CHMP/SWP/4447/00 corr 2, 2006 and EMA/CHMP/SWP/44609/2010 Rev.1, 2016.

Fpen and PECsurfacewater refined values, in line with the Guidelines are endorsed.

Since PECsurfacewater of 0.003 µg/L is evidently below the action limit of 0.01 µg/L, the environmental risk assessment can stop in Phase I, in agreement with EMA Guideline EMEA/CHMP/SWP/4447/00 corr 2, 2006.

2.  Experimental log Kow values for treosulfan and its epoxides, of -1.58, -1.18 and -0.40, were far below the trigger value of 4.5, for further screening of persistence, bioaccumulation and toxicity (PBT).  Log Kow values were experimentally determined using the shake-flask method (OCDE 107), according to EMA/CHMP/SWP/44609/2010 Rev. 1, 2016, and the original study was provided by the MAH (Glówka, Romanski and Siemiatkowska, 2013). Thus, no formal PBT assessment is required.

According  to  EMA  guidelines,  if  the  PECsurfacewater  value  is  below  0.01  μg/L,  and  no  other environmental concerns are apparent, it is assumed that the medicinal product is unlikely to represent a  risk  for  the  environment  following  its  prescribed  usage.  Furthermore,  the  octanol-water  partition coefficient (log Kow) far below 4.5 indicating that the risk of bioaccumulation in aquatic organisms is low. Phase II ERA is deemed not necessary, in agreement with EMA Guideline.

In summary, Trecondi 1 g/5 g powder for solution for infusion is not predicted to present a risk to the environment, following its prescribed usage.

3. The precautionary and safety measures taken to reduce any risk to the environment on the SmPC and PL have been applied and are considerable acceptable.

## 2.2.6. Discussion on non-clinical aspects

## Pharmacology

Treosulfan  has  known  cytotoxic,  myeloablative  and  immunesuppressive  effects  whichconstitute  the mechanism  of  action  of  this  prodrug  supporting  the  approved  and  the  extended  indication,  i.e. conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT).

Under physiological conditions, treosulfan is converted to reactive intermediates which alkylate DNA and create inter-strand cross-links besides affecting also other biological molecules and structures involved in  various  physiological  functions.  Its  myeloablative  and  immunosuppressive  effects  were  shown  in various in vitro and in vivo models with treosulfan alone or combined with other conditioning regimens such as fludarabine or cyclophosphamide, total body (thymus in particular) irradiation (TBI) or anti-T cell antibodies. The clinical development of treosulfan-based conditioning, however, is focused on the combination with fludarabine for additional pre-transplant immunosuppression.

Treosulfan has a high potential to eliminate a broad range of haematopoietic progenitor cell subsets when administered in repeat-dose treatment regimens, which facilitates the induction of high levels of engraftment and donor-type chimerism after allogeneic HSCT. It also exhibits a strong immunosuppressive potential which is required to suppress acute recipient mediated allograft rejection.

From  the  information  provided  the  conclusion  that  the  safety  pharmacology  studies  on  treosulfan provided no evidence of clinically relevant adverse effects is supported.

## Pharmacokinetics

<div style=\"page-break-after: always\"></div>

Appropriate analytical methods were developed and validated for the detection of treosulfan and its transformation products EBDM and DEB in aqueous solutions, biological fluids and tissues. As treosulfan does not undergo conjugation with GSH, it prevents interpatient variability of drug clearance due to GST activity,  GSH  depletion,  and  interactions  or  competition  with  GSH  conjugated  drugs.  Nevertheles, metabolic phenotyping identified treosulfan as a substrate of CYP2D6, and in vitro and ex-vivo studies did not exclude a potential DDI between treosulfan and CYP3A4 and CYP2C19 substrates; this cautionary wording is already included in PI and was not changed in the scope of this variation.

Treosulfan  and  its  active  metabolites  were  rapidly  metabolised  and  eliminated,  mainly  via  renal excretion. The kinetics of biotransformation is strongly dependent on the pH which is highly regulated in the in vivo system. No relevant sex differences have been observed and there is no indication for an accumulation in blood or any tissues after repeated exposure. The predominant distribution of treosulfan in primary lymphatic organs probably facilitates its myeloablative potential.

## Toxicology

Toxicity studies revealed occasional gastro-intestinal effects including emesis and diarrhoea as well as haematuria  and  lymphohistiocytic  infiltration  in  the  skeletal  muscle.  However,  exposure  of  different animal species to treosulfan did not reveal dose-limiting functional or structural changes regarding liver, kidneys, the cardiovascular, respiratory, or central nervous system. Some of these observations are also reflected in the list of adverse reactions included in the SmPC for both adult and paediatric population.

Overall, systemic toxicity upon treosulfan administration seems to be similar among the animal species employed in the nonclinical toxicological program and is independent of the route of administration. The observed  haematotoxic  and  immunotoxic  effects  of  treosulfan,  at  least,  should  be  overcome  after subsequent HSCT as well known from clinical experience.

Treosulfan, as other alkylating drugs, is mutagenic and provides a carcinogenic potential in animals and humans. Accordingly, a warning of the risk of secondary malignancies after treatment with treosulfan is already included in the approved SmPC and was not changed in the scope of this variation.

## Ecotoxicity/environmental risk assessment

The MAH submitted an ERA Phase I arising from the use of Trecondi 1g/5g powder for solution for infusion, according to on the guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00, June 2006) and the Questions and Answers on Guideline on the environmental risk assessment of medicinal products for human use (EMA/CHMP/SWP/44609/2010 Rev. 1, 2016).

Fpen has been refined based on prevalence data, and the PECsurfacewater value of 0.003 µg/L is far below the action limit of 0.01 µg/l.  Regarding screening on persistence, bioaccumulation and toxicity, the provided experimental log Kow values for treosulfan and its epoxides, of -1.58, -1.18 and -0.40, are far below the trigger value of 4.5. Thus, there is no need for further assessment of potential persistence, bioaccumulation and toxicity (PBT).

The provided data are acceptable and the risk assessment stopped in Phase I of the procedure. Trecondi 1g/5g powder for solution for infusion, following its prescribed usage, is unlikely to represent a risk for the environment.

The precautionary and safety measures taken to reduce any risk to the environment on the SmPC and PL have been applied.

<div style=\"page-break-after: always\"></div>

## Assessment of paediatric data on non-clinical aspects

Histopathological examinations on juvenile or adult rats revealed no necrotic or inflammatory lesions in the liver, kidneys, heart, lungs or adrenals. Complete reversibility of haematological effects and delay of post-natal development was demonstrated in the study in juvenile rats with only a slight delay of the physical development.

Minor signs of toxicity were noted in the subchronic toxicity study when juvenile rats were treated with a maximum intravenous dose of 100 mg/kg/day. A slightly decreased ALAT plasma activity (-20% to 30%) is considered toxicologically not relevant in the absence of evidence for corresponding signs of organ dysfunctions or morphological tissue lesions.

Functional differences of maturing BBB, which results in a higher permeability of BBB in juvenile animals compared to adults, induced a higher ratio of treosulfan concentrations in brain versus plasma in juvenile animals. However, penetration of BBB is overall at a low level in both juvenile as well as adult rats. This finding is consistent with the comparably low frequency of clinical observations on CNS-related toxicities. In juvenile rats, treosulfan plasma half-life was slightly prolonged and the exposure is higher compared to young adults when dosed intravenously on a mg/kg body weight calculation. This information is already included in the approved PI and was not changed in the scope of this variation. Moreover, the clinical relevance of this finding is adequately addressed by the established BSA related dose calculation for treosulfan in children, which based on PK data was updated in PI.

## 2.2.7. Conclusion on the non-clinical aspects

The nonclinical safety, efficacy and pharmacokinetic data provided for treosulfan is considered adequate to  support  the  application  for  the  extension  of  the  indication  to  conditioning  treatment  prior  to haematopoietic  progenitor  cell  transplantation  in  paediatric  patients  with  non-malignant  diseases. Relevant information is already reflected in the current SmPC and no changes have been introduced within this variation.

Based on the updated data submitted in this application, the extended indication, to include additional non-malignant transplant indications (non-malignant diseases in the paediatric population), for Trecondi 1 g/5 g powder for solution for infusion does not lead to a significant increase in environmental exposure further to the use of treosulfan. Treosulfan should be used according to the precautions stated in the SmPC in order to minimize any potential risks to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

In the scope of this variation application the MAH intends to extent the indication to include additional non-malignant transplant indications (non-malignant diseases in the paediatric population) for Trecondi 1 g/5 g powder for solution for infusion based on final 12-months follow-up results of the study MCFludT.16/NM;  a  randomised  phase  II  interventional  study  aimed  to  compare  Treosulfan-based conditioning  therapy  with  Busulfan-based  conditioning  prior  to  allogeneic  haematopoietic  stem  cell transplantation in paediatric patients with non-malignant diseases.

<div style=\"page-break-after: always\"></div>

Further, the MAH proposes to amend an existing warning on skin toxicity based on new literature data. In  a  recent  publication  from  Even-Or  et  al.  2020  1   regarding  skin  toxicities  (e.g.  rash,  dermatitis) following  TREO-thiotepa-FLU-based  conditioning  regimen  in  non-malignant  paediatric  patients,  an increase of skin disorders was observed when patients received sodium bicarbonate-containing hydration in the course of TREO infusion. The MAH postulated that this effect could be due to the acceleration of the pH-dependent formation of alkylating epoxides. The effect may be prevented by keeping the skin clean and dry on days of treosulfan infusion. Therefore, the MAH suggested to include this information in medac's SmPC as follows:

| Currenttext      | Proposedtext                                                                                                                                                                                                                                                                          |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Dermatitisdiaper | Dermatitis diaperSkindisorders                                                                                                                                                                                                                                                        |
|                  | Anincreaseofskindisorders(e.g.rash dermatitis)wasobservedwhenpatients receivedsodiumbicarbonate-containing hydrationinthecourseoftreosulfaninfusion, potentiallybecauseofaccelerationofthepH- dependentformationofalkylatingepoxides. Keepskincleananddryondaysoftreosulfan infusion. |

Moreover, the MAH proposes to introduce a slightly modified dosing regimen according to the patient's body surface based on long-term follow-up data of paediatric study MC-FludT.17/M ; a Phase II trial to  describe  the  safety  and  efficacy  of  Treosulfan  based  conditioning  therapy  prior  to  allogeneic haematopoietic stem cell transplantation in paediatric patients with haematological malignancies, as well as  a  final  analysis  of  the  population  pharmacokinetics  of  Treosulfan  in  paediatric  patients.  As  a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are proposed to be updated.

Treosulfan (TREO) is an analogue of busulfan (BU) differing by two additional hydroxyl groups in positions 2 and 3. These two additional hydroxyl groups confer water-soluble properties allowing TREO dissolution in aqueous media in the contrary to BU. Though resembling BU in chemical formula, there are a number of important differences. In contrast to BU, which directly ('primarily') alkylates thiols, TREO has to be converted  non-enzymatically,  but  pH-dependent  to  alkylating  monoepoxide  intermediates  and  Ldiepoxybutane, which are considered responsible for the alkylating and cytotoxic effects [Fennelly 1979].

Treosulfan is a bifunctional alkylating agent which has been shown to possess antineoplastic activity in the animal tumour screen and in clinical trials. Since many years the clinical usefulness of TREO in the treatment of ovarian cancer has been proved within several Phase II and Phase III studies.

Currently,  TREO  is  approved  in  several  European  countries  (DE,  DK,  IE,  NL,  UK)  for  the  palliative treatment of epithelial ovarian cancer. It is available as powder for solution for injection or infusion as well as capsules for oral use. The usual intravenous (IV) dose in this indication is 8 g/m2 given every 34 weeks if used as a single agent and 5 g/m2 if combined with cisplatin.

Furthermore, TREO has been tested in phase II trials for several other tumour types, including small cell lung cancer, breast cancer, malignant melanoma, and as a stem cell toxic agent within a conditioning regimen before autologous or allogeneic haematopoietic stem cell transplantation.

On  20  June  2019,  TREO  (trade  name  Trecondi®)  was  approved  in  the  European  Union  for  the conditioning  treatment  prior  to  allogeneic  haematopoietic  stem  cell  transplantation  (alloHSCT).  In Switzerland, Trecondi® was approved on 10 August 2020. In Canada, TREO (trade name Trecondyv®) was approved on July 28, 2021.

Treosulfan  is  indicated  as  part  of  conditioning  treatment  prior  to  alloHSCT  in  malignant  and  nonmalignant diseases in adults up to the age of 70 years and paediatric patients older than one month in non-malignant diseases. HSCT  involves the intravenous infusion of autologous or allogeneic haematopoietic stem cells (HSCs) collected from bone marrow, peripheral blood, or umbilical cord blood

<div style=\"page-break-after: always\"></div>

to re-establish haematopoietic function in patients with damaged or defective bone marrow or immune system. This procedure is often performed as part of therapy to eliminate a bone marrow infiltrative process such as leukaemia, or to correct congenital immunodeficiency disorders. In addition, HSCT is used to allow patients with cancer to receive higher doses of chemotherapy than bone marrow can usually  tolerate;  bone  marrow  function  is  then  salvaged  by  replacing  the  marrow  with  previously harvested HSCs (autoHSCT). Allogeneic HSCT can be a curative option for some malignant conditions, bone marrow failure, hereditary metabolic disorders, and severe congenital immunodeficiencies that would otherwise have been fatal.

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH

## · Tabular overview of clinical studies

Table 1: Tabular listings of all clinical studies

| CTD Section   | Type of study                                                     | Study code/ Reference                                             | Study title                                                                                                                                                                                                                                                                                                                                 | Report location                                                   |
|---------------|-------------------------------------------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| 5.3.1         | Reports of Biopharmaceutic Studies                                | Reports of Biopharmaceutic Studies                                | Reports of Biopharmaceutic Studies                                                                                                                                                                                                                                                                                                          | Reports of Biopharmaceutic Studies                                |
| 5.3.1.1       | Bioavailability (BA) Study Reports                                |                                                                   |                                                                                                                                                                                                                                                                                                                                             |                                                                   |
| 5.3.1.2       | Comparative BA and Bioequivalence (BE) Study Reports              |                                                                   |                                                                                                                                                                                                                                                                                                                                             |                                                                   |
| 5.3.1.3       | In vitro-InvivoCorrelation Study Reports                          |                                                                   |                                                                                                                                                                                                                                                                                                                                             |                                                                   |
| 5.3.1.4       | Reports of Bioanalytical and Analytical Methods for Human Studies | CRS Study No.: 106/09-05.TN                                       | Validation of a chromatographic method for determination of the concentrations of treosulfan in human plasma and in human urine Part I: Assay validation (plus amendment to this report) Determination of the concentrations of treosulfan in human plasma and in human urine of the clinical study MC-FludT.14/L Part II: Routine analysis | 5.3.1.4                                                           |
| 5.3.1.4       | Reports of Bioanalytical and Analytical Methods for Human Studies | Celerion Study No.: CA12939                                       | Validationof anLC-MS/MSMethodfor theDetermination of Treosulfan anditsMonoepoxide Metabolite in Diluted HumanPlasma (Citrate) [26-Mar-2015]                                                                                                                                                                                                 | 5.3.1.4                                                           |
| 5.3.1.4       | Reports of Bioanalytical and Analytical Methods for Human Studies | Celerion Study No.: CA13526                                       | Validation ofanLC-MS/MSMethodfor theDeterminationofTreosulfanDiepoxideinDiluted HumanPlasma(Citrate)[09-Nov-2016]                                                                                                                                                                                                                           | 5.3.1.4                                                           |
| 5.3.2.        | ReportsofStudiesPertinenttoPharmacokineticsusingHumanBiomaterials | ReportsofStudiesPertinenttoPharmacokineticsusingHumanBiomaterials | ReportsofStudiesPertinenttoPharmacokineticsusingHumanBiomaterials                                                                                                                                                                                                                                                                           | ReportsofStudiesPertinenttoPharmacokineticsusingHumanBiomaterials |
| 5.3.2.1       | Plasma ProteinBinding Study Reports                               | Schwarzner2017                                                    | Determination of the binding properties of treosulfan tohuman serum albumin by microscale thermophoresis.                                                                                                                                                                                                                                   | 5.3.2.1                                                           |
| CTD Section   | Type of study                                                     | Study code / Reference                                            | Study title                                                                                                                                                                                                                                                                                                                                 | Report location                                                   |
|               |                                                                   | Feit et al. 1970                                                  | Feit PW, Rastrup-Andersen N, Matagne R. Studies on epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. The preparation and biological activity of (2S,3S)-1,2-epoxy-3,4- butanediol4-methanesulfonate.J Med Chem.1970 Nov;13(6):1173-5.PMID: 547985                                                                            | 5.4                                                               |
| 5.3.2.2       | Reports of Hepatic Metabolism and Drug Interaction Studies        | BioDynamics study no: MDC/02 (Cole 2003)                          | Treosulfan:Investigationof thepotential toinhibit humanCYP450-mediatedmetabolismin vitro                                                                                                                                                                                                                                                    | 4.2.2.4                                                           |
| 5.3.2.3       | Reports of Studies Using OtherHumanBiomaterials                   | Bath Analytical Report No. 94.23 (Bosanquet 1994)                 | Efficacy of treosulfan against freshhuman tumour cells invitro                                                                                                                                                                                                                                                                              | 4.2.1.2                                                           |
|               |                                                                   | Meinhardt 2003                                                    | Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cellsfrom patients                                                                                                                                                                                                                               | 5.4                                                               |
|               |                                                                   | Lanvers- Kaminsky 2006                                            | Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines                                                                                                                                                                                                                                                                       | 5.4                                                               |
|               |                                                                   | Ristovska 2009                                                    | Apoptosis inductionby treosulfanissuperior tobusulfaninrisk-defined humanCLLcells                                                                                                                                                                                                                                                           | 5.4                                                               |
|               |                                                                   | Schmidmaier 2004                                                  | Treosulfan-induced apoptosis in acute myeloidleukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1                                                                                                                                                                                          | 5.4                                                               |
|               |                                                                   | Nitsch 2014                                                       | Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines                                                                                                                                                                                                                                                | 5.4                                                               |
|               |                                                                   | Linz 2014                                                         | Can in-vitro chemoresponse assays help find new treatment regimens for malignant gliomas?                                                                                                                                                                                                                                                   | 5.4                                                               |
|               |                                                                   | Munkelt 2008                                                      | Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients                                                                                                                                                                                                                                                   | 5.4                                                               |
|               |                                                                   | Kopadze 2007                                                      | Treosulfanimpedesthemigrationofimmunocompetentcells.                                                                                                                                                                                                                                                                                        | 5.4                                                               |

<div style=\"page-break-after: always\"></div>

| CTD Section   | Type of study                                                        | Study code / Reference                   | Study title                                                                                                                                                                                                                                                          | Report location                          |
|---------------|----------------------------------------------------------------------|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| CTD Section   | Type of study                                                        | Glowka 2012                              | HPLC method for determination of biologically active epoxy-transformers of treosulfan in human plasma                                                                                                                                                                | 5.4                                      |
| 5.3.3         | ReportsofHumanPharmacokinetic(PK)Studies                             | ReportsofHumanPharmacokinetic(PK)Studies | ReportsofHumanPharmacokinetic(PK)Studies                                                                                                                                                                                                                             | ReportsofHumanPharmacokinetic(PK)Studies |
| 5.3.3.1       | Healthy Subject PK and Initial Tolerability Study Reports            |                                          |                                                                                                                                                                                                                                                                      |                                          |
| 5.3.3.2       | Patient PK and Initial Tolerability Study Reports                    | PK-substudy of MC-FludT.14/L Trial I     | Pharmacokinetic sub-study for patients randomised into the test arm\"treosulfan-based conditioning\"ofstudyMC-FludT.14/L                                                                                                                                               | 5.3.3.2                                  |
| 5.3.3.2       | Patient PK and Initial Tolerability Study Reports                    | Beelen 2005                              | Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimenfor allogeneic haematopoieticstem cell transplantationin patientswith anincreased risk forregimen-related complications.                                                 | 5.4                                      |
| 5.3.3.2       | Patient PK and Initial Tolerability Study Reports                    | Hilger 1998                              | Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors.                                                                                                                                                                          | 5.4                                      |
| 5.3.3.2       | Patient PK and Initial Tolerability Study Reports                    | Nemecek 2011                             | Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.                                                                                                                       | 5.4                                      |
| 5.3.3.2       | Patient PK and Initial Tolerability Study Reports                    | Scheulen 2000                            | Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.                                                               | 5.4                                      |
| 5.3.3.2       | Patient PK and Initial Tolerability Study Reports                    | Glowka 2008                              | Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparativeregimen for allogeneichaematopoieticSCT.                                                                                                                            | 5.4                                      |
| 5.3.3.2       | Patient PK and Initial Tolerability Study Reports                    | Glowka 2015                              | Pharmacokinetics of treosulfan and its active monoepoxide in pediatric patients after intravenous infusion of high-dose treosulfan prior to HSCT.                                                                                                                    | 5.4                                      |
| CTD Section   | Type of study                                                        | Study code / Reference                   | Study title                                                                                                                                                                                                                                                          | Report location                          |
| CTD Section   | Type of study                                                        | Koyyalamudi 2016                         | Development and Validation of a High Pressure Liquid Chromatography-UV Method for the Determination of Treosulfan andIts EpoxyMetabolites in HumanPlasma and Its Application in PharmacokineticStudies.                                                              | 5.4                                      |
| CTD Section   | Type of study                                                        | Ten Brink 2014                           | Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation.                                                                                                                                                             | 5.4                                      |
| 5.3.3.3       | IntrinsicFactorPKStudy Reports                                       | Kinesis Reference CD140025               | Non-compartmental analysisof treosulfan andmonoepoxideinpaediatricpatientsbased on studies FludT.16/NM and FludT.17/M (pharmacokinetic analysis). Clinical pharmacokinetic interim reportVersion1.0dated 09Jun2017.                                                  | 5.3.3.3                                  |
| 5.3.3.3       | IntrinsicFactorPKStudy Reports                                       | VennLife Sciences Report CD140025        | Non-compartmental analysis of Treosulfan and monoepoxide in paediatric patients based on studies MC-FludT.16/NM and MC-FludT.17/M (pharmacokinetic analysis). [21-Apr-2020]                                                                                          | 5.3.3.3                                  |
| 5.3.3.4       | Extrinsic Factor PK Study Reports                                    |                                          |                                                                                                                                                                                                                                                                      |                                          |
| 5.3.3.5       | Population PK Study Reports                                          | Kinesis 2011                             | Kinesis.Population PK modelling of treosulfan: a covariate analysis. Version 1.0 dated 30-12- 2011.                                                                                                                                                                  | 5.3.3.5                                  |
| 5.3.3.5       | Population PK Study Reports                                          | Kinesis 2012                             | Addendum I to “Population PK modelling of treosulfan: a covariate analysis. Version 1.0 dated 30-12-2011\".Version 2.0dated14-09-2012.                                                                                                                                | 5.3.3.5                                  |
| 5.3.3.5       | Population PK Study Reports                                          | Kinesis 2017                             | Kinesis. Population pharmacokinetic modelling of treosulfan in paediatric patients - Interim analysis report. Version 1.0 dated 12-June-2017.                                                                                                                        | 5.3.3.5                                  |
| 5.3.3.5       | Population PK Study Reports                                          | Venn Life Sciences Report CD140025       | PopulationPharmacokinetic Modelling of Treosulfan in PaediatricPatients -Final Analysis Report.[02-Apr-2020]                                                                                                                                                         | 5.3.3.5                                  |
| 5.3.4         | ReportsofHumanPharmacodynamic(PD)Studies                             | ReportsofHumanPharmacodynamic(PD)Studies | ReportsofHumanPharmacodynamic(PD)Studies                                                                                                                                                                                                                             | ReportsofHumanPharmacodynamic(PD)Studies |
| CTD Section   | Type of study                                                        | Study code / Reference                   | Study title                                                                                                                                                                                                                                                          | Report location                          |
| 5.3.4.1       | Healthy Subject PD and PK/PD Study Reports                           |                                          |                                                                                                                                                                                                                                                                      |                                          |
| 5.3.4.2       | Patient PD and PK/PD Study Reports                                   | MC-FludT.14/L                            | [PD: For study titles please refer to CTD section 5.3.5.1 and 5.3.5.2.]                                                                                                                                                                                              | 5.3.5.1                                  |
| 5.3.4.2       | Patient PD and PK/PD Study Reports                                   | MC-FludT.6 /L                            | [PD: For study titles please refer to CTD section 5.3.5.1 and 5.3.5.2.]                                                                                                                                                                                              | 5.3.5.2                                  |
| 5.3.4.2       | Patient PD and PK/PD Study Reports                                   | MC-FludT.7 /AML MC-FludT.8 /MDS          | [PD: For study titles please refer to CTD section 5.3.5.1 and 5.3.5.2.]                                                                                                                                                                                              | 5.3.5.2 5.3.5.2                          |
| 5.3.4.2       | Patient PD and PK/PD Study Reports                                   | MC- FludT.16/NM                          | [PD: For study titles please refer to CTD section 5.3.5.1 and 5.3.5.2.]                                                                                                                                                                                              | 5.3.5.2                                  |
| 5.3.4.2       | Patient PD and PK/PD Study Reports                                   | MC-FludT.17/M                            | [PD: For study titles please refer to CTD section 5.3.5.1 and 5.3.5.2.]                                                                                                                                                                                              | 5.3.5.2                                  |
| 5.3.4.2       | Patient PD and PK/PD Study Reports                                   | MC-FludT.6 /L                            | [PK/PD:For study title please refer toCTDsection5.3.5.2.]                                                                                                                                                                                                            | 5.3.5.2                                  |
| 5.3.5         | Reports ofEfficacy andSafetyStudies                                  | Reports ofEfficacy andSafetyStudies      | Reports ofEfficacy andSafetyStudies                                                                                                                                                                                                                                  | Reports ofEfficacy andSafetyStudies      |
| 5.3.5.1       | Study Reports of Controlled ClinicalStudies Pertinent to the Claimed | MC-FludT.14/L TrialI                     | Clinical phase III trial to compare TREO-based conditioning therapy with busulfan-based reduced intensity conditioning prior to alloHSCT in patients with AML or MDS considered ineligible to standard conditioning regimens [TREO regimen: 14 g/m2/d; day -6 to -4] | 5.3.5.1                                  |

<div style=\"page-break-after: always\"></div>

Table 2: Listing of clinical studies in adult patients

| CTD Section   | Type of study                                        | Study code / Reference    | Study title                                                                                                                                                                                                                                                                                           | Report location   |
|---------------|------------------------------------------------------|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
|               | Indication                                           |                           | Additional Engraftment Analyses to“Clinical phase II trial to compareTREO-based conditioning therapy with busulfan-based reduced intensity conditioning prior to alloHSCT in patients with AML or MDS considered ineligible to standard conditioning regimens [TREO regimen: 14 g/m2/d; day -6 to -4] |                   |
|               | Indication                                           | MC-FludT.14/L Trial II    | Clinical phaseIlI trial to compareTREO-based conditioning therapywithbusulfan-based reduced intensity conditioning prior to alloHSCT in patients with AML or MDS considered ineligible to standard conditioning regimens [TREO regimen: 10 g/m2/d; day -4 to -2]                                      | 5.3.5.1           |
| 5.3.5.2       | Study Reports of Uncontrolled Clinical Studies       | MC-FludT.6 /L             | Allogeneic haematopoietic stem cell transplantation in patients with advanced haematological malignancies after treosulfan-based conditioning therapy                                                                                                                                                 | 5.3.5.2           |
| 5.3.5.2       | Study Reports of Uncontrolled Clinical Studies       | MC-FludT.7 /AML           | Clinical phase II trial to evaluate the safety and efficacy of treosulfan based conditioning prior to allogeneichaematopoieticstem cell transplantation in patientswith acutemyeloid leukaemia                                                                                                        | 5.3.5.2           |
| 5.3.5.2       | Study Reports of Uncontrolled Clinical Studies       | MC-FludT.8 /MDS           | ClinicalphaseII trial toevaluate the safety and efficacy of treosulfanbased conditioningprior to allogeneic haematopoieticstem cell transplantation in patients withmyelodysplastic syndrome (MDS)                                                                                                    | 5.3.5.2           |
| 5.3.5.2       | Study Reports of Uncontrolled Clinical Studies       | MC- FludT.16/NM           | Clinical phase II trial to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation (HSCT) in paediatric patientswith non-malignant diseases                                                                       | 5.3.5.2           |
| 5.3.5.2       | Study Reports of Uncontrolled Clinical Studies       | MC- FludT.16/NM Final CTR | Clinical phase II trial to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation (HSCT) in paediatric patients with non-malignant diseases.[CTR V 1.0; 02-Dec-2021]                                             | 5.3.5.2           |
| 5.3.5.2       | Study Reports of Uncontrolled Clinical Studies       | MC-FludT.17/M             | Clinical phase II trial to describe the safety and efficacy of Treosulfan-based conditionning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haematological malignancies                                                                            | 5.3.5.2           |
| CTD Section   | Type of study                                        | Study code / Reference    | Study title                                                                                                                                                                                                                                                                                           | Report location   |
| CTD Section   | Type of study                                        |                           | Additional Engraftment Analyses to“Clinical phase II trial to describe the safety and efficacy of Treosulfan-based conditionning therapy prior to allogeneic haematopoietic stem cell transplantationinpaediatricpatientswithhaematologicalmalignancies\"                                              |                   |
| CTD Section   | Type of study                                        | MC-FudT.17/M Final CTR    | Clinical Phase 2 trial to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haematologicalmalignancies.[CTRV2.0;24-Mar-2020]                                                         | 5.3.5.2           |
| 5.3.5.3       | Reports of Analyses of Data from More Than One Study | Baumgart 2017             | Comparison of engraftment data: Paediatric treosulfan phase II conditioning trial MC- FludT.17/M with historical paediatric engraftment data and data from the adult treosulfan conditioning trial MC-FludT.14/L. V1.0 dated 25-Jul-2017.                                                             | 5.3.5.3           |
| 5.3.5.3       | Reports of Analyses of Data from More Than One Study | ISS                       | Integrated summary of safety on treosulfan [11-Aug-2017]                                                                                                                                                                                                                                              | 5.3.5.3           |
| 5.3.5.4       | Other Clinical Study Reports                         | Peters 2011               | Meta-analysisontreosulfanforconditioninginchildren andadolescentsbeforehaematopoietic stem cell transplantation.                                                                                                                                                                                      | 5.3.5.4           |
| 5.3.5.4       | Other Clinical Study Reports                         | Peters 2017               | RetrospectiveEBMT-PD/IE-WP analysis:Treosulfan orBusulfanbased conditioning before allogeneic haematopoieticstem cell transplantation in paediatric patientswith non-malignant diseases.                                                                                                              | 5.3.5.4           |

Table 3: Listing of clinical studies in paediatric patients

<!-- image -->

| Type of Study            | Study Identifier (code)   | Location of Study Report   | Objective(s)of the Study                                                                                                                     | Study Design and Iype of Control                                | Test Product; Dosage Regimen; Route of Adnini- stration   | Number of Subjects (FAS)                | Healthy Subjects or Diagnosis of Patients                                                                                                                                                                     | Duration of Treatment   | Study Status; Type of Report   |
|--------------------------|---------------------------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|--------------------------------|
| PhaseII efficacy         | MC-FludT.6/L              | 5.3.5.2                    | Feasibility and tolerability ofa treosulfan prior to alloHSCT conditioning therapy based on three different dose levels of                   | non-controlled, Non-randomised, open label                      | Treosulfan IV(2h) Days -6, -5, and -4 10/12 or 14 g/m/dx3 | 56                                      | Patients with a haematological risk for classical (high-dose presenting an increased toxicity busulfan or standard-dose TBI) chemosensitive malignancy indica- ted for an alloHSCT,but conditioning therapies | 3 days                  | Final study report Complete    |
| Phase II efficacy safety | MC. FludT.7/AML           | 5.3.5.2                    | Evaluation of engrafument                                                                                                                    | Non-randomised, non-controlled open-label                       | Treosulfan Days -6, -5, and -4 14 g/m/d x 3 IV(2h)        | 38                                      | Patients with AML                                                                                                                                                                                             | 3 days                  | Final study Complete report    |
| safety Phase II efficacy | MC- FludT.8/MDS           | 5.3.5.2                    | Evaluation of engrafment                                                                                                                     | non-controlled, open-label Non-randomised,                      | Treosulfan Days -6, -5, and -4 14 g/m/d x 3 IV(2h)        | 16                                      | Patients with MDS                                                                                                                                                                                             | 3 days                  | Final study report Complete    |
| safety Phase II efficacy | MC- FludT.14/L TnialI     | 5.3.5.1                    | tation between Treosulfan-based conditioning and Busulfan-based within one year after transplan- conditioning.                               | label, non- infenionity hial Randomised active controlled, open | IV(2h) Treosulfan 14 g/m/d×3 Days -6, -5, and -4          | (171 test drug; 159 active control) 320 | Patients with AML or MDS                                                                                                                                                                                      | 3 days                  | report Final study Complete    |
| Phase II effcacy safety  | FludT.14/L MC. TnialII    | 5.3.5.1                    | conditioning and Busulfan-based within one year after transplan- conditioning. To compare event-free swvival tation between Treosulfan-based | infenonty hial Randomised active controlled, open label, non-   | IV(2h) 10 g/m/d x3 Treosulfan Days -4, -3, and -2         | (220 test dug; 240 active control) 460  | PatientswithAMLorMDS                                                                                                                                                                                          | 3 days                  | Final study report Complete    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Type of Study            | Study Identifier (code)   | Location of Study Report   | Objective(s)oftheStudy                                                                                                                                                                                          | StudyDesign andTypeof Control                  | Test Product; DosageRegimen; RouteofAdmini- stration    | Nunberof Subjects                    | HealthySubjectsor DiagnosisofPatients                                                                                                                                                                | Duration of Treatment   | Study Status; Typeof Report         |
|--------------------------|---------------------------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|---------------------------------------------------------|--------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|-------------------------------------|
| safety Phase II efficacy | MC- FludT.16/NM           | 5.3.5.2                    | Safety and efficacyof treosulfan administered aspart ofa (test)compared to the conventional dose i.v.busulfan (conhrol), each standardised fludarabine- containing conditioning regimen. Population PK analysis | Randomisedactive label study controlled, open- | Days -6, -5, and -4 Treosulfan 10-14 g/m/dx3 IV (2hous) | (51 test dug; 50 active 101 control) | Children with non-maligmant including inbom enrors of myeloablative alloHSCT, metabolism,primary disease indicated for first immmodeficiencies, haemoglobinopathies and bone manrowfailhre symdromes | 3 days                  | report Final study Complete 5.3.5.2 |
| Phase II efficacy safety | MC- FludT.17/M            | 5.3.5.2                    | Safety and efficacyof treosulfan standardised fludarabine- administered aspart of a containing conditioning. PopulationPKanalysis                                                                               | Non-conholled study                            | Treosulfan 10-14g/m/dx3 Days -6, -5, and -4 IV (2hous)  | 70                                   | Children with haematological maligmant diseases (ALL, AML MDS, JMML),requiring myelo- ablative conditioningtheatment followedbyalloHSCT                                                              | 3 days                  | Complete Final study report 5.3.5.2 |

## 2.3.2. Pharmacokinetics

As a requirement of the EMA/PDCO approved paediatric investigational plan (PIP) for Treosulfan, the MAH had to analyse all available PK data on paediatric uses of Treosulfan and to conduct two clinical transplantation studies in paediatric patient populations.

Study MC-FludT.16/NM was conducted in children of different age groups with non-malignant diseases requiring myeloablative conditioning treatment prior to AlloHSCT to describe the safety and efficacy of Treosulfan-based conditioning therapy compared to Busulfan-based conditioning therapy.

Study  MC-FludT.17/M was  conducted  in  children  of  different  age  groups  with  haematological malignancies requiring myeloablative conditioning treatment prior AlloHSCT to describe the safety and efficacy of Treosulfan-based conditioning therapy.

PK data were analyzed in a sufficient sized subset of subjects enrolled in studies MC-FludT.16/NM and MC-FludT.17/M . Further details about these studies can be found in the clinical trial protocols.

Both medac-sponsored trials contributed to the initially built population PK model (December 2011) for Treosulfan. This model was based on PK data acquired in 7 different historical studies from mostly adults and only a limited number of children. The model was used to evaluate and predict the pharmacokinetics of Treosulfan in children and is described in Pop PK report. By this model, disposition of Treosulfan was described by two compartments and linear kinetics. A covariate analysis was performed and detected body surface area (BSA) as the only clinically relevant covariate for clearance and volumes of distribution of Treosulfan. The model was used to establish dose recommendations for Treosulfan in children based on BSA. Using the final PK data from both new paediatric studies, the current dose recommendation based on BSA will be validated or updated, if necessary.

## Data used

For the final analysis, data of 24 subjects from study MC-FludT.16/NM and of 59 subjects from study MC-FludT.17/M were available for analysis and their stratification is visible in table 2:

<div style=\"page-break-after: always\"></div>

Table 2: Number of subjects for PK analyses in studies MC-FludT.16/NM and MCFludT.17/M stratified by BSA and age groups.

|               | MC-FludT.16/NM   | MC-FludT.17/M   |
|---------------|------------------|-----------------|
| BSA group     |                  |                 |
| ≤0.5 m2       | 9                | 7               |
| >0.5 - 1.0 m2 | 13               | 25              |
| >1.0 m2       | 2                | 27              |
| Age group     |                  |                 |
| <1 yr         | 6                | 5               |
| ≥1 -<2 yr     | 7                | 4               |
| ≥2 -<4 yr     | 2                | 11              |
| ≥4 -<12 yr    | 7                | 17              |
| ≥12 -<18 yr   | 2                | 22              |
| Total         | 24               | 59              |

Covariate data were provided by the sponsor according to the DTS. In the two novel studies BSA was calculated using the formula from Mosteller. The GFR was estimated according to the Schwartz formula using serum creatinine and patient's body height.

For subjects with missing dosing date or dosing time, the affected records were flagged and dosing time was imputed using scheduled dosing date or time. For subjects with missing sampling date or sampling time, the affected records were flagged and excluded from the analysis. By default, missing covariates were imputed by the last observation carried forward (LOCF) method, except for baseline values for which backward propagation was used, if feasible. If for a covariate no information was available for a subject, the median value of the missing covariate was imputed for continuous covariates, while for discrete covariates the most frequent value was used. Extreme and unexpected individual data points ('outliers') were excluded if they had a considerable impact on the modelling results. Decisions were based on model-free exploratory outlier analysis of individual concentration curves and/or on conditional weighted  residuals  and  combined  profile  plots  per  treatment  from  intermediate  modelling  results. Reasons for exclusion are described in the report. Excluded data are re-included in the final model to evaluate the impact of exclusion(s) on the parameter estimates and model performance.

## METHODS

Non-linear  mixed  effects  modelling  was  performed  using  the  software  NONMEMxvi.  Results  were analysed and graphically displayed by means of the statistical software package Rxvii (version 3.2.2). Compilation  of  NONMEM  executable  files  were  performed  by  using  the  FORTRAN  compiler  gfortran (version 4.5.0). The same software environment was used for conducting visual predictive checks (VPC) and simulations. For simulation, the random seed in NONMEM were set to an arbitrary 8-digits number. SAS  and  R  for  Windows  were  used  for  data  handling  and  additional  statistics.  Throughout  model development, the first-order conditional estimate approximation with interaction (FOCE INTERACTION) was used for estimation.

A  Pop  PK  or  mixed-effects  model  was  previously  developed  to  describe  blood  concentrations  of Treosulfan,  and  to  perform  a  covariate  analysis.  The  initially  developed  Pop  PK  model  describing disposition of Treosulfan comprises two compartments (with dosing in the central compartment) with linear intercompartmental clearance and elimination. A diagram of its structure is displayed in Figure 1. This structure was unchanged for the updated model, unless there were strong indications that the structure should be changed.

<div style=\"page-break-after: always\"></div>

Figure 1: Two compartmental model describing disposition of Treosulfan. After IV administration into the central compartment V1, Treosulfan is distributed into the peripheral compartment V2 and eliminated. Both processes have linear kinetics determined by inter-compartmental clearance Q and clearance CL.

<!-- image -->

In the initially developed Pop PK model, inter-individual variability on pharmacokinetic parameters was assumed to be log-normally distributed. IIV was investigated for each parameter and was included in the  model  if  it  led  to  an  improvement  in  OFV  after  a  successful  minimization  and  covariance  step. Furthermore,  additional  criteria  like  condition  number,  goodness-of-fit  plots,  and  IIV  of  remaining parameters were considered as well. The residual error, which accounts for unexplained errors (e.g. measurement  and  experimental  errors,  or  model  misspecification  to  some  extent)  in  the  plasma concentrations, was described by the constant CV + constant additive error model.

In the initially developed Pop PK model, BSA was implemented as a covariate on volume of distribution of  the  central  compartment  (V1),  volume  of  distribution  of  the  peripheral  compartment  (V2),  and clearance (CL). Unless during model development strong indications were present that this needed to be changed, these covariate relations were kept in the model. To determine the final covariate model, the following  covariates  were  considered  for  testing:  age,  body  weight,  body  height,  BSA,  GFR  (CCG), gender, background conditioning regimen, study (site ID), data indicator (historical or new data). The Stepwise Covariate Model (SCM) building tool of PsN was used for covariate selection. Before running the SCM method, correlations between covariates were analysed. For highly correlated covariates, e.g. body weight with BSA, only one was considered for the first forward-backward analysis. The other was reconsidered in a second analysis. During the forward inclusion stage, covariates were added until no significant relations at the 0.05 level remain; during the backward deletion stage, significance was tested at the 0.01 level. The impact of covariates was also judged by the decrease in inter-subject variability, general appearance of goodness-of-fit plots, effect size of the covariate on the particular parameter, and physiologic plausibility.

The  model's  ability  to  describe  and  predict  observed  data  was  assessed  by  a  variety  of  numerical, statistical, and graphical methods. Among them were evaluation of OFV, goodness-of-fit plots, analysis of  residuals,  VPCs,  and  scientific  plausibility  of  parameter  estimates.  As  much  as  possible  standard methods available in PsN were used.

Simulations using the two types of models (Dosing Model (the initial model) and Updated Model) were used for model evaluations and dose recommendations. The following rationale was given for dosing, with an objective AUC of 1355 ug×h/mL.

<div style=\"page-break-after: always\"></div>

- No relation between AUC and (time to) engraftment was observed in the AUC range of 760-3600 ug×h/mL.
- Dosing according to an objective AUC &lt; 1355 ug×h/mL increases the risk that AUC for some subjects will be lower than 760 yg×h/mL (i.e., outside the range for which time to engraftment versus AUC information is available).

## RESULTS

The  initial  Dosing  Model  was  finalised  with  data  derived  from  studies  MC-FludT.16/NM  and  MCFludT.17/M. To compensate for the different bioanalytical methods used for acquiring the historical and newly obtained data an additional model parameter was estimated to allow a proportional shift of the data derived from studies MC-FludT.16/NM and MC-FludT.17/M towards the historical data. Using the same  statistical  model  (IIV  on  all  model  parameters),  minimization  was  successful  with  successful covariance step. Diagnostic plots on pooled data revealed no relevant bias. Hence, it was decided to retain its deterministic and statistical structure, and the model was chosen as base model. Inclusion of a sigmoidal age function scaling clearance in the base model had a modest effect on the model fit. The OFV dropped only by 5 points while the estimated maturation parameters (a TM50 value of 49 weeks (assuming a gestational age of 40 weeks) and a Hill coefficient of 6.6) indicated a rather abrupt effect appearing at a relatively young age. For most subjects the age function approached 1 and for those subjects with lower values the effect on the AUC was below 5%. As a consequence, no maturation function was included at this stage of modelling. The base Pop PK model for Treosulfan on historical data and data from studies MCFludT.16/NM and MC-FludT.17/N is a two compartmental model with zero order infusion, and linear elimination and inter-compartmental clearance including an effect of BSA on CL, V1 and V2.

An exploratory covariate analysis was performed to get a general overview of the covariate data. The evaluated categorical covariates were gender (SEX), study identifier (STID), data indicator (STFLAG, historical or new data), background conditioning regimen (CREG). The continuous covariates were body surface area (BSA), height (HGT), body weight (WGT), age (AGE) and glomerular filtration rate (CCG, creatinine clearance or glomerular filtration rate).

Table 2: Summary of the continuous covariates

Table6:Summaryofcontinuouscovariatesforthesubjectsincludedininputfile nmpk\\_treosul\\_v16.csv.

|          | BSA[m²]   | AGE [yr]   | WGT[kg]    | HGT [cm]   | CCG [ml/min/1.73m²]   |
|----------|-----------|------------|------------|------------|-----------------------|
| n        | 198       | 198        | 198        | 198        | 198                   |
| Mean     | 1.35      | 27.03      | 49.12      | 140.90     | 137.30                |
| SD       | 0.60      | 23.83      | 29.49      | 37.60      | 54.27                 |
| Min-Max  | 0.30-2.38 | 0.33-77    | 5.60-114.0 | 57.0-189.0 | 47.0-403.7            |
| Median   | 1.62      | 16.0       | 54.6       | 161.0      | 126.4                 |
| 5% perc  | 0.41      | 0.69       | 8.00       | 69.85      | 68.91                 |
| 95% perc | 2.11      | 65.15      | 97.01      | 178.3      | 231.44                |

Since the Dosing Model described historical data adequately and the current dosing scheme was based on BSA, the effect of BSA on CL, V1 and V2 was retained when additional covariate-parameter relations were tested. The following covariate-model parameter relations were tested in a full (forward inclusion and backward deletion) SCM analysis:

<div style=\"page-break-after: always\"></div>

- V1: SEX, STFLAG, AGE, CCG;  CL: SEX, STFLAG, AGE, CCG ; V2: SEX, STFLAG, AGE, CCG; Q: SEX, STFLAG, AGE, CCG, BSA

Note that CCG contains the normalized GFR values for the new studies and the creatinine clearance or (normalized) GFR values for the historical studies. The SCM analysis was performed with p=0.05 for forward inclusion and p=0.01 for backward deletion. The final backward model described an allometric effect of BSA on Q, CL, V1 and V2 and an effect of CCG on CL. Minimization of the final backward model exited successfully with successful covariance step. However, the effect of CCG on CL could not precisely be estimated. It was estimated with a rather large RSE value of 33%. Removing CCG on CL had a minimal effect on the resulting AUC so it was decided also to remove this model-parameter-covariate relation from the final SCM model.

The final Pop PK model for Treosulfan based on historical data, and data derived from the studies MCFludT.16/NM  and  MC-FludT.17/M  is  a  two  compartmental  model  (with  dosing  in  the  central compartment) with linear elimination and intercompartmental clearance, see Figure 1. IIV was included on CL, V1, V2, and Q. The model describes an effect of BSA on CL, V1, V2 and Q (PK=TVPK*(BSA/1.75)theta  where  PK  represents  CL,  V1,  V2  or  Q).  Unexplained  residual  error  is described by a constant CV. To compensate for bioassay differences between historical and new data, a SHIFT model parameter was included describing this difference. Final model parameters and Numerical diagnostic measures are presented are listed in Table 12. Standard Goodness-of-Fit plots are presented i n Figure 6. These plots revealed no model bias based on the pooled data. ETA shrinkage (shη) of V1, V2 and Q were high (between 27 and 44%). shη of CL and epsilon (shε) shrinkage were low (less than 10%) as can be seen in Table 22. A representative selection of individual fits and visual predictive checks (VPC) are presented below.

<div style=\"page-break-after: always\"></div>

Table12:Finalparameterestimatesof thecovariatemodel FinalfinalSCMa5.mdl

| Parameter      |      Value | S.E.    | RSE   | Low95Cl   | Upp95CI   |
|----------------|------------|---------|-------|-----------|-----------|
| V1[L]          |    18.9    | 1.77    | 9.38  | 15.4      | 22.3      |
| CL [L/h]       |    17.7    | 0.427   | 2.41  | 16.9      | 18.6      |
| V2 [L]         |    20.3    | 1.55    | 7.61  | 17.3      | 23.4      |
| Q [L/h]        |    26      | 3.97    | 154.2 | 18.2      | 33.8      |
| BSA on V1      |     1.17   | 0.116   | 9.96  | 0.939     | 1.39      |
| BSA on CL      |     1.19   | 0.0458  | 3.85  | 1.10      | 1.28      |
| BSAonV2        |     1.82   | 0.205   | 11.3  | 1.42      | 2.22      |
| BSA on Q       |     1.57   | 0.355   | 22.6  | 0.874     | 2.27      |
| SHIFT bioassay |     1.36   | 0.0654  | 4.81  | 1.23      | 1.49      |
| IIV V1         |     0.146  | 0.0317  | 21.7  | 0.0839    | 0.208     |
| IIV CL         |     0.0557 | 0.00725 | 13.0  | 0.0415    | 0.0699    |
| IIVV2          |     0.0578 | 0.0189  | 32.6  | 0.0208    | 0.0948    |
| IIV Q          |     0.196  | 0.0613  | 31.2  | 0.0761    | 0.316     |
| Q(V1,CL)       |     0.0566 | 0.0112  | 19.7  | 0.0348    | 0.0785    |
| Q(CL,V2)       |     0.019  | 0.00717 | 37.8  | 0.00489   | 0.033     |
| αcCV           |     0.0475 | 0.00473 | 9.95  | 0.0382    | 0.0567    |
| OFV            | 17627.3    |         |       |           |           |

llV=varianceofbetween-subjectvariability

Q=covariancebetweenbetween-subjectvariability

o=varianceofresidualerror&amp;

Table 22: Eta (she) and epsilon (sh,) shrinkage in the final model.

| Random Effect   | Description        |   Shrinkage (%) |
|-----------------|--------------------|-----------------|
| ETA1            | IV on V1           |         27.15   |
| ETA2            | IIV on CL          |          6.9712 |
| ETA3            | IV on V2           |         34.152  |
| ETA4            | IIV on Q           |         43.729  |
| EPS1            | CCV residual error |          9.3396 |

<div style=\"page-break-after: always\"></div>

Figure 6: Standard diagnostic plots on new data. Upper row displays observed versus population and individual prediction [μg/mL]. Lower row displays CWRES versus time [h] and population prediction.

<!-- image -->

## BSAgrp=1;Area=90%

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 11: VPCs of the Updated Model on new data displayed by BSA groups.BSA group 1: BSA≤0.5m²;BSAgroup2:0.5&lt;BSA≤1m²;BSAgroup3:BSA&gt;1m².Concentration refers to treosulfan concentration in μg/mL and TALD refers to time after last dose in hours.

<!-- image -->

<!-- image -->

In general, prediction of the Final Model improved compared to the prediction of the Dosing Model but the prediction of observed concentrations in subjects with BSA larger than 1 m2 (BSAgrp = 3) is still biased. Concentrations between 2 and 3 h after start of infusion are within the prediction range but almost all concentrations are above the median of the simulated concentrations. Concentrations at later timepoints are all centered around the median.

## SIMULATIONS

Simulations were made in order to calculate the geometric mean and 95% prediction interval of AUCs (AUC∞ based on analytical form ula)  by  use  of  the  Updated  Model.  For  that  500  concentration-time profiles were simulated and distribution of simulated AUC∞ based on posterior estimates of CL was

<div style=\"page-break-after: always\"></div>

calculated. Distributions of predicted AUCinf displayed by BSA groups are shown in Figure 12. For all BSA groups, 0.77% of simulated AUCinf are below 760 and 0.03% above 3600 μg×h/mL. Since this is below the maximum of 2.5%, dose adjustment criterion is passed. For each separate BSA group the dose adjustment criterium is passed as well.

Figure 12: Distributions of AUCinr Stratified by BSA groups. The left and right red vertical lines indicate AUCinf of 760 and 3600 μgxh/mL, respectively.

<!-- image -->

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

Dosing scheme based on the initial Dosing Model and Final Model are given in Table 14. According to the final dosing scheme children with a BSA of 0.4, 0.5, 0.9 and 1.0 m2 would receive a higher dose from a PK perspective.

Table14:Initial andfinaldosingschemes

<!-- image -->

| BSA   | Dosing Scheme by initial protocol MC- FludT16/NM and FludT17/M (2011)   | Dosing Scheme by initial protocol MC- FludT16/NM and FludT17/M (2011)   | Dosing scheme based onFinal Model   | Dosing scheme based onFinal Model   | Final Dosing Scheme   | Final Dosing Scheme   |
|-------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------|-------------------------------------|-----------------------|-----------------------|
| (m)   | (g)                                                                     | (g/m²)                                                                  | (g)                                 | (g/m²)                              | (g)                   | (g/m²)                |
| 0.3   | 3.0                                                                     | 10                                                                      | 2.94                                | 9.8                                 | 3.0                   | 10                    |
| 0.4   | 4.0                                                                     | 10                                                                      | 4.14                                | 10.3                                | 4.8                   | 12                    |
| 0.5   | 5.0                                                                     | 10                                                                      | 5.40                                | 10.8                                | 6.0                   | 12                    |
| 0.6   | 6.6                                                                     | 12                                                                      | 6.71                                | 11.2                                | 7.2                   | 12                    |
| 0.7   | 7.7                                                                     | 12                                                                      | 8.06                                | 11.5                                | 8.4                   | 12                    |
| 0.8   | 8.8                                                                     | 12                                                                      | 9.45                                | 11.8                                | 9.6                   | 12                    |
| 0.9   | 10.8                                                                    | 12                                                                      | 10.9                                | 12.1                                | 12.6                  | 14                    |
| 1.0   | 12.0                                                                    | 12                                                                      | 12.3                                | 12.3                                | 14.0                  | 14                    |
| 1.1   | 15.4                                                                    | 14                                                                      | 13.8                                | 12.5                                | 15.4                  | 14                    |
| 1.2   | 16.8                                                                    | 14                                                                      | 15.3                                | 12.8                                | 16.8                  | 14                    |
| 1.3   | 18.2                                                                    | 14                                                                      | 16.8                                | 12.9                                | 18.2                  | 14                    |
| 1.4   | 19.6                                                                    | 14                                                                      | 18.4                                | 13.1                                | 19.6                  | 14                    |
| 1.5   | 21.0                                                                    | 14                                                                      | 20.0                                | 13.3                                | 21.0                  | 14                    |
| 1.6   | 22.4                                                                    | 14                                                                      | 21.6                                | 13.5                                | 22.4                  | 14                    |
| 1.7   | 23.8                                                                    | 14                                                                      | 23.2                                | 13.6                                | 23.8                  | 14                    |
| 1.8   | 25.2                                                                    | 14                                                                      | 24.8                                | 13.8                                | 25.2                  | 14                    |
| 1.9   | 26.6                                                                    | 14                                                                      | 26.4                                | 13.9                                | 26.6                  | 14                    |
| 2.0   | 28.0                                                                    | 14                                                                      | 28.1                                | 14.0                                | 28.0                  | 14                    |

The following observations were made:

- In VPCs using the Dosing Model (the initially developed modeliii), Cmax was underestimated and median of simulated concentrations were not centered on observed new data in the largest BSA group;
- In VPCs using the Updated Model, observed concentrations were covered by the predicted region but were above the median of simulated concentrations between 2 and 3 hrs in subjects with a BSA &gt; 1.0 m 2 ;
- 0.03% of simulated AUCinf was higher than 3600 μg×h/mL and 0.77% of simulated AUCinf were below 760 μg×h/mL;
- According to predictions by the Updated Model, from a PK perspective, the updated dosing scheme indicated that children with a BSA of 0.4, 0.5, 0.9 and 1.0 m2 should receive a higher dose than currently indicated by the study protocol to obtain the target exposure of 1355 μg×h/mL. Deviations ranged between 9% for BSA levels 0.6, 0.7 and 0.8 m 2 , up to 20% for BSA levels 0.4 and 0.5 m 2 and 17% for BSA levels 0.9 and 1.0 m 2 .

Based on these observations at this final analysis, an increase of the current dose levels for children with a BSA of 0.4, 0.5, 0.9 and 1.0 m 2  might be considered from a PK perspective. Paediatric subjects with a BSA &lt; 0.4 m 2  should receive a daily dose of 10 g/m 2  while paediatric subjects with a BSA ≥ 0.4 m 2  and a BSA &lt; 0.9 m 2  should receive a daily dose of 12 g/m 2 while children with a BSA ≥ 0.9 m 2  should receive a daily dose of 14 g/m 2 .

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacodynamics

## Mechanism of action

̈

TREO is  considered  a  \"prodrug\"  of  a  bifunctional  alkylating  cytotoxic  drug.  The  introduction  of  two hydroxyl groups in position 2 and 3 of the molecule is responsible for the striking differences between TREO and BU with respect to physico-chemical, pharmacological and toxicological characteristics, but also with respect to the mode of activation and mechanism of alkylation [Brookes 196112; Feit 197036; Hartley 199950; Ko pf-Maier 1996]. TREO has to be activated by transformation into epoxide species, which are considered responsible for alkylation and cross-linking of macromolecules like DNA. Cytotoxic effects  are  predominantly,  but  not  exclusively,  affecting  rapidly  proliferating  cells  and  tissues  like malignant cells or e.g. normal haematopoietic cells [Feit 1970; Hartley 1999; Munkelt 2008].

TREO presents end-standing methanesulfonyloxy groups in the neighborhood of hydroxyl groups. In consequence, an intramolecular  alkylation  and  formation  of  epoxide  rings  occurs.  Afterwards,  these epoxides are able to alkylate nucleophilic centers. In contrast, BU directly alkylates nucleophilic centers. Under  physiological  conditions  (pH  7.4,  temperature  37°C),  this  intra-  molecular  reaction  occurs spontaneously  (non-enzymatically),  converting  the  pharmacologically  inactive  TREO  into  an  active monoepoxide intermediate and finally to L-diepoxibutane as shown in Figure 1:

Figure 1: Non-enzymatic activation pathway of treosulfan [Feit 1970]

<!-- image -->

Given the known mechanism of action of treosulfan, it is pharmacologically plausible and expect that it can also act as preconditioning agent for non-malignant diseases. Therefore, from a mechanistic point of view, the extension of indication can be supported.

## Primary and secondary pharmacology

Regarding  the  relevant  pharmacodynamic  data  to  support  this  variation,  namely  the  extension  of indication to non-malignant disease, it can be considered that the MAH has presented data to support it.

Sufficient toxicity against haematopoietic stem cells (HSCs) is a requirement for a conditioning agent. Preclinical in vitro and in vivo studies have clearly shown that TREO is evidently cytotoxic to all HSC subsets,  both  primitive  and  committed.  HSC  toxicity  is  most  pronounced  when  TREO  is  given  in fractionated doses instead of a single dose administration [Ploemacher 2004; Sjöö 2006; Van Pel 2003,

<div style=\"page-break-after: always\"></div>

Westerhof 2000]. A study with non-malignant HSCs from 5 healthy donors has shown that purified CD34+ HSCs were most sensitive to TREO, followed by CD56+CD3- NK and CD3+ T cells [Munkelt 2008].

When used in doses higher than conventional ones, TREO demonstrates also immunosuppressive action, e.g. inhibition of T cell proliferation, induction of apoptosis of immunocompetent cells (T cells, B cells, NK cells, monocytes) and reduced expression of proinflammatory cytokines [Kopadze 2007; Munkelt 2008; Sjöö 2006].  Immunosuppressive properties of TREO are considered to be of great importance with regard to its application in a conditioning regimen for alloHSCT. Together with the myeloablative activity,  they  contribute  to  the  achievement  of  stable  transplant  engraftment,  complete  donor-type chimerism as well as prevention of GvHD.

Engraftment  of  donor  stem  cells  and  time  to  100%  donor  cell  engraftment  are  parameters  which characterise the pharmacodynamic  effects of TREO-based  conditioning. Concentration-response relationship was investigated within the PopPK study. The AUCs of three patients for which engraftment was not established were in the same range as AUCs of subjects for which engraftment was established. Since engraftment is reached in nearly all patients, time to 100% donor cell engraftment was considered as a better suited parameter to study this concentration-response relationship. However, no correlation between AUC and time to engraftment in the investigated range of AUCs was seen.

Figure 13 Relation between time to engraftment and AUC of TREO

<!-- image -->

(Datasource:VennLifeSciences2020,PopPKReport,Figure13)

## 2.3.4. PK/PD modelling

All available data on PK of TREO in children of different age groups and adults were used to develop a first PopPK model [Kinesis 2011]. PK data from trial MC-FludT.14/L [PK Study Report, 26/03/2012] and published data in adults [Beelen 2005; Hilger 1998; Scheulen 2000; Nemecek 2011] and paediatric patients [Beier 2012; Gł ówka 2008] were used. This model revealed that conventional dosing simply based on body surface area (BSA) results in a significantly higher exposure (AUC) of smaller children and infants  with  low  BSA  compared  to  adolescents  or  adults.  Various  paediatric  transplant  working groups published their results of PK evaluation of TREO in children and reported similar observations [Beier 2012; Chiesa 2014; Gł ówka 2015; Koyyalamudi 2016; Ten Brink 2014].

<div style=\"page-break-after: always\"></div>

The  developed  model  consists  of  two  compartments  with  first  order  distribution  and  elimination processes.

The model estimated relation between clearance and BSA suggests that for dosing the following formula should be used:

Dosemodel (g) = Target AUC (µg/mL × h)/1000 × 17.8 × (BSA/1.75) 1.29

No relation between time of engraftment and AUC was observed in the range of 760-3600 µg/mL × h. Therefore, considering the variability between subjects, aiming for a dose to reach a target AUC of about 1300 µg/mL × h (as observed in adults after administration of 14 g/m² TREO) should be sufficient. Higher dosing would not decrease time to engraftment while there is not enough data to imply that lower dosing would not increase time to engraftment. For an AUC of 1300 µg/mL × h, the following dosing scheme was presented:

Figure 9 RelationbetweenBSAandrecommendeddose

<!-- image -->

The initial modelling report [Kinesis 2011] was amended in 2012 [Kinesis 2012]. The MAH aimed for an exposure level  (AUC0∞) in children  comparable  to  that  observed  with  a  dose  of  14 g/m²  in  adult patients. Aimed AUC for a dose of 14 g/m² was calculated by ordinary least squares regression analysis, including now only adult data for all dose groups. This was done on log transformed data, due to log normality of the calculated AUC's. Based on the regression equation, the calculated geometric mean AUC after administration of 14 g/m² was 1355 (90% CI 1308 - 1404) µg/mL × h. This target AUC was chosen for the paediatric studies. Conventional dosing (based on g/m² BSA only) results in significantly higher exposure for smaller children with lower BSA, while exposure in adolescents/adults is more or less equal. In addition, no clear differences in exposure for adults with high BSA (&gt; 2.0 m²) compared to adults with lower BSA were observed; however, the available data for adults with BSA &gt; 2.0 m² was relatively limited. Table 21 shows a comparison of exposure simulations (n = 200) for conventional dosing (14 g/m²) and model-based dosing, aiming for an AUC of 1355 µg/mL × h, indicating the reduced variability in Cmax and AUC between BSA levels.

Based on this PopPK report, a dose recommendation was derived for the paediatric transplant trials MCFludT.17/M and MC-FludT.16/NM aiming a target AUC for TREO in all paediatric age groups of 1355 μg/mL × h corresponding to an exposure of 14 g/m² in adult patients [Table 22].

<div style=\"page-break-after: always\"></div>

Table22Recommendeddosingscheme

| BSA (m2)   | Conventional dosingscheme   | Model-baseddosingscheme (Target AUC =1355 μg/mL xh)   | Model-baseddosingscheme (Target AUC =1355 μg/mL xh)   | Recommendeddosingschedule   | Recommendeddosingschedule   |
|------------|-----------------------------|-------------------------------------------------------|-------------------------------------------------------|-----------------------------|-----------------------------|
|            | 14 g/m2                     | Final model (g)                                       | Final model (g) excl.2outliers                        | g                           | g/m2                        |
| 0.3        | 4.2                         | 2.5                                                   | 2.8                                                   | 3.0                         | 10                          |
| 0.4        | 5.6                         | 3.6                                                   | 3.9                                                   | 4.0                         | 10                          |
| 0.5        | 7.0                         | 4.8                                                   | 5.2                                                   | 5.0                         | 10                          |
| 0.6        | 8.4                         | 6.1                                                   | 6.5                                                   | 6.6                         | 11                          |
| 0.7        | 9.8                         | 7.4                                                   | 7.9                                                   | 7.7                         | 11                          |

| BSA (m2)   | Conventional dosing scheme                                                      | Model-baseddosingscheme (TargetAUC=1355μg/mL×h)                                 | Model-baseddosingscheme (TargetAUC=1355μg/mL×h)                                 | Recommended dosing schedule                                                     | Recommended dosing schedule                                                     |
|------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
|            | 14 g/m2                                                                         | Final model (g)                                                                 | Final model (g) excl.2outliers                                                  | g                                                                               | g/m2                                                                            |
| 0.8        | Table 23 BSA-dependent dosing for children based on 14 g/m2 TREO dose in adults | Table 23 BSA-dependent dosing for children based on 14 g/m2 TREO dose in adults | Table 23 BSA-dependent dosing for children based on 14 g/m2 TREO dose in adults | Table 23 BSA-dependent dosing for children based on 14 g/m2 TREO dose in adults | Table 23 BSA-dependent dosing for children based on 14 g/m2 TREO dose in adults |
| 0.9        | Body surface area (m2)                                                          | Body surface area (m2)                                                          | Treosulfan dose (g/m2)                                                          | Treosulfan dose (g/m2)                                                          |                                                                                 |
| 1.0        | 0                                                                               | 0                                                                               | 10                                                                              | 10                                                                              |                                                                                 |
| 1.1        | >0.5-1.0                                                                        | >0.5-1.0                                                                        | 12                                                                              | 12                                                                              |                                                                                 |
| 1.2        | > 1.0                                                                           | > 1.0                                                                           | 14                                                                              | 14                                                                              |                                                                                 |
| 1.3        | Datasource:FinalstudyprotocolMC-FludT.16/NMandMC-FludT.17/M                     | Datasource:FinalstudyprotocolMC-FludT.16/NMandMC-FludT.17/M                     | Datasource:FinalstudyprotocolMC-FludT.16/NMandMC-FludT.17/M                     | Datasource:FinalstudyprotocolMC-FludT.16/NMandMC-FludT.17/M                     | Datasource:FinalstudyprotocolMC-FludT.16/NMandMC-FludT.17/M                     |
| 1.4        | 19.6                                                                            | 18.1                                                                            | 18.4                                                                            | 18.2                                                                            | 13                                                                              |
| 1.5        | 21.0                                                                            | 19.8                                                                            | 20.1                                                                            | 19.5                                                                            | 13                                                                              |
| 1.6        | 22.4                                                                            | 21.5                                                                            | 21.7                                                                            | 20.8                                                                            | 13                                                                              |
| 1.7        | 23.8                                                                            | 23.2                                                                            | 23.4                                                                            | 23.8                                                                            | 14                                                                              |
| 1.8        | 25.2                                                                            | 25.0                                                                            | 25.1                                                                            | 25.2                                                                            | 14                                                                              |
| 1.9        | 26.6                                                                            | 26.8                                                                            | 26.8                                                                            | 26.6                                                                            | 14                                                                              |
| 2.0        | 28.0                                                                            | 28.7                                                                            | 28.6                                                                            | 28.0                                                                            | 14                                                                              |
| 2.1        | 29.4                                                                            | 30.5                                                                            | 30.4                                                                            | 29.4                                                                            | 14                                                                              |
| 2.2        | 30.8                                                                            | 32.4                                                                            | 32.1                                                                            | 30.8                                                                            | 14                                                                              |
| 2.3        | 32.2                                                                            | 34.3                                                                            | 33.9                                                                            | 32.2                                                                            | 14                                                                              |
| 2.4        | 33.6                                                                            | 36.3                                                                            | 35.8                                                                            | 33.6                                                                            | 14                                                                              |

At the end, the following more simplified BSA-adjusted dosing table was used in trials FludT.16/NM (n = 17) and MC-FludT.17/M [Table 23].

Pharmacokinetic  data  for  TREO  and  its  monoepoxide  metabolite  from  two  paediatric  studies  were analysed. For this final analysis, data of 24 subjects from study MC-FludT.16/NM and of 59 subjects from study MC-FludT.17/M were available. Patient's ages were less than 1 year (n = 11), 1 to &lt; 2 years (n = 11), 2 to &lt; 4 years (n = 13), 4 to &lt; 12 years (n = 24), and 12 to &lt; 18 years (n = 24). Patients with a body surface area (BSA) ≤ 0.5 m² had received 10 g/m² TREO, &gt; 0.5 to 1.0 m² had received 12 g/m² TREO, and patients &gt; 1.0 m² BSA had received 14 g/m² TREO.  Pharmacokinetic and statistical analysis were done by Venn Life Sciences ED BV [former name Kinesis Pharma BV] (Breda, The Netherlands) using the validated computer program Phoenix™ WinNonlin® (version 6.2.1).

Non-compartmental analysis model 202 (constant infusion input, plasma data) was applied for the PK analysis of TREO, model 200 (extravascular input, plasma data) was applied for monoepoxide. All blood samples taken to determine TREO and monoepoxide plasma concentrations were available for the PK analysis. Treosulfan and monoepoxide concentrations were reported as 'corrected' (corrected for dilution and hematocrit). For the PK analysis of TREO and monoepoxide 'corrected' concentrations were used. In the report, TREO and monoepoxide refer to the 'corrected' values. The lower limit of quantification of

<div style=\"page-break-after: always\"></div>

TREO and monoepoxide was 500 ng/mL and 10 ng/mL, respectively.  The actual individual infusion duration ranged between 1.97 h and 2.50 h. Maximum TREO concentrations were reached directly after end of the infusion.

The individual PK profiles were similar in shape and magnitude, independent of age group or BSA group, except for one subject with a lower profile compared to other subjects in the lower age/BSA groups. Decline of TREO concentrations after the end of infusion was bi-exponentially. Inter-subject variability of plasma concentrations by time-point based on percent of geometric coefficient of variation ranged from 10.2% to 96.4% in the different age and BSA groups.  Maximum plasma concentration of TREO ranged between 118 and 2,060 μg/mL and almost all were reached directly after end of infusion. AUC0 -∞ values ranged between 274 and 3,212 µg/mL × h. The AUC0 -∞ of one subject (i.e., 274 µg/mL × h) was below the range what is considered safe and effective (760 - 3,600 µg/mL × h), for all other subjects AUC0∞ was within this range. No major differences in mean C max were observed. Mean AUClast and AUC0∞ values of TREO were comparable for the lower three ag e groups and appeared slightly higher with increasing age group for the two higher age groups. However, the ranges for Cmax and AUC0-∞ were overlapping and therefore Cmax and AUC0∞ can be considered comparable for all age groups. Mean values of Cl and Vd were comparable between age groups 1 (1 month to &lt; 1 year), 2 (1 to &lt; 2 years) and 3 (2 to &lt; 4 years) and thereafter increased with increasing age group. Mean apparent terminal half-life was comparable between the different age groups and ranged between 1.3 and 1.6 h, due to CL and Vd increasing in a similar extent.

Mean Cmax values were comparable between the different BSA groups.  Mean AUClast and AUC0∞ values of  TREO  were  slightly  higher  with  increasing  BSA  group.  Based  on  mean  values,  AUCs  were approx imately 20% higher in the BSA group ≥ 1.0 m² compared to the BSA group ≤ 0.5 m². However, the  ranges  for  Cmax and  AUC∞  were  overlapping  and  therefore  C max and  AUC∞  can  be  considered comparable for all BSA groups. Mean values of Cl and Vd were increased with increasing BSA group. Mean apparent terminal half-life was comparable between the different BSA groups and ranged between 1.3 and 1.6 h, due to CL and Vd increasing in a similar extent. With respect to the shape of the mean plasma concentration-time profiles of the monoepoxide, no major differences were observed between the age groups or BSA groups, except for the lowest age and BSA group where a large variability in the peak concentrations was observed. Maximum monoepoxide concentrations were reached directly after end of the infusion. The individual PK profiles were similar in shape and magnitude, independent of age group or BSA group, except for two subjects in the lower age/BSA groups and one subject in the 2 to &lt;4  years  and  &gt;0.5  to  ≤  1.0  m²  group.  No major  differences  in  Cmax,  AUClast  and  AUC0∞  of monoepoxide were observed between the different age and BSA groups. Mean apparent terminal halflife is comparable between the different age groups and ranged between 1.3 and 1.7 h.

The PopPK model was updated in 2018 with the inclusion of new PK data from studies MCFludT.16/NM (n  =  21)  and  MC-FludT.17/M  (n  =  59)  [Kinesis  2018].  Since  no  relation  between  AUC  and  time  to engraftment was previously observed in the AUC range of 7603600 μg/mL × h, an AUC value in this exposure interval was considered as safe and effective. In a first step, prediction of the dosing model was evaluated by means of dose normalized visual predictive checks (VPCs) and distributions of AUClast. The VPCs predicted historical concentrations adequately for all three BSA groups. The updated PopPK model is a two-compartment model with linear elimination and intercompartmental clearance. After IV administration into the central compartment (V1), TREO is distributed into the peripheral compartment (V2) and eliminated. Both processes have linear kinetics determined by intercompartmental clearance (Q) and clearance (CL). The model described an effect of BSA on CL, V1, V2 and Q.

The following observations were made: - In VPCs using the initially developed dosing model, Cmax was underestimated and median of simulated concentrations were not centered on observed new data in the largest BSA group. - In VPCs using the updated model, observed concentrations were covered by the

<div style=\"page-break-after: always\"></div>

predicted region but were above the median of simulated concentrations in the largest BSA group. 0.03% of simulated AUC0∞ was higher than 3600 μg/mL × h and less or equal than 1.13% of simulated AUC0∞ were below 760 μg/mL × h. -  According  to  predictions  by  the  updated  model,  from  a  PK perspective, the updated dosing scheme indicated that children with a BSA of 0.4, 0.5, 0.9 and 1.0 m² would receive a higher dose than currently indicated by the study protocol to obtain the target exposure of 1355 μg/mL × h. Deviations ranged be tween 9% for BSA levels 0.6, 0.7 and 0.8 m², up to 20% for BSA levels 0.4 and 0.5 m² and 17% for BSA levels 0.9 and 1.0 m². This new BSA-adapted dosing regimen was implemented in the ongoing trial MC-FludT.16/NM (protocol version 5.1, dated 15-May-2019). Since then up to the end of recruitment the following schedule was used.

The final PopPK model was reported to medac in 2020 [Venn Life Sciences 2020].

Distributions of predicted AUC0∞ displayed by BSA groups are shown in Figure 12. For all BSA groups, 0.77% of simulated AUC0∞  are below 760 and 0.03% above 3,600 μg/mL × h.

<!-- formula-not-decoded -->

Table 24 BSA-dependent dosing for children based on 14 g/m2 TREO dose in adults

| Body surface area (m?)                      | Treosulfan dose (g/m2)   |
|---------------------------------------------|--------------------------|
| ≤0.3                                        | 10                       |
| >0.3-0.8                                    | 12                       |
| >0.8                                        | 14                       |
| Datasource:FinalstudyprotocolMC-FludT.16/NM |                          |

AUCut

AUCur

AUCot

TheleftandrightredverticallinesindicateAUCinfof760and3600μgxh/mL,respectively.

(Datasource:VennLifeSciences2020,PopPKReport,Figure12)

Based on these observations at this final analysis, an increase of the current dose levels for children with a BSA of 0.4, 0.5, 0.9 and 1.0 m² might be considered from a PK perspective [Table 24].

## 2.3.5. Discussion on clinical pharmacology

## Pharmacokinetics

An initial PopPK model was develop by the MAH in order to predict the PK of Treosulfan in children. This model was based on published data, and studies MC-FludT.16/NM and MC-FludT.17/M were undertaken after a PIP, in order to validate the initial PopPK model but only included a partial subset of subjects for whom data was available. This interim PopPK model was evaluated at the initial submission and the company is now submitting the updated one with the full data available. In practice, no major changes are expected as the number of included subjects is only slightly increased from the 2017 PopPK model with the inclusion of new PK data from study MCFludT.16/NM (n = 24 an increase in 7 subjects). In general, the procedure for data management, covariates considered, and data removal is the same as previously undertaken by the MAH. Out of the 2505 data records, 139 data records (5,5%) were flagged and excluded. Of these 139 data records, 111 occurred at exactly the same time as a dosing event, 8 showed a positive concentration before the first dosing was applied and 20 (0.8%) records showed suspicious behaviour as observed in exploratory data analysis prior to modelling. These are acceptable.

The nonlinear mixed effects modelling approach as implemented in NONMEM version 7.1.0 was used for model estimation, with first-order conditional estimation method with interaction (FOCEI). The previous developed model was used as starting model and a final covariate model was then developed by forwardbackward analysis. The descriptive and predictive performance of the developed population PK model

<div style=\"page-break-after: always\"></div>

was  investigated  using  commonly  used  methods.  Overall,  the  modelling  strategy  is  considered acceptable.

The starting model, updated with the new available data, consisted in a 2-compartmental mammillary model with first order distribution and elimination processes with BSA as a covariate associated to all the model parameters. This model was considered sufficient to explain the data, as the introduction of a maturation function did not result in a significant improvement of the model fitting characteristics.

The  introduction  of  covariates  by  forward-backward  selection  resulted  in  the  inclusion  of  the  CCG (creatinine clearance or glomerular filtration rate) in the CL parameter. The MAH considered that this inclusion was not supported due to a low precision of the estimated parameter, with an RSM = 33%.

Based on the provided model, CL of Treosulfan was found to be 17.7 L/h at the recommended 14 g/m 2 dose and the volume of distribution (sum of V1 and V2) was 39.2 L for a subject with a BSA of 1.75 m 2 . These values are basically similar to the ones previously determined with a reduced data.

Goodness-of-Fit plots revea led no model bias based on the pooled data. ETA shrinkage (shη) of V1, V2 and Q were high (between 27 and 44%). This is not much problematic due to the covariate selection process that was independent of the EBE of the model.

Based on the VPC, prediction of the Final Model improved compared to the prediction of the initial model but the prediction of observed concentrations in subjects with BSA larger than 1 m 2  (BSAgrp = 3) is still biased.  This  should  be  further  explored  and  the  reason  for  the  under  prediction  of  the  initial concentrations for the BSAgrp 3 properly discussed. Also, the VPC of the two studies and by BSAgrp should  be  provided  showing  also  the  median,  5th  &amp;  95th  confidence  intervals  of  the  observed  and simulated  data  for  better  assessment  of  the  model  according  to  Bergstrand  et  al  2011  (Predictioncorrected visual predictive checks for diagnosing nonlinear mixed-effects models). VPCs stratified on age groups are considered relevant given the submission and should, therefore, be presented. Finally, the estimated exponents of the BSA covariate (1.17 for V1, 1.19 for CL, 1.82 for V2 and 1.57 for Q) indicate that  the  central  compartment  scales  almost  proportionally  with  BSA,  however  for  the  peripheral compartment, the effects are stronger and scale more than proportionally with BSA. The MAH evaluated whether bodyweight-based scaling (with conventional exponents of 0.75 for CL and Q, and 1.0 for V1 and V2) as compared to BSA-based scaling is not a better alternative to describe the pharmacokinetics of treosulfan.

Simulations under the final model and for the current drug administration regime for the 3 BSA groups showed that 0.77% of simulated AUCinf are below 760 and 0.03% above 3600 μg×h/mL. This indicates that the current regime is resulting in AUC inside the target interval of 760 - 3600 ugxh/mL and since the defined dosing criteria were considered fulfilled, the original dosing schedule was to be kept. The MAH was asked to justify why a new dosing schedule is still proposed. Regarding the new proposed dosing schedule, the MAH provided simulations on the resulting AUCs for the newly proposed BSAgrp dosing with particular relevance for the newly proposed children with a BSA of 0.4, 0.5, 0.9 and 1.0 m 2 that would receive a higher dose from a PK perspective. The detailed description of the maturation function explored during the PopPK model development and discussion of its non-inclusion in the final model was requested to the MAH.

After receiving responses to the issues raised above two other concerns remained to be solved. These were related with: a) the newly proposed regime and the potential risk of increased safety issues; and b) the fact that subsequent to observations of some cases of secondary graft failure in the Treosulfan arm during the MC-FludT.16/NM study some patients received higher doses than the ones in the new proposed dosage regimen. With the responses to the second RSI, the MAH provided sufficient information that indicate that the proposed final BSA-categories for dose calculation seem adequate. In addition, the MAH included in section 5.1 of the SmPC, as requested, information related with the two subjects that

<div style=\"page-break-after: always\"></div>

in MCFludT.16/NM trial were effectively dosed with higher doses that the original posology proposed. Overall, all the issues raised in the assessment were resolved.

## Pharmacodynamics

Given the known mechanism of action of treosulfan, it is pharmacologically plausible and expected that it can also act as preconditioning agent for non-malignant diseases. Therefore, from a mechanistic point of view, the extension of indication can be supported.

Given the absence of a clear relationship of the AUC of treosulfan with the primary endpoint chosen, no direct relation can be performed regarding a PK/PD relationship. Further support to this indication should be performed with efficacy rather than PD data.

The proposed TREO dose regimen for adult patients is 10 g/m²/d, given on three consecutive days from Day -4 to  -2  before  HSCT.  All  268  patients  treated  with  this  regimen  within  the  pivotal  study  MCFludT.14/L  Trial  II  achieved  engraftment  of  donor  HSCTs.  Only  one  patient  in  the  TREO  group experienced a primary graft failure. Complete donor-type chimerism at Day + 28 was achieved in a similar proportion of patients compared to the higher dose regimen used in MC-FludT.14/L Trial I. The duration of neutropenia was reduced with the modified regimen compared to the formerly used TREO regimen of 14 g/m²/d × 3 (Day -6 to -4) used in study MC-FludT.14/L Trial I (14.0 vs. 17.5 days). As a result of this regimen change, the incidence of infections (27.0% vs. 43.5%; TREO-related: 8.1% vs. 11.9%) and infection-related death (9.3% vs. 16.1%) could be significantly reduced. Additionally, eventfree (EFS) and overall survival (OS) at 24 months increased significantly (EFS: 65.7% vs. 51.2%; OS: 72.7% vs. 60.2%).

Paediatric patients are usually treated with MAC instead of RIC regimens to avoid graft failure or disease relapse [Algeri 20211; Ali 20202, Lum 2019]. This is justified because children usually do not have comorbidities  and  tolerate  higher  doses  of  chemotherapy.  Therefore,  the  paediatric  dose  regimen includes  a  TREO  dose  that  corresponds  to  a  14  g/m²  exposure  in  adult  patients  and  most  patients additionally received thiotepa. Results of the two paediatric studies support this strategy as OS is much better and non-relapse mortality (NRM) lower compared to the two studies 14/L in adults. Based on the resulting PopPK model the MAH recommended a BSA-dependent dose calculation for children. However, based on the data obtained from this PopPK model the proposed slightly modified dosing regimen needs to be further justified as outlined above.

After receiving responses to the request for supplementary information raised above two other concerns remained to be solved. These were related with the newly proposed regime and the potential risk of increased safety issues. In addition, the fact that subsequent to observations of some cases of secondary graft failure in the Treosulfan arm during the MC-FludT.16/NM study some patients with BSA from &gt;0.3 to &lt;0.4 m 2  and from &gt; 0.8 to &lt; 0.9 m 2  received higher doses than the ones in the new proposed dosage regimen, was considered that should be reflected in section 5.1 of the SmPC (with indication of the number of patients involved).

With the responses to the second request for supplementary information the MAH provided sufficient arguments to support that an increased safety risk by application of the proposed final BSA categories for dose calculation of treosulfan is not expected despite the absence of historical values of treosulfan with AUCinf&gt;3600 mg.h/L observed in the paediatric trials MC-FludT.16NM and MC-FludT.17/M, that prevents the establishment of a correlation between AUCinf and the number of related adverse events. This conclusion is instead supported by historical values of Treosulfan AUC as high as 6302 mg.h/L in adult patients which were considered safe. In this line of reasoning, the higher simulated values for the critical BSA levels are well below this value. Taking this in consideration, as well as the increased risk of secondary graft failures after treosulfan-based conditioning, the proposed final BSA-categories for

<div style=\"page-break-after: always\"></div>

dose calculation seem adequate. In addition, the MAH also clarified that after the protocol amendment, two subjects were effectively dosed with higher doses that the original posology proposed. These presented a BSA value of 0.5 m 2  and 0.9 m 2  having received 12 g/m 2 /day and 14 g/m 2 /day. These values would be the same under the final proposed regime. Both patients did not experience graft failure and survived while censored at day 366. This information will be included in section 5.1 of the SmPC.

## 2.3.6. Conclusions on clinical pharmacology

The clinical pharmacology documentation is in overall sufficient to support the proposed changes. The MAH  provided  additional  information  that  indicate  that  the  proposed  final  BSA-categories  for  dose calculation seem adequate. In addition, the MAH included in section 5.1 of the SmPC, as requested, information related with the two subjects that in MCFludT.16/NM trial were effectively dosed with higher doses that the original posology proposed.

## 2.4. Clinical efficacy

Seven studies (5 in adult patients and 2 in paediatric patients) were performed by the MAH which provide important information on the efficacy of TREO as part of a conditioning regimen before alloHSCT:

- One dose-response study (MC-FludT.6/L)
- Two  non-randomised  phase  II  studies  in  two  specific  haematological  malignancies  (MCFludT.7/AML; MC-FludT.8/MDS), and
- Two  randomised,  active-controlled  trials  (MC-FludT.14/L  Trial  I  and  Trial  II),  all  using  a conditioning regimen consisting of treosulfan (TREO) plus fludarabine (FLU) in adult patients have been performed by the MAH.
- One  completed  non-controlled  trial (MC-FludT.17/M) with  TREO-based  conditioning  in paediatric patients with haematological malignancies (incl. ALL, AML, MDS and JMML).
- One  completed  randomised  active-controlled  trial  in  paediatric  patients  with  non-malignant diseases (MC-FludT.16/NM) has also been.

A deferral for these two last studies had been granted by the Paediatric Committee of the EMA (see Paediatric  Investigation  Plan  [PIP]).  According  to  the  PIP,  one  meta-analysis  of  engraftment  data [Baumgart 2017] and an EBMT registry study [Peters 2011] on the use of TREO-based conditioning in paediatric patients with malignant and non-malignant diseases were performed and integrated into the data package.

Additionally, another EBMT registry study [Peters 2017] on the use of TREO- or BU-based conditioning in paediatric patients with non-malignant diseases was performed and is part of the documentation.

## 2.4.1. Dose response studies

## MC-FludT.6/L

This international, non-controlled, multicentre dose-response phase II study investigated a conditioning regimen of TREO in combination with FLU. Patients with a haematological chemosensitive malignancy indicated for alloHSCT (CML, NHL, CLL, HL, MM, AML, ALL, MDS), but presenting an increased toxicity

<div style=\"page-break-after: always\"></div>

risk for classical (high-dose busulfan [BU] or standard-dose total body irradiation [TBI]) conditioning therapies were recruited into this trial. Age &gt; 50 years (51%), previous high-dose chemotherapy and autologous HSCT (38%), previous infectious complications (29%) and previous intensive chemotherapy (20%) were the most frequent risk categories, homogeneously distributed between the different dose groups. Stem cell donors were either HLA-identical siblings (MRD) or HLA-identical unrelated (MUD) or one mismatch (out of the 6 standard markers) siblings (1 misMRD). This study was initiated at seven study centres in Germany, Finland, Poland and Sweden.

## 2.4.2. Main studies

## MC-FludT.16/NM

## Title of Study

Clinical Phase II trial to compare treosulfan-based conditioning therapy with busulfan-based conditioning prior  to  allogeneic  haematopoietic  stem  cell  transplantation  (HSCT)  in  paediatric  patients  with  nonmalignant diseases.

## Methods

## Objectives

To  describe  the  safety  and  efficacy  of  TREO  compared  to  the  conventional  dose  BU  (control),  each administered  as  part  of  a  standardised  FLU-containing  conditioning  regimen  and  to  contribute  to  a pharmacokinetic model.

## Primary Objective

The  primary  objective  of  this  trial  was  the  comparative  evaluation  of  freedom  from  transplantation (treatment)-related mortality, defined as death from any transplantation (treatment)-related cause from start of conditioning treatment (visit Day - 7) until day +100 after HSCT.

This multicentre study was conducted in Germany, Poland, the Czech Republic and Italy.

## Secondary Objectives

1. Comparative evaluation of engraftment after HSCT, defined as the first of 3 consecutive days for each of the following 4 criteria:
- A leucocyte count of &gt; 1 x 10 9 /L
- An absolute neutrophil count of &gt; 0.5 x 10 9 /L
- A platelet (PLT) count of at least 20 x 10 9 /L
- A PLT count of at least 50 x 10 9 /L
2. Comparative evaluation of safety including early toxicity (defined as toxicities occurring until day +28) based on the Common Terminology Criteria for Adverse Events (CTCAE, version 4.03) until day +100 after HSCT, serious adverse reactions (SARs) until the end of the longer-term follow-up phase.

<div style=\"page-break-after: always\"></div>

3. Comparative evaluation of 'Hepatic sinusoidal obstruction syndrome' ('HSOS', according to Jones et al [1], 'Lung toxicity' (CTCAE term 'Pulmonary fibrosis'), 'Hepatic toxicity' (according to Bearman [2]), and 'Infections of any CTCAE grade' (non-serious and serious) until day +100.
4. Comparative evaluation of donor-type chimerism on day +28, day +100, and 12 months after HSCT.
5. Comparative evaluation of overall survival (OS) until 12 months after HSCT.
6. Comparative evaluation of primary and secondary graft failure until 12 months after HSCT.
7. Comparative evaluation of incidence and severity of acute (a) graft-versus-host disease (GvHD) (until day +100) and chronic GvHD (cGvHD) (until 12 months after HSCT).
8. Comparative evaluation of use of rescue therapies including donor-lymphocyte infusions (DLIs), stem cell infusions with or without further conditioning regimens, re-occurrence of transfusion dependence (ie, necessity of regular transfusions of red blood cells or PLTs.
9. Evaluation of pharmacokinetic (PK) parameters of treosulfan and its epoxides and to develop a PK model for assessing relevant covariates.
10.  Comparative  evaluation  of  secondary  graft  failure,  cGvHD,  donor-type  chimerism,  OS  and transplantation-related mortality (TRM) during the longer-term follow-up phase.

## Methodology

Prospective, randomised (1:1), open-label, multicentre, active-controlled, parallel-group Phase 2 clinical trial to describe the safety and efficacy of intravenous (i.v.) treosulfan compared to the conventional (myeloablative) dose of i.v. busulfan, each administered as part of a standardised fludarabine-containing conditioning regimen, and to contribute to a PK model.

Subjects were randomised to receive conditioning treatment with treosulfan on day -6, -5, and -4 (body surface area [BSA] adapted dosing), or busulfan on day -7, -6, -5, and -4 (actual body weight adapted dosing)  followed  by  allogeneic  HSCT  on  day  0.  Randomisation  was  stratified  by  2  pre-specified background conditioning regimens:

- Stratum A: conditioning therapy with additional thiotepa.
- Stratum B: conditioning therapy without additional thiotepa.

The trial duration per subject consisted of 4 phases:

-  Treatment  phase:  7  days  with  either  3  days  of  treosulfan  administration  or  4  days  of  busulfan administration (completed)
- Observation phase: until day +100 after HSCT (according to the PIP, this is defined until at least visit Day +100 [inclusive] of HSCT procedure) (completed)
- Follow-up phase: until 12 months after HSCT (completed)
- Longer-term follow-up phase (after completion of PIP): a minimum of 3 years of HSCT (ongoing).

The current clinical trial report (CTR) focusses mainly on the complete and final 12-month data, but also contains longer-term follow-up data that were available by data cut-off on 07-Jun-2021. Longer-term follow-up  data  will  be  collected  until  the  last  recruited  subject  has  completed  visit  Month  36  and presented in an updated version of the CTR expected in 2023.

Test product, Dose, Mode of Administration:

<div style=\"page-break-after: always\"></div>

Intravenous treosulfan 1 g or 5 g: 10 or 12 or 14 g/m²/day (BSA-adapted) on day -6 to day -4 before HSCT

Busulfan 60 mg: 3.2 to 4.8 mg/kg/day (actual body weight adapted) on day -7 to day -4 before HSCT

## Duration of Treatment:

Subjects within the test arm received treosulfan on 3 consecutive days (day -6 to day -4), while subjects in the reference arm received busulfan on 4 consecutive days (day -7 to day -4).

Subjects within both treatment arms received i.v. fludarabine (30 mg/m²/d) on 5 consecutive days (day -7 to -3) as mandatory non-investigational product. On Investigator's discretion, subjects could receive i.v. thiotepa in 2 single doses of 5 mg/kg given on day -2.

Allogeneic HSCT was performed on day 0.

## Criteria for Evaluation:

## Efficacy:

Freedom from transplantation (treatment)-related mortality: Freedom from transplantation (treatment)related mortality was the primary endpoint of the trial and defined as death from any transplantation (treatment)-related cause from start of conditioning treatment (ie, visit Day -7) until day +100 after HSCT. The associated time span of TRM (see endpoint TRM) was defined as the interval from end of HSCT to death due to transplantation-related cause whereas the time span of treatment related mortality was defined as interval from start of conditioning treatment, ie, visit Day -7, until end of HSCT.

Transplantation-related mortality: TRM was defined as the probability of dying from GvHD, interstitial pneumonitis, pulmonary toxicity, infection (bacterial, viral, fungal, parasitic, unknown), Epstein Barr Virus (EBV) proliferative disease, rejection / poor graft function, HSOS, haemorrhage, cardiac toxicity, central  nervous  system  toxicity,  gastrointestinal  toxicity,  skin  toxicity,  renal  failure,  multiple  organ failure, other HSCT-related cause. The associated time span was defined as the interval from end of HSCT to death due to transplantation-related cause. TRM was evaluated from the end of HSCT until the end of the longer-term follow-up phase.

Overall survival: Overall survival (OS) was defined as the probability of surviving. Survival time was defined as the time length between end of HSCT and the day of death due to any cause. OS was evaluated from the end of HSCT until the end of the longer-term follow-up phase.

Graft failure: The incidence of graft failure was defined as the probability of having a graft failure (primary or secondary) and being alive without using 'stem cell infusion (re-transplant) with conditioning' rescue therapy (ie, second allogenic transplantations) between the end of HSCT and the end of the longer-term follow-up phase. In addition, the rate of primary and secondary graft failures was assessed.

Engraftment: Neutrophilic granulocytes engraftment was defined as the first of 3 consecutive days with an granulocyte count &gt; 0.5 x 10 9 /L in PB, leucocyte engraftment was defined as the first of 3 consecutive days with a total leucocyte count &gt; 1 x 10 9 /L in PB, PLT engraftment was defined as the first of 3 consecutive  days  with  a)  PLTs  &gt;  20  x  10 9 /L  or  b)  PLTs  &gt;  50  x  10 9 /L  in  PB  in  the  absence  of  PLT transfusion. Time to engraftment was defined as the time span between end of HSCT and neutrophil granulocyte  /  leucocyte  /  PLT  engraftment.  In  addition,  the  duration  of  neutropenia  (neutrophilic granulocytes ≤ 0.5 x 10 9 /L) and leukopenia (leucocytes granulocytes ≤ 1.0 x 10 9 /L) was analysed based on documented laboratory values.

Quantification of donor type chimerism: Complete donortype chimerism was defined if a value of ≥ 95% donor-type was detected. Mixed chimerism was defined as having a recipient fraction &gt; 5% (to 94%).

<div style=\"page-break-after: always\"></div>

Incidences of complete donor-type chimerism were estimated as the number of subjects with complete chimerism divided by the total number of subjects at risk. To investigate the mixed donor-type chimerism the frequency of subjects with at least 20% or 50% donor-type chimerism was calculated. Chimerism was evaluated on visit Day +28, +100 and Month 12, and during longer-term follow-up.

Event-free survival: Event-free survival (EFS) was defined as the time length between end of HSCT and the  date  of  graft  failure  or  'stem  cell  infusion  (re-transplant)  with  conditioning'  rescue  therapy  (ie, second allogenic transplantations) or death (whatever occurred first). EFS was evaluated from the end of HSCT until the end of the longer-term follow-up phase.

GvHD-free survival: GvHD-free survival was measured from end of HSCT to time of event. The associated time span was defined as the interval from end of HSCT to aGvHD of at least grade III, moderate or severe cGvHD, or death (whatever occurred first). GvHD-free survival was evaluated from the end of HSCT until the end of the longer-term follow-up phase.

Chronic GvHD-free survival: cGvHD-free survival was measured from end of HSCT to time of event. The associated time span was defined as the interval from end of HSCT to moderate or severe cGvHD or death (whatever occurred first). cGvHD-free survival was evaluated from the end of HSCT until the end of the longer-term follow-up phase.

Rescue therapies: The use of and duration of using rescue therapies like DLIs, stem cell boost, stem cell infusion (retransplantation) with conditioning, stem cell infusion (re-transplantation) without conditioning, transfusion dependence for red blood cells, transfusion dependence for PLTs, and other was described from end of HSCT until the end of the longer-term follow-up phase.

## Pharmacokinetics:

Pharmacokinetic (PK) data were collected to contribute to a population model and to assess covariates. On day -6, blood samples were collected from a subset of subjects allocated to treosulfan treatment. Bioanalytical methods applied and results of PK and population pharmacokinetic analysis are reported by Celerion and Venn Life Science.

## Study participants

In total, 101 subjects (67 male, 34 female) have been analysed in this clinical trial including:

- 44 subjects from 28 days to &lt; 4 years of age
- 41 subjects from 4 years to &lt; 12 years of age.

The number of subjects in each analysis set was: All subjects 54 (Bu) 52 (Treo) 106 (Total); Safety set 50 (Bu) 51 (Treo) 101 (Total); Full analysis set 50 (Bu) 51 (Treo) 101 (Total)

## Inclusion criteria

1. Non-malignant  disease  indicated  for  first  myeloablative  allogeneic  HSCT:  inborn  errors  of metabolism,  primary  immunodeficiencies  (PIDs),  haemoglobinopathies  (Hb-pathies),  and  bone marrow failure syndromes.
2. First allogeneic HSCT.
3. Available  matched  sibling  donor,  matched  family  donor  or  matched  unrelated  donor.  For  bone marrow (BM) and peripheral blood (PB) match was defined as at least 9/10 allele matches after four digit typing in human leucocyte antigen (HLA)-A, -B, -C, -DRB1 and -DQB1 antigens. For umbilical cord blood match was defined as at least 5/6 matches after 2 digit typing in HLA-A and -B and four digit typing in -DRB1 antigens.

<div style=\"page-break-after: always\"></div>

4. Age at time of registration from 28 days to less than 18 years of age.
5. Lansky (subjects &lt; 16 years of age) or Karnofsky (subjects ≥ 16 years of age) performance score of at least 70%.
6. Written informed consent of the parents/legal guardian and subject's assent/consent according to national regulations.
7. Female subjects of child-bearing potential or partner of male subjects with child-bearing potential must use a highly effective method of contraception (pearl index &lt; 1%) such as complete sexual abstinence,  combined  oral  contraceptive,  hormone  intrauterine  contraceptive  device,  vaginal hormone  ring,  transdermal  contraceptive  patch,  contraceptive  implant  or  depot  contraceptive injection in combination with a second method of contraception like a condom or a cervical cap / diaphragm with spermicide or surgical sterilisation (vasectomy) in male subjects or male partners during the trial and at least 6 months thereafter. For female subjects on the trial, the vasectomised male partner should be the sole partner for that subject.
8. Negative pregnancy test for females of child-bearing potential.

## Results

The CSR of study MC-FludT.16/NM focusses on completed 12 month follow-up data for all subjects, but also contains follow-up data available as of the data cut-off on 07-Jun-2021. Longer-term follow-up data will be collected until the last recruited subject has completed visit Month 36 and presented in an updated version  of  the  CSR  expected  in  2023.  The  study  is  based  on  an  approved  PIP,  incl.  four  agreed modifications.

The results of the primary endpoint were: In the Full analysis set (FAS), the proportion of subjects which had died from transplantation- or treatment-related cause until day +100 was higher in the busulfan arm (5 of 50 subjects; 10.0%) than the treosulfan arm (0 of 51 subjects, 0.0%). The incidence of freedom from transplantation (treatment)-related mortality until day +100 was 90.0% (90% CI: 80.1%, 96.0%) in the busulfan arm and 100.0% (90% CI: 94.3%, 100.0%) in the treosulfan arm (p=0.0528), thus in favour of treosulfan.

<!-- image -->

a Adjusted for thiotepa and disease; b Stratified Cochran-Mantel-Haenszel test;  Fisher's exact test

Abbreviations:CI=confidenceinterval;N=total number of subjects.

Results from exploratory subgroup analyses (incidences of transplantation (treatment)-related mortality until day +100 by disease, donor type, thiotepa, serotherapy, CTP age group, and ICH age group) are presented. The forest plot for transplantation (treatment)-related mortality until day +100 by subgroups is  given  in  Figure  11.4.1.1.A.  The  results  of  the  subgroup  analyses  were  consistent  with  the  main analysis.

<div style=\"page-break-after: always\"></div>

<!-- image -->

The key results of the exploratory analysis of the secondary endpoints were:

- TRM at visit Month 12 was 12.0% (90% CI: 6.3%, 22.1%) in the busulfan arm and 3.9% (90% CI: 1.2%, 12.0%) in the treosulfan arm (HR 0.29, 90% CI: 0.08, 1.09; p=0.1244), thus in favour of treosulfan.

<div style=\"page-break-after: always\"></div>

Table 11.4.1.2.A Sunmaryresultsoftransplantation-relatedmortality (Full Analysis Set)

|                                                              | Busulfan (N=50)   | Treosulfan (N=51)   |
|--------------------------------------------------------------|-------------------|---------------------|
| Subjects with event                                          | 7 (14.0%)         | 2 (3.9%)            |
| Subjects without event                                       | 43 (86.0%)        | 49 (96.1%)          |
| Transplantation-related mortality at 12 months* [%] (90% CI) | 12.0 (6.3, 22.1)  | 3.9 (1.2, 12.0)     |
| Transplantation-related mortality at 24 monthsa[%] (90%CI)   | 12.0 (6.3, 22.1)  | 3.9 (1.2, 12.0)     |
| Transplantation-related mortality at 36months[%](90%CI)      | 16.0 (8.6, 28.6)  | 3.9 (1.2, 12.0)     |
| Hazard Ratio (Treosulfan/Busulfan)b (90% CI)                 | 0.29 (0.08, 1.09) | 0.29 (0.08, 1.09)   |
| p-valueb                                                     | 0.1244            | 0.1244              |
| Unadjusted p-valuec                                          | 0.0718            | 0.0718              |

Abbreviations: CI = confidence interval; N = total number of subjects.

Figure 11.4.1.2.A Kaplan-Meier estimates of transplantation-related mortality (Full Analysis Set)

<!-- image -->

Sources:Figure14.2.2A

Abbreviations:CI=confidence interval

Results from exploratory subgroup analyses (Kaplan-Meier estimates for TRM by disease, donor type, thiotepa, serotherapy, CTP age group, and ICH age group) are presented. A forest plot for TRM displaying 12-month rates by subgroups for the FAS is given in Figure 11.4.1.2.B. The results of the subgroup analyses were consistent with the main analysis.

Sources:Figure14.2.2B

<div style=\"page-break-after: always\"></div>

donor;MUD=matchedunrelateddonor.

<!-- image -->

In the 14 g/m²/day dose group, 2 of 10 subjects (20%) died from transplantation-related cause; no event (0.0%) occurred in the 2 lower dose groups. The Kaplan-Meier estimate of TRM at 12 months was 20.0% (90% CI: 6.7%, 51.1%) in the 14 g/m²/day dose group and 0% (90% CI: 0.0%, 0.0%) in the other dose groups. This apparent dose-dependency has to be seen in the context of PK data, which showed a comparable drug exposure for all 3 dose groups. Thus, other prognostic factors (like age, disease, donor type) have to be taken into account when interpreting the observed effect between dose groups.

- OS at visit Month 12 was 88.0% (90% CI: 77.9%, 93.7%) in the busulfan arm and 96.1% (90% CI: 88.0%, 98.8%) in the treosulfan arm (HR 0.29, 90%CI: 0.08, 1.09, p=0.1244), thus in favour of treosulfan.

<div style=\"page-break-after: always\"></div>

Table 11.4.1.3.A Summary results of overall survival(Full AnalysisSet)

|                                                       | Busulfan (N=50)   | Treosulfan (N=51)   |
|-------------------------------------------------------|-------------------|---------------------|
| Median follow-up? [months] (range of those surviving) | 25.4 (11.7, 63.3) | 25.6 (10.7, 60.9)   |
| Subjects with event                                   | 7 (14.0%)         | 2 (3.9%)            |
| Subjectswithout event                                 | 43 (86.0%)        | 49 (96.1%)          |
| Overall survival at 12 monthsb [%] (90% CI)           | 88.0 (77.9, 93.7) | 96.1 (88.0, 98.8)   |
| Overall survival at 24 monthsb [%] (90% CI)           | 88.0 (77.9, 93.7) | 96.1 (88.0, 98.8)   |
| Overall survival at 36 monthsb [%] (90% CI)           | 84.0 (71.4, 91.4) | 96.1 (88.0, 98.8)   |
| Hazard Ratio (Treosulfan/Busulfan)(90%CI)             | 0.29 (0.08, 1.09) | 0.29 (0.08, 1.09)   |
| p-valuec                                              | 0.1244            | 0.1244              |
| Unadjusted p-valued                                   | 0.0718            | 0.0718              |

Abbreviations: CI = confidence interval; N = total number of subjects.

Figure 11.4.1.3.A Kaplan-Meierestimatesofoverallsurvival (Full AnalysisSet)

<!-- image -->

Source:Figure14.2.3A

Results from exploratory subgroup analyses (Kaplan-Meier estimates for OS by disease, donor type, thiotepa, serotherapy, CTP age group, and ICH age group) are presented. A forest plot for OS displaying 12-month rates by subgroups for the FAS is presented. The results of the subgroup analyses were consistent with the main analysis.

<div style=\"page-break-after: always\"></div>

<!-- image -->

N -Nunber of subjects,I1 -Nunber of events

[al not adjusted, all other HRs are adjusted for Thiotepa and disease as factor using Cox regression model

Source:Figure14.2.3B

Abbreviations:BM=bone marrow;CI=confidence interval; CTP =clinical trial protocol;HR =hazard ratio;ICH= International CouncilforHarmonization;Inbom err.ofmetab.=Inbomerrorof metabolism;MRD=matchedrelated donor;MuD=matched unrelated donor.

In the 14 g/m²/day dose group, 2 of 10 subjects (20%) died; no event occurred in the 2 lower dose groups. The Kaplan-Meier estimate of OS at 12 months was 80.0% (90% CI: 48.9%, 93.3%) in the 14 g/m²/day dose group, and 100% (90% CI: 100.0%, 100.0%) in the other dose groups. This apparent dose-dependency has to be seen in the context of PK data, which showed a comparable drug-exposure for all 3 dose groups. Thus, other prognostic factors (like age, disease, or donor type) have to be taken into account when interpreting the observed difference between dose groups.

- The rate of graft failures at visit Month 12 was 4.0% (90% CI: 0.0%, 8.6%) in the busulfan arm and 15.8% (90% CI: 7.4%, 24.3%) in the treosulfan arm (HR 5.48, 90% CI: 1.44, 20.91, p=0.0366), thus statistically significant in favour of busulfan. Primary and secondary graft failures were evaluated as secondary endpoints.

<div style=\"page-break-after: always\"></div>

Table 11.4.1.4.A Rates ofprimary andsecondarygraftfailure (Full AnalysisSet)

|                         | Busulfan (N=50)   | Treosulfan (N=51)   | Total (N=101)   |
|-------------------------|-------------------|---------------------|-----------------|
| Primary graft failure   | 2/ 50 ( 4.0%)     | 2/ 51( 3.9%)        | 4/101 ( 4.0%)   |
| Secondary graft failure | 0/ 48 ( 0.0%)     | 9 / 49 (18.4%)      | 9/ 97 ( 9.3%)   |

Source:Table 14.2.4A

Note:Rateofprimary/secondarygraftfailurecalculated as numberof subjectswithgraftfailureby the number of subjects at risk.

-At risk for primary graft failure: Subjects with HSCT

- At risk for secondary graft failure: Subjects whose neutrophilic granulocytes engrafted after HSCT or were never below the required level

Abbreviations:N= total number of subjects.

Table 11.4.1.4.B

Summaryresultsofgraftfailure(FullAnalysisSet)

|                                                           | Busulfan (N=50)    | Treosulfan (N=51)   |
|-----------------------------------------------------------|--------------------|---------------------|
| Subjects with event                                       | 2 (4.0%)           | 11 (21.6%)          |
| Subjects without event (censored) or with competing event | 48 (96.0%)         | 40 (78.4%)          |
| Censored                                                  | 41 (82.0%)         | 38 (74.5%)          |
| Deatha                                                    | 6 (12.0%)          | 2 (3.9%)            |
| Second allogenic transplantation                          | 1 (2.0%)           | 0 (0.0%)            |
| Cumulative incidence at 12 months [%] (90% CI)            | 4.0 (0.0, 8.6)     | 15.8 (7.4, 24.3)    |
| Cumulative incidence at 24 months [%] (90% CI)            | 4.0 (0.0, 8.6)     | 21.0 (11.2,30.9)    |
| Cumulative incidence at 36 months [%] (90% C1)            | 4.0 (0.0, 8.6)     | 24.8 (13.6, 35.9)   |
| Hazard Ratio (Treosulfan/Busulfan) (90% CI)               | 5.48 (1.44, 20.91) | 5.48 (1.44, 20.91)  |
| p-valueb                                                  | 0.0366             | 0.0366              |
| Unadjusted p-valuec                                       | 0.0097             | 0.0097              |

Abbreviations:CI=confidence interval; N=total number of subjects.

Figure 11.4.1.4.A Cunulative incidence of graft failure (Full Analysis Set)

<!-- image -->

[a] adjusted for Thiotepa and disease as factorsusingFine and Gray model

Source:Figure14.2.4A

b adjusted for thiotepa and disease as factors using Fine and Gray model

minimumandmaximumofobservedeventtimes

cbased on Gray test

Abbreviations: CI=confidence interval;Max=maximum;Min =minimum.

Results from exploratory subgroup analyses (cumulative incidences of graft failure by disease, donor type, thiotepa, serotherapy, CTP age group, and ICH age group) are presented. A forest plot for graft failure displaying 12-month rates by subgroups is presented. The results of the subgroup analyses were

<div style=\"page-break-after: always\"></div>

consistent with the main analysis. All graft failures reported for subjects treated with treosulfan were in the subgroup of MUD, and 9 out of 11 subjects (81.8%) with graft failure received serotherapy.

<!-- image -->

N =Number of subjects,n =Number of events

[al| not adjusted, all other HRs are adjusted for Thiotepa and disease as factor using Fine and Gray model

Source:Figure14.2.4B

Abbreviations:BM=bone marrow;CI=confidence interval;CTP=clinicaltrialprotocol;HR=hazard ratio;ICH= Intermational CouncilforHarmonization;Inbomerr.of metab.=Inbom errorofmetabolism;MRD=matchedrelated donor;MUD=matched unrelateddonor.

The cumulative incidences of graft failure at 12 months were 22.2% (90% CI: 0.0%, 45.0%) in the 10 g/m²/day dose group, 19.1% (90% CI: 7.5%, 30.7%) in the 12 g/m²/day dose group, and 0.0% (90% CI: 0.0%, 0.0%) in the 14 g/m²/day dose group. This apparent dose-dependency has to be seen in the context  of  PK  data,  which  showed  a  comparable  drug-exposure  for  all  3  dose  groups.  Thus,  other prognostic factors (like age, disease, or donor type) have to be taken into account when interpreting the observed difference between dose groups.

- Reconstitution  of  granulopoiesis,  leukopoiesis,  and  thrombopoiesis  was  similar  in  the  treatment arms. However, the median duration of CTCAE grade IV neutropenia was statistically significantly longer in the treosulfan arm than the busulfan arm (20.0 days compared to 14.5 days, p=0.0108). Similar results were seen for duration of CTCAE grade IV leukopenia (19.0 days in the treosulfan arm compared to 14.5 days in the busulfan arm, p=0.0087).

Results  from  exploratory  subgroup  analyses  (conditional  cumulative  incidences  of  reconstitution  of thrombopoiesis &gt; 50 x10 9 /L by disease, donor type, thiotepa, serotherapy, CTP age group, and ICH age group) are presented. Subgroup analyses were generally consistent with the main analysis.

- The fraction of subjects with complete donor type chimerism decreased between visit Day +28 and visit Month 12 in both treatment arms, however, the incidence of complete donor-type chimerism was  comparable  between  the  treatment  arms  (visit  Day  +100:  p=0.1196;  visit  Month  12: p=0.2445). The fraction of subjects with mixed donor type chimerism ≥ 20% and ≥ 50% decreased between  visit  Day  +28  and  visit  Month  12  in  the  treosulfan  arm  whereas  it  remained  nearly

<div style=\"page-break-after: always\"></div>

unchanged in the busulfan arm. However, the incidences of mixed donortype chimerism ≥ 20% and ≥ 50% were comparable between the treatment arms, apart from visit Month 12, when the i ncidence of mixed donor type chimerism ≥ 50% was statistically significantly higher in the busulfan arm (p=0.0189).

<!-- image -->

| Table 11.4.1.6.A                                                                                         | Incidence of complete donor type chimerisim until Month 12 visit (Full Analysis Set)                     | Incidence of complete donor type chimerisim until Month 12 visit (Full Analysis Set)                     | Incidence of complete donor type chimerisim until Month 12 visit (Full Analysis Set)                     |
|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
|                                                                                                          | Busulfan                                                                                                 |                                                                                                          | Treosulfan                                                                                               |
| Subjects atrisk at Day+28visita                                                                          | N=50                                                                                                     |                                                                                                          | N=51                                                                                                     |
| Subjects with complete chimerism                                                                         |                                                                                                          | 41 ( 82.0%)                                                                                              | 43 ( 84.3%)                                                                                              |
| Subjectswithout complete chimerism                                                                       | 9 ( 18.0%)                                                                                               |                                                                                                          | 7 ( 13.7%)                                                                                               |
| Subjects without information                                                                             |                                                                                                          | 0 ( 0.0%)                                                                                                | 1 ( 2.0%)                                                                                                |
| Incidence [%] (90% C1) (95% CI) Odds ratio (90% CI) (95% CI) p-valuebed                                  | 82.0 (70.7, 90.3) (68.6, 91.4)                                                                           | 84.3 (73.5, 91.9) (71.4, 93.0)                                                                           | 1.5824 (0.61, 4.08) (0.51, 4.89)                                                                         |
|                                                                                                          |                                                                                                          | 0.4250                                                                                                   | 0.4250                                                                                                   |
| Unadjusted p-valuebe                                                                                     |                                                                                                          | 0.7858 N=51                                                                                              | 0.7858 N=51                                                                                              |
| Subjects at risk at Day +100 visit                                                                       | N=46                                                                                                     |                                                                                                          |                                                                                                          |
| Subjectswith complete chimerism                                                                          | 39 ( 84.8%)                                                                                              |                                                                                                          | 34 ( 66.7%)                                                                                              |
| Subjectswithout complete chimerism                                                                       | 5 (10.9%)                                                                                                |                                                                                                          | 14 (27.5%)                                                                                               |
| Subjectswithout information                                                                              | 2 ( 4.3%)                                                                                                |                                                                                                          | 3 ( 5.9%)                                                                                                |
| Incidence [%] (90% C1) (95% CI)                                                                          | 84.8 (73.3, 92.6) (71.1, 93.7)                                                                           | 66.7 (54.3, 77.5) (52.1, 79.2)                                                                           | 66.7 (54.3, 77.5) (52.1, 79.2)                                                                           |
| Odds ratio (90% CI) (95% CI) p-valuebcd                                                                  |                                                                                                          | 0.3972 (0.15,1.06) (0.12, 1.28) 0.1196                                                                   | 0.3972 (0.15,1.06) (0.12, 1.28) 0.1196                                                                   |
| Unadjusted p-valuebe Subjects at risk at Month 12 visita                                                 | N=43                                                                                                     | 0.0418 N=49                                                                                              | 0.0418 N=49                                                                                              |
| Subjects with complete chimerism                                                                         | 33 ( 76.7%)                                                                                              |                                                                                                          | 24 ( 49.0%)                                                                                              |
| Subjectswithoutcompletechimerism                                                                         | 9 ( 20.9%)                                                                                               |                                                                                                          | 14 ( 28.6%)                                                                                              |
| Subjects without information                                                                             | 1 ( 2.3%)                                                                                                |                                                                                                          | 11 (22.4%)                                                                                               |
| Incidence [%] (90% C1) (95% CI)                                                                          | 76.7 (63.8, 86.8) (61.4, 88.2)                                                                           | 49.0 (36.5, 61.5) (34.4, 63.7)                                                                           | 49.0 (36.5, 61.5) (34.4, 63.7)                                                                           |
| Odds ratiok (90% CI) (95% CI)                                                                            |                                                                                                          | 0.5429 (0.23, 1.28) (0.20, 1.51)                                                                         | 0.5429 (0.23, 1.28) (0.20, 1.51)                                                                         |
| p-valuebcd                                                                                               |                                                                                                          | 0.2445                                                                                                   | 0.2445                                                                                                   |
| Unadjusted p-valuebe                                                                                     |                                                                                                          |                                                                                                          |                                                                                                          |
| Source: Table 14.2.9A day +30, +107, +379, respectively.                                                 |                                                                                                          | 0.1455                                                                                                   | 0.1455                                                                                                   |
| Subjects are atrisk if theyhave anexamination at theDay+28,Day+100,Month 12visit orif they have survived | Subjects are atrisk if theyhave anexamination at theDay+28,Day+100,Month 12visit orif they have survived | Subjects are atrisk if theyhave anexamination at theDay+28,Day+100,Month 12visit orif they have survived | Subjects are atrisk if theyhave anexamination at theDay+28,Day+100,Month 12visit orif they have survived |
| b Missing values are excluded for odds ratio calculation and tests.                                      | b Missing values are excluded for odds ratio calculation and tests.                                      | b Missing values are excluded for odds ratio calculation and tests.                                      | b Missing values are excluded for odds ratio calculation and tests.                                      |

- EFS at visit Month 12 was 86.0% (90% CI: 75.5%, 92.2%) in the busulfan arm and 80.3% (90% CI: 69.2%, 87.8%) in the treosulfan arm (p=0.3343), thus in favour of busulfan. As graft failure is included in the event definition, the lower EFS observed in the treosulfan arm reflects the higher rate of secondary graft failures in the treosulfan arm, while death was more frequently reported in the busulfan arm.

<div style=\"page-break-after: always\"></div>

Table 11.4.1.7.A Summaryresultsofevent-freesurvival(Full AnalysisSet)

|                                                | Busulfan (N=50)   | Treosulfan (N=51)   |
|------------------------------------------------|-------------------|---------------------|
| Subjects with event                            | 9 (18.0%)         | 13 (25.5%)          |
| Deatha                                         | 6 (12.0%)         | 2 (3.9%)            |
| Primary graft failured                         | 2 (4.0%)          | 2 (3.9%)            |
| Secondary graft failured                       | 0 (0.0%)          | 9 (17.6%)           |
| Second allogeneic transplantationa             | 1 (2.0%)          | 0 (0.0%)            |
| Subjects without event                         | 41 (82.0%)        | 38 (74.5%)          |
| Event-free survival at 12 monthsb [%] (90% CI) | 86.0 (75.5, 92.2) | 80.3 (69.2, 87.8)   |
| Event-free survival at 24 months [%] (90% CI)  | 86.0 (75.5, 92.2) | 75.3 (63.2, 83.9)   |
| Event-free survival at 36 monthsb [%] (90% CI) | 81.9 (69.0, 89.8) | 71.9 (58.8, 81.4)   |
| Hazard Ratio (Treosulfan/Busulfan)(90% CI)     | 1.54 (0.74, 3.22) | 1.54 (0.74, 3.22)   |
| p-valuec                                       | 0.3343            | 0.3343              |
| Unadjusted p-valued                            | 0.3683            | 0.3683              |

Figure 11.4.1.7.A Kaplan-Meier estimates of event-free survival (Full Analysis Set)

<!-- image -->

[a] adjusted forThioteqa and discase asfactors using Coxregressionmodel

Source:Figure14.2.10A

minimum andmaximumof observedevent times

b adjusted for thiotepa and disease as factors using Cox regression model

cLog-rank test

d stratified by thiotepa and disease

Abbreviations:CI=confidenceinterval.

Results from exploratory subgroup analyses (Kaplan-Meier estimates for EFS by disease, donor type, thiotepa, serotherapy, CTP age group, and ICH age group) are presented. A forest plot for EFS displaying 12-month rates by subgroups is given in Figure 11.4.1.7.B. The results of the subgroup analyses were consistent with the main analysis.

<div style=\"page-break-after: always\"></div>

<!-- image -->

- cGvHD-free survival at visit Month 12 was 69.4% (90% CI: 57.1%, 78.8%) in the busulfan arm and 89.3% (90% CI: 79.0%, 94.7%) in the treosulfan arm (p=0.0308), thus statistically significant in favour of treosulfan.

<div style=\"page-break-after: always\"></div>

Table 11.4.1.8.A Summary results of GvHD-free survival (Full Analysis Set)

|                                              | Busulfan (N=50)   | Treosulfan (N=51)   |
|----------------------------------------------|-------------------|---------------------|
| Subjects with event                          | 15 (30.0%)        | 8 (15.7%)           |
| Deatha                                       | 4 (8.0%)          | 0 (0.0%)            |
| AcuteGvHDofatleastGradeIIIa                  | 4 (8.0%)          | 7 (13.7%)           |
| Moderate/severe chronicGvHDa                 | 7 (14.0%)         | 1 (2.0%)            |
| Subjectswithout event                        | 35 (70.0%)        | 43 (84.3%)          |
| GvHD-free survival at 12 monthsb [%] (90%CI) | 69.4 (57.1, 78.8) | 82.9 (71.5, 90.1)   |
| GvHD-free survival at 24 months [%] (90% CI) | 69.4 (57.1, 78.8) | 82.9 (71.5, 90.1)   |
| GvHD-free survival at 36 months[%] (90%CI)   | 69.4 (57.1, 78.8) | 82.9 (71.5, 90.1)   |
| Hazard Ratio (Treosulfan/Busulfan)(90% CI)   | 0.58 (0.28, 1.20) | 0.58 (0.28, 1.20)   |
| p-valuec                                     | 0.2178            | 0.2178              |
| Unadjusted p-valued                          | 0.1610            | 0.1610              |

Abbreviations: CI = confidence interval; GvHD = graft-versus-host disease; N = total number of subjects.

d Log-rank test

Figure 11.4.1.8.A Kaplan-Meier estimates of GvHD-free survival (Full Analysis Set)

<!-- image -->

Source:Figure 14.2.11A

Abbreviations:CI=confidence interval;GvHD=graft-versus-host disease.

Results from exploratory subgroup analyses (Kaplan-Meier estimates for GvHD-free survival by disease, donor type, thiotepa, serotherapy, CTP age group, and ICH age group) are presented. A forest plot for GvHD-free survival displaying 12-month rates by subgroups is presented. The results of the subgroup analyses were consistent with the main analysis.

<div style=\"page-break-after: always\"></div>

<!-- image -->

N = Number of subjects,n = Number of events

[al not adjusted, all other HRs are adjusted for Thiotepa and disease as factor using Cox regression model

Source:Figure14.2.11B

Abbreviations:BM=bonemarrow;CI=confidence interval;CTP=clinicaltrialprotocol;GvHD=graft-versus-host disease;HR=hazardratio;ICH=InternationalCouncilforHarmonization;Inbornerr.ofmetab.=Inbomerror of metabolism;MRD=matchedrelateddonor;MUD=matchedumrelateddonor.

- cGvHD-free survival at 12 months was 69.4% (90% CI:57.1%, 78.8%) in the busulfan arm and 89.3% (90% CI: 79.0%, 94.7%) in the treosulfan arm (p=0.0308, adjusted for thiotepa and disease as factors using the Cox regression model). This observation has to be considered in the context of reported incidence of cGvHD and OS. The HR for cGvHD-free survival of 0.32 (90% CI: 0.14, 0.76) was statistically significant in favour of treosulfan.

Table11.4.1.9.A SummaryresultsofcGvHD-freesurvival(Full AnalysisSet)

|                                                       | Busulfan (N=50)   | Treosulfan (N=51)   |
|-------------------------------------------------------|-------------------|---------------------|
| Subjects with event                                   | 15 (30.0%)        | 5 (9.8%)            |
| Deatha                                                | 5 (10.0%)         | 0 (0.0%)            |
| Moderate/severe chronicGvHDa                          | 10 (20.0%)        | 5 (9.8%)            |
| Subjectswithout event                                 | 35 (70.0%)        | 46 (90.2%)          |
| Chronic GvHD-free survival at 12 months [%] (90% CI)  | 69.4 (57.1, 78.8) | 89.3 (79.0, 94.7)   |
| Chronic GvHD-free survival at 24 months [%] (90% CI)  | 69.4 (57.1, 78.8) | 89.3 (79.0, 94.7)   |
| Chronic GvHD-free survival at 36 months* [%] (90% CI) | 69.4 (57.1, 78.8) | 89.3 (79.0, 94.7)   |
| Hazard Ratio(Treosulfan/Busulfan)(90%CI) p-valuec     | 0.32 (0.14, 0.76) | 0.32 (0.14, 0.76)   |
|                                                       | 0.0308            | 0.0308              |
| Unadjusted p-valued                                   | 0.0147            | 0.0147              |

Source:Table14.2.12A

Note:ChronicGvHD-freedefinedasnomoderate/severechronicGvHD

bbased on Kaplan-Meier estimates

onlyif thisevent occurredfirst

adjusted for thiotepa and disease as factors using Cox regression model d Log-rank test

Abbreviations:CI=confidence interval;(c)GvHD=(chronic)graft-versus-host disease;N=totalnumberof subjects

<div style=\"page-break-after: always\"></div>

Figure 11.4.1.9.A Kaplan-Meier estimates of chronic GvHD-free survival (Full Analysis Set)

Source:Figure14.2.12A

Abbreviations:CI=confidence interval;GvHD=graft-versus-host disease.

<!-- image -->

Results from exploratory subgroup analyses (Kaplan-Meier estimates for cGvHD-free survival by disease, donor type, thiotepa, serotherapy, CTP age group, and ICH age group) are presented. A forest plot for cGvHD-free survival displaying 12-month rates by subgroups is presented. The results of the subgroup analyses were consistent with the main analysis.

<div style=\"page-break-after: always\"></div>

<!-- image -->

N =Number of subjects,n =Number of events [a| not adjusted, all other HRs are adjusted for Thiotepa and disease as factor using Cox regression model

Source: Figure 14.2.12B

- The frequency of subjects with rescue therapies is given. In total, 21 subjects (42.0%) in the busulfan arm and 21 subjects (41.2%) in the treosulfan arm received any rescue therapy, mostly red blood cell or PLT transfusions. No differences were observed between the treatment arms. One subject (ID163112) in the busulfan arm received a re-transplantation with conditioning treatment as rescue therapy because of recurrent haemolytic episodes and recurrent CMV reactivations. The subject did not experience graft failure, but presented a 50% mixed chimerism.

<div style=\"page-break-after: always\"></div>

Table 11.4.1.10.A Frequency of subjects with rescue therapies (Full Analysis Set)

|                                                      | Busulfan (N=50)                | Treosulfan (N=51)                                               |
|------------------------------------------------------|--------------------------------|-----------------------------------------------------------------|
| Any rescue therapy                                   |                                |                                                                 |
| Subjects with rescue therapy                         | 21 ( 42.0%)                    | 21 ( 41.2%)                                                     |
| Subjects without rescue therapy                      | 29 ( 58.0%)                    | 30 ( 58.8%)                                                     |
| Incidence [%] (90% CI) (95% CI)                      | 42.0 (30.1, 54.6) (28.2, 56.8) | 41.2 (29.5, 53.7) (27.6, 55.8)                                  |
| Odds ratio* (90% CI) (95% CI)                        |                                | 0.7592 (0.38, 1.54) (0.33, 1.76)                                |
| p-valueab                                            |                                | 0.5264                                                          |
| Unadjusted p-valuec                                  |                                | 1.0000                                                          |
| DLIs                                                 |                                |                                                                 |
| Subjects with rescue therapy                         | 2 ( 4.0%)                      | 5 ( 9.8%)                                                       |
| Subjects without rescue therapy                      | 48 (96.0%)                     | 46 ( 90.2%)                                                     |
| Incidence [%] (90% C1) (95% CI)                      | 4.0 (0.7, 12.1) (0.5, 13.7)    | 9.8 (3.9, 19.5) (3.3, 21.4)                                     |
| Odds ratio (90% CI) (95% CI                          |                                | 1.6932 (0.37, 7.68) (0.28, 10.25)                               |
| p-valuedb                                            |                                | 0.5716                                                          |
| Unadjusted p-valuec                                  |                                | 0.4364                                                          |
| Stem cell boost                                      |                                |                                                                 |
| Subjects with rescue therapy                         | 1 ( 2.0%)                      | 2 ( 3.9%)                                                       |
| Subjects without rescue therapy                      | 49 (98.0%)                     | 49 (96.1%)                                                      |
| Incidence [%] (90% C1) (95% CI)                      | 2.0 (0.1, 9.1) (0.1, 10.6)     | 3.9 (0.7, 11.8) (0.5, 13.5)                                     |
| Odds ratio* (90% CI) (95% CI                         |                                | 0.8574 (0.07, 10.65) (0.04, 17.26)                              |
| p-valuedb                                            |                                | 0.9252                                                          |
| Unadjusted p-valuec                                  |                                | 1.0000                                                          |
| Stem cell infusion (re-transplant) with conditioning |                                |                                                                 |
| Subjects with rescue therapy                         | 1 ( 2.0%)                      | 0 ( 0.0%)                                                       |
| Subjects without rescue therapy                      | 49 (98.0%)                     | 51 (100.0%)                                                     |
| Incidence [%] (90% C1) (95% CI)                      | 2.0 (0.1, 9.1) (0.1, 10.6)     | 0.0 (0.0, 5.7) (0.0, 7.0)                                       |
| Odds ratio (90% C1) (95% CI)                         | <.0001 (NA) (NA)               | 0.3566                                                          |
| p-valuedb Unadjusted p-valuec                        |                                | 0.4950                                                          |
| Stem cellinfusion (re-transplant)                    |                                |                                                                 |
| without conditioning                                 |                                |                                                                 |
| Subjects with rescue therapy                         | 0 ( 0.0%)                      | (%00 ) 0                                                        |
| Subjects without rescue therapy                      | 50 (100.0%)                    | 51 (100.0%)                                                     |
| Incidence [%] (90% C1) (95% CI)                      | 0.0 (0.0, 5.8) (0.0, 7.1)      | 0.0 (0.0, 5.7) (0.0, 7.0)                                       |
| Transfusion dependenceforred blood                   |                                |                                                                 |
| cells                                                |                                |                                                                 |
| Subjects with rescue therapy                         | 17 (34.0%)                     | 17 (33.3%)                                                      |
| Subjects without rescue therapy                      | 33 (66.0%)                     | 34 ( 66.7%)                                                     |
| Incidence [%] (90% C1) (95% CI)                      | 34.0 (23.0, 46.5) (21.2, 48.8) | 33.3 (22.5, 45.7) (20.8, 47.9)                                  |
| Odds ratio* (90% CI) (95% CI) p-valuedb              |                                | 0.7725 (0.37, 1.62) (0.32, 1.86)                                |
|                                                      |                                | 0.5741                                                          |
| Unadjusted p-valuec                                  |                                | 1.0000                                                          |
| Transfusiondependenceforplatelets                    |                                |                                                                 |
| Subjects with rescue therapy                         | 14 ( 28.0%)                    | 14 ( 27.5%)                                                     |
| Subjects without rescue therapy                      | 36 ( 72.0%)                    | 37 ( 72.5%)                                                     |
| Incidence [%] (90% CI) (95% CI)                      | 28.0 (17.8, 40.3) (16.2, 42.5) | 27.5 (17.4, 39.5) (15.9, 41.7) 0.8631 (0.40, 1.86) (0.35, 2.16) |
| Odds ratio (90% CI) (95% CI) p-valuedb               |                                | 0.7566                                                          |
| Unadjusted p-valuec                                  |                                | 1.0000                                                          |
| Other rescue therapies                               |                                |                                                                 |
| Subjects with rescue therapy                         | 2 ( 4.0%)                      | 4 ( 7.8%)                                                       |
| Subjects without rescue therapy                      | 48 (96.0%)                     | 47 (92.2%)                                                      |
| Incidence [%] (90% CI) (95% CI)                      | 4.0 (0.7, 12.1) (0.5, 13.7)    | 7.8 (2.7, 17.1) (2.2, 18.9) 1.4174 (0.31, 6.58) (0.23,8.83)     |
| Odds ratio* (90% CI) (95% CI) p-valuedb              |                                | 0.7045                                                          |
| Unadjusted p-valuec                                  |                                | 0.6779                                                          |
| Source:Table 14.2.13A                                |                                | (2 of2)                                                         |

Abbreviations:CI=confidence interval;DLIs=;donor lymphocyte infusions;N= total number of subjects

Results from exploratory subgroup analyses (frequency of subjects with any rescue therapy by disease, donor type, thiotepa, serotherapy, CTP age group, and ICH age group) are presented. A forest plot for GvHD-free  survival  displaying  12-month  incidences  by  subgroups  is  presented.  The  results  of  the subgroup analyses were consistent with the main analysis. The treatment effect on rescue therapy was not relevantly influenced by other factors as shown in the logistic regression models.

<div style=\"page-break-after: always\"></div>

## MC-FludT.17/M

## Title of Study

Clinical phase II trial to describe the safety and efficacy of TREO-based conditioning therapy prior to allogeneic haematopoietic stem  cell transplantation in paediatric patients with haematological malignancies

## Methods

The overall  objective of  this  Phase  2  trial  was  to  describe  the  safety  and  efficacy  of  i.v.  Treosulfan administered as part of a standardised Fludarabine containing conditioning and to contribute to a PK model  which  permits  to  extend  the  use  of  Treosulfan  in  the  paediatric  population  by  extrapolating efficacy.

## Primary Objective

The primary objective of this trial  was  to  estimate  the  freedom  from transplant  (treatment)-related mortality until 100 days after HSCT.

The patient recruitment in this study was successfully completed within the planned recruitment period until end of September 2016. In total, 18 of the 24 centres initiated have enrolled 70 patients.

The trial was conducted in centres for stem cell transplantations in 5 countries: 10 sites in Germany, 4 sites in Poland, 1 site in the UK, 2 sites in Italy, and 1 site in the Czech Republic.

## Secondary Objectives

1.  Evaluation of  engraftment  after  HSCT,  defined  as  the  first  of  3  consecutive  days  for  each  of  the following 4 criteria:
- A leucocyte count of &gt; 1 x 10 9 /L
- An absolute neutrophil count (ANC) of &gt; 0.5 x 10 9 /L
- A platelet count of ≥ 20 x 10 9 /L in the absence of platelet transfusion
- A platelet count of ≥ 50 x 10 9 /L in the absence of platelet transfusion
2. Evaluation of safety including early toxicity based on the Common Terminology Criteria for Adverse Events (CTCAE, version 4.03) until day +100 after HSCT, serious adverse reactions (SARs) until the end of the longer-term follow-up phase
3. Evaluation of hepatic sinusoidal obstruction syndrome (HSOS, according to Jones et al [23]), lung toxicity  (CTCAE  term  'Pulmonary  Fibrosis'),  hepatic  toxicity  (according  to  Bearman  [6]),  and infections of any CTCAE grade (non-serious and serious) until day +100
4. Evaluation of donor-type chimerism on day +28, day +100, and 12 months after HSCT
5.  Evaluation  of  non-relapse  mortality  (NRM),  transplant-related  mortality  (TRM),  graft  failure  rate, incidence of relapse / progression, relapse-free survival (RFS) / progression free survival (PFS), and overall survival (OS) until 12 months after HSCT
6. Evaluation of incidence and severity of aGvHD (until day +100) and cGvHD (until 12 months after HSCT)
7.  Evaluation  of  use  of  rescue  therapies  including  donor-lymphocyte  infusions  (DLIs)  and  further conditioning regimens

<div style=\"page-break-after: always\"></div>

8. Evaluation of PK parameters of Treosulfan and its epoxides and to develop a PK model for assessing relevant covariates
9. Evaluation of NRM, TRM, secondary graft failures, relapse / progression, RFS / PFS, OS, and GvHD during the longer-term follow-up phase

## Methodology

Prospective, single arm, open-label, multicentre, non-controlled, Phase 2 clinical trial with trial duration per subject consisting of 4 phases:

- Treatment phase: 7 days with 3 days of Treosulfan administration
- Observation phase: until day +100 after HSCT (according to the PIP, this is defined until at least visit Day +100 [inclusive] of HSCT procedure)
- Follow-up phase: until 12 months after HSCT
- Longer-term follow-up phase (after completion of PIP): a minimum of 3 years after HSCT

## Treatments Administered

The required total dose of Treosulfan was calculated on the basis of the subject's BSA.  In a retrospective meta-analysis of the EBMT, data of 521 allogeneic and 83 autologous transplanted paediatric subjects were evaluated. Subjects received 3 doses of Treosulfan. The administered total dose ranged from 30 g/m 2  to 42 g/m 2 . Efficacy and safety analysis revealed that the conditioning treatment using Treosulfan was tolerable and effective in children of all age groups.

A PK analysis was conducted with all available data on any paediatric use of Treosulfan and a population PK model was developed using data of 23 children and 93 adults. A BSA dependant, tabulated modelbased dose recommendation was derived aimed at a Treosulfan area under the curve (AUC) of 1355 μg/h*ml, corresponding to an exposure of 3 x 14 g/m 2  in adult subjects.

Within this clinical trial, paediatric subjects were treated with Treosulfan according to the simplified BSAadjusted dosing table. This was implemented to avoid substantial over-exposure of the smallest infants (with BSA 0.3 to 0.5 m 2 ) and accounted for biological differences in the diverse paediatric age (BSA) groups.

<!-- formula-not-decoded -->

| BSA (m)   |   Treosulfan dose (g/m²/day) |
|-----------|------------------------------|
| ≤0.5      |                           10 |
| > 0.5-1.0 |                           12 |
| > 1.0     |                           14 |

In general, the administered dose of Treosulfan was not to be differed by &gt; 10% from the calculated dose.

Treosulfan  intravenous  (i.v.):  At  dose  levels  10  g/m²,  12  g/m²,  and  14  g/m²  over  2  hours  on  3 consecutive days on visit Days -6, -5, and -4 before alloHSCT.

This trial allowed administration of 2 different background conditioning regimens with Treosulfan for the treatment  of  ALL,  AML,  MDS,  and  JMML:  one  background  conditioning  regimen  consisted  of  a standardised Fludarabine-containing regimen (regimen A) whereas the other consisted of an intensified

<div style=\"page-break-after: always\"></div>

regimen with Fludarabine and Thiotepa (regimen B). The Investigator decided for each individual subject whether to treat the subject with regimen A or with regimen B.

- Fludarabine i.v. as single doses of 30 mg/m2 on 5 consecutive days (from visit Day -7 to -3).
- Subjects may receive Thiotepa i.v. in 2 single doses of 5 mg/kg given on visit Day -2 given at the discretion of the investigator

<!-- image -->

| Regimen A (\"standard regimen\"):                                                                                      | Regimen A (\"standard regimen\"):   | Regimen A (\"standard regimen\"):   | Regimen A (\"standard regimen\"):   | Regimen A (\"standard regimen\"):   | Regimen A (\"standard regimen\"):   | Regimen A (\"standard regimen\"):   | Regimen A (\"standard regimen\"):   | Regimen A (\"standard regimen\"):   | Regimen A (\"standard regimen\"):   | Regimen A (\"standard regimen\"):   | Regimen A (\"standard regimen\"):   |
|----------------------------------------------------------------------------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Day                                                                                                                  | -7                                | -6                                | -5                                | -4                                | -3                                | -2                                | -1                                | 0                                 | +1                                | +3                                | +6                                |
| Treosulfan i.v.(trialmedication) (BSA-adapted:10,12,or14g/m²/day over 120min,to be administeredprior to Fludarabine) |                                   | X                                 | X                                 | X                                 |                                   |                                   |                                   |                                   |                                   |                                   |                                   |
| Fludarabine i.y. (30 mg/m²/day)                                                                                      | X                                 | X                                 | X                                 | X                                 | X                                 |                                   |                                   |                                   |                                   |                                   |                                   |
| Allogeneicstemcelltransplantation                                                                                    |                                   |                                   |                                   |                                   |                                   |                                   |                                   | X                                 |                                   |                                   |                                   |
| Regimen B (\"intensified regimen\"):                                                                                   |                                   |                                   |                                   |                                   |                                   |                                   |                                   |                                   |                                   |                                   |                                   |
| Day                                                                                                                  | -7                                | -6                                | -5                                | -4                                | -3                                | -2                                | -1                                | 0                                 | +1                                | +3                                | +6                                |
| Treosulfan i.y.(trial medication) (BSA-adapted:10,12,or14g/m²/dayover                                                |                                   | X                                 | X                                 | X                                 |                                   |                                   |                                   |                                   |                                   |                                   |                                   |
| 120min,tobe administeredprior to Fludarabine)                                                                        |                                   |                                   |                                   |                                   |                                   |                                   |                                   |                                   |                                   |                                   |                                   |
| Fludarabine i.y. (30 mg/m²/day)                                                                                      | X                                 | X                                 | X                                 | X                                 | X                                 |                                   |                                   |                                   |                                   |                                   |                                   |
| Thiotepa i.v. (2 x 5 mg/kg/day)                                                                                      |                                   |                                   |                                   |                                   |                                   | XX                                |                                   |                                   |                                   |                                   |                                   |
| Allogeneicstemcelltransplantation                                                                                    |                                   |                                   |                                   |                                   |                                   |                                   |                                   | X                                 |                                   |                                   |                                   |

All subjects with ALL (38.6%), AML (41.4%), MDS (14.3%), or JMML (5.7%) received Treosulfan i.v. at a dose of 10 g/m2/day (8.6%), 12 g/m2/day (37.1%), or 14 g/m2/day (54.3%) according to their individual BSA. In addition, majority of the subjects (92.9%) received an intensified regimen with i.v. Thiotepa.

## Criteria for Evaluation:

## Efficacy:

Freedom  from  transplantation  (treatment)-related  mortality:  Freedom  from  transplant  (treatment)related mortality until 100 days after HSCT was assessed as the primary endpoint of the trial, and was defined as death from any transplant (treatment)-related cause from the day of first administration of conditioning treatment until 100 days after HSCT. This endpoint is a combination of TRM and treatmentrelated mortality. Treatment-related deaths were defined as any death prior to HSCT. Treatment-related mortality was planned to be evaluated from the day of the first administration of trial medication, ie, visit Day -6, until HSCT but was finally evaluated from the day of the first administration of conditioning treatment,  ie,  visit  Day  -7,  until  HSCT.  For  TRM  refer  to  the  related  endpoint  'transplant-related mortality'

Transplantation-related  mortality:  TRM  after  HSCT  was  defined  as  the  probability  of  dying  from  a transplant-related cause, i.e. which could not be attributed to disease relapse / progression or by deaths without previous relapse / progression. TRM was evaluated from end of HSCT to visit 12 months after HSCT. TRM was continuously assessed during the longer term follow up phase.

Overall survival: OS after HSCT was defined as the probability of surviving and was evaluated from the end of HSCT up to the visit 12 months after HSCT. OS was continuously assessed during the longer term follow up phase.

<div style=\"page-break-after: always\"></div>

Relapse / Progression Incidence: The incidence of relapse / progression after HSCT was defined as the probability of having relapse / progression of the underlying disease, death due to any cause, or End of Trial, whatever comes first. RFS / PFS was continuously assessed during the longer term follow up phase.

Relapse-free / Progression-free Survival: RFS / PFS until 12 months after HSCT was defined as the time length between end of HSCT and the date of relapse / progression of the underlying disease or death due to any cause, or End of Trial, whatever comes first. RFS / PFS was continuously assessed during the longer term follow up phase.

Graft Failures: All subjects were continuously assessed for primary or secondary graft failure from end of the HST up to visit 12 months after HSCT. Secondary graft failure was continuously assessed during the longer term follow up phase.

Non-relapse  Mortality:  NRM  after  HSCT  was  defined  as  the  probability  of  dying  in  the  absence  of persisting disease or previous occurrence of relapse / progression or graft failure. NRM was evaluated from end of the HSCT to visit 12 months after HSCT. NRM was continuously assessed during the longer term follow up phase.

Engraftment: Engraftment was defined as neutrophil count &gt; 0.5 x 10 9 /L, leucocyte count &gt; 1 x 10 9 /L, and platelet counts &gt; 20 x 10 9 /L or &gt; 50 x10 9 /L) and assessed up to 100 days after HSCT.

Donor-type Chimerism: Complete donortype chimerism was defined as ≥ 95% donor cells detected and was evaluated on visit Day +28, +100 and the visit 12 months after HSCT.

Event-free Survival: EFS was assessed as an additional exploratory endpoint of the trial and was defined as the length of time between end of HSCT and the date of relapse / progression, graft failure, or death (whatever occurs first).

GvHD-free Relapse-free / Progression-free Survival: GvHD-free and RFS / PFS (GRFS) was assessed as an additional exploratory endpoint of the trial.

Chronic GvHD-free and Relapse-free / Progression-free Survival: Chronic GvHD-free and RFS / PFS was also assessed as an additional exploratory endpoint of the trial.

Rescue Therapies: Use of rescue therapies in order to prevent acute graft failure or disease relapse / progression was also assessed.

## Pharmacokinetics:

Pharmacokinetics: Pharmacokinetic (PK) data were collected to contribute to a population model and to assess covariates. On day -6, blood samples were collected from a subset of subjects.

## Study participants

This trial included paediatric subjects (infants / toddlers, children, and adolescents) with haematological malignant disease, who require myeloablative conditioning treatment followed by alloHSCT (first HSCT or second HSCT due to disease relapse, graft failure or secondary malignancy after previous autologous or alloHSCT).

There was no gender-specific effects or adverse reactions (ARs) known or to be expected. Thus, male and female subjects were to be included into the trial.

At least 70 evaluable male and female paediatric subjects from 28 days to &lt; 18 years of age were to be included in this clinical trial and in the analysis. However, at least:

• 30 subjects from 28 days to &lt; 10 years of age

<div style=\"page-break-after: always\"></div>

- 30 subjects from 10 years to &lt; 18 years of age
- 50 subjects receiving a first HSCT were to be included.

A maximum of 30 subjects with second alloHSCT were to be included in the trial. The recruitment for a specific age group was to be closed when a maximum of 40 subjects had been included in this age group.

Subjects were equally distributed between the CTP age groups of 28 days to &lt; 10 years and 10 years to &lt; 18 years (50% each), and more subjects were in the ICH age group of 12 to 17 years (47.1%) and 2 to 11 years (40.0%) than 28 days to 23 months (12.9%).

The intensified regime with TT was given to 65 patients (92.9%).

The donor type was matched unrelated donor (MUD) for 56 patients (80.0%), matched sibling donor (MSD) for 13 patients (18.6%) and matched family donor (MFD) for 1 patient (1.4%).

Baseline disease characteristics included ALL (n = 27), AML (n = 29), MDS (n = 10), and JMML (n = 4).

## Inclusion criteria

1. Haematological malignant disease ie, ALL, AML, MDS, or JMML, indicated for alloHSCT
2. Indication for first alloHSCT or second alloHSCT due to disease relapse, graft failure, or secondary malignancy after previous HSCT
3. Available matched sibling donor (MSD), matched family donor (MFD), or matched unrelated donor (MUD). For BM and PB match was defined as 9 / 10 or 10 / 10 allele matches after 4 digit typing in human leucocyte antigens (HLAs)-A, B, C, and DRB1 and DQB1
4. Subjects with ALL or AML in complete morphologic remission (blast counts &lt; 5% in BM) and subjects with MDS or JMML with blast counts &lt; 20% in BM at trial entry
5. Age at time of registration from 28 days to &lt; 18 years of age
6. Lansky (subjects aged &lt; 16 years) or Karnofsky (subjects aged ≥ 16 years) performance score of at least 70%
7. Written informed consent of the parents / legal guardians and subject's assent / consent according to national regulations
8. Females of child-bearing potential or male subjects' partners with child-bearing potential had to have been using a highly effective method of contraception (pearl index &lt; 1%) such as complete sexual abstinence, combined oral contraceptive, hormone intrauterine contraceptive device, vaginal hormone  ring,  transdermal  contraceptive  patch,  contraceptive  implant  or  depot  contraceptive injection in combination with a second method of contraception like a condom, or a cervical cap / diaphragm with spermicide, or surgical sterilisation (vasectomy) in male subjects or male partners during the trial and at least 6 months thereafter
9. Negative pregnancy test for females of child bearing potential
10. All inclusion criteria had to be checked within 3 weeks before start of conditioning treatment on day -7.  In  case  of  repeated  examinations  due  to  hospital  standards,  the  most  current  result  was applicable (e.g., laboratory results)

## Results

The results of the primary objective and the results of secondary objectives until Visit M 12 have been described in version 1.0 of this CTR. The longer-term follow-up efficacy results from subjects until 3

<div style=\"page-break-after: always\"></div>

years after transplantation of the last registered subject are provided in this final CTR (version 2.0). The study is based on an approved PIP, incl. four agreed modifications. The agreed PIP includes a comparison of engraftment data (cumulative incidence) from trial MC-FludT.17/M with historical paediatric data and with  data  from  each  of  the  arms  of  the  trial  in  adult  patients  with  malignant  diseases  comparing conditioning with TREO or BU (MC-FludT.14/L). Results comparing the month 12 data of MC-FludT.17/M trial with historical engraftment data are given.

The results of the primary endpoint were: Overall, the rate for freedom from transplant (treatment)related mortality until 100 days after HSCT was 98.6% (90% CI: 93.4, 99.9). Due to the occurrence of only 1 event, no differential effects between subgroups could be identified. The respective subgroups in which the event appeared are shown in the forest plot.

<!-- image -->

N = Number of subjects, n = Number of events until 100 days

Sources:Figure14.2.1A.Table14.2.1A,Listing16.2.6F

Abbreviations: ALL = acute lymphoblastic leukaemia; AML= acute myeloid leukaemia; CI = confidence interval; CTP = Clinical Trial Protocol; HSCT = haematopoietic stem cell transplantation; ICH = Intermational Council of Harmonisation;JMML =juvenile myelomonocytic leukaemia; MDS =myelodysplastic syndrome;MRD =matched related donor; MUD = matched unrelated donor,

The key results of the exploratory analysis of the secondary endpoints were:

1. TRM: At the end of the longer-term follow-up period, 4 subjects (5.7%) had died from a transplantrelated cause. The Kaplan-Meier estimate of TRM at 12 months was 1.4% (90% CI: 0.3, 7.2) and increased to 4.6% (90% CI: 1.8, 11.4) at 36 months.

<div style=\"page-break-after: always\"></div>

Table 11.4.1.2.A Summaryresultsoftransplant-relatedmortality(FullAnalysisSet)

Sources: Table 14.2.2A, Table 14.2.2B, Listing 16.2.6F

|                                                           | Treosulfan (N=70)   |
|-----------------------------------------------------------|---------------------|
| Subjects with event [n (%)]                               | 4 (5.7)             |
| Subjects without event [n (%)]                            | 66 (94.3)           |
| Transplantation-related mortality at 100 days² [%] 1D %06 | 1.4 (0.3, 7.2)      |
| Transplantation-related mortality at 12 months* [%]       | 1.4                 |
| I%06                                                      | (0.3, 7.2)          |
| Transplantation-related mortality at 24 months* [%]       | 4.6                 |
| ID %06                                                    | (1.8, 11.4)         |
| Transplantation-related mortality at 36 months* [%]       | 4.6                 |
| ID %06                                                    | (1.8, 11.4)         |

Figure 11.4.1.2.A1 Kaplan-Meier estimatesoftransplant-relatedmortality(FullAnalysi Set)

<!-- image -->

[a] based on Kaplan-Meicr estimates

Sources:Figure14.2.2A,Table14.2.2A,Table14.2.2B,Listing16.2.6F

Abbreviations:CI=confidenceinterval.

A statistically significant difference in TRM was recorded between CTP age groups; however, only few events were observed and small numbers of subjects were in these groups, which also cover different diseases and risk groups.

<div style=\"page-break-after: always\"></div>

<!-- image -->

N = Number of subjects, n = Number of events until 36 months

Table 14.2.2H,Table14.2.2I,Table14.2.2J,Listing 16.2.6F.

2. OS: The median duration of follow-up based on reverse Kaplan-Meier estimate was 41.8 months (range of those surviving: 24.2 months to 57.5 months). At the end of the longer-term follow-up period, 58 subjects (82.9%) were alive. The Kaplan-Meier estimate of OS at 12 months after HSCT was 91.4% (90% CI: 83.9, 95.5) and was 84.3% (90% CI: 75.5, 90.1) at 36 months after HSCT.

<div style=\"page-break-after: always\"></div>

Table 11.4.1.3.A Summary results of overall survival (Full AnalysisSet)

|                                                       | Treosulfan (N=70)   |
|-------------------------------------------------------|---------------------|
| Median follow-up² [months] (range of those surviving) | 41.8 (24.2, 57.5)   |
| Subjects with event [n (%)]                           | 12 (17.1)           |
| Subjects without event [n (%)]                        | 58 (82.9)           |
| Overall survival at 12 months [%]                     | 91.4                |
| I %06                                                 | (83.9, 95.5)        |
| Overall survival at 24 months* [%]                    | 85.7                |
| 1D %06                                                | (77.1, 91.2)        |
| Overall survival at 36 months [%]                     | 84.3                |
| ID %06                                                | (75.5, 90.1)        |

Sources: Table 14.2.3A,Table 14.2.3B,Listing 16.2.6F

Based on Kaplan-Meier estimates

Abbreviations: CI = confidence interval; N = number of subjects; n = number of subjects in category.

Figure 11.4.1.3.A Kaplan-Meier estimates of overall survival (Full Analysis Set)

<!-- image -->

Sources:Figure 14.2.3A,Table 14.2.3A,Table14.2.3B,Listing16.2.6F. Abbreviations:CI=confidenceinterval.

OS at 36 months was comparable for the disease groups, ie, 81.5% for ALL subjects, 86.2% for AML subjects, 90.0% for MDS subjects, and 75.0% for JMML subjects. Due to the individual BSA-related dose calculation,  OS was 100% in the 10 g/m 2 /day Treosulfan group, however with only 6 subjects, and 76.2% in the 14 g/m 2 /day Treosulfan group. As expected, a statistically significant difference in OS was recorded between subjects in first HSCT (36-month rate: 86.1%) and subjects in second HSCT (36month rate: 60.0%); however, only few events were observed and only 5 subjects were in the latter group. A statistically significant difference in OS was also observed between the CTP age groups.

<div style=\"page-break-after: always\"></div>

<!-- image -->

N = Number of subjects, n = Number of events until 36 months

Sources: Figure 14.2.3B,Tab1e 14.2.3A,Tab1e 14.2.3C,Table 14.2.3D,Table 14.2.3E, Table 14.2.3F,

Table14.2.3G,Table14.2.3H,Table14.2.31,Listing16.2.6F

3. Relapse  /  Progression  Incidence:  At  the  end  of  the  longer-term  follow-up  period,  16  subjects (22.9%)  had  experienced  disease  relapse  /  progression.  The  cumulative  incidence  of  relapse  / progression at 12 months was 15.7% (90% CI: 8.6, 22.9) and at 36 months was 23.0% (90% CI: 14.7, 31.3). No relapse was observed beyond 24 months after HSCT.

Table 11.4.1.4.A Summary results ofrelapse/progression (Full AnalysisSet)

Sources:Table 14.2.4A,Table 14.2.4B,Listing16.2.6F

|                                                                 | Treosulfan (N=70)   |
|-----------------------------------------------------------------|---------------------|
| Subjects with event [n (%)]                                     | 16 (22.9)           |
| Subjects without event(censored) or with competing event [n(%)] | 54 (77.1)           |
| Censored                                                        | 51 (72.9)           |
| Deatha                                                          | 2 (2.9)             |
| Primary graft failurea                                          | 0 (0.0)             |
| Secondarygraft failure?                                         | 1 (1.4)             |
| Cumulative incidence ofrelapse/progression at 12months(%)       | 15.7                |
| I%06                                                            | (8.6, 22.9)         |
| Cumulativeincidence ofrelapse/progression at 24months(%)        | 23.0                |
| I0%06                                                           | (14.7, 31.3)        |
| Cumulativeincidenceofrelapse/progression at36months(%)          | 23.0                |
| I%06                                                            | (14.7, 31.3)        |

<div style=\"page-break-after: always\"></div>

Figure 11.4.1.4.A Cumulative incidence ofrelapse/progression (Full Analysis Set)

<!-- image -->

[a] minimum and maximum of observed event times

Sources:Figure14.2.4A,Table 14.2.4A,Tab1e 14.2.4B,Listing16.2.6F

In  the  disease  subgroups,  a  statistically  significant  difference  in  relapse  /  progression  was  recorded between JMML (75%), ALL (29.6%), AML (17.2%), and MDS (0.0%) subgroups; however, only small numbers of JMML and MDS subjects were in these groups. A statistically significant difference in relapse / progression was also recorded between subjects in first HSCT (20.1%) and subjects in second HSCT (60.0%); however, only 5 subjects were in the second transplant group reflecting their poor prognosis in general.

<div style=\"page-break-after: always\"></div>

<!-- image -->

N = Numbcr of subjccts, n = Number of events until 36 months

Sources:Figure 14.2.4B,Table14.2.4B,Table 14.2.4C,Table 14.2.4D,Table14.2.4E,Table14.2.4F, Table14.2.4G,Table14.2.4H,Table 14.2.4I,Listing16.2.6F

4. RFS / PFS until 12 months after HSCT: At the end of the longer-term follow-up period, 16 subjects (22.9%) had experienced disease relapse / progression and 3 subjects (4.3%) had died without previous relapse / progression. The Kaplan-Meier estimate of RFS / PFS at 12 months was 82.9% (90% CI: 73.9, 89.0), reached a plateau at 24 months and remained 72.7% (90% CI: 62.7, 80.4) at 36 months after HSCT.

<div style=\"page-break-after: always\"></div>

Table11.4.1.5.A Summaryresults ofrelapse-free/progression-free survival (Full Analysis Set)

|                                                          | Treosulfan (N=70)   |
|----------------------------------------------------------|---------------------|
| Subjects with event [n (%)]                              | 19 (27.1)           |
| Deatha                                                   | 3 (4.3)             |
| Relapse/Progression?                                     | 16 (22.9)           |
| Subjects without event [n (%)]                           | 51 (72.9)           |
| Relapse-free/progression-free survival at 12 months° (%) | 82.9                |
| ID %06                                                   | (73.9, 89.0)        |
| Relapse-free/progression-free survival at 24 monthsb (%) | 72.7                |
| ID %06                                                   | (62.7, 80.4)        |
| Relapse-free/progression-free survival at 36 monthsb (%) | 72.7                |
| ID %06                                                   | (62.7, 80.4)        |

Sources:Table 14.2.5A, Tab1e 14.2.5B, Listing 16.2.6F

Based onKaplan-Meier estimates

Only if this event occurred first

Abbreviations: CI = confidence interval; N = number of subjects; n = number of subjects in category.

Figure 11.4.1.5.A Kaplan-Meier estimates of relapse-free /progression-free survival (Ful Analysis Set)

<!-- image -->

[a] based on Kaplan-Meier estimates

Sources:Figure14.2.5A,Table 14.2.5A,Table 14.2.5B,Listing16.2.6F

In the disease subgroups, a statistically significant difference in RFS / PFS was recorded between JMML (25.0%), ALL (66.7%), AML (79.3%), and MDS (88.9%) subgroups; however, only small numbers JMML and MDS subjects were in these groups. As expected, a statistically significant difference in RFS / PFS was  also  recorded  between  subjects  in  first  HSCT  (75.2%)  and  subjects  in  second  HSCT  (40.0%); however, only 5 subjects were in the second HSCT group. In contrast, no significant differences were observed between the different dose groups.

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                | Figure 11.4.1.5.B Forestplotfor relapse-free/progression-freesurvivaldisplaying36. months rates by subgroups (Full Analysis Set)   | Figure 11.4.1.5.B Forestplotfor relapse-free/progression-freesurvivaldisplaying36. months rates by subgroups (Full Analysis Set)   | Figure 11.4.1.5.B Forestplotfor relapse-free/progression-freesurvivaldisplaying36. months rates by subgroups (Full Analysis Set)   | Figure 11.4.1.5.B Forestplotfor relapse-free/progression-freesurvivaldisplaying36. months rates by subgroups (Full Analysis Set)   |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
|                                | N                                                                                                                                  | n                                                                                                                                  | Rate at 36 months [%] (90% CI)                                                                                                     | Rate at 36months [%] (90% CI)                                                                                                      |
| Overall                        | 70                                                                                                                                 | 19                                                                                                                                 | 72.7 (62.7, 80.4)                                                                                                                  |                                                                                                                                    |
| Disease                        | Disease                                                                                                                            | Disease                                                                                                                            | Disease                                                                                                                            | Disease                                                                                                                            |
| ALL                            | 27                                                                                                                                 | 9                                                                                                                                  | 66.7 (49.4, 79.2)                                                                                                                  |                                                                                                                                    |
| AML                            | 29                                                                                                                                 | 6                                                                                                                                  | 79.3 (63.5, 88.8)                                                                                                                  |                                                                                                                                    |
| MDS                            | 10                                                                                                                                 | 1                                                                                                                                  | 88.9 (54.3, 97.8)                                                                                                                  |                                                                                                                                    |
| JMML                           | 4                                                                                                                                  | 3                                                                                                                                  | 25.0 (2.1, 60.9)                                                                                                                   |                                                                                                                                    |
| Treosulfan dose                | Treosulfan dose                                                                                                                    | Treosulfan dose                                                                                                                    | Treosulfan dose                                                                                                                    | Treosulfan dose                                                                                                                    |
| 10 g/m2/day                    | 6                                                                                                                                  | 1                                                                                                                                  | 83.3 (38.8, 96.5)                                                                                                                  |                                                                                                                                    |
| 12 g/m2/day                    | 26                                                                                                                                 | 8                                                                                                                                  | 69.2 (51.7, 81.5)                                                                                                                  |                                                                                                                                    |
| 14 g/m2/day                    | 38                                                                                                                                 | 10                                                                                                                                 | 73.3 (59.2, 83.2)                                                                                                                  |                                                                                                                                    |
| Number of HSCT                 | Number of HSCT                                                                                                                     | Number of HSCT                                                                                                                     | Number of HSCT                                                                                                                     | Number of HSCT                                                                                                                     |
| 1st                            | 65                                                                                                                                 | 16                                                                                                                                 | 75.2 (65.0, 82.8)                                                                                                                  |                                                                                                                                    |
| 2nd                            | 5                                                                                                                                  | 3                                                                                                                                  | 40.0 (8.6, 71.0)                                                                                                                   |                                                                                                                                    |
| Thiotepa                       | Thiotepa                                                                                                                           | Thiotepa                                                                                                                           | Thiotepa                                                                                                                           | Thiotepa                                                                                                                           |
| yes                            | 65                                                                                                                                 | 17                                                                                                                                 | 73.6 (63.3, 81.5)                                                                                                                  |                                                                                                                                    |
| no                             | 5                                                                                                                                  | 2                                                                                                                                  | 60.0 (19.1, 85.4)                                                                                                                  |                                                                                                                                    |
| Donor type                     | Donor type                                                                                                                         | Donor type                                                                                                                         | Donor type                                                                                                                         | Donor type                                                                                                                         |
| MRD                            | 14                                                                                                                                 | 2                                                                                                                                  | 85.7 (61.0, 95.3)                                                                                                                  |                                                                                                                                    |
| MUD                            | 56                                                                                                                                 | 17                                                                                                                                 | 69.4 (57.9, 78.3)                                                                                                                  |                                                                                                                                    |
| CTP age group                  | CTP age group                                                                                                                      | CTP age group                                                                                                                      | CTP age group                                                                                                                      | CTP age group                                                                                                                      |
| 28 days to lcss than 10 years  | 35                                                                                                                                 | 10                                                                                                                                 | 71.4 (56.7, 81.9)                                                                                                                  |                                                                                                                                    |
| 10 years to less than 18 years | 35                                                                                                                                 | 9                                                                                                                                  | 73.9 (59.2, 84.0)                                                                                                                  |                                                                                                                                    |
| ICH age group                  | ICH age group                                                                                                                      | ICH age group                                                                                                                      | ICH age group                                                                                                                      | ICH age group                                                                                                                      |
| 28days to 23months             | 9                                                                                                                                  | 1                                                                                                                                  | 88.9 (54.3, 97.8)                                                                                                                  |                                                                                                                                    |
| 2 to 11 years                  | 28                                                                                                                                 | 10                                                                                                                                 | 64.3 (47.4, 77.0)                                                                                                                  |                                                                                                                                    |
| 12 to 17 years                 | 33                                                                                                                                 | 8                                                                                                                                  | 75.3 (60.2, 85.4)                                                                                                                  |                                                                                                                                    |
|                                |                                                                                                                                    |                                                                                                                                    |                                                                                                                                    | 0 20 40 60 80 001                                                                                                                  |

N = Number of subjects, n = Number of events until 36 months

Sources:Figure 14.2.5B,Table14.2.5A,Table 14.2.5C,Table 14.2.5D,Table 14.2.5E,Table 14.2.5F. Table 14.2.5G, Table 14.2.5H, Table 14.2.51, Listing 16.2.6F.

5. Graft failure after HSCT: No subject experienced a primary graft failure and only 1 subject with ALL experienced a secondary graft failure.

Table11.4.1.6.A Resultsofprimaryandsecondarygraftfailure(FullAnalysisSet)

|                       | n/N (%)    | 10 %06     |
|-----------------------|------------|------------|
| Primarygraftfailure   | 0/70 (0.0) | (0.0, 4.2) |
| Secondarygraftfailure | 1/69 (1.4) | (0.1, 6.7) |

Source:Table14.2.6A,Table14.2.6B,Listing16.2.6B

No.of events (n)/No.atrisk (N),where No.ofevents =No.of subjects with graft failure Note:Atriskforprimarygraftfailure:subjectswithHSCT.Atriskforsecondarygraftfailure:Subjectswhose neutrophilicgranulocytesengraftedafterHSCTorwereneverbelowtherequiredlevel Abbreviations:CI=confidenceinterval;HSCT=haematopoieticstem cell transplantation;N=numberof subjects; n=numberofsubjectsincategory.

6. NRM after HSCT: At the end of the longer-term follow-up period, 2 subjects (2.9%) had died without relapse or graft failure. The cumulative incidence of NRM at 12 months was 1.4% (90% CI: 0.0, 3.8) and was only 2.9% (90% CI: 0.0, 6.1) at 36 months after HSCT.

<div style=\"page-break-after: always\"></div>

Table 11.4.1.7.A Summary results of non-relapse mortality (Full Analysis Set)

|                                                                   | Treosulfan (N=70)   |
|-------------------------------------------------------------------|---------------------|
| Subjects with event [n (%)]                                       | 2 (2.9)             |
| Subjects without event (censored) or with competing event [n (%)] | 68 (97.1)           |
| Censored                                                          | 51 (72.9)           |
| Relapse/Progression?                                              | 16 (22.9)           |
| Primary graft failure?                                            | 0 (0.0)             |
| Secondary graft failure?                                          | 1 (1.4)             |
| Cumulative incidence of non-relapse mortality at 12 months (%)    | 1.4                 |
| ID %06                                                            | (0.0, 3.8)          |
| Cumulative incidence of non-relapse mortality at 24 months (%)    | 2.9                 |
| I%06                                                              | (0.0, 6.1)          |
| Cumulative incidence of non-relapse mortality at 36 months (%)    | 2.9                 |
| I%06                                                              | (0.0, 6.1)          |

Sources:Table 14.2.7A,Table 14.2.7B,Listing16.2.6F

Only if this event occurred first

Abbreviations: CI = confidence interval; N = number of subjects; n = number of subjects in category.

Figure 11.4.1.7.ACumulative incidence of non-relapse mortality (Full AnalysisSet)

<!-- image -->

[al] minimum and maximum of observed event times

Sources: Figure 14.2.7A, Table 14.2.7A, Table 14.2.7B, Listing 16.2.6F.

7. Engraftment: The number of subjects with reconstitution of granulopoiesis was 69 (98.6%). The conditional  cumulative  incidence  at  14  days  after  HSCT  was  28.6%  (90%  CI:  18.7,  38.4)  and increased  to  86.9%  (90%  CI:  79.8,  93.9)  at  28  days  after  HSCT.  The  maximum  conditional cumulative incidence reached was 100.0% (90% CI: 97.7, 100.0).

<div style=\"page-break-after: always\"></div>

Table 11.4.1.8.A Summaryresultsofreconstitutionofgranulopoiesis(FullAnalysisSet)

|                                                                   | Treosulfan (N=70)   |
|-------------------------------------------------------------------|---------------------|
| Subjects with event [n (%)]                                       | 69 (98.6)           |
| Subjects without event (censored) or with competing event [n (%)] | 1 (1.4)             |
| Censored                                                          | 1 (1.4)             |
| Deatha                                                            | 0 (0.0)             |
| Relapse/Progression?                                              | 0 (0.0)             |
| Rescue therapiesa                                                 | 0 (0.0)             |
| Conditional cumulative incidence at 14 days (%)                   | 28.6                |
| I %06                                                             | (18.7,38.4)         |
| Conditional cumulative incidence at 28 days (%)                   | 86.9                |
| 1 %06                                                             | (79.8, 93.9)        |
| Maximum conditional cumulativeincidence reached (%)               | 100.0               |
| ID %06                                                            | (97.7, 100.0)       |

Sources:Table14.2.8A,Table14.2.8B,Listing16.2.6E

aOnly if thisevent occurredfirst.

Abbreviations: CI = confidence interval; N = number of subjects; n = number of subjects in category.

Figure 11.4.1.8.A Conditional cumulativeincidence of reconstitutionofgranulopoiesis (Full Analysis Set)

<!-- image -->

[a] minimum and maximum of observed event times

Sources:Figure14.2.8A,Table14.2.8A,Table14.2.8B,Listing16.2.6E

All subjects experienced neutropenia. Despite the excellent engraftment rate, the median duration of neutropenia was long (22 days; range 7 days to 44 days).

Table11.4.1.8.B Descriptive analysis of durationof neutropenia(Full AnalysisSet)

Source:Table14.2.8K,Listing16.2.6E

|                              | Treosulfan (N=70)   |
|------------------------------|---------------------|
| Neutropenia [n (%)]          |                     |
| Yesd                         | 70 (100.0)          |
| Duration ofneutropenia[days] |                     |
| N                            | 69                  |
| Mean (SD)                    | 22.3 (7.7)          |
| Median (Q1,Q3)               | 22.0 (17.0, 26.0)   |
| Min, Max                     | 7,44                |

<div style=\"page-break-after: always\"></div>

The number of subjects with reconstitution of leukopoiesis was 69 (98.6%). The conditional cumulative incidence at 14 days after HSCT was 30.0% (90% CI: 20.6, 39.4) and increased to 95.6% (90% CI: 90.9, 100.0) at 28 days after HSCT. The maximum conditional cumulative incidence reached was 100.0% (90% CI: 97.7, 100.0).

Table 11.4.1.8.C Summaryresultsofreconstitutionofleukopoiesis(FullAnalysisSet)

|                                                                   | Treosulfan (N=70)   |
|-------------------------------------------------------------------|---------------------|
| Subjects with event [n (%)]                                       | 69 (98.6)           |
| Subjects without event (censored) or with competing event [n (%)] | 1 (1.4)             |
| Censored                                                          | 1 (1.4)             |
| Deatha                                                            | 0 (0.0)             |
| Relapse/Progressiona                                              | 0 (0.0)             |
| Rescue therapiesa                                                 | 0 (0.0)             |
| Conditional cumulative incidence at 14 days (%)                   | 30.0                |
| 1D %06                                                            | (20.6, 39.4)        |
| Conditional cumulative incidence at 28 days (%)                   | 95.6                |
| I%06                                                              | (90.9, 100.0)       |
| Maximumconditionalcumulativeincidencereached(%)                   | 100.0               |
| I%06                                                              | (97.7, 100.0)       |

Sources:Table14.2.9A,Table14.2.9B,Listing16.2.6E

a Only if this event occurred first

Abbreviations: CI = confidence interval; N = number of subjects; n = number of subjects in category.

Figure 11.4.1.8.C Conditional cunulativeincidenceofreconstitution of leukopoiesis (Full Analysis Set)

<!-- image -->

[a] minimum and maximum of observed event times

Sources:Figure14.2.9A,Table 14.2.9A,Table14.2.9B,Listing 16.2.6E

All  subjects experienced leukopenia. Despite the excellent engraftment rate, the median duration of leukopenia was long (20 days; range 11 days to 42 days).

<div style=\"page-break-after: always\"></div>

Table11.4.1.8.D Descriptiveanalysisofdurationofleukopenia(FullAnalysisSet)

Source:Table14.2.9K,Listing16.2.6E

|                               | Treosulfan (N=70)   |
|-------------------------------|---------------------|
| Leukopenia[n (%)]             |                     |
| Yesa                          | 70 (100.0)          |
| Duration of leukopenia [days] |                     |
| N                             | 69                  |
| Mean (SD)                     | 20.5 (6.1)          |
| Median (Q1, Q3)               | 20.0 (16.0, 24.0)   |
| Min, Max                      | 11, 42              |

Leucocytes ≤ 1 G/L at least once between Day -7 and Day +28.

First date with leukopenia until date of engraftment (subjects at risk = subjects with leukopenia and leucopoesis).

Abbreviations:Max=maximum;Min=minimum;N=number of subjects;n=number of subjects in category,

Q1=firstquartile;Q3=thirdquartile;SD=standarddeviation.

The  number  of  subjects  with  reconstitution  of  thrombopoiesis  &gt;  20  x  109/L  was  65  (92.9%).  The conditional cumulative incidence at 14 days after HSCT was 34.3% (90% CI: 24.5, 44.1) and increased to 78.0% (90% CI: 69.5, 86.5) at 28 days after HSCT. The maximum conditional cumulative incidence reached was 94.1% (90% CI: 88.4, 99.9). In the disease subgroups, a statistically significant difference in reconstitution of thrombopoiesis &gt; 20 x 109/L was recorded between AML (100.0%), ALL (92.6%), MDS (90.0%), and JMML (75.0%) subgroups; however, only small number of MDS and JMML subjects were in these groups.

<div style=\"page-break-after: always\"></div>

Table11.4.1.8.E Summary results of reconstitution of thrombopoiesis &gt; 20 x 10°/L (Full Analysis Set)

|                                                           | Treosulfan (N=70)   |
|-----------------------------------------------------------|---------------------|
| Subjects with event [n (%)]                               | 65 (92.9)           |
| Subjects without event (censored) or with competing event | 5 (7.1)             |
| Censored                                                  | 5 (7.1)             |
| Death                                                     | 0 (0.0)             |
| Relapse/Progression                                       | 0 (0.0)             |
| Rescue therapiesa                                         | 0 (0.0)             |
| Conditional cumulative incidence at 14 days (%)           | 34.3                |
| 1D %06                                                    | (24.5, 44.1)        |
| Conditional cumulativeincidence at 28days (%)             | 78.0                |
| I%06                                                      | (69.5, 86.5)        |
| Maximum conditional cumulativeincidence reached (%)       | 94.1                |
| ID %06                                                    | ($8.4, 99.9)        |

Sources:Table 14.2.10A,Table14.2.10B,Listing 16.2.6E

Only if this event occurred first.

Abbreviations: CI = confidence interval; N = number of subjects; n = number of subjects in category.

Figure 11.4.1.8.E Conditional cumulative incidence of reconstitution 01 thrombopoiesis &gt; 20 x 10\"/L (Full Analysis Set)

<!-- image -->

[a] minimum and maximum of observed event times

Sources:Figure14.2.10A,Table14.2.10A,Table14.2.10B,Listing16.2.6E

The  number  of  subjects  with  reconstitution  of  thrombopoiesis  &gt;  50  x  10 9 /L  was  63  (90.0%).  The conditional cumulative incidence at 14 days after HSCT was 15.7% (90% CI: 8.4, 23.0) and increased to 62.2% (90% CI: 52.5, 71.9) at 28 days after HSCT. The maximum conditional cumulative incidence reached was 91.9% (90% CI: 84.9, 98.8). In the disease subgroups, a statistically significant difference in reconstitution of thrombopoiesis &gt; 50 x 10 9 /L was recorded between AML (100.0%) and ALL (90.1%) subgroups; however, only small numbers of subjects were in these groups.

<div style=\"page-break-after: always\"></div>

Table 11.4.1.8.F Sunmary results of reconstitution of thrombopoiesis &gt; 50 x 10°/L (Full Analysis Set)

|                                                                   | Treosulfan (N=70)   |
|-------------------------------------------------------------------|---------------------|
| Subjects with event [n (%)]                                       | 63 (90.0)           |
| Subjects without event (censored) or with competing event [n (%)] | 7 (10.0)            |
| Censored                                                          | 7 (10.0)            |
| Deatha                                                            | 0 (0.0)             |
| Relapse/Progression?                                              | 0 (0.0)             |
| Rescue therapiesa                                                 | 0 (0.0)             |
| Conditional cumulative incidence at 14 days (%)                   | 15.7                |
| I0%06                                                             | (8.4, 23.0)         |
| Conditional cumulative incidence at 28 days (%)                   | 62.2                |
| I %06                                                             | (52.5, 71.9)        |
| Maximumconditionalcumulativeincidencereached(%)                   | 91.9                |
| I %06                                                             | (84.9, 98.8)        |

Sources:Table14.2.11A,Table14.2.11B,Listing16.2.6E

Onlyif thiseventoccurredfirst

Abbreviations: CI = confidence interval; N = number of subjects; n = number of subjects in category.

Figure 11.4.1.8.F Conditional cumulative incidence of reconstitution of thrombopoiesis &gt; 50 x 10*/L (Full Analysis Set)

<!-- image -->

[a] minimum and maximum of observed event times

Sources:Figure14.2.11A,Table14.2.11A,Table14.2.11B,Listing16.2.6E

8. Donor-type Chimerism: At visit Day +28, the incidence of complete donor-type chimerism was 94.2% (90% CI: 87.2, 98.0), at visit Day +100 the incidence was 91.3% (90% CI: 83.6, 96.1), and  at  visit  Month  12  the  incidence  was  91.2%  (90%  CI:  82.4,  96.5).  In  the  subgroups,  a statistically significant difference was recorded for disease at visit Day +100 and at visit Month 12, and for the use of Thiotepa at visit Day +28. An incomplete donor-type chimerism was detected for 3 subjects at visit Day +28. However, 2 of them developed a complete donor-type chimerism by visit Day +100. Only one subject with JMML was assessed with a mixed donor-type chimerism of only 12% on visit Day +28, further decreasing to 2% on visit Month 12 suggesting an autologous recovery of haematopoiesis. The detected Treosulfan AUC∞ (ie, 271 μg/h*mL) of this subject was far below the expected range considered safe and effective (760 to 3600 μg.h/mL). No relapse was reported for this subject until 12 months after HSCT.

<div style=\"page-break-after: always\"></div>

Table11.4.1.9.A Incidence of complete donor-typechimerism (Full AnalysisSet)

|                                                               | Treosulfan   |
|---------------------------------------------------------------|--------------|
| Subjects at risk at Day +28 visita                            | N=69         |
| Subjects with complete chimerism at Day +28 visit [n (%)]     | 65 (94.2)    |
| Subjects without complete chimerism at Day +28 visit [n (%)]  | 3 (4.3)      |
| Subjects without information at Day +28 visit [n (%)]         | 1 (1.4)      |
| Incidence of complete chimerism at Day +28 visit (%)          | 94.2         |
| I0%06                                                         | (87.2, 98.0) |
| Subjects at risk at Day +100 visit                            | N=69         |
| Subjects with complete chimerism at Day +100 visit [n (%)]    | 63 (91.3)    |
|                                                               | 6 (8.7)      |
| Incidence of complete chimerism at Day +100 visit (%)         | 91.3         |
| I%06                                                          | (83.6, 96.1) |
| Subjects at risk at Month 12 visita                           | N=57         |
| Subjects with complete chimerism at Month 12 visit [n (%)]    | 52 (91.2)    |
| Subjects without complete chimerism at Month 12 visit [n (%)] | 3 (5.3)      |
| Subjects without information at Month 12 visit [n (%)]        | 2 (3.5)      |
| Incidence of complete chimerism at Month 12 visit (%)         | 91.2         |
| I0%06                                                         | (82.4, 96.5) |

Source:Table14.2.12A,Listing16.2.6C

Subjects are atrisk ifthey have a chimerism examination at the Day +28, Day +100, or Month 12 visit or if they have survived day +30, day +107, or day +379, and did not experience any relapse/progression or graft failure until the start of the visit that is,day +28,day +100 or day+365respectively.

Abbreviations: CI = confidence interval; N = number of subjects; n = number of subjects in category.

9. Event-free  Survival:  At  the  end  of  the  longer-term  follow-up  period,  19  subjects  (27.1%) experienced an event. The Kaplan-Meier estimate of EFS at 12 months was 81.4% (90% CI: 72.3, 87.8), reached a plateau after 24 months and was 72.7% (62.8, 80.4) at 36 months.

<div style=\"page-break-after: always\"></div>

Table11.4.1.10.ASummaryresultsofevent-freesurvival (FullAnalysisSet)

|                                       | Treosulfan (N=70)   |
|---------------------------------------|---------------------|
| Subjects with event [n (%)]           | 19 (27.1)           |
| Deatha                                | 2 (2.9)             |
| Relapse/Progression?                  | 16 (22.9)           |
| Primary graft failure?                | 0 (0.0)             |
| Secondary graf failured               | 1 (1.4)             |
| Subjects without event [n (%)]        | 51 (72.9)           |
| Event-free survival at 12 monthsb (%) | 81.4                |
| 10 %06                                | (72.3, 87.8)        |
| Event-free survival at 24 monthsb (%) | 72.7                |
| ID %06                                | (62.8, 80.4)        |
| Event-free survival at 36 monthsb (%) | 72.7                |
| ID %06                                | (62.8, 80.4)        |

Sources:Table14.2.13A,Table14.2.13B,Listing16.2.6G

Based on Kaplan-Meier estimates

Only if this event occurred first

Abbreviations: CI = confidence interval; N = number of subjects; n = number of subjects in category.

Figure11.4.1.10.AKaplan-Meier estimates of event-freesurvival (Full AnalysisSet)

<!-- image -->

[a] based on Kaplan-Meier estimates

Sources:Figure14.2.13A,Table14.2.13A,Table 14.2.13B,Listing16.2.6G.

A statistically  significant  difference  in  EFS  was  recorded  between  JMML  (25.0%), ALL (66.7%), AML (79.3%), or MDS (88.9%) disease subgroups, however, only small numbers of subjects were in the JMML and MDS groups. No statistically significant difference was recorded between the age subgroups and the dose subgroups. As expected, a statistically difference in EFS was also recorded between subjects in  first  HSCT  (75.2%) and subjects in second HSCT (40.0%), however, only 5 subjects were in the second HSCT group.

<div style=\"page-break-after: always\"></div>

<!-- image -->

N  Number of subjects, n - Number of events until 36 months

Sources:Figure 14.2.13B,Table 14.2.13A,Table14.2.13C,Table 14.2.13D,Table14.2.13E,Table 14.2.13F Table14.2.13G,Table14.2.13H,Table14.2.131,Listing16.2.6G

10. GvHD-free Relapse-free / Progression-free Survival: At the end of the longer-term follow-up period, 39 subjects (55.7%) were alive and had not experienced GvHD (ie, aGvHD ≥ Grade III or moderate / severe cGvHD) or relapse / progression. The Kaplan-Meier estimate of GRFS at 12 months was 65.7% (90% CI: 55.5, 74.1), reached a plateau at 24 months, and was 55.5% (90% CI: 45.2, 64.6) at 36 months.

Table 11.4.1.11.ASummary results of GvHD-free and relapse/progression-free survival (Full Analysis Set)

|                                                                   | Treosulfan (N=70)   |
|-------------------------------------------------------------------|---------------------|
| Subjects with event [n (%)]                                       | 31 (44.3)           |
| Deatha                                                            | 3 (4.3)             |
| Relapse/Progression?                                              | 14 (20.0)           |
| Acute GvHD of at least Grade IIIr                                 | 6 (8.6)             |
| Moderate/severe chronic GvHD*                                     | 8 (11.4)            |
| Subjects without event [n (%)]                                    | 39 (55.7)           |
| GvHD-free and relapse/progression-fee survival at 12 months* (%)  | 65.7                |
| ID%06                                                             | (55.5, 74.1)        |
| GvHD-free and relapse/progression-free survival at 24 monthsb (%) | 55.5                |
| I%06                                                              | (45.2, 64.6)        |
| GvHD-free and relapse/progression-fee survival at 36 months* (%)  | 55.5                |
| I%06                                                              | (45.2, 64.6)        |

Sources:Table14.2.14A,Table14.2.14B,Listing16.2.6G

°Based on Kaplan-Meier estimates

Onlyif thisevent occurredfirst

Note:GvHD-freedefined asno acuteGvHDofat leastGradeIII andnomoderate/severechronicGvHD

Abbreviations: CI=confidence interval; GvHD = graft-versus-host disease; N=number of subjects;n =number of subjects in category.

<div style=\"page-break-after: always\"></div>

Figure 11.4.1.11.A Kaplan-Meier estimates of GvHD-freeand relapse/progression-free survival (Full Analysis Set)

<!-- image -->

Note: GvHD-free defined as no acute GvHD of at least grade III and no moderate/severe chronic GvHD [a] based on Kaplan-Meier estimates

Sources:Figure 14.2.14A,Table14.2.14A,Table14.2.14B,Listing16.2.6G

In the disease subgroups, GRFS at 36 months was 51.9% for ALL subjects, 69.0% for AML subjects, 36.0% for MDS subjects, and 25.0% for JMML subjects. A statistically significant difference in GRFS was recorded between subjects in first HSCT (58.2%) and subjects in second HSCT (20.0%), however, only five subjects were in the second HSCT group. No difference was obvious when dose and age groups were compared.

<div style=\"page-break-after: always\"></div>

Figure 11.4.1.11.BForestplotforGvHD-freeandrelapse/progression-freesurvival displaying 36-months rates by subgroups (Full Analysis Set)

<!-- image -->

|                                | N   | n   | Rate at 36months [%] (90% CI)   | Rate at 36months [%](90%CI)   |
|--------------------------------|-----|-----|---------------------------------|-------------------------------|
| Overall                        | 70  | 31  | 55 5 (45 2., 64 6)              |                               |
| Disease                        |     |     |                                 |                               |
| ALL                            | 27  | 13  | 51.9 (35.2, 66.2)               |                               |
| AML                            | 29  | 9   | 69.0 (52.5, 80.7)               |                               |
| MDS                            | 10  | 6   | 36.0 (12.3, 60.8)               |                               |
| JMML                           | 4   | 3   | 25.0 (2.1, 60.9)                |                               |
| Treosulfan dose                |     |     |                                 |                               |
| 10 g/m2/day                    | 6   | 2   | 66.7 (27.0, 88.2)               |                               |
| 12 g/m2/day                    | 26  | 13  | 50.0 (33.2, 64.7)               |                               |
| 14 g/m2/day                    | 38  | 16  | 57.4 (43.0, 69.4)               |                               |
| Number ofHSCT                  |     |     |                                 |                               |
| 1st                            | 65  | 27  | 58.2 (47.4, 67.5)               |                               |
| 2nd                            | 5   | 4   | 20.0 (1.8, 52.5)                |                               |
| Thiotepa                       |     |     |                                 |                               |
| yes                            | 65  | 28  | 56.7 (45.9, 66.1)               |                               |
| no                             | 5   | 3   | 40.0 (8.6, 71.0)                |                               |
| Donor type                     |     |     |                                 |                               |
| MRD                            | 14  | 5   | 64.3 (39.6, 81.0)               |                               |
| MUD                            | 56  | 26  | 53.2 (41.6, 63.5)               |                               |
| CTP age group                  |     |     |                                 |                               |
| 28 days to less than 10 years  | 35  | 16  | 54.3 (39.6, 66.9)               |                               |
| 10 years to less than 18 years | 35  | 15  | 56.6 (41.7, 69.1)               |                               |
| ICH age group                  |     |     |                                 |                               |
| 28 days to 23 months           | 9   | 3   | 66.7 (34.8, 85.6)               |                               |
| 2 to 11 years                  | 28  | 14  | 50.0 (33.8, 64.2)               |                               |
| 12 to 17 years                 | 33  | 14  | 57.0 (41.6, 69.8)               |                               |

N  Number of subjects, n  Number of events until 36 months

Sources:Figure 14.2.14B,Tab1e 14.2.14A,Table 14.2.14C,Tab1e 14.2.14D,Table 14.2.14E,Table 14.2.14F,

Table14.2.14G,Table14.2.14H,Table14.2.14I,Listing16.2.6G

11. Chronic GvHD-free and Relapse-free / Progression-free Survival: At the end of the longer-term follow-up period, 40 subjects (57.1%) were alive and had not experienced moderate / severe cGvHD or relapse / progression. The Kaplan-Meier estimate of CRFS at 12 months was 67.1% (90% CI: 57, 75.4), reached a plateau at 24 months and finally resulted in 56.9% (90% CI: 46.6, 66.0) at 36 months.

Table11.4.1.12.A Summaryresults of chronicGvHD-free and relapse/progression-free survival (Full Analysis Set)

|                                                                           | Treosulfan (N=70)   |
|---------------------------------------------------------------------------|---------------------|
| Subjects with event                                                       | 30 (42.9%)          |
| Deatha                                                                    | 3 (4.3%)            |
| Relapse/Progression?                                                      | 14 (20.0%)          |
| Moderate/severe chronic GvHD                                              | 13 (18.6%)          |
| Subjects without event                                                    | 40 (57.1%)          |
| Chronic GvHD-free and relapse/progression-free survival at 12 months [%]  | 67.1                |
| ID%06                                                                     | (57.0, 75.4)        |
| Chronic GvHD-free and relapse/progression-free survival at 24 months° [%] | 56.9                |
| ID%06                                                                     | (46.6, 66.0)        |
| Chronic GvHD-free and relapse/progression-free survival at 36 months° [%] | 56.9                |
| I%06                                                                      | (46.6, 66.0)        |

Sources:Table 14.2.15A,Table 14.2.15B,Listing 16.2.6G

Based on Kaplan-Meier estimates.

Only if this event occurredfirst.

Note:Chronic GvHD-freedefined asnomoderate/severe chronic GvHD

Abbreviations:CI=confidenceinterval;GvHD=graft-versus-host disease;N=number of subject;n=number of subjects in category.

<div style=\"page-break-after: always\"></div>

Figure 11.4.1.12.A Kaplan-MeierestimatesofchronicGvHD-freeand relapsefree /progression-free survival (Full Analysis Set)

<!-- image -->

Note: Chronic GvHD-free defined as no moderate/severe chronic GvHD [a] based on Kaplan-Meier estimates

Sources:Figure14.2.15A,Table14.2.15A,Table 14.2.15B,Listing 16.2.6G

In the disease subgroups, CRFS at 36-months was 55.6% for ALL subjects, 69.0% for AML subjects, 36.0% for MDS subjects, and 25.0% for JMML subjects. A statistically significant difference in CRFS was recorded between subjects in first HSCT (59.8%) and subjects in second HSCT (20.0%), however, only 5 subjects were in the second HSCT group (Table 14.2.15J). No difference was obvious when dose and age groups were compared.

<div style=\"page-break-after: always\"></div>

<!-- image -->

N  Number of subjects, n  Number of events until 36 months

Sources:Figure 14.2.15B,Table14.2.15A,Table14.2.15C,Table14.2.15D,Table14.2.15E,Table 14.2.15F,

Tab1e14.2.15G,Table 14.2.15H,Table 14.2.151,Listing16.2.6G

12. Rescue Therapies: Five subjects (7.1%) were treated with DLIs (2 subjects thereof in the context of documented relapse events), 4 subjects (5.7%) were treated with stem cell boost (1 subject thereof in the context of documented relapse event and 1 subject in the context of graft failure event).  At  the  end  of  the  longer-term  follow-up  period,  11  subjects  (15.7%)  had  used  rescue therapies. The 2 additional subjects (Subject ID 170403 and Subject ID 173204) received a rescue therapy of chemotherapy (both in the context of documented relapse events).

<div style=\"page-break-after: always\"></div>

Table 11.4.1.13.A Frequency of subjects with rescue therapies (Full Analysis Set)

|                                               | Treosulfan (N=70)   |
|-----------------------------------------------|---------------------|
| Any rescue therapies [n (%)]                  |                     |
| No                                            | 58 (82.9)           |
| Yes                                           | 11 (15.7)           |
| Missing                                       | 1 (1.4)             |
| Use of DLIs [n (%)]                           |                     |
| No                                            | 64 (91.4)           |
| Yes                                           | 5 (7.1)             |
| Missing                                       | 1 (1.4)             |
| Use of stem cell boost [n (%)]                |                     |
| No                                            | 65 (92.9)           |
| Yes                                           | 4 (5.7)             |
| Missing                                       | 1 (1.4)             |
| Use of chemotherapy treatment [n (%)]         |                     |
| No                                            | 67 (95.7)           |
| Yes                                           | 2 (2.9)             |
| Missing                                       | 1 (1.4)             |
| Use of further conditioning treatment [n (%)] |                     |
| No                                            | 69 (98.6)           |
| Missing                                       | 1 (1.4)             |
| Use of other rescue therapies [n (%)]         |                     |
| No                                            | 66 (94.3)           |
| Yes                                           | 3 (4.3)             |
| Missing                                       | 1 (1.4)             |

Source:Table14.2.16A,Listing16.2.6H

Note: Multiple use of rescue therapies per subject possible

Abbreviations: DLI = donor-lymphocyte infusions; N = number of subjects; n = number of subjects in category.

## Registry study on treosulfan-conditioning in paediatric patients with malignant and non-malignant diseases

Patients below 18 years with malignant or non-malignant disease who underwent HSCT between January 2005 and July 2010 registered in the EBMT database were analysed.

## Selection of the treatment regimen

Any TREO-based conditioning followed by allogeneic or autologous HSCT was analysed.

## Study endpoints

The following endpoints were analysed: overall survival (OS) and causes of death, event-free survival (EFS),  relapse  incidence,  disease-related  mortality  (DRM),  transplantation-related  mortality  (TRM), engraftment, graft failure, acute and chronic graft versus host disease (aGvHD, cGvHD), specific adverse events (stomatitis, diarrhoea, vomiting, respiratory toxicity, liver toxicity, neurological toxicity.

## Study status

843 patients met the inclusion criteria and 75% could be included into the analysis (533 allogeneic, 93 autologous). In a supplemental analysis, data from 41 children below the age of 6 months were analysed for toxicity.

## Efficacy Results - Allogeneic HSCT

Incidence of grade III/IV acute GvHD was 10% with no correlation with age. Incidence of limited and extensive chronic GvHD was 13% and 6%, respectively, again with no correlation with age. TREO dose had no significant impact on GvHD. Incidence of grade III/IV stomatitis, diarrhoea, and vomiting were 22%, 24%, and 14%, respectively (no correlation with TREO dose). Incidence of grade III/IV respiratory toxicity was 12%. There is a significant association between age and respiratory toxicity. Children below the age of one year (mainly NMDs) experienced more grade III/IV respiratory toxicity. Incidence of grade III/IV hyperbilirubinemia, AST increase, and mild/severe VOD was 10%, 25%, and 5%, respectively.

<div style=\"page-break-after: always\"></div>

CNS and peripheral neurological toxicity grade III/IV were 4% and 2%, respectively. There was more severe pulmonary toxicity in the youngest age group (&gt; 6 months) compared to other age groups.

Incidence of graft failure was 2%. There was no significant correlation of the rate of graft failure (within 100 days) with age. Dose had no significant impact on the rate of graft failure in both univariate and multivariate analysis. Furthermore, there was no significant correlation of the time to engraftment (ANC &gt; 0.5) with age and dose.

There was a border-line significant impact of age on overall survival. The 3-year OS in children below 6 months of age is 75%, children between 6 month and 1 year have a 3-year OS of 84%. The 3-year OS of children between 1-12 years and &gt; 12 years was 70% and 60%, respectively. This difference is mainly caused  by  a  difference  in  disease  related  mortality  (DRM).  The  transplant  related  mortality  is  not significantly different in the different age groups. No significant impact of dose on overall survival could be found in univariate or adjusted analysis. There was a significant impact of age on EFS and 3-year EFS decrease with increasing age. 3-year EFS in patients less than 1 year of age, 1-12 years, and &gt; 12 years was 75%, 62%, and 53%, respectively. This difference was mainly caused by a difference in the relapse incidence.

## Registry study on treosulfan-conditioning in paediatric patients with nonmalignant diseases

The MAH asked the EBMT Paediatric and Inborn Error Working Party to have a look on the use of TREO and BU for the conditioning of children and adolescents who recently underwent HSCT for non-malignant diseases (NMD). The EBMT registry is the most comprehensive registry for HSCT in Europe, including 536 transplant centres in 57 different countries including also non-EU-countries.

The EBMT Paediatric and the EBMT Inborn Working party performed a retrospective EBMT registry study for the time period January 2010 to December 2014 according to EBMT guidelines. NMDs include huge varieties on congenital or acquired disorders of early and later childhood and are divided in the subgroups primary immunodeficiency (PID) - severe combined immune deficiency (SCID) [PID-SCID], PID-chronic granulomatous disease [PID-CGD)], PID-other, haemoglobinopathies, bone marrow failure syndromes, histiocytic disorders, and inherited disorders-other.

## Selection of the treatment regimen

In the past five years, data from several hundreds of children with NMD who underwent either TREObased or BU-based conditioning therapy in combination with FLU were reported and included in the EBMT registry  data  base.  Moreover,  the  additional  use  of  TT  as  part  of  the  conditioning  regimen  was  of particular interest for the analysis.

## Study endpoints

The following endpoints were analysed: overall survival (OS), disease-free survival (DFS), incidence of disease recurrence (IDR), transplantation-related mortality (TRM), engraftment, and acute and chronic graft versus host disease (aGvHD, cGvHD).

## Study status

The centre  survey  was  performed  in  February  2016  and  the  retrospective  EBMT-analysis  started  in September 2016 and was finished in May 2017.

## Efficacy Results

Patients  with  NMD  who  are  eligible  for  HSCT  present  different  challenges  compared  to  those  with malignant diseases: children with inherited disorders such as SCID often come to transplant as infants

<div style=\"page-break-after: always\"></div>

under one year of age with organ damage and co-morbidities. GvHD which may be associated with a beneficial graft-versus-leukaemia effect in patients with high risk haematological diseases, is of no added value  in  controlling  the  underlying  genetic  illness  and  may  adversely  affect  subsequent  immune reconstitution and have an unnecessarily negative impact on HSCT-related morbidity and quality of life in the short and long term outcome of patients with NMDs. On the other hand, graft rejection is a known severe complication.

Data  from  several  hundreds  of  children  with  NMD  who  underwent  either  TREO-based  or  BU-based conditioning therapy in combination with FLU were reported and included in the EBMT registry data base. Moreover, the additional use of TT as part of the conditioning regimen was of particular interest for the analysis. TT is increasingly used with TREO-and BU-based conditioning because it has shown added value for preventing graft failure in patients with haemoglobinopathies and other diseases with high rejection risk. Additionally, TT is penetrating the brain which is supportive in correcting metabolic diseases with neurological impairment.

This registry study included patients with PID-SCID (n = 320), PID-CGD (n = 202), PID-Wiskott (n = 82), PID-other (n = 242), haemoglobinopathies (n = 590), bone marrow failure syndromes (n = 191), and histiocytic disorders (n = 183).

The patients were grouped according to the given conditioning regimen, i.e. a combination of TREO/FLU (n = 422), BU/FLU (n = 1063), TREO/FLU/TT (n = 473) or BU/FLU/TT (n = 220). The choice of the conditioning regimen before alloHSCT was under discretion of the treating physician. The median age at transplantation was 3.7 years (range 0-18 years) and was significantly different for the conditioning groups (1.5 vs. 4 vs. 4.8 vs. 4.5, respectively; P &lt; 0.001). Fifty-two percent of children were transplanted below 4 years of age, 489 patients were less than 12 months old, and 61.5% were male. Most patients received a stem cell graft from unrelated donors (52.3%), followed by transplantation from an HLAidentical sibling or twin donor: 33.1% and 8.4% were grafted from a HLA-phenotypically identical family member  or  an  HLA-mismatched  family  member.  The  stem  cell  source  was  bone  marrow  (59.4%), peripheral blood stem cells (21.4%) or cord blood (17.9%), respectively.

The use of TREO-based conditioning has significantly increased during the years, especially in children with inherited disorders and haemoglobinopathies.

The primary outcome parameters of this retrospective analysis are in favour for the combination of TREO/FLU/TT with significantly better results in 1-year OS (89.5%; 95% CI 86.5-92.6%), day 100 TRM (4.8%; 95% CI 2.8-6.7%) and 1-year TRM (8.3%; 95% CI 5.5-11%). This translated also for DFS which was significantly best after TREO/FLU/TT conditioning (86%; 95% CI 82.6-89.5%).

When testing  for  univariate  Cox-regression,  TREO/FLU/TT  remained  superior  for  OS,  TRM  and  DFS compared to the three other conditioning regimens. However,  when adjusted for age at transplant, diagnosis, year of transplant, stem cell sources and donor type, the significances were not reached.

Most patients with thalassaemia major (TM) and sickle cell disease (SCD) are nowadays transplanted after a conditioning regimen with TREO/FLU/TT and for TM-patients 1 year TRM is best after this drug combination.  In  contrast,  only  few  patients  with  SCID  received  a  TT-containing  regimen  because rejection risk is not as high as in haemoglobinopathies and there is no need to cross the blood-brainbarrier.

Outcome of patients with chronic granulomatous disease who were transplanted below 4 years of age or older than 12 years was excellent with no TRM and 100% OS when conditioned with a TREO-containing regimen. The group of patients with the highest treatment failures due to TRM are children above 4 years of  age  who  suffer  from  histiocytic  disorders.  Unfortunately,  so  far,  none  of  the  applied  conditioning regimen resulted in superior outcome.

<div style=\"page-break-after: always\"></div>

When looking to other influencing factors in a multivariate Cox model, the underlying disease, age at transplantation and stem cell source was highly influencing OS, TRM and DFS with the worst prognosis for older patients, histiocytic disorders and cord blood as stem cell source. Year of transplantation did not significantly influence the primary outcome. TREO/FLU ± TT showed a trend for better outcome compared to BU/FLU ± TT and was never worse.

## Summary of main studies

The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 1. Summary of Efficacy for trial MC-FludT.16/NM

| Title: Clinical Phase 2 trial to compare treosulfan-based conditioning therapy with busulfan- based conditioning prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with non-malignant diseases   | Title: Clinical Phase 2 trial to compare treosulfan-based conditioning therapy with busulfan- based conditioning prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with non-malignant diseases   | Title: Clinical Phase 2 trial to compare treosulfan-based conditioning therapy with busulfan- based conditioning prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with non-malignant diseases                                                                                                                                                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                   | MC-FludT.16/NM (EudraCT number 2013-005508-33; Clinicaltrials.gov Identifier NCT02349906)                                                                                                                                          | MC-FludT.16/NM (EudraCT number 2013-005508-33; Clinicaltrials.gov Identifier NCT02349906)                                                                                                                                                                                                                                                                                                                                                                      |
| Design                                                                                                                                                                                                                             | Prospective, randomised (1:1), multicentre, open-label, active-controlled, parallel-group trial                                                                                                                                    | Prospective, randomised (1:1), multicentre, open-label, active-controlled, parallel-group trial                                                                                                                                                                                                                                                                                                                                                                |
| Design                                                                                                                                                                                                                             | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                     | Treatment phase: 7 days with either 3 days of treosulfan administration or 4 days of busulfan administration (completed) Observation phase: until day +100 after HSCT (according to the Paediatric Investigational Plan [PIP], this is defined until at least visit Day +100 [inclusive] of HSCT procedure) (completed) Follow-up phase: until 12 months after HSCT (completed) Longer-term follow-up phase (after completion of PIP): a minimum of 3 years of |
| Hypothesis                                                                                                                                                                                                                         | HSCT (ongoing). Non-inferiority                                                                                                                                                                                                    | HSCT (ongoing). Non-inferiority                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Treatments groups                                                                                                                                                                                                                  | Treosulfan (i.v.) 1 g or 5 g + Fludarabine (i.v)                                                                                                                                                                                   | 10 or 12 or 14 g/m²/day (BSA-adapted) on day -6 to day -4 before HSCT 30 mg/m²/d) on 5 consecutive days (day -7 to -3 before HSCT                                                                                                                                                                                                                                                                                                                              |
| Treatments groups                                                                                                                                                                                                                  | Busulfan (i.v.) 60 mg + Fludarabine (i.v)                                                                                                                                                                                          | 3.2 to 4.8 mg/kg/day (actual body weight adapted) on day -7 to day -4 before HSCT 30 mg/m²/d) on 5 consecutive days (day -7 to -3 before HSCT                                                                                                                                                                                                                                                                                                                  |
| Treatments groups                                                                                                                                                                                                                  | +/- Thiotepa (i.v.) (Investigator's discretion)                                                                                                                                                                                    | 2 single doses of 5 mg/kg given on day -2 before HSCT                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Endpoints and definitions   | Primary endpoint   | Freedom from transplantat ion (treatment) -related mortality   | Comparative evaluation of Freedom from transplantation (treatment)-related mortality, defined as death from any transplantation (treatment)-related cause from start of conditioning treatment (visit Day -7) until day +100 after HSCT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------------------------|--------------------|----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions   | Secondary endpoint | Transplanta tion-related mortality                             | Probability of dying from GvHD, interstitial pneumonitis, pulmonary toxicity, infection (bacterial, viral, fungal, parasitic, unknown), Epstein Barr Virus (EBV) proliferative disease, rejection / poor graft function, HSOS, haemorrhage, cardiac toxicity, central nervous system toxicity, gastrointestinal toxicity, skin toxicity, renal failure, multiple organ failure, other HSCT-related cause                                                                                                                                                                                                                                                                                                                                                   |
| Endpoints and definitions   | Secondary endpoint | Overall survival                                               | Probability of surviving. Survival time was defined as the time length between end of HSCT and the day of death due to any cause. Evaluated from the end of HSCT until the end of the longer-term follow-up phase                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                             | Secondary endpoint | Graft failure                                                  | Probability of having a graft failure (primary or secondary) and being alive without using 'stem cell infusion (re-transplant) with conditioning' rescue therapy (ie, second allogenic transplantations) between the end of HSCT and the end of the longer-term follow- up phase. In addition, the rate of primary and secondary graft failures was assessed                                                                                                                                                                                                                                                                                                                                                                                               |
|                             | Secondary endpoint | Engraftmen t                                                   | Neutrophilic granulocytes engraftment was defined as the first of 3 consecutive days with an granulocyte count > 0.5 x 10 9 /L in PB, leucocyte engraftment was defined as the first of 3 consecutive days with a total leucocyte count > 1 x 10 9 /L in PB, PLT engraftment was defined as the first of 3 consecutive days with a) PLTs > 20 x 10 9 /L or b) PLTs > 50 x 10 9 /L in PB in the absence of PLT transfusion. Time to engraftment was defined as the time span between end of HSCT and neutrophil granulocyte / leucocyte / PLT engraftment. In addition, the duration of neutropenia (neutrophilic granulocytes ≤ 0.5 x 10 9 /L) and leukopenia (leucocytes granulocytes ≤ 1.0 x 10 9 /L) was analysed based on documented laboratory values |
|                             | Secondary endpoint | Quantificati on of donor type chimerism                        | If a value of ≥ 95% donor-type was detected. Mixed chimerism was defined as having a recipient fraction > 5% (to 94%). Incidences of complete donor-type chimerism were estimated as the number of subjects with complete chimerism divided by the total number of subjects at risk. To investigate the mixed donor-type chimerism the frequency of subjects with at least 20% or 50% donor-type chimerism was calculated. Chimerism was evaluated on visit Day +28, +100 and Month 12, and during longer-term follow-up                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                            | Exploratory endpoint                                                                                                                                                       | Event-free survival                                                                                                                                                        | Time length between end of HSCT and the date of graft failure or 'stem cell infusion (re- transplant) with conditioning' rescue therapy (ie, second allogenic transplantations) or death (whatever occurred first). EFS was evaluated from the end of HSCT until the end of the longer-term follow-up phase.                                                                         |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                            | Secondary endpoint                                                                                                                                                         | GvHD-free survival                                                                                                                                                         | Measured from end of HSCT to time of event. The associated time span was defined as the interval from end of HSCT to aGvHD of at least grade III, moderate or severe cGvHD, or death (whatever occurred first). GvHD-free survival was evaluated from the end of HSCT until the end of the longer-term follow-up phase.                                                              |
|                                                                                                                                                                            | Secondary endpoint                                                                                                                                                         | Chronic GvHD-free survival                                                                                                                                                 | Measured from end of HSCT to time of event. The associated time span was defined as the interval from end of HSCT to moderate or severe cGvHD or death (whatever occurred first). cGvHD-free survival was evaluated from the end of HSCT until the end of the longer- term follow-up phase.                                                                                          |
|                                                                                                                                                                            | Secondary endpoint                                                                                                                                                         | Rescue therapies                                                                                                                                                           | Use of and duration of using rescue therapies like DLIs, stem cell boost, stem cell infusion (retransplantation) with conditioning, stem cell infusion (re-transplantation) without conditioning, transfusion dependence for red blood cells, transfusion dependence for PLTs, and other was described from end of HSCT until the end of the longer-term follow-up phase             |
| Database lock 07-Jun-2021                                                                                                                                                  | Database lock 07-Jun-2021                                                                                                                                                  | Database lock 07-Jun-2021                                                                                                                                                  | Database lock 07-Jun-2021                                                                                                                                                                                                                                                                                                                                                            |
| Title: Clinical Phase 2 trial to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in | Title: Clinical Phase 2 trial to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in | Title: Clinical Phase 2 trial to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in | Title: Clinical Phase 2 trial to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in                                                                                                                                                                                                           |
| Study identifier                                                                                                                                                           | MC-FludT.17/M (EudraCT number 2013-003604-39)                                                                                                                              | MC-FludT.17/M (EudraCT number 2013-003604-39)                                                                                                                              | MC-FludT.17/M (EudraCT number 2013-003604-39)                                                                                                                                                                                                                                                                                                                                        |
| Design                                                                                                                                                                     | Prospective, single arm, open-label, multicentre, non-controlled, Phase 2                                                                                                  | Prospective, single arm, open-label, multicentre, non-controlled, Phase 2                                                                                                  | Prospective, single arm, open-label, multicentre, non-controlled, Phase 2                                                                                                                                                                                                                                                                                                            |
|                                                                                                                                                                            | clinical trial Duration of main phase: Duration of Run-in phase: Duration of                                                                                               | Extension phase:                                                                                                                                                           | Treatment phase: 7 days with 3 days of Treosulfan administration Observation phase: until day +100 after HSCT (according to the Paediatric Investigation Plan [PIP], this is defined until at least visit Day +100 (inclusive) of HSCT procedure) Follow-up phase: until 12 months after HSCT Longer-term follow-up phase (after completion of PIP): a minimum of 3 years after HSCT |
| Hypothesis                                                                                                                                                                 | Superiority                                                                                                                                                                | Superiority                                                                                                                                                                | Superiority                                                                                                                                                                                                                                                                                                                                                                          |
| Treatments groups                                                                                                                                                          | Treosulfan (i.v.) 1 g or 5 g + Fludarabine                                                                                                                                 | (i.v)                                                                                                                                                                      | At dose levels 10 g/m², 12 g/m², and 14 g/m² over 2 hours on 3 consecutive days on visit Days -6, -5, and -4 before alloHSCT single doses of 30 mg/m2 on 5 consecutive days (from visit Day -7 to -3)                                                                                                                                                                                |
|                                                                                                                                                                            | +/- Thiotepa (i.v.) (Investigator's discretion)                                                                                                                            | +/- Thiotepa (i.v.) (Investigator's discretion)                                                                                                                            | in 2 single doses of 5 mg/kg given on visit Day -2 before HSCT                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| Endpoints and definitions   | Co-Primary endpoint   | Freedom from transplantat ion (treatment) -related mortality   | Death from any transplant (treatment)-related cause from the day of first administration of conditioning treatment until 100 days after HSCT. This endpoint is a combination of TRM and treatment-related mortality                                                    |
|-----------------------------|-----------------------|----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions   | Co-Primary endpoint   | Transplanta tion-related mortality                             | probability of dying from a transplant-related cause, i.e. which could not be attributed to disease relapse / progression or by deaths without previous relapse / progression                                                                                          |
| Endpoints and definitions   | Secondary endpoint    | Overall survival                                               | Probability of surviving and was evaluated from the end of HSCT up to the visit 12 months after HSCT. OS was continuously assessed during the longer term follow up phase                                                                                              |
|                             | Secondary endpoint    | Relapse / Progression Incidence                                | Probability of having relapse / progression of the underlying disease, death due to any cause, or End of Trial, whatever comes first. RFS / PFS was continuously assessed during the longer term follow up phase                                                       |
|                             | Secondary endpoint    | Relapse- free / Progression -free Survival                     | Time length between end of HSCT and the date of relapse / progression of the underlying disease or death due to any cause, or End of Trial, whatever comes first. RFS / PFS was continuously assessed during the longer term follow up phase                           |
|                             | Secondary endpoint    | Graft failure                                                  | Probability of having a graft failure (primary or secondary) from end of the HST up to visit 12 months after HSCT. Secondary graft failure was continuously assessed during the longer term follow up phase                                                            |
|                             | Secondary endpoint    | Non-relapse Mortality                                          | Probability of dying in the absence of persisting disease or previous occurrence of relapse / progression or graft failure. NRM was evaluated from end of the HSCT to visit 12 months after HSCT. NRM was continuously assessed during the longer term follow up phase |
|                             | Secondary endpoint    | Engraftmen t                                                   | Neutrophil count > 0.5 x 10 9 /L, leucocyte count > 1 x 10 9 /L, and platelet counts > 20 x 10 9 /L or > 50 x10 9 /L) and assessed up to 100 days after HSCT                                                                                                           |
|                             | Secondary endpoint    | Quantificati on of donor type chimerism                        | ≥ 95% donor cells detected and was evaluated on visit Day +28, +100 and the visit 12 months after HSCT                                                                                                                                                                 |
|                             | Exploratory endpoint  | Event-free survival                                            | Length of time between end of HSCT and the date of relapse / progression, graft failure, or death (whatever occurs first)..                                                                                                                                            |
|                             | Exploratory endpoint  | GvHD-free Relapse- free / Progression -free Survival           |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                      | Exploratory endpoint   | Chronic GvHD-free and Relapse- free / Progression -free Survival   |                                               |
|----------------------|------------------------|--------------------------------------------------------------------|-----------------------------------------------|
|                      | Secondary endpoint     | Rescue therapies                                                   | Use of and duration of using rescue therapies |
| Database lock        | 07-Jun-2021            | 07-Jun-2021                                                        | 07-Jun-2021                                   |
| Results and Analysis | Results and Analysis   | Results and Analysis                                               | Results and Analysis                          |

Table 2.7.3.3.2.3-13: Freedom from TRM until Day +100 (Kaplan-Meier estimates)

| Study                                                                                              | MC-FludT.16/NM                                                                                     | MC-FludT.16/NM                                                                                     | MC-FludT.17/M                                                                                      |
|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| Data source in CSR                                                                                 | Table 11.4.1.1.A                                                                                   | Table 11.4.1.1.A                                                                                   | Table 14.2.1A                                                                                      |
| Study arm                                                                                          | TREO                                                                                               | BU                                                                                                 | TREO                                                                                               |
| Total number of patients                                                                           | 51 (100%)                                                                                          | 50 (100%)                                                                                          | 70 (100%)                                                                                          |
| Patients with event                                                                                | 0 (0%)                                                                                             | 5 (10%)                                                                                            | 1 (1.4%)                                                                                           |
| Patients without event                                                                             | 51 (100%)                                                                                          | 45 (90%)                                                                                           | 69 (98.6%)                                                                                         |
| Freedom from TRM until Day +100 (90% CI)                                                           | 100% (94.3, 100)                                                                                   | 90% (80.1, 96.0)                                                                                   | 98.6% (93.4, 99.9)                                                                                 |
| Odds ratio² (90% CI)                                                                               | <0.0001 (NA)                                                                                       | <0.0001 (NA)                                                                                       |                                                                                                    |
| P valueb                                                                                           | 0.0528                                                                                             | 0.0528                                                                                             |                                                                                                    |
| Unadjusted P valuec                                                                                | 0.0267                                                                                             | 0.0267                                                                                             |                                                                                                    |
| Adjusted for thiotepa and disease; b Stratified Cochran-Mantel-Haenszel test; ~Fisher's exact test | Adjusted for thiotepa and disease; b Stratified Cochran-Mantel-Haenszel test; ~Fisher's exact test | Adjusted for thiotepa and disease; b Stratified Cochran-Mantel-Haenszel test; ~Fisher's exact test | Adjusted for thiotepa and disease; b Stratified Cochran-Mantel-Haenszel test; ~Fisher's exact test |

| Study                                             | MC-FludT.16/NM    | MC-FludT.16/NM    | MC-FludT.17/M     |
|---------------------------------------------------|-------------------|-------------------|-------------------|
| Data sowrce                                       | Table11.4.1.2.A   | Table11.4.1.2.A   | Tables 11.4.1.2.A |
| Study arm                                         | TREO              | BU                | TREO              |
| Total number of patients                          | 51 (100%)         | 50 (100%)         | 70 (100%)         |
| Medianfollow-up; months(range of those surviving) | 25.6 (10.7, 60.9) | 25.4 (11.7, 63.3) | 41.8 (24.2, 57.9) |
| Patients with event                               | 2 (3.9%)          | 7 (14.0%)         | 4 (5.7%)          |
| Patients without event                            | 49 (96.1%)        | 43 (86.0%)        | 66 (94.3%)        |
| TRM at 12 months; % (90% CI)                      | 3.9 (1.2, 12.0)   | 12.0 (6.3, 22.1)  | 1.4 (0.3, 7.2)    |
| TRM at 24 months; % (90% CI)                      | 3.9 (1.2, 12.0)   | 12.0 (6.3, 22.1)  | 4.6 (1.8, 11.4)   |
| TRM at 36 months; % (90% CI)                      | 3.9 (1.2, 12.0)   | 16.0 (8.6, 28.6)  | 4.6 (1.8, 11.4)   |

| Hazard ratio (TREO/BU)°; 90%CI                                                                    | 0.29 (0.08, 1.09)                                                                                 |
|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| P valueb                                                                                          | 0.1244                                                                                            |
| Unadjusted P valuec                                                                               | 0.0718                                                                                            |
| basedonKaplan-Meierestimates;adjustedforTTanddiseaseasfactorsusingCoxregressionmodel;Log-ranktest | basedonKaplan-Meierestimates;adjustedforTTanddiseaseasfactorsusingCoxregressionmodel;Log-ranktest |

<div style=\"page-break-after: always\"></div>

Table 2.7.3.3.2.3-9: Overall survival (Kaplan-Meier estimates)

| Study                                                     | MC-FludT.16/NM                                            | MC-FludT.16/NM                                            | MC-FludT.17/M                                             |
|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| Data source                                               | Table 11.4.1.3.A                                          | Table 11.4.1.3.A                                          | Table 11.4.1.3.A                                          |
| Study arm                                                 | TREO                                                      | BU                                                        | TREO                                                      |
| Total number of patients                                  | 51 (100%)                                                 | 50 (100%)                                                 | 70 (100%)                                                 |
| Median follow-up; months (range of those surviving)       | 25.6 (10.7-60.9)                                          | 25.4 (11.7, 63.3)                                         | 41.8 (24.2-57.5)                                          |
| Patients with event                                       | 2 (3.9%)                                                  | 7 (86.0%)                                                 | 12 (17.1%)                                                |
| Patients without event                                    | 49 (96.1%)                                                | 43 (100%)                                                 | 58 (82.9%)                                                |
| OS at 12 months; % (90% CI)                               | 96.1 (88.0, 98.8)                                         | 88.0 (77.9, 93.7)                                         | 91.4 (83.9, 95.5)                                         |
| OS at 24 months; % (90% CI)                               | 96.1 (88.0, 98.8)                                         | 88.0 (77.9, 93.7)                                         | 85.7 (77.1, 91.2)                                         |
| OS at 36 months; % (90% CI)                               | 96.1 (88.0, 98.8)                                         | 84.0 (71.4, 91.4)                                         | 84.3 (75.5, 90.1)                                         |
| HR (TREO/BU)(90% CI)                                      | 0.29 (0.08, 1.09)                                         | 0.29 (0.08, 1.09)                                         |                                                           |
| P value                                                   | 0.1244                                                    | 0.1244                                                    |                                                           |
| adjustedforTT anddiseaseasfactors usingCoxregressionmodel | adjustedforTT anddiseaseasfactors usingCoxregressionmodel | adjustedforTT anddiseaseasfactors usingCoxregressionmodel | adjustedforTT anddiseaseasfactors usingCoxregressionmodel |

Table 2.7.3.3.2.3-7: Graft failure rates

| Study                   | MC-FludT.16/NM   | MC-FludT.16/NM   | MC-FludT.17/M    |
|-------------------------|------------------|------------------|------------------|
| Data source             | Table 11.4.1.4.A | Table 11.4.1.4.A | Table 11.4.1.6.A |
| Study arm               | TREO             | BU               | TREO             |
| Total numberofpatients  | 51               | 50               | 70               |
| Primary graft failure   | 2 (3.9%)         | 2 (4.0%)         | 0                |
| Secondary graft failure | 9 (18.4%)        | 0 (0.0%)         | 1 (1.4%)         |

Table 2.7.3.3.2.3-1: Conditional cumlative incidence of reconstitution of gramulopoiesis

| Study                                                                                                                                                                                                      | MC-FludT.16/NM                                                                                                                                                                                             | MC-FludT.16/NM                                                                                                                                                                                             | MC-FludT.17/M                                                                                                                                                                                              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Data sourceinCSR                                                                                                                                                                                           | Tables 11.4.1.5.A/-B                                                                                                                                                                                       | Tables 11.4.1.5.A/-B                                                                                                                                                                                       | Tables 11.4.1.8.A/-B                                                                                                                                                                                       |
| Study arm                                                                                                                                                                                                  | TREO                                                                                                                                                                                                       | BU                                                                                                                                                                                                         | TREO                                                                                                                                                                                                       |
| No. of patients                                                                                                                                                                                            | 51 (100%)                                                                                                                                                                                                  | 50 (100%)                                                                                                                                                                                                  | 70 (100%)                                                                                                                                                                                                  |
| Patients with event                                                                                                                                                                                        | 40 78.4%)                                                                                                                                                                                                  | 36 (72.0%)                                                                                                                                                                                                 | 69 (98.6%)                                                                                                                                                                                                 |
| Patientswithout event(censored) or with competing event                                                                                                                                                    | 11 (21.6%)                                                                                                                                                                                                 | 14 (28.0%)                                                                                                                                                                                                 | 1 (1.4%)                                                                                                                                                                                                   |
| Censored                                                                                                                                                                                                   | 2 (3.9%)                                                                                                                                                                                                   | 2 (4.0%)                                                                                                                                                                                                   | 1 (1.4%)                                                                                                                                                                                                   |
| Death*                                                                                                                                                                                                     | 0                                                                                                                                                                                                          | 0                                                                                                                                                                                                          | 0                                                                                                                                                                                                          |
| Rescue therapy                                                                                                                                                                                             | 9 (17.6%)                                                                                                                                                                                                  | 12 (24.0%)                                                                                                                                                                                                 | 0                                                                                                                                                                                                          |
| Conditional cumulative incidence, % (90% CI)                                                                                                                                                               |                                                                                                                                                                                                            |                                                                                                                                                                                                            |                                                                                                                                                                                                            |
| Day +14                                                                                                                                                                                                    | 23.8 (13.0, 34.6)                                                                                                                                                                                          | 47.4 33.1, 61.6)                                                                                                                                                                                           | 28.6 (18.7, 38.4)                                                                                                                                                                                          |
| Day +28                                                                                                                                                                                                    | 81.0 (68.2, 93.7)                                                                                                                                                                                          | 88.5 (77.9, 99.1)                                                                                                                                                                                          | 86.9 (79.8, 93.9)                                                                                                                                                                                          |
| Maximumincidence                                                                                                                                                                                           | 97.3 (88.7, 100.0)                                                                                                                                                                                         | 100.0 (94.1, 100.0)                                                                                                                                                                                        | 100.0 (97.7, 100.0)                                                                                                                                                                                        |
| Duration of neutropenia (days)                                                                                                                                                                             |                                                                                                                                                                                                            |                                                                                                                                                                                                            |                                                                                                                                                                                                            |
| n                                                                                                                                                                                                          | 49                                                                                                                                                                                                         | 48                                                                                                                                                                                                         | 69                                                                                                                                                                                                         |
| Mean (SD)                                                                                                                                                                                                  | 19.9 (7.7)                                                                                                                                                                                                 | 15.9 (7.3)                                                                                                                                                                                                 | 22.3 (7.7)                                                                                                                                                                                                 |
| Median (Q1, Q3)                                                                                                                                                                                            | 20.0 (15.0, 25.0)                                                                                                                                                                                          | 14.5 (10.0, 21.0)                                                                                                                                                                                          | 22.0 (17.0, 26.0)                                                                                                                                                                                          |
| Min, Max                                                                                                                                                                                                   | 8,43                                                                                                                                                                                                       | 5,34                                                                                                                                                                                                       | 7,44                                                                                                                                                                                                       |
| Pvaluet                                                                                                                                                                                                    | 0.0108                                                                                                                                                                                                     | 0.0108                                                                                                                                                                                                     |                                                                                                                                                                                                            |
| *onlyif this event occurred first;First date with neutropenia until date of engrafiment (patients at risk =patients with neutropenia and neutrophilicgranulopoiesis);+basedontheWilcoxon-Mann-Whitmey test | *onlyif this event occurred first;First date with neutropenia until date of engrafiment (patients at risk =patients with neutropenia and neutrophilicgranulopoiesis);+basedontheWilcoxon-Mann-Whitmey test | *onlyif this event occurred first;First date with neutropenia until date of engrafiment (patients at risk =patients with neutropenia and neutrophilicgranulopoiesis);+basedontheWilcoxon-Mann-Whitmey test | *onlyif this event occurred first;First date with neutropenia until date of engrafiment (patients at risk =patients with neutropenia and neutrophilicgranulopoiesis);+basedontheWilcoxon-Mann-Whitmey test |

<div style=\"page-break-after: always\"></div>

Table 2.7.3.3.2.3-3: Conditional cumlative incidence of reconstitution of leukopoiesis

| Study                                                    | MC-FludT.16/NM                   | MC-FludT.16/NM                   | MC-FludT.17/M                    |
|----------------------------------------------------------|----------------------------------|----------------------------------|----------------------------------|
| Data source inCSR                                        | Table 11.4.1.5.C                 | Table 11.4.1.5.C                 | Table 11.4.1.8.C                 |
| Study arm                                                | TREO                             | BU                               | TREO                             |
| No. of patients                                          | 51 (100%)                        | 50 (100%)                        | 70 (100%)                        |
| Patients with event                                      | 40 (78.4%)                       | 36 (72.0%)                       | 69 (98.6%)                       |
| Patients without event (censored) or with competing even | 11 (21.6%)                       | 14 (28.0%)                       | 1 (1.4%)                         |
| Censored                                                 | 2 (3.9%)                         | 2 (4.0%)                         | 1 (1.4%)                         |
| Death                                                    | 0                                | 0                                | 0                                |
| Rescue therapy                                           | 9 (17.6%)                        | 12 (24.0%)                       | 0                                |
| Conditional cumulative incidence, % (90% CI)             |                                  |                                  |                                  |
| Day +14                                                  | 23.8 (13.0, 34.6)                | 50.0 (35.8, 64.2)                | 30.0 (20.6, 39.4)                |
| Day +28                                                  | 90.5 (83.5, 97.4)                | 88.5 (77.7, 99.3)                | 95.6 (90.9, 100.0)               |
| Maximum incidence                                        | 96.8 (87.1, 100.0)               | 100.0 (94.1, 100.0)              | 100.0 (97.7, 100.0)              |
| P value (Pepe-Mori test)                                 | 0.2469                           | 0.2469                           |                                  |
| *only if this eventoccurredfirst                         | *only if this eventoccurredfirst | *only if this eventoccurredfirst | *only if this eventoccurredfirst |

Table 2.7.3.3.2.3-4: Conditional cumulative incidence of reconstitution of thrombopoiesis &gt; 20 × 10°/L

| Study                                                    | MC-FludT.16/NM                     | MC-FludT.16/NM                     | MC-FludT.17/M                      |
|----------------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|
| Data sourcein CSR                                        | Table 11.4.1.5.E                   | Table 11.4.1.5.E                   | Table 11.4.1.8.E                   |
| Study arm                                                | TREO                               | BU                                 | TREO                               |
| No. of patients                                          | 51 (100%)                          | 50 (100%)                          | 70 (100%)                          |
| Patients with event                                      | 40 (78.4%)                         | 35 (70.0%)                         | 65 (92.9%)                         |
| Patients without event (censored) or with competing even | 11 (21.6%)                         | 15 (30.0%)                         | 5 (7.1%)                           |
| Censored                                                 | 2 (3.9%)                           | 3 (6.0%)                           | 5 (7.1%)                           |
| Death*                                                   | 0                                  | 0                                  | 0                                  |
| Rescue therapy                                           | 9 (17.6%)                          | 12 (24.0%)                         | 0                                  |
| Conditional cumulative incidence, % (90% CI)             |                                    |                                    |                                    |
| Day +14                                                  | 33.3 (20.5, 46.1)                  | 34.2 (21.3, 47.1)                  | 34.3 (24.5, 44.1)                  |
| Day +28                                                  | 85.7 (77.3, 94.2)                  | 77.6 (64.0, 91.3)                  | 78.0 (69.5, 86.5)                  |
| Maximumincidence                                         | 100.0 (93.8, 100.0)                | 96.8 (86.6, 100.0)                 | 94.1 (88.4, 99.9)                  |
| Pvalue (Pepe-Mori test)                                  | 0.8595                             | 0.8595                             |                                    |
| *only if this event occurred first                       | *only if this event occurred first | *only if this event occurred first | *only if this event occurred first |

<div style=\"page-break-after: always\"></div>

Table 2.7.3.3.2.3-5:Conditional cummlative incidence of reconstitution of thrombopoiesis &gt; 50 × 10°/L

| Study                                                   | MC-FludT.16/NM                | MC-FludT.16/NM                | MC-FludT.17/M                 |
|---------------------------------------------------------|-------------------------------|-------------------------------|-------------------------------|
| Data source in CSR                                      | Table11.4.1.5.F               | Table11.4.1.5.F               | Table 11.4.1.8.F              |
| Study arm                                               | TREO                          | BU                            | TREO                          |
| No. ofpatients                                          | 51 (100%)                     | 50 (100%)                     | 70 (100%)                     |
| Patients with event                                     | 39 (76.5%)                    | 35 (70.0%)                    | 63 (90.0)                     |
| Patientswithout event (censored) or with competing even | 12 (23.5%)                    | 15 (30.0%)                    | 7 (10.0)                      |
| Censored                                                | 3 (5.9%)                      | 3 (6.0%)                      | 7 (10.0)                      |
| Death*                                                  | 0                             | 0                             | 0                             |
| Rescue therapy                                          | 9 (17.6%)                     | 12 (24.0%)                    | 0                             |
| Conditional cumulative incidence, % (90% CI)            |                               |                               |                               |
| Day +14                                                 | 19.0 (8.4, 29.7)              | 28.9 (16.3, 41.6)             | 15.7 (8.4, 23.0)              |
| Day +28                                                 | 73.8 (61.9, 85.7)             | 50.4 (36.4, 64.4)             | 62.2 (52.5, 71.9)             |
| Maximm incidence                                        | 94.8 (86.3, 100.0)            | 97.1 (87.9, 100.0)            | 91.9 (84.9, 98.8)             |
| Pvalue (Pepe-Mori test)                                 | 0.3635                        | 0.3635                        |                               |
| *onlyifthiseventoccurredfirst                           | *onlyifthiseventoccurredfirst | *onlyifthiseventoccurredfirst | *onlyifthiseventoccurredfirst |

Table 2.7.3.3.2.3-6: Incidence of complete donor type chimerism

| Study                                                                                                                                                           | MC-FludT.16/NM                                                                                                                                                  | MC-FludT.16/NM                                                                                                                                                  | MC-FludT.17/M                                                                                                                                                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Data solrce                                                                                                                                                     | Table 14.2.9A                                                                                                                                                   | Table 14.2.9A                                                                                                                                                   | Table 11.4.1.9.A                                                                                                                                                |
| Study arm                                                                                                                                                       | TREO                                                                                                                                                            | BU                                                                                                                                                              | TREO                                                                                                                                                            |
| Patients at risk Day +28visit                                                                                                                                   | 51 (100%)                                                                                                                                                       | 50 (100%)                                                                                                                                                       | 69 (100%)                                                                                                                                                       |
| Complete chimerism                                                                                                                                              | 43 (84.3%)                                                                                                                                                      | 41 (82.0%)                                                                                                                                                      | 65 (94.2%)                                                                                                                                                      |
| No complete chimerism                                                                                                                                           | 7 (13.7%)                                                                                                                                                       | 9 (18.0%)                                                                                                                                                       | 3 (4.3%)                                                                                                                                                        |
| No information                                                                                                                                                  | 1 (2.0%)                                                                                                                                                        | 0                                                                                                                                                               | 1 (1.4%)                                                                                                                                                        |
| Incidence of complete chimerism; % (90% CI)                                                                                                                     | 84.3 (73.5, 91.9)                                                                                                                                               | 82.0 (70.7, 90.3)                                                                                                                                               | 94.2 (87.2, 98.0)                                                                                                                                               |
| Adjusted Pvalue                                                                                                                                                 | 0.425                                                                                                                                                           | 0.425                                                                                                                                                           |                                                                                                                                                                 |
| Patients atrisk Day +l00visit                                                                                                                                   | 51 (100%)                                                                                                                                                       | 46 (100%)                                                                                                                                                       | 69 (100%)                                                                                                                                                       |
| Complete chimerism                                                                                                                                              | 34 (66.7%)                                                                                                                                                      | 39 (84.8%)                                                                                                                                                      | 63 (91.3%)                                                                                                                                                      |
| No complete chimerism                                                                                                                                           | 14 (27.5%)                                                                                                                                                      | 5 (10.9%)                                                                                                                                                       | 6 (8.7%)                                                                                                                                                        |
| No information                                                                                                                                                  | 3 (5.9%)                                                                                                                                                        | 2 (4.3%)                                                                                                                                                        | 0                                                                                                                                                               |
| Incidence of complete chimerism; % (90% CI)                                                                                                                     | 66.7 (54.3, 77.5)                                                                                                                                               | 84.8 (73.3, 92.6)                                                                                                                                               | 91.3 (83.6, 96.1)                                                                                                                                               |
| AdjustedPvalue                                                                                                                                                  | 0.1196                                                                                                                                                          | 0.1196                                                                                                                                                          |                                                                                                                                                                 |
| Patients at risk Months 12 visit                                                                                                                                | 49 (100%)                                                                                                                                                       | 43 (100%)                                                                                                                                                       | 57 (100%)                                                                                                                                                       |
| Complete chimerism                                                                                                                                              | 24 (49.0%)                                                                                                                                                      | 33 (76.6%)                                                                                                                                                      | 52 (91.2%)                                                                                                                                                      |
| No complete chimerism                                                                                                                                           | 14 (28.6%)                                                                                                                                                      | 9 (20.9%)                                                                                                                                                       | 3 (5.3%)                                                                                                                                                        |
| No information                                                                                                                                                  | 11 (22.4%)                                                                                                                                                      | 1 (2.3%)                                                                                                                                                        | 2 (3.5%)                                                                                                                                                        |
| Incidence of complete chimerism; % (90% CI)                                                                                                                     | 49.0 (36.5, 61.5)                                                                                                                                               | 76.7 (57.0, 86.0)                                                                                                                                               | 91.2 (82.4, 96.5)                                                                                                                                               |
| Adjusted P value                                                                                                                                                | 0.2445                                                                                                                                                          | 0.2445                                                                                                                                                          |                                                                                                                                                                 |
| Patients at risk Months 24 visit                                                                                                                                | 31                                                                                                                                                              | 30                                                                                                                                                              | no data                                                                                                                                                         |
| Complete chimerism                                                                                                                                              | 12 (38.7%)                                                                                                                                                      | 22 (73.3%)                                                                                                                                                      |                                                                                                                                                                 |
| No complete chimerism                                                                                                                                           | 11 (35.5%)                                                                                                                                                      | 6 (20.0%)                                                                                                                                                       |                                                                                                                                                                 |
| No information                                                                                                                                                  | 8 (25.8%)                                                                                                                                                       | 2 (6.7%)                                                                                                                                                        |                                                                                                                                                                 |
| Incidence of complete chimerism; % (90% CI)                                                                                                                     | 38.7 (24.1, 55.0)                                                                                                                                               | 73.3 (57.0, 86.0)                                                                                                                                               |                                                                                                                                                                 |
| Adjusted Pvalue                                                                                                                                                 | 0.1058                                                                                                                                                          | 0.1058                                                                                                                                                          |                                                                                                                                                                 |
| Patients are atriskifthey havean examinationat theDay+28,Day+100,orMonth12visit oriftheyhave suvivedday +29/30,day+107, day +372/379, or day +760, respectively | Patients are atriskifthey havean examinationat theDay+28,Day+100,orMonth12visit oriftheyhave suvivedday +29/30,day+107, day +372/379, or day +760, respectively | Patients are atriskifthey havean examinationat theDay+28,Day+100,orMonth12visit oriftheyhave suvivedday +29/30,day+107, day +372/379, or day +760, respectively | Patients are atriskifthey havean examinationat theDay+28,Day+100,orMonth12visit oriftheyhave suvivedday +29/30,day+107, day +372/379, or day +760, respectively |

<div style=\"page-break-after: always\"></div>

Table 2.7.3.3.2.3-8: Event-free survival (Kaplan-Meier estimates)

| Study                                                                                                                     | MC-FludT.16/NM                                                                                                            | MC-FludT.16/NM                                                                                                            | MC-FludT.17/M                                                                                                             |
|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|
| Data source in CSR                                                                                                        | Tables 11.4.1.7.A                                                                                                         | Tables 11.4.1.7.A                                                                                                         | Table 11.4.1.3.A/-10.A                                                                                                    |
| Study arm                                                                                                                 | TREO                                                                                                                      | BU                                                                                                                        | TREO                                                                                                                      |
| Total number of patients                                                                                                  | 51 (100%)                                                                                                                 | 50(100%)                                                                                                                  | 70 (100%)                                                                                                                 |
| Median follow-up; months (range of those surviving)                                                                       | 25.6 (10.7, 60.9)                                                                                                         | 25.4 (11.7, 63.3)                                                                                                         | 41.8 (24.2, 57.5)                                                                                                         |
| Event-free survival                                                                                                       |                                                                                                                           |                                                                                                                           |                                                                                                                           |
| Patients with event                                                                                                       | 13 (25.5%)                                                                                                                | 9 (18.0%)                                                                                                                 | 19 (27.1%)                                                                                                                |
| Deatha                                                                                                                    | 2 (3.9%)                                                                                                                  | 6 (12.0%)                                                                                                                 | 2 (2.9%)                                                                                                                  |
| Relapse/progression                                                                                                       |                                                                                                                           |                                                                                                                           | 16 (22.9%)                                                                                                                |
| Primary graft failure?                                                                                                    | 2 (3.9%)                                                                                                                  | 2 (4.0%)                                                                                                                  | 0                                                                                                                         |
| Secondary graft failure?                                                                                                  | 9 (17.6%)                                                                                                                 | 0                                                                                                                         | 1 (1.4)                                                                                                                   |
| Second allogeneic transplant?                                                                                             | 0                                                                                                                         | 1 (2.0%)                                                                                                                  |                                                                                                                           |
| Patients without event                                                                                                    | 38 (74.5%)                                                                                                                | 41 (82.0%)                                                                                                                | 51 (72.9%)                                                                                                                |
| EFS at 12 months; (90% CI)b                                                                                               | 80.3 (69.2, 87.8)                                                                                                         | 86.0 (75.5, 92.2)                                                                                                         | 81.4% (72.3; 87.8)                                                                                                        |
| EFS at 24 months; (90% CI)b                                                                                               | 75.3 (63.2, 83.9)                                                                                                         | 86.0 (75.5, 92.2)                                                                                                         | 72.7 (62.8, 80.4)                                                                                                         |
| EFS at 36 months; (90% CI)                                                                                                | 71.9 (58.8, 81.4)                                                                                                         | 81.9 (69.0, 89.8)                                                                                                         | 72.7 (62.8, 80.4)                                                                                                         |
| Hazard Ratio (TREO/BU)^ (90% CI)                                                                                          | 1.54 (0.74,3.22)                                                                                                          | 1.54 (0.74,3.22)                                                                                                          |                                                                                                                           |
| P-valuec                                                                                                                  | 0.3343                                                                                                                    | 0.3343                                                                                                                    |                                                                                                                           |
| only if this event occurred first based onKaplan-Meierestimates adjustedforTT and diseaseasfactorsusingCoxregressionmodel | only if this event occurred first based onKaplan-Meierestimates adjustedforTT and diseaseasfactorsusingCoxregressionmodel | only if this event occurred first based onKaplan-Meierestimates adjustedforTT and diseaseasfactorsusingCoxregressionmodel | only if this event occurred first based onKaplan-Meierestimates adjustedforTT and diseaseasfactorsusingCoxregressionmodel |

Table 2.7.3.3.2.3-10: Summary results of relapse/remission in trial MC-FludT.17/M

| Study                                                    | MC-FludT.17/MI    |
|----------------------------------------------------------|-------------------|
| Data source                                              | Table 11.4.1.4.A  |
| No. of patients                                          | 70 (100%)         |
| Patients with event                                      | 16 (22.9%)        |
| Patients without event (censored) or with competing even | 54 (77.1%)        |
| Censored                                                 | 51 (72.9%)        |
| Death*                                                   | 2 (2.9%)          |
| Primary graft failure                                    | 0                 |
| Secondary graft failure                                  | 1 (1.4%)          |
| Conditional cumulative incidence, % (90%CI)              |                   |
| At 12months                                              | 15.7 (8.6, 22.9)  |
| At24months                                               | 23.0 (14.7, 31.3) |
| At36months                                               | 23.0(14.7, 31.3)  |
| only ifthis event occured first                          |                   |

Table 2.7.3.3.2.3-14: Cumulative incidence ofNRM in trial MC-FludT.17/M

| Study                                                    | MC-FludT.17/M   |
|----------------------------------------------------------|-----------------|
| Data source                                              | Table11.4.1.7.A |
| No. of patients                                          | 70 (100%)       |
| Patients with event                                      | 2 (2.9%)        |
| Patients without event (censored) or with competing even | 68 (97.1%)      |
| Censored                                                 | 51 (72.9%)      |
| Relapse/progression                                      | 16 (22.9%)      |
| Primary graft failure                                    | 0               |
| Secondary graft failure*                                 | 1 (1.4%)        |
| Cumulative incidence at 12months,%(90%CI)                | 1.4 (0.0, 3.8)  |
| Cumulative incidence at 24 months,%(90%CI)               | 2.9 (0.0, 6.1)  |
| Cumulative incidence at 36 months, % (90% CI)            | 2.9 (0.0, 6.1)  |
| only ifthis event occuredfirst                           |                 |

<div style=\"page-break-after: always\"></div>

Table 2.7.3.3.2.3-11:Rescue therapies

| Study                                | MC-FludT.16/NM   | MC-FludT.16/NM   | MC-FludT.17/M     |
|--------------------------------------|------------------|------------------|-------------------|
| Data source                          | Table11.4.1.10.A | Table11.4.1.10.A | Listing 11.4.13.A |
| Study arm                            | TREO             | BU               | TREO              |
| Total number of patients             | 51 (100%)        | 50 (100%)        | 70 (100%)         |
| Rescue therapy                       | 21 (41.2%)       | 21 (42.0%)       | 11 (15.7%)        |
| Kind of rescue therapy               |                  |                  |                   |
| Transfiusion dependent for RBCs      | 17 (33.3%)       | 17 (34.0%)       |                   |
| Transfiusion dependent for platelets | 14 (27.5%)       | 14 (28.0%)       |                   |
| DLI                                  | 5 (9.8%)         | 2 (4.0%)         | 5 (7.1%)          |
| Stemcellboost                        | 2 (3.9%)         | 1 (2.0%)         | 4 (5.7%)          |
| Re-transplantwith conditioning       | 0                | 1 (2.0%)         |                   |
| Chemotherapy                         |                  |                  | 2 (2.9%)          |
| Other                                | 4 (7.8%)         | 2 (4.0%)         | 3 (4.3%)          |

## 2.4.3. Discussion on clinical efficacy

The current variation aims to include an additional non-malignant transplant indication in the paediatric population for Trecondi 1 g/5 g powder for solution for infusion based on final 12-months follow-up results  of  study  MC-FludT.16/NM;  a  randomised  phase  II  interventional  study  aimed  to  compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with non-malignant diseases.

Moreover, the MAH proposes to introduce a slightly modified dosing regimen according to the patient's body surface based on long-term follow-up data of paediatric Phase II study MC-FludT.17/M, on the efficacy  of  Treosulfan  based  conditioning  therapy  prior  to  allogeneic  haematopoietic  stem  cell transplantation in paediatric patients with haematological malignancies, as well as a final analysis of the population  pharmacokinetics  of  treosulfan  in  paediatric  patients.  Additionally,  one  meta-analysis  of engraftment data [Baumgart 2017] and two EBMT registry studies [Peters 2011, Peters 2017] on the use of TREO-based conditioning in paediatric patients with malignant and non-malignant diseases were performed and integrated into the data package.

Considering the aim of the current variation the discussion of clinical efficacy  is  focused  in  the  two paediatric clinical trials MC-FludT.16/NM and MC-FludT.17/M .

A non-controlled trial (MC-FludT.17/M) with treosulfan (TREO)-based conditioning in combination with fludarabine (FLU) and with or without Thiotepa (TT) has been performed in paediatric patients with haematological malignancies (MD). Another randomised active-controlled trial in paediatric patients with non-malignant diseases (NMD) and where TREO/FLU/TT is compared with busulfan (BU)/FLU/TT has been  completed  recently  (MC-FludT.16/NM).  Efficacy  data  with  TREO-based  conditioning  from  70 patients with malignant and 51 patients with various non-malignant diseases have been assessed.

Main  indications  for  alloHSCT  in  children  are  haematological  malignancies  such  as  ALL  (26%),  AML (14%), and MDS/MPS (8%), but also non-malignant disorders (NMD) like primary immunodeficiency (PID; 16%), bone marrow failure (BMF; 12%), and thalassaemia (9%) [Passweg 2014]. However, the use of tresosulfan as part of the conditioning-regimen prior alloHSCT is only currently approved for paediatric patients with malignant disease.

<div style=\"page-break-after: always\"></div>

All  such  patients  were  included  in  the  two  above-mentioned  paediatric  trials  with  treosulfan-based conditioning besides published reports.

AlloHSCT is a very complex treatment method which consists of the conditioning regimen, the infusion of  allogeneic  HSCs,  and  pre/post-transplant  immunosuppressive  measures  (GvHD  prevention).  The efficacy  of  the  conditioning  regimen  can  therefore  be  measured  only  in  the  context  of  the  whole transplant procedure. Engraftment (as conditional cumulative incidence of engraftment) of the donor HSCs  is  the  only  parameter  which  is  generally  considered  directly  dependent  on  the  efficacy  of  a conditioning  therapy  and  as  such  it  was  selected  as  the  primary  endpoint  in  the  three  initial  noncontrolled trials in adult patients and included as a secondary endpoint in all other studies, including MCFludT.16/NM and MC-FludT.17/M.

Almost all  patients  achieve  engraftment  after  conditioning  with  TREO/FL  or  BU/FL  and  as  such  it  is accepted that it was not the primary endpoint in the assessed trials. Other typical efficacy endpoints used in clinical trials with alloHSCT include cumulative incidence of relapse (CIR), non-relapse mortality (NRM)  or  transplant-related  mortality  (TRM),  and  Graft  versus  Host  disease  (GvHD)  [Kim  2013]; considering the curative potential of this treatment also survival endpoints such as disease-free survival (DFS),  event-free  survival  (EFS),  and  overall  survival  (OS)  were  adequately  selected  as  secondary endpoint.

For the MC-FludT.16/NM and MC-FludT.17/M trials and upon request from PDCO, the selected primary endpoint was Freedom from transplant (treatment) related mortality until day +100 after HSCT, defined as death from any transplant-related cause from start of conditioning treatment (day -7) until day +100 after HSCT. The analysis of the estimates from Kaplan-Meier for freedom from TRM until Day+100 after alloHSCT indicates that both treosulfan and busulfan give good results but the treosulfan behaves better with 0% (.16/NM) or 1.4% subjects (.17/M) with event for treosulfan vs 10% for busulfan (unadjusted p-value 0.0267; adjusted p-value 0.0528).

Transplant-related mortality (KM estimates) after TREO-based conditioning was very low in patients with both non-malignant (3.9%) as well as malignant diseases (5.7%) but somewhat higher with BU in nomalignant diseases (14.0%) (HR (TREO/BU) 0.29 (90% CI 0.0, 1.09); p value 0.1244). This was also seen in the EBMT registry analysis with no influence of age or dose of treosulfan and significantly lower TRM  for  TREO/FLU/TT  than  for  BU/FLU/TT  conditioning  [Peters  2017].  In  both  treatments  for  nonmalignant diseases the TRM was maintained over time however it increases after 2 years in malignant disease with treosulfan.

TREO dosing in the paediatric studies aimed to reach TREO plasma levels in the range observed with the 14 g/m² dose in adults. The data from both studies suggest that paediatric patients tolerate TREO-based conditioning better than adult patients and justify that there was no need to reduce the TREO dose in this patient population. Even so some adjustment of the TREO dose according with patient's BSA is being proposed in the current variation and justification for that proposal and clarification of some other PKrelated issues were provided (see above Discussion on Clinical Pharmacology).

Overall survival at 3 years after TREO-based conditioning was 84.3% (95% CI 75.5-90.1%) in patients with malignant diseases and similar to BU-based conditioning in patients with non-malignant disease (84.0%; 95% CI 75.5-90.1%). The later patients when treated with TREO presented a numerically (p value 0.1244) better OS (96.1%) than BU with an HR (TREO/BU) of 0.29 (90% CI 0.08, 1.09). This is also seen from the data available from the EBMT registry specially after a first HSCT [Peters 2011] and statistically significance is seen in the case of non-malignant diseases at 1 year (89.5% for TREO/FLU/TT vs 81.3%; for BU/FLU/TT (log rank test P = 0.012)[Peters 2017].

The maximum conditional cumulative incidence of neutrophil engraftment was 97.3% in patients with non-malignant diseases for TREO and 100% for BU and for TREO in patients with malignant diseases.

<div style=\"page-break-after: always\"></div>

Median  duration  of  neutropenia  was  significantly  longer  with  TREO  compared  to  BU  in  trial  MCFludT.16/NM  (20  days  vs.  14.5  days)  (p  value  0.0108).  The  MAH  justifies  this  difference  with  an imbalance in the underlying diseases of both treatment arms but the same duration is seen in the case of  TREO  treatment  in  paediatric  patients  with  malignant  diseases  which  may  require  more  close monitoring  of  these  patients  when  under  treatment  with  TREO.  Similar  data  were  obtained  for  the reconstitution of leukopoiesis (96.8% TREO-NMD, 100% BU-NMD and 100% TREO-MD; p value 0.2469) and thrombopoiesis (&gt;20x10 9 /L: 100% TREO-NMD, 96.8% BU-NMD and 94.1% TREO-MD - p value 0.8595; &gt;50x10 9 /L: 94.8% TREO-NMD, 97.1% BU-NMD and 91.9% TREO-MD - p value 0.3635). These data are also in line with the meta-analysis of engraftment data from trial MC-FludT.17/M, published paediatric data, and data from each of the arms of the two active-controlled studies in adult patients (MC-FludT.14/L Trials I/II), as per the PIP [Baumgart 2017] and with the date from the two metaanalyses of the EBMT [Peters 2011]. However, in patients with non-malignant diseases [2017 EBMT; Peters 2017], a significant correlation between conditioning treatment and neutrophil engraftment was observed for those patients who additionally received thiotepa (TT) with at day +100 after alloHSCT only 83.5% of patients reached neutrophil engraftment in the BU/FLU/TT group compared to 96.1% in the TREO/FLU/TT cohort. Only 2 of 121 paediatric patients (NMD and MD) (1.7%) treated with TREO-based or with BU-based conditioning had a primary graft failure; however in the case of NMD treatment with TREO seems to lead to higher rate of secondary graft failure (18.4% TREO-NMD vs 0% BU-NMD vs 1.4% TREO-MD) but all the graft failures in the TREO-NMD occurred in patients who had received a transplant from a matched unrelated donor which may explain the outcome.

The incidence of complete donor-type chimerism was lower in the patients treated with TREO with nonmalignant diseases compared to the patients with malignant diseases up to 24 months and also lower than with BU-treatment from Day+100 onwards.

Event-free survival was assessed as an additional exploratory endpoint in both paediatric trials. Overall EFS rates are similar for the TREO treatment in both NMD and MD patients and decreases with time for NMD ad reaches a plateau at 2 years for MD being higher (although non-significantly, p value 0.3343) for TREO than for BU-treatment (HR 1.54 (90% CI 0.74, 3.22). Nevertheless, this is due to mostly due to secondary graft failure and no on death number, where BU treatment has higher rate (3.9% TREO vs 12.0% BU). This follows the data available from the EBMT registry analysis [Peters 2011] which also indicates some influence of age likely related with difference in relapse incidence.

The cumulative incidence of relapse/progression in the 70 patients with MD treated with TREO-based conditioning in trial MC-FludT.17/M was 23.0% at 24 and 36 months with 15.7% (n=11) of these patients requiring rescue therapy mainly of donor lymphocyte infusion (DLI) or stem cell boost. Patients with non-malignant diseases required more rescue therapies (41.2%; especially transfusions for RBCs [33%] and platelets [27.5%]) than patients with malignant diseases. Nevertheless, no difference is observed regarding rescue therapies between the two treatment arms of the MC-FludT.16/NM trial. This is aligned with data on incidence of disease relapse (IDR) in these patients available from the EBMT registry [Peters 2017]. Of note, in the disease subgroups of the MC-FludT.17/M trial, a statistically significant difference in relapse/progression was recorded between JMML (75%), ALL (29.6%), AML (17.2%), and MDS (0.0%) subgroups; however, these results may be due to the small number of subjects with these pathologies included in the study as well with the general poor prognosis of these pathologies.

Overall the efficacy results of the first randomised Phase II alloHSCT trial (MC-FludT.16/NM) in paediatric patients with non-malignant diseases demonstrated a benefit for the treosulfan conditioning regimen over busulfan conditioning regimen in the selected subject population regarding Freedom from transplant (treatment) related mortality until day +100 after HSCT, TRM, OS, GvHD-free and cGvHD-free survival and EFS despite a higher rate of secondary graft failures and lower complete donor-type chimerism.

<div style=\"page-break-after: always\"></div>

Therefore, in children with non-malignant diseases indicated for alloHSCT the risk of graft failure must be carefully weighed against the risk of TRM when choosing the conditioning regimen.

The second Phase II trial in paediatric patients with malignant haematological disease (MC-FludT.17/M) has shown that a BSA-adapted i.v. dose of 10 g/m 2 , 12 g/m 2 , or 14 g/m 2  Treosulfan given on Days -6, -5, and 4 can be successfully used as conditioning treatment before alloHSCT in the selected paediatric population. After two rounds of assessment, the selected BSA-adapted dosing and additional PK issues were adequately justified/clarified (see above Discussion on Clinical Pharmacology).

Most of the subjects (92.9%) were treated with the intensified conditioning regimen (Thiotepa in addition to Fludarabine). The primary endpoint of the trial in paediatric patients with malignant diseases and of the trial in paediatric population with non-malignant disease treated with treosulfan, the rate for freedom from transplant (treatment)-related mortality until 100 days after HSCT, was 98.6% (90% CI: 93.4, 99.9) and 100% (90% CI: 94.3, 100), respectively indicating the tolerability and safety of this regimen in both conditions with favourable outcome when compared with busulfan-containing regimen (90%; 90% CI: 80.1, 96.0). The detailed safety analysis along with the Kaplan Meier estimation of NRM at 12 months and 36 months supports this observation.

Based on the engraftment and chimerism data approaching 100% and &gt; 90%, respectively, efficacy parameters like  EFS,  OS,  and  GvHD-free  and  relapse-free  survival  confirm  the  effectiveness  of  this conditioning  treatment.  Statistically  significant  unfavourable  results  for  JMML  and  second  HSCT subgroups with regard to relapse / progression as well as the survival parameters were noted. However, these results may be due to the small number of subjects with the pathologies included in the study as well with the general poor prognosis of these pathologies.

In overall, the efficacy of treosulfan as part of the conditioning treatment conditioning treatment prior to alloHSCT in paediatric patients with non-malignant diseases is based on the following considerations:

- The final  analysis  of  MC-FludT.14/L Trial  II  has  confirmed  the  non-inferiority  of  TREO-based conditioning  compared  to  reduced-intensity  conditioning  therapy  based  on  intravenous  BU. Additionally, superiority of TREO versus BU could now be shown with the final data set.
- The final  analysis  of  MC-FludT.14/L Trial  II  has  confirmed  the  non-inferiority  of  TREO-based conditioning  compared  to  reduced-intensity  conditioning  therapy  based  on  intravenous  BU. Additionally, superiority of TREO versus BU could now be shown with the final data set.
- Furthermore, both paediatric studies have been completed. Final CSRs are now available, with 3-year follow-up survival data for study MC-FludT.17/M and 1-year follow-up data for study MCFludT.16/NM.
- Moreover, the PopPK model for TREO was updated and the BSA-adapted dose regimen of TREO in paediatric patients slightly modified.

## 2.4.4. Conclusions on the clinical efficacy

Overall, the reported efficacy results of these two Phase II allo-HSCT trials resulted in a benefit for the Treosulfan-based conditioning regimen used in paediatric patients with selected malignant diseases, confirming the approved indication as well as in paediatric patients with selected non-malignant diseases in respect to a Busulfan-based condition regimen and thus to allow to support the extension of the use of Treosulfan to this population.

As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated as well as the Package Leaflet.

<div style=\"page-break-after: always\"></div>

The MAH agreed to a CHMP recommendation to submit the final study report of study MC-FludT.16/NM when available. This is of interest as allo-HSCT will be applied in the treatment for non-malignant diseases with the expectation of long-term treatment benefit.

## 2.5. Clinical safety

## Introduction

The most commonly reported undesirable effects of treosulfan are myelosuppression (leukocytopenia, thrombocytopenia, anaemia) and gastrointestinal complaints (nausea, vomiting). They are usually mild and resolve after treatment.

Bone marrow suppression is the dose-limiting side effect. However, it is this toxicity that supported the development of TREO for conditioning treatment prior to HSCT, especially in the allogenic setting. For this indication, TREO is always combined with FLU. Most paediatric patients receive additionally thiotepa (TT). This conditioning regimen is followed by infusion of haematopoietic stem cells. Furthermore, other immunosuppressive agents are usually given concomitantly or shortly thereafter.

Bone marrow depression (neutropenia, leukocytopenia, thrombocytopenia, anaemia) and immunosuppression  are  therefore  desired  therapeutic  effects  of  the  conditioning  regimen  and consequently cannot be considered as undesirable effects. Therefore, any changes in blood counts and differential blood counts occurring between Day -6 and Day +28 had not to be documented as AEs. Especially during the time of bone marrow aplasia induced by the conditioning regimen, infections may develop and are a major source of morbidity and mortality of patients.

Hyperbilirubinemia, mucositis/stomatitis, seizures, and HSOS (formerly designated as veno-occlusive disease/VOD)  are  considered  as  significant  adverse  events  of  conditioning  treatment  followed  by alloHSCT.  These  significant  AEs  were  of  special  interest  in  all  clinical  studies  with  TREO-based conditioning.

Graft versus host disease (GvHD) is commonly observed after alloHSCT. GvHD is considered not related to TREO but to the engraftment of the allogeneic immune system. How much the conditioning regimen influences the frequency and severity of GvHD is a matter of debate. Therefore, incidences of acute and chronic GvHD were intensively monitored in all studies.

Facing the above, the adverse events (AEs) and adverse reactions (ARs) observed with TREO-based conditioning  followed  by  alloHSCT  are  not  only  due  to  TREO  alone but  relate  to  the  whole  complex treatment procedure of alloHSCT.

Study MC-FludT.16/NM was  performed against busulfan (BU)-containing regimen. Busulfan is also used for conditioning prior to alloHSCT, mostly together with FLU or CY. Important ARs of conditioning regimens with BU/FLU followed by alloHSCT include infections or reactivation of opportunistic infectious pathogens, nervous system disorders, eye disorders, cardiac disorders, vascular disorders, respiratory thoracic  and  mediastinal  disorders  ,  gastrointestinal  disorders,  hepato-biliary  disorders,  skin  and subcutaneous  tissue  disorders,  musculoskeletal  and  connective  tissue  disorders,  renal  and  urinary disorders,  reproductive  system  and  breast  disorders  ,  general  disorders  and  administration  site conditions  and investigations. Such ARs could potentially also be observed with TREO.

In order to support pooled analyses of medical coded terms across all TREO trials, AEs of all studies were recoded according to MedDRA Version 20.0.

The results are summarised in an integrated summary of safety (ISS 2021; Report location: CTD Section 5.3.5.3). The primary objective of this ISS was to characterise the safety profile of TREO in the transplant

<div style=\"page-break-after: always\"></div>

setting,  for  adult  and  paediatric  population.  The  characterisation  of  TREO's  undesirable  effects  and respective frequencies is reflected in the Summary of Product Characteristics (SmPC) which has been updated in the current variation in respect to Summary of the safety profile, as well as the Tabulated list of adverse reactions for Paediatric population and Description of selected adverse reactions.

## Patient exposure

A total 121 paediatric patients have been treated with TREO-based conditioning, including 51 patients with non-malignant diseases (primary immunodeficiency, haemoglobinopathy, inborn error of metabolism and bone marrow failure syndromes) and 70 patients with malignant diseases (AML, ALL, MDS, and JMML).

The study in non-malignant diseases (MC-FludT.16/NM) also included an active-control group with 50 evaluable patients treated with the reference conditioning regimen BU/FLU ± TT.

This safety data set is supplemented by safety data derived from two registry studies of the EBMT [Peters 201193; Peters 2017] which included a total  of  1  521  paediatric  patients  with  malignant  and  nonmalignant diseases who had been treated with TREO-based conditioning. Therefore, available safety data cover all paediatric patients which are currently treated with alloHSCT.

Table2.7.4.1.3-6:Demographicprofileofpaediatricpatients

| Study                                                                          | MC-FludT.16/NM                                                                 | MC-FludT.16/NM                                                                 | MC-FludT.17/M                                                                  |
|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Datasource                                                                     | Tables 11.2.1.A and 11.2.4.B                                                   | Tables 11.2.1.A and 11.2.4.B                                                   | Tables 11.2.A and 11.2.3.B                                                     |
| Study arm                                                                      | TREO                                                                           | BU                                                                             | TREO                                                                           |
| No. of patients                                                                | 51 (100%)                                                                      | 50 (100%)                                                                      | 70 (100%)                                                                      |
| Gender n (%)                                                                   |                                                                                |                                                                                |                                                                                |
| Female                                                                         | 15 (29.4%)                                                                     | 19 (38.0%)                                                                     | 26 (37.1%)                                                                     |
| Male                                                                           | 36 (70.6%)                                                                     | 31 (62.0%)                                                                     | 44 (62.9%)                                                                     |
| Age (vears)                                                                    |                                                                                |                                                                                |                                                                                |
| Mean (SD)                                                                      | 5.0 (4.4)                                                                      | 6.0 (5.3)                                                                      | 9.1 (5.8)                                                                      |
| Median (Range)                                                                 | 4 (0, 17)                                                                      | 5 (0, 17)                                                                      | 9.5 (0-17)                                                                     |
| ICH age group, n (%)                                                           |                                                                                |                                                                                |                                                                                |
| 28 days to 23 months                                                           | 14 (27.5%)                                                                     | 14 (28.0%)                                                                     | 9 (12.9%)                                                                      |
| 2 years to 11years                                                             | 31 (60.8%)                                                                     | 26 (52.0%)                                                                     | 28 (40.0%)                                                                     |
| 12 years to 17 years                                                           | 6 (11.8%)                                                                      | 10 (20.0%)                                                                     | 33 (47.1%)                                                                     |
| Race, n (%)                                                                    |                                                                                |                                                                                |                                                                                |
| White                                                                          | 41 (80.4%)                                                                     | 43 (86.0%)                                                                     | 70 (100%)                                                                      |
| Black orAfricanAmerican                                                        | 2 (3.9%)                                                                       | 2 (4.0%)                                                                       | 0 (0.0%)                                                                       |
| Asian                                                                          | 6 (11.8%)                                                                      | 1 (2.0%)                                                                       | 0 (0.0%)                                                                       |
| Arabian                                                                        | 1 (2.0%)                                                                       | 1 (2.0%)                                                                       | 0 (0.0%)                                                                       |
| Arabic                                                                         | 0                                                                              | 2 (4.0%)                                                                       | 0 (0.0%)                                                                       |
| Turkish                                                                        | 1 (2.0%)                                                                       | 1 (2.0%)                                                                       | 0 (0.0%)                                                                       |
| Body surface area, m²                                                          |                                                                                |                                                                                |                                                                                |
| Mean (SD)                                                                      | 0.746 (0.297)                                                                  | 0.836 (0.396)                                                                  | 1.110 (0.480)                                                                  |
| Median (Range)                                                                 | 0.67 (0.30, 1.50)                                                              | 0.71 (0.35, 1.97)                                                              | 1.100 (0.32-2.00)                                                              |
| Applied performance score*,n(%)                                                |                                                                                |                                                                                |                                                                                |
| Lanskyperformancescore                                                         | 50 (98.0%)                                                                     | 48 (96.0%)                                                                     | 58 (82.9%)                                                                     |
| Karnafsbyperformancescore                                                      | 1 (2.0%)                                                                       | 2 (4.0%)                                                                       | 12 (17.1%)                                                                     |
| Karnofsky/Lansky score*, n (%)                                                 |                                                                                |                                                                                |                                                                                |
| 70                                                                             | 1 (2.0%)                                                                       | 2 (4.0%)                                                                       | 1 (1.4%)                                                                       |
| 80                                                                             | 0 (0.0%)                                                                       | 1 (2.0%)                                                                       | 9 (12.9%)                                                                      |
| 90                                                                             | 7 (13.7%)                                                                      | 9 (18.0%)                                                                      | 22 (31.4%)                                                                     |
| 100                                                                            | 43 (84.3%)                                                                     | 38 (76.0%)                                                                     | 38 (54.3%)                                                                     |
| Karnofsky/Lansky score* Median (range)                                         | 100 (70-100)                                                                   | 100 (70-100)                                                                   | 100 (70-100)                                                                   |
| Karnofskyscoreifage≥16yearsatregistrationLanskyscoreifage16yearsatregistration | Karnofskyscoreifage≥16yearsatregistrationLanskyscoreifage16yearsatregistration | Karnofskyscoreifage≥16yearsatregistrationLanskyscoreifage16yearsatregistration | Karnofskyscoreifage≥16yearsatregistrationLanskyscoreifage16yearsatregistration |

The majority of patients received the intensified regimen with thiotepa and a transplant from a matched unrelated donor.

<div style=\"page-break-after: always\"></div>

Table2.7.4.1.3-7:Diseases,donor type,and conditioningregimeninthetwopaediatricstudies

| Study                      | MC-FludT.16/NM                 | MC-FludT.16/NM                 | MC-FludT.17/M             |
|----------------------------|--------------------------------|--------------------------------|---------------------------|
| Datasource                 | Tables 11.2.1.A, -4.B, 14.1.1D | Tables 11.2.1.A, -4.B, 14.1.1D | Tables 11.2.A, 14.1.4C/-P |
| Study arm                  | TREO                           | BU                             | TREO                      |
| No.of patients             | 50 (100%)                      | 51 (100%)                      | 70 (100%)                 |
| Disease, n (%)             |                                |                                |                           |
| AML                        |                                |                                | 29 (41.4%)                |
| ALL                        |                                |                                | 27 (38.6%)                |
| MDS                        |                                |                                | 10 (14.3%)                |
| JMML                       |                                |                                | 4 (5.7%)                  |
| Haemoglobinopathy          | 23 (45.1%)                     | 28 (56.0%)                     |                           |
| Primaryimmunodeficiency    | 21 (41.2%)                     | 13 (26.0%)                     |                           |
| Bonemarrowfailuresyndrome  | 5 (9.8%)                       | 5 (10.0%)                      |                           |
| Inbornerrorofmetabolism    | 2 (3.9%)                       | 4 (8.0%)                       |                           |
| Donor type, n (%)          |                                |                                |                           |
| MRD                        | 14 (27.4%)                     | 17 (34.0%)                     | 14 (20.0%)                |
| MUD                        | 37 (72.6%)                     | 33 (66.0%)                     | 56 (80.0%)                |
| Conditioningregimen,n(%)   |                                |                                |                           |
| Intensifiedregimen(withTT) | 43 (84.3%)                     | 42 (84.0%)                     | 65 (92.9%)                |
| Standardregimen            | 8 (15.7%)                      | 8 (16.0%)                      | 5 (7.1%)                  |

For treatment of infants and smaller children consideration a population-pharmacokinetic model for dose calculation was developed. According to this model, body surface area was the only clinically relevant covariate  for  plasma  clearance  and  volume  of  distribution  of  TREO  ( see  above  section  5.3.2. Pharmacokinetics and LoQ ). The proposed dose regimen for TREO in children therefore ranges from 10-14 g/m²/d, given on days -6 to -4.

| Study                       | MC-FludT.16/NM                      | MC-FludT.16/NM                      | MC-FludT.17/M                       |
|-----------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| Study arm                   | Treosulfan                          | Busulfan                            | Treosulfan                          |
| Data source in CSR          | Table 14.3.6.1A/B/C/E               | Table 14.3.6.1A/B/C/E               | Table 12.1.A/B                      |
| Number of patients          | 51                                  | 50                                  | 70                                  |
| Doseregimen treosulfan      |                                     |                                     |                                     |
| 10 g/m2/d × 3               | 9 (17.6%)                           |                                     | 6 (8.6%) patients                   |
| 12 g/m2/d × 3               | 32 (62.7%)                          |                                     | 26 (37.1%) patients                 |
| 14 g/m²/d × 3               | 10 (19.6%)                          |                                     | 38 (54.3%) patients                 |
| Mean total dose (SD); g/m²  | 36.00 (3.82)                        |                                     | 38.65 (3.95)                        |
| Mean total dose (SD); g     | 27.77 (13.67)                       |                                     | 44.53 (21.98)                       |
| Dose regimen busulfan       |                                     |                                     | Not applicable                      |
| Regimen                     |                                     | 3.2-4.8 mg/kg/d, Days -7,-6,-5,-4   |                                     |
| Mean total dose (SD); mg/kg |                                     | 16.63 (2.88)                        |                                     |
| Mean total dose (SD); mg    |                                     | 363.0 (194.7)                       |                                     |
| Dose regimenfludarabine     |                                     |                                     |                                     |
| Regimen                     | 30 mg/m2/d, Days -7, -6, -5, -4, -3 | 30 mg/m2/d, Days -7, -6, -5, -4, -3 | 30 mg/m2/d, Days -7, -6, -5, -4, -3 |
| Dose regimen thiotepa       |                                     |                                     |                                     |
| Number of patients          | 43 (84.3%)                          | 42 (84.0%)                          | 65 (92.6%)                          |
| Regimen                     | 2 × 5 mg/kg, Day -2                 | 2 × 5 mg/kg, Day -2                 | 2 ×5 mg/kg, Day -2                  |
| Mean total dose [SD]; mg    |                                     |                                     | 349.6 (198.8)                       |
| SD=standarddeviation        |                                     |                                     |                                     |

## Adverse events (overall)

The following table gives an overall summary of AEs observed in the two paediatric trials. In the BU group, more patients than in the TREO group experienced life-threatening SAEs and SAEs resulting in death as well as drug-related SAEs. In the TREO group, more patients than in the BU group experienced SAEs that required hospitalisation or prolongation of hospitalisation.

<div style=\"page-break-after: always\"></div>

Table 2.7.4.2.1.1-6:Overall summary of adverse events in two paediatric trials

| Study                                          | MC-FludT.16/NM   | MC-FludT.16/NM   | MC-FludT.17/M   |
|------------------------------------------------|------------------|------------------|-----------------|
| Treatmentarm                                   | TREO             | BU               | TREO            |
| Datasource                                     | Table 12.2.1.A   | Table 12.2.1.A   | Table 12.2.1.A  |
| Number of patients                             | 51 (100%)        | 50 (100%)        | 70 (100%)       |
| Any adverse event                              |                  |                  |                 |
| Patients with AEs of any CTCAE Grade           | 96.1%            | 96.0%            | 97.1%           |
| PatientswithAEsofatleast CTCAEGradeII          | 80.4%            | 82.0%            | 75.7%           |
| Drug-relatedadverseevents                      |                  |                  |                 |
| PatientswithADRsof any CTCAEGrade              | 80.4%            | 74.0%            | 90.0%           |
| Patients with ADRs of at least CTCAE Grade II  | 51.0%            | 50.0%            | 48.6%           |
| Serious adverse events                         |                  |                  |                 |
| Patients with at least one serious AE          | 35.3%            | 32.0%            | 32.9%           |
| Results in death                               | 0%               | 8.0%             | 1.4%            |
| Life-threatening                               | 5.9%             | 8.0%             | 8.6%            |
| Hospitalisationorprolongationofhospitalisation | 31.4%            | 16.0%            | 28.6%           |
| Disability/Incapacity                          | 0%               | 2.0%             | 1.4%            |
| Congenital anomalyorbirthdefect                | 0%               | 0%               | 0%              |
| Drug-related serious adverse events            |                  |                  |                 |
| PatientswithdrugrelatedseriousAEs              | 3.9%             | 6.0%             | 1.4%            |
| Patients with maximum CTCAE Grade              |                  |                  |                 |
| CTCAE GradeI                                   | 0%               | 2.0%             | 4.3%            |
| CTCAE Grade II                                 | 15.7%            | 12.0%            | 17.1%           |
| CTCAE GradeIII                                 | 66.7%            | 60.0%            | 60.0%           |
| CTCAE GradeIV                                  | 13.7%            | 16.0%            | 15.7%           |
| CTCAE Grade V                                  | 0%               | 6.0%             | 0%              |

## Treatment-emergent adverse events

The most frequently observed TEAEs after TREO-based conditioning include: gastrointestinal disorders (90.9%;  includes  stomatitis  [74.4%],  vomiting  [67.8%],  diarrhoea  [62.8%],  nausea  [38.8%], abdominal pain [37.2%], and constipation [13.2%]), pyrexia (71.9%), infections (63.6%), skin and subcutaneous tissue disorders (58.7%; includes maculopapular rash [27.3%], pruritus [22.3%], and alopecia [9.9%]; Dermatitis diaper may occur in small children because of excretion of TREO in the urine. Therefore, diapers should be changed frequently up to 6-8 hours after each infusion of TREO), hepatotoxicity  (41.3%),  investigations  (37.2%;  includes  increased  ALT  [13.2%],  positive  viral  test [11.6%],  increased  AST  [9.9%],  and  increased  bilirubin  [9.9%]),  hypertension  (33.9%),  headache (27.3%), pain in extremity (18.2%), cough (19.0%), hypokalaemia (11.6%), hypersensitivity (10.7%), and sinus tachycardia (10.7%).

The most frequent (&gt; 10%) severe at least CTCAE grade III TEAEs in the two paediatric trials include infections (38.0%), stomatitis (35.5%), diarrhoea (14.0%), nausea (12.4%), vomiting (12.4%), and hypertension  (11.6%).  There  was  a  significant  association  between  age  and  respiratory  toxicity  in paediatric patients in the EBMT registry [Peters 2011]. Children below the age of one year (mainly nonmalignant  diseases)  experienced  more  respiratory  grade  III/IV  toxicity.  This  observation  could  be explained by the fact that it is likely that babies underwent HSCT for immunodeficiencies, i.e. diseases which are often associated with severe pulmonary infections even before HSCT.

More patients (&gt; 5% difference) transplanted for malignant versus non-malignant diseases experienced viremia (20.0% vs. 2.0%), device-related infection (11.4% vs. 3.9%), hypersensitivity reactions (17.1% vs. 2.0%), hypokalaemia (15.7% vs. 5.9%), psychiatric disorders (7.1% vs. 0%), nausea (45.7% vs. 29.4%), bone pain (10.0% vs. 0%), positive viral test (20% vs. 0%), and increased blood bilirubin (12.9% vs. 5.9%).

Epistaxis (2.9% vs. 15.7%), abdominal pain (31.4% vs. 45.1%), hepatotoxicity (34.3% vs. 51.0%), pruritus (18.6% vs. 27.5%), alopecia (1.4% vs. 21.6%), increased CRP (0% vs. 11.8%), and infusionrelated reaction (7.1% vs. 17.6%) were more frequently seen in patients transplanted for non-malignant diseases.

<div style=\"page-break-after: always\"></div>

The frequency of  TEAEs  was  broadly  similar  in  the  2 treatment  arms  of study 16/NM ,  with  a  few exceptions. Differences ≥ 10% for TREO vs. BU were seen for diarrhoea (58.8% vs. 46.0%), abdominal pain (45.1% vs. 30.0%), lung infection (2.0% vs. 12.0%), dry skin (0% vs. 10.0%) and maculo-papular rash (25.5% vs. 14.0%) while more patients in the BU arm compared to the TREO arm experienced (BU vs TREO) oral mucositis (48.0% vs. 27.5%), nausea (18.0% vs. 5.9%). Differences ≥ 5% TREO vs. BU were seen for infections (39.2% vs. 34.0%), febrile neutropenia (7.8% vs. 0%), and vascular events (19.6% vs. 12.0%), whereas more patients in the BU vs TREO presented vomiting (14.0% vs. 7.8%) and respiratory disorders (18.0% vs. 7.8%).

## Drug-related TEAEs

The  most  frequently  (≥ 5%)  observed  TREO-related  TEAEs  include  stomatitis  (66.1%),  vomiting (42.1%), diarrhoea (33.1%), nausea (26.4%), hepatotoxicity (26.4%), abdominal pain (16.5%), pyrexia (13.2%),  infections  (11.6%),  ALT  increased  (10.7%),  and  pruritus  (10.7%).  Most  frequent  (≥ 5%) severe ARs (≥ Grade III) after TREO-based conditioning include stomatitis (32.2%), nausea (8.3%), diarrhoea (7.4%), and infections (5.0%). The overall incidence of drug-related infections (11.6%) in 121 paediatric patients was slightly higher to that seen in adults and a frequency higher in the paediatric age group 12-17 years (6 of 39 [15.4%]) compared to infants &lt; 2 years of age (1 of 23 [4.3%]) but the limited  number  of  patients  included  into  the  two  paediatric  studies  is  insufficient  to  reach  to  final conclusions.

Drug-related TEAEs were reported by 74.0% of subjects in the BU arm, and 80.4% of subjects in the TREO arm. Substantial differences (&gt; 10% difference) between the 2 treatment arms (BU vs. TREO) were seen in the incidence of diarrhoea (22.0% vs. 39.2%), nausea (30.0% vs. 17.6%), abdominal pain (12.0% vs. 23.5%), other hepatobiliary disorders (46.0% vs. 33.3%), and pruritus (4.0% vs. 15.7%).

Drug-related TEAEs with at least CTCAE grade III TEAEs were reported by 50.0% of patients in the BU arm, and 51.0% of patients in the TREO arm. There was a substantial difference (&gt; 10% difference) between the 2 treatment arms in the incidence of oral mucositis (BU vs. TREO: 36.0% vs. 25.5%).

The  most  frequent  AR  reported  in  blood  and  lymphatic  system  disorders  SOC  category  was  febrile neutropenia, which was recorded in only 2 of 121 paediatric patients (1.7%) treated with TREO-based conditioning.

In  respect  to  endocrine  disorders,  data  from  a  retrospective,  multicentre  study  of  137  children undergoing  alloHSCT,  indicate  that  the  frequency  of  gonadal  damage  associated  with  TREO  was significantly lower than that observed after BU [Faraci 2019]. This is a small study where very few TREObased treated patients were included (19) versus BU-based treated patients (118), but this observation is corroborated by data from a more recent study [Leiper 2020] where the fertility in survivors of HSCT after  three  chemotherapy-conditioning  regimens  of  different  intensity  which  included  TREO-based, BU/cyclophosphamide (BU/Cy) and Fludarabine/melphalan (Flu-Mel) containing regimens was assessed by measuring serum concentrations of Anti-Müllerian hormone (AMH) and Inhibin B. The MAH data obtained suggested less ovarian reserve impairment after TREO and Flu-Mel than after Bu-Cy and the mean serum AMH conce ntration was significantly better with treosulfan (&gt;1.0 μg/L) than with Flu -Mel or  Bu-Cy.  The  same  more  favourable  trend  for  TREO-based  conditioning  regimen  is  seen  in  males regarding Inhibin B data with the Flu-Mel group suffering greatest impairment. These authors reach the same conclusion, that a TREO-based regimen confers a more favourable gonadal compromise than FluMel or Bu-Cy in both sexes.

Only 5 paediatric patients developed neurological ARs (3 x headache, 2 x paraesthesia, 1 x seizure) after TREO-based conditioning. Only two paediatric patients developed ARs belonging to Eye disorders SOC category. Only three vascular disorders related ARs (Capillary leak syndrome,  hypertension, hypotension) were seen in paediatric patients. No paediatric patient developed ARs belonging to ear and

<div style=\"page-break-after: always\"></div>

labyrinth  disorders  or  cardiac  disorders.  Two  cases  of  acute  kidney  injury  (AKI)  were  seen  in  the paediatric studies (1.7%).

## Serious adverse event/deaths/other significant events

The following table summarises the death cases in the two paediatric trials. Death rate in paediatric patients after TREO-based conditioning was much lower than that observed in adult patients. Only 14 of 121  patients  (11.6%)  included  so  far  into  the  two  paediatric  trials  died,  and  only  6  (5.0%)  from transplant-related  causes.  In  the  study  in  patients  with  non-malignant  diseases  more  patients  died transplant-related in the BU group compared to the TREO group (7 vs. 2). Only two patients in the TREO group died in MU-FludT.16/NM trial so far.

Table2.7.4.2.1.2-3:Deathcasesinthetwopaediatrictrials

|                                       | MC-FludT.16/NM                        | MC-FludT.16/NM                        | MC-FludT.17/M                         | Overall                               |
|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| Treatment                             | Busulfan                              | Treosulfan                            | Treosulfan                            | Treosulfan                            |
| Total number ofpatients               | 50                                    | 51                                    | 70                                    | 121                                   |
| Survivalstatusatstudytermination;n(%) | Survivalstatusatstudytermination;n(%) | Survivalstatusatstudytermination;n(%) | Survivalstatusatstudytermination;n(%) | Survivalstatusatstudytermination;n(%) |
| Alivea                                | 43 (86.0%)                            | 49 (96.1%)                            | 58 (82.9%)                            | 107 (88.4%)                           |
| Dead                                  | 7 (14.0%)                             | 2 (3.9%)                              | 12 (17.1%)                            | 14 (11.6%)                            |
| Cause of death;n (%)                  | Cause of death;n (%)                  | Cause of death;n (%)                  | Cause of death;n (%)                  | Cause of death;n (%)                  |
| Relapse/progression                   | 0                                     | 0                                     | 8 (11.4%)                             | 8 (6.6%)                              |
| Transplantationrelated                | 7 (14.0%)                             | 2 (3.9%)                              | 4 (5.7%)                              | 6 (5.0%)                              |

|                                        | MC-FludT.16/NM                         | MC-FludT.16/NM                         | MC-FludT.17/M                          | Overall                                |
|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Treatment                              | Busulfan                               | Treosulfan                             | Treosulfan                             | Treosulfan                             |
| GvHD                                   | 2 (4.0%)                               | 2 (3.9%)                               | 1 (1.4%)                               | 3 (2.5%)                               |
| Pulmonary toxicity                     | 1 (2.0%)                               | 0 (0.0%)                               | 1 (1.4%)                               | 1 (0.8%)                               |
| Haemorrhage                            | 1 (2.0%)                               | 0 (0.0%)                               | 1 (1.4%)                               | 1 (0.8%)                               |
| Renal failure                          | 0 (0.0%)                               | 1 (2.0%)                               | 0 (0.0%)                               | 1 (0.8%)                               |
| Gastrointestinal toxicity              | 0 (0.0%)                               | 1 (2.0%)                               | 0 (0.0%)                               | 1 (0.8%)                               |
| Interstitial pneumonia                 | 1 (2.0%)                               | 0 (0.0%)                               | 2 (2.9%)                               | 2 (1.7%)                               |
| EBVproliferative disease               | 0 (0.0%)                               | 1 (2.0%)                               | 0 (0.0%)                               | 1 (0.8%)                               |
| Infection                              | 5 (10.0%)                              | 1 (2.0%)                               | 3 (4.3%)                               | 4 (3.3%)                               |
| Multiple organ failure                 | 1 (2.0%)                               | 2 (3.9%)                               | 4 (3.3%)                               | 4 (3.3%)                               |
| Other                                  | 1 (2.0%)                               | 0 (0.0%)                               | 0 (0.0%)                               | 0 (0.0%)                               |
| Timefromtransplantationtodeath(months) | Timefromtransplantationtodeath(months) | Timefromtransplantationtodeath(months) | Timefromtransplantationtodeath(months) | Timefromtransplantationtodeath(months) |
| Mean (SD)                              | 6.44 (8.44)                            | 5.73 (2.49)                            | 14.97 (12.35)                          | 13.65 (11.87)                          |
| Median (Range)                         | 2.96 (2.2, 25.3)                       | 5.73 (4.0, 7.5)                        | 11.01 (0.5, 46.7)                      | 9.69 (0.5, 46.7)                       |

Data in paediatric patients with non-malignant diseases are also available from the 2017 EBMT registry [Peters 2017] and also show a lower number of death cases with TREO/FLU/TT versus BU/FLU/TT (10.1% vs. 17.0%). The most common causes of death after HSCT for non-malignant diseases were infection, graft versus host disease, the original disease and transplant associated organ complications. Deaths due to graft failure or due to secondary malignancies were rare events.

Table 2.7.4.2.1.2-4:Causes ofdeath in children with non-malignant diseases;n(%)

| Regimen                           | TREO/FLU                         | BU/FLU                           | TREO/FLU/TT                      | BU/FLU/TT                        |
|-----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| Number of patientsin the registry | 422                              | 1063                             | 473                              | 229                              |
| Totalnumber of deaths             | 69 (16.4%)                       | 182 (17.1%)                      | 48 (10.1%)                       | 39 (17.0%)                       |
| Cardiac toxicity                  | 0                                | 4 (2.5%)                         | 2 (4.5%)                         | 2 (6.2%)                         |
| Haemorrhage                       | 3 (4.6%)                         | 6 (3.8%)                         | 2 (4.5%)                         | 2 (6.2%)                         |
| Failure/rejection                 | 1 (1.5%)                         | 4 (2.5%)                         | 1 (2.3%)                         | 2 (6.2%)                         |
| Infection                         | 28 (43.1%)                       | 45 (28.1%)                       | 13 (29.5%)                       | 11 (34.4%)                       |
| Interstitialpneumonitis           | 8 (12.3%)                        | 11 (6.9%)                        | 3 (6.8%)                         | 1 (3.1%)                         |
| GvHD                              | 8 (12.3%)                        | 43 (26.9%)                       | 8 (18.2%)                        | 5 (15.6%)                        |
| Original disease                  | 7 (10.8%)                        | 21 (13.1%)                       | 9 (20.5%)                        | 5 (15.6%)                        |
| Second malignancy                 | 1 (1.5%)                         | 1 (0.6%)                         | 0                                | 0                                |
| Other                             | 2 (3.1%)                         | 10 (6.2%)                        | 2 (4.5%)                         | 1 (3.1%)                         |
| Transplant-related                | 7 (10.8%)                        | 15 (9.4%)                        | 4 (9.1%)                         | 3 (9.4%)                         |
| Not reported/unknown              | 4                                | 22                               | 4                                | 7                                |
| Data source:Peters 2017(Table12)  | Data source:Peters 2017(Table12) | Data source:Peters 2017(Table12) | Data source:Peters 2017(Table12) | Data source:Peters 2017(Table12) |

Table 2.7.4.2.1.4.3-1 shows the incidence of selected significant AEs observed in the two paediatric trials. No pulmonary fibrosis was seen. In trial MC-FludT.16/NM, more patients in the BU arm developed HSOS (5 versus 1). All other parameters were comparable in both groups.

<div style=\"page-break-after: always\"></div>

Table 2.7.4.2.1.4.3-1:Incidence of selected toxicities in twopaediatric trials (Safety Set)

| Adverseevent                    | MC-FludT.16/NM    | MC-FludT.16/NM    | MC-FludT.17/M     |
|---------------------------------|-------------------|-------------------|-------------------|
| Treatment arm                   | BU                | TREO              | TREO              |
| Number of patients              | 50                | 51                | 70                |
| HSOS[Jones1987]                 |                   |                   |                   |
| Patients with event             | 5 (10.0%)         | 1 (2.0%)          | 1 (1.4%)          |
| Incidenceofevent[%](95%CI)      | 10.0 (3.3, 21.8)  | 2.0 (0.0, 10.4)   | 1.4 (0.0, 7.7)    |
| P value                         | 0.1120            | 0.1120            |                   |
| Early toxicity (until Day+28)   |                   |                   |                   |
| Patients with event             | 48 (96.0%)        | 48 (94.1%)        | 68 (97.1%)        |
| Incidence of event [%] (95% CI) | 96.0 (86.3, 99.5) | 94.1 (83.8, 98.8) | 97.1 (90.1, 99.7) |
| P value                         | 1.0000            | 1.0000            |                   |
| Hepatictoxicity[Bearman1988]    |                   |                   |                   |
| Patients with event             | 27 (54.0%)        | 26 (51.0%)        | 24 (34.3%)        |
| Incidenceofevent[%](95%CI)      | 54.0 (39.3, 68.2) | 51.0 (36.6, 65.2) | 34.3 (23.3, 46.6) |
| P value                         | 0.8429            | 0.8429            |                   |
| Infections                      |                   |                   |                   |
| Patients with event             | 35 (70.0%)        | 31 (60.8%)        | 50 (71.4%)        |
| Incidenceofevent[%](95%CI)      | 70.0 (55.4, 82.1) | 60.8 (46.1, 74.2) | 71.4 (59.4, 81.6) |
| P value                         | 0.4044            | 0.4044            |                   |
| Data source in CSR              | Table 12.3.1.3.A  | Table 12.3.1.3.A  | Table 12.3.1.3.A  |

## Other Serious Adverse Events

The frequency of SAEs occurring in at least 2 of the total 121 patients treated with TREO within two clinical studies in paediatric patients is shown in the table below. Results are comparable in both trials. A total of 41 of 121 paediatric patients (33.9%) experienced an SAE after TREO-based conditioning. Most frequent SAEs were infection (22.3%), pyrexia (6.6%) and febrile neutropenia (2.5%).

|                                                                                             | MC-FludT.16/NM                                                                              | MC-FludT.17M                                                                                | Overall                                                                                     |
|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Total number of patients                                                                    | 51                                                                                          | 70                                                                                          | 121                                                                                         |
| Patients with any event                                                                     | 18 (35.3%)                                                                                  | 23 (32.9%)                                                                                  | 41 (33.9%)                                                                                  |
| Infections andinfestations                                                                  |                                                                                             |                                                                                             |                                                                                             |
| Any event                                                                                   | 12 (23.5%)                                                                                  | 15 (21.4%)                                                                                  | 27 (22.3%)                                                                                  |
| Cytomegalovirus infection                                                                   | 3 (5.9%)                                                                                    | 3 (4.3%)                                                                                    | 6 (5.0%)                                                                                    |
| Sepsis                                                                                      | 2 (3.9%)                                                                                    | 2 (2.9%)                                                                                    | 4 (3.3%)                                                                                    |
| Upperrespiratory tract infection                                                            | 1 (2.0%)                                                                                    | 3 (4.3%)                                                                                    | 4 (3.3%)                                                                                    |
| Device related infection                                                                    | 1 (2.0%)                                                                                    | 1 (1.4%)                                                                                    | 2 (1.7%)                                                                                    |
| Encephalitis                                                                                | 1 (2.0%)                                                                                    | 1 (1.4%)                                                                                    | 2 (1.7%)                                                                                    |
| Epstein-Barr virus infection                                                                | 1 (2.0%)                                                                                    | 1 (1.4%)                                                                                    | 2 (1.7%)                                                                                    |
| Blood and lymphatic system disorders                                                        |                                                                                             |                                                                                             |                                                                                             |
| Any event                                                                                   | 2 (3.9%)                                                                                    | 3 (4.3%)                                                                                    | 5 (4.1%)                                                                                    |
| Febrile neutropenia                                                                         | 0 (0.0%)                                                                                    | 3 (4.3%)                                                                                    | 3 (2.5%)                                                                                    |
| Nervous system disorders                                                                    |                                                                                             |                                                                                             |                                                                                             |
| Any event                                                                                   | 1 (2.0%)                                                                                    | 2 (2.9%)                                                                                    | 3 (2.5%)                                                                                    |
| Encephalopathy                                                                              | 1 (2.0%)                                                                                    | 1 (1.4%)                                                                                    | 2 (1.7%)                                                                                    |
| Respiratory,thoracic and mediastinal disorders                                              |                                                                                             |                                                                                             |                                                                                             |
| Any event                                                                                   | 0 (0.0%)                                                                                    | 2 (2.9%)                                                                                    | 2 (1.7%)                                                                                    |
| Gastrointestinaldisorders                                                                   |                                                                                             |                                                                                             |                                                                                             |
| Any event                                                                                   | 1 (2.0%)                                                                                    | 3 (4.3%)                                                                                    | 4 (3.3%)                                                                                    |
| General disorders                                                                           |                                                                                             |                                                                                             |                                                                                             |
| Any event                                                                                   | 6 (11.8%)                                                                                   | 2 (2.9%)                                                                                    | 8 (6.6%)                                                                                    |
| Pyrexia                                                                                     | 6 (11.8%)                                                                                   | 2 (2.9%)                                                                                    | 8 (6.6%)                                                                                    |
| Note:Absoluteandrelativefrequenciesofpatientswitheventrelativetothetotalnumberofpatients(N) | Note:Absoluteandrelativefrequenciesofpatientswitheventrelativetothetotalnumberofpatients(N) | Note:Absoluteandrelativefrequenciesofpatientswitheventrelativetothetotalnumberofpatients(N) | Note:Absoluteandrelativefrequenciesofpatientswitheventrelativetothetotalnumberofpatients(N) |
| Data source:ISS2021,Table 4.2.2A                                                            | Data source:ISS2021,Table 4.2.2A                                                            | Data source:ISS2021,Table 4.2.2A                                                            | Data source:ISS2021,Table 4.2.2A                                                            |

Frequency of SAEs was also comparable in both groups of trial MC-FludT.16/NM, with the occurrence of more infections and more general disorders (all cases were fever) in the TREO group.

<div style=\"page-break-after: always\"></div>

Table2.7.4.2.1.3-8:FrequencyofpatientswithSAEsbySOCintrialMC-FludT.16/NM

|                                            | MC-FludT.16/NM                  | MC-FludT.16/NM                  |
|--------------------------------------------|---------------------------------|---------------------------------|
| Treatment                                  | Treosulfan                      | Busulfan                        |
| Total numberofpatients                     | 51                              | 50                              |
| Patientswith any event                     | 18 (35.3%)                      | 16 (32.0%)                      |
| Infections and infestations                | 12 (23.5%)                      | 7 (14.0%)                       |
| Neoplasms                                  | 1 (2.0%)                        | 0                               |
| Bloodandlymphaticsystemdisorders           | 1 (2.0%)                        | 4 (8.0%)                        |
| Immune system disorders                    | 1 (2.0%)                        | 0                               |
| Nervous system disorders                   | 1 (2.0%)                        | 1 (2.0%)                        |
| Respiratory disorders                      | 0                               | 4 (8.0%)                        |
| Gastrointestinaldisorders                  | 1 (2.0%)                        | 0                               |
| Hepatobiliarydisorders                     | 0                               | 2 (4.0%)                        |
| Generaldisorders                           | 6 (11.8%)                       | 1 (2.0%)                        |
| Investigations                             | 1 (2.0%)                        | 0                               |
| Injury,poisoningandproceduralcomplications | 1 (2.0%)                        | 0                               |
| Data source:CSRTable 12.3.1.2.A            | Data source:CSRTable 12.3.1.2.A | Data source:CSRTable 12.3.1.2.A |

The following table summarises the results of aGvHD observed in the two paediatric trials. Incidences were slightly higher in patients with non-malignant diseases. The cumulative incidence of aGvHD after TREO-based  conditioning  in  the  two  paediatric  studies  was  54.9%  in  patients  with  non-malignant diseases and 43.5% in patients with malignant diseases. This incidence is comparable to that observed in adult patients.

Table2.7.4.2.1.5.1-6:Summary tableofaGvHD

| Study                                                   | MC-FludT.16/NM                                          | MC-FludT.16/NM                                          | MC-FludT.17/M                                           |
|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
| Treatment arm                                           | TREO                                                    | BU                                                      | TREO                                                    |
| Number of patients                                      | 51                                                      | 50                                                      | 70                                                      |
| CumulativeincidenceaGxHD,all grades                     |                                                         |                                                         |                                                         |
| At Day 14;% (90% CI)                                    | 13.7 (5.8, 21.7)                                        | 2.0 (0.0, 5.3)                                          | 7.2 (2.1, 12.4)                                         |
| AtDay28;% (90%CI)                                       | 37.3 (26.1, 48.4)                                       | 30.0 (19.3, 40.7)                                       | 37.7 (28.1, 47.3)                                       |
| At Day100;% (90% CI)                                    | 54.9 (43.4, 66.4)                                       | 42.0 (30.5, 53.5)                                       | 43.5 (33.7, 53.3)                                       |
| HR TREO/BU* (90% CI)                                    | 1.65 (1.02, 2.67)                                       | 1.65 (1.02, 2.67)                                       |                                                         |
| Pvalue*                                                 | 0.0889                                                  | 0.0889                                                  |                                                         |
| CumulativeincidenceaGxHDgradeIII/IV                     |                                                         |                                                         |                                                         |
| At Day 14; % (90% CI)                                   | 2.0 (0.0, 5.2)                                          | 2.0 (0.0, 5.3)                                          | 0.0 (0.0, 0.0)                                          |
| At Day 28;%(90% CI)                                     | 2.0 (0.0, 5.2)                                          | 4.0 (0.0, 8.6)                                          | 5.8 (1.2, 10.4)                                         |
| AtDay100;%(90%CI)                                       | 13.7 (5.8, 21.7)                                        | 8.0 (1.7, 14.3)                                         | 8.7 (3.1, 14.3)                                         |
| HR TREO/BU*(90%CI)                                      | 1.63 (0.55, 4.81)                                       | 1.63 (0.55, 4.81)                                       |                                                         |
| Pvalue*                                                 | 0.4598                                                  | 0.4598                                                  |                                                         |
| Datasource                                              | Tables 14.3.5.1A; 14.3.5.3A                             | Tables 14.3.5.1A; 14.3.5.3A                             | Table 14.3.5B                                           |
| *adjustedforTTanddisease asfactorsusingFineandGraymodel | *adjustedforTTanddisease asfactorsusingFineandGraymodel | *adjustedforTTanddisease asfactorsusingFineandGraymodel | *adjustedforTTanddisease asfactorsusingFineandGraymodel |

Results of GvHD from the two EBMT registry studies indicate that the incidence of grade III/IV aGvHD after TREO-based conditioning was 10% with no significant correlation with age. Also, the TREO dose had no significant impact on aGvHD in both univariate and multivariate analysis adjusted for diagnoses, age, number of HSCTs, remission status, donor and conditioning regimen. For malignant diseases, there was a borderline significant impact of age-group on the incidence of aGvHD of any grade (P = 0.045), the  aGvHD-incidence  is  monotonously  decreasing  with  age  [Peters  2011  (chapter  3.1.1)].  For  nonmalignant diseases, there is no significant association between grade III/IV toxicity and dose-group in the subgroups of patients according to donor type, and diagnoses [Peters 2011].

<div style=\"page-break-after: always\"></div>

Table 2.7.4.2.1.5.1-8: Acute GvHD and age group

| Patientgroup   | Agegroup   |   N | aGxHDallgrades   |    P* | aGvHDgradeII/IV   |    P* |
|----------------|------------|-----|------------------|-------|-------------------|-------|
| A11            | <0.5 years |  41 | 28%              | 1     | 5%                | 0.464 |
| A11            | 0.5-1 year |  65 | 50%              | 1     | 9%                | 0.464 |
| A11            | 1-12 years | 314 | 46%              | 1     | 11%               | 0.464 |
| A11            | 12 years   | 101 | 35%              | 1     | 10%               | 0.464 |
| Malignant      | <0.5 years |   0 |                  | 0.045 |                   | 1     |
| Malignant      | 0.5-1 year |   7 | 71%              | 0.045 | 0                 | 1     |
| Malignant      | 1-12 years | 100 | 54%              | 0.045 | 14%               | 1     |
| Malignant      | 12 years   |  58 | 40%              | 0.045 | 12%               | 1     |
| Non-malignant  | <0.5 years |  41 | 28%              | 0.947 | 5%                | 0.737 |
| Non-malignant  | 0.5-1 year |  58 | 47%              | 0.947 | 11%               | 0.737 |
| Non-malignant  | 1-12 years | 214 | 43%              | 0.947 | 10%               | 0.737 |
| Non-malignant  | 12 years   |  43 | 28%              | 0.947 | 7%                | 0.737 |
| FirstHSCT      | <0.5years  |  40 | 28%              | 0.953 | 5%                | 0.315 |
| FirstHSCT      | 0.5-1 year |  62 | 52%              | 0.953 | 10%               | 0.315 |
| FirstHSCT      | 1-12 years | 254 | 48%              | 0.953 | 13%               | 0.315 |
| FirstHSCT      | 12 years   |  81 | 36%              | 0.953 | 11%               | 0.315 |

Cumulative incidence of cGvHD was higher in the BU arm of trial MC-FludT.16/NM.

Table2.7.4.2.1.5.1-7: Summary table ofcGvHD

| Study                                                   | MC-FludT.16/NM                                          | MC-FludT.16/NM                                          | MC-FludT.17/M                                           |
|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
| Treatmentarm                                            | TREO                                                    | BU                                                      | TREO                                                    |
| Number of patients                                      | 51                                                      | 50                                                      | 70                                                      |
| Cumulativeincidence ofcGvHD                             |                                                         |                                                         |                                                         |
| At 12 months; % (90% CI)                                | 12.8 (4.8, 20.8)                                        | 38.6 (26.6, 50.7)                                       | 23.9 (15.3, 32.4)                                       |
| At 24 months;%(90% CI)                                  | 12.8 (4.8, 20.8)                                        | 38.6 (26.6, 50.7)                                       | 25.4 (16.6, 34.1)                                       |
| At 36 months;%(90%CI)                                   | 12.8 (4.8, 20.8)                                        | 38.6 (26.6, 50.7)                                       | 25.4 (16.6, 34.1)                                       |
| HR TREO/BU*(90% CI)                                     | 0.31 (0.14, 0.69)                                       | 0.31 (0.14, 0.69)                                       |                                                         |
| Pvalue*                                                 | 0.0168                                                  | 0.0168                                                  |                                                         |
| Cumulativeincidenceofmoderate/severecGvHD               |                                                         |                                                         |                                                         |
| At 12 months; % (90% CI)                                | 10.6 (3.2, 18.0)                                        | 22.7 (12.3, 33.1)                                       | 17.9 (10.2, 25.6)                                       |
| At 24 months; % (90% CI)                                | 10.6 (3.2,18.0)                                         | 22.7 (12.3, 33.1)                                       | 19.4 (11.5, 27.4)                                       |
| At 36 months; % (90% CI)                                | 10.6 (3.2, 18.0)                                        | 22.7 (12.3, 33.1)                                       | 19.4 (11.5, 27.4)                                       |
| HR TREO/BU*(90%CI)                                      | 0.46 (0.18, 1.15)                                       | 0.46 (0.18, 1.15)                                       |                                                         |
| Pvalue*                                                 | 0.1611                                                  | 0.1611                                                  |                                                         |
| Datasource                                              | Tables 14.3.5.4A; 14.3.5.5A                             | Tables 14.3.5.4A; 14.3.5.5A                             | Table14.3.5ZA                                           |
| *adjustedforTTand diseaseasfactorsusingFineandGraymodel | *adjustedforTTand diseaseasfactorsusingFineandGraymodel | *adjustedforTTand diseaseasfactorsusingFineandGraymodel | *adjustedforTTand diseaseasfactorsusingFineandGraymodel |

No significant correlation between the rate of cGvHD and age was found. For all alloHSCT, TREO dose had no significant impact on cGvHD in both univariate analysis and multivariate analysis adjusted for diagnoses, age, number of HSCTs, remission status, donor and conditioning regimen.

Secondary malignancies are well established complications in long-term survivors after alloHSCT. Two children treated in trial MC-FludT.17/M developed skin papilloma after TREO-based conditioning. One patient treated in the TREO arm of trial MC-FludT.16/NM developed MDS. In a retrospective analysis of 944 children who underwent HSCT for PID at two UK centres, 12 patients (1.27%) developed a nonposttransplant lymphoproliferative disorder malignancy. Three of these patients had received a TREObased conditioning regimen [Unni 2018]. Primary immunodeficiencies are diseases associated with an increased risk for neoplasias per se.

## Laboratory findings

Haematology: In trial MC-FludT.16/NM, the median level of WBCs at baseline was similar in the two treatment arms. The median level of WBC fell severely after Day -3. The lowest median value was recorded at Day +6 for both treatment arms, 0.08 G/L in the BU arm and 0.02 G/L in the TREO arm. The median value in both arms rose steadily from this point, and at Day +100 the median value was 3.23 G/L for the BU arm, and 4.40 G/L for the TREO arm. In trial MC-FludT.17/M, the median WBC level at baseline was 1.99 G/L (Q1 1.42; Q3 3.34). The level of WBC fell severely at visit Day -1 and continued to fall further with continuation of conditioning treatment. The lowest median value was recorded at visit

<div style=\"page-break-after: always\"></div>

Day +6, 0.02 G/L (Q1: 0.01; Q3: 0.05). The median value rose steadily from this point, and at visit Day +100 the median value was 3.57 G/L (Q1: 2.30; Q3: 5.33).

Clinical  chemistry: Incidence  of  increased  bilirubin/ALT/AST  in  121  paediatric  TREO  patients  was 6.6%/10.7%/ 6.6%, comparable to  the  data  seen  in  adults. In  trial  MC-FludT.16/NM  no  significant differences between both treatment groups were seen. Median levels of liver parameters were always below the upper limit of normal (ULN) with the exception of ALT which was slightly elevated at Day +6; median levels of electrolytes (sodium, potassium) did not much change from baseline in both treatment groups;  median  levels  of  CRP  and  procalcitonin  increased  after  conditioning  treatment  but  values normalized up to Day +28. The other parameters were relatively unaffected. In trial MC-FludT.17/M, baseline values of the liver function parameters (ALT, AST, γG T, AP, bilirubin) showed a considerable variability. Only γGT and bilirubin showed a significant increase of values compared to baseline while the other parameters were always below ULN. No SAE related to a change in laboratory values was reported; median  levels  of  electrolytes  did  not  much  change  from  baseline;  median  values  of  LDH,  CRP  and procalcitonin  increased  to  some  extent  after  baseline  but  CRP  and  procalcitonin  rapidly  returned  to normal values.

## Vital signs, physical findings, and other observations related to safety

In trial MC-FludT.16/NM, treatment with TREO did not remarkably influence systolic or diastolic blood pressure, pulse rate and body temperature. Six patients in the BU arm (12.0%) and 8 patients in the TREO arm (15.7%) experienced CTCAE grade III 'Hypertension'. No patient in the BU arm but one patient in the TREO arm experienced CTCAE grade III 'Hypotension'. No CTCAE grade IV event was reported. The median Karnofsky/Lansky Performance Score (KPS/LPS) did not change significantly and usually ranged between 90 and 100. The Kaplan Meier estimate at 12 months for subjects showing a deterioration to less than 60 points was 8.3% in the TREO group and 12.7% in the BU group.

In trial MC-FludT.17/M, treatment with TREO did not remarkably influence systolic or diastolic blood pressure,  pulse  rate  and  body  temperature.  Five patients  reported  AE  of  CTCAE  Grade III  Term 'Hypertension' (all resolved, except for 1 patient with not recovered/not resolved), 1 patient reported AE  for  each  CTCAE  Grade III  Term  'Hypotension'  and  'Fever'  (both  resolved).  The  median Karnofsky/Lansky Performance Score (KPS/LPS) did not change significantly and usually ranged between 90 and 100. The overall Kaplan-Meier estimate at 12 months for subjects showing a deterioration to less than 60 points was 13.6% (90% CI 7.3, 24.5).

## Adverse events (per trial)

## MC-FludT.16/NM

Criteria for Evaluation:

Safety:

Freedom from transplantation (treatment)-related mortality &amp; Transplantation-related mortality: refer to efficacy evaluation.

Acute GvHD: Time to aGvHD was defined as the time between end of HSCT and the date of first occurrence of aGvHD. Acute GvHD was evaluated from the end of HSCT until 100 days after transplantation.

<div style=\"page-break-after: always\"></div>

Chronic GvHD: Time to cGvHD was defined as the time between 100 days after end of HSCT and the first episode of cGvHD. Chronic GvHD was evaluated from 100 days after transplantation until the end of the longer-term follow-up.

Adverse events: All adverse events (AEs) (serious and non-serious) occurring between day -7 and day +100 were recorded continuously. After day +100, only serious AEs with suspected relatedness (serious adverse reactions [SAR]) to the investigational medicinal product (IMP) were documented up to the end of the longer-term follow-up phase.

Clinical  laboratory  tests: The  subject's  viral  status was  characterised  by  HIV,  cytomegalovirus,  EBV, hepatitis A, B, C, and herpes tests within 3 weeks prior to day -7. Pregnancy was assessed routinely in the  subject's  urine  or  serum  within  3  weeks  prior  to  day  -7,  in  any  female  who  had  experienced menarche.  The  standard  laboratory  parameters  (total  blood  count,  differential  blood  count,  serum chemistry, were documented once within 3 weeks prior to Day -7 (also for calculated GFR), at given time points between visit Day -7 and Day +28, and at visit Day +100 (total and differential blood count only).

Vital signs, physical examinations: Blood pressure, pulse, height, weight, and body temperature were assessed between day - 10 and day -8, blood pressure, pulse, and body temperature were assessed in addition at visit Day 0, +28, +100, Month 6, 9, and 12. Karnofsky Performance Score (KPS) or Lansky Performance Score (LPS) were assessed within 3 weeks prior to Day - 7, and at visit Day 0, Day +28, Day +100, Month 6, 9, and 12.

## Results

## SAFETY:

- The incidences of total Treatment-emergent adverse events (TEAEs) (busulfan: 96.0%, treosulfan: 96.1%) and subcategories of TEAEs were broadly similar in the 2 treatment arms. Differences of ≥ 10% between the treatment arms were noted only in a few cases.

More  subjects  in  the  treosulfan  arm  than  the  busulfan  arm  had  events  in  the  SOCs  'Skin  and subcutaneous tissue disorders' and 'Nervous system disorders'.

Table 12.2.1.A Overallsummaryoftreatmentemergentadverseevents (Safety Analysis Set)

|                                                          | Busulfan (N=50)   | Treosulfan (N=51)   | Total (N=101)   |
|----------------------------------------------------------|-------------------|---------------------|-----------------|
| Any adverse event [n (%)]                                |                   |                     |                 |
| Subjects with any adverse event                          | 48 ( 96.0%)       | 49 (96.1%)          | 97 (96.0%)      |
| SubjectswithAEs ofat least CTCAEgradeIII                 | 41 ( 82.0%)       | 41 ( 80.4%)         | 82 (81.2%)      |
| Drug-related adverse events [n (%)]                      |                   |                     |                 |
| Subjects with any drug-related adverse event             | 37 ( 74.0%)       | 41 (80.4%)          | 78 (77.2%)      |
| Subjects with drug-related AEs of at least CTCAE gradeII | 25 ( 50.0%)       | 26 (51.0%)          | 51 (50.5%)      |
| Serious adverse events [n (%)]                           |                   |                     |                 |
| Subjects with any serious adverse event                  | 16 ( 32.0%)       | 18 (35.3%)          | 34 (33.7%)      |
| - Results in death                                       | 4 ( 8.0%)         | 0 ( 0.0%)           | 4 ( 4.0%)       |
| - Life-threatening                                       | 4( 8.0%)          | 3 ( 5.9%)           | 7( 6.9%)        |
| -Hospitalizationorprolongation of hospitalization        | 8 ( 16.0%)        | 16 (31.4%)          | 24 (23.8%)      |
| - Disability/incapacity                                  | 1 ( 2.0%)         | 0 ( 0.0%)           | 1 ( 1.0%)       |
| -Congenital anomaly or birth defect                      | (%00 ) 0          | 0 ( 0.0%)           | (%00 ) 0        |
| Drug-related serious adverse events [n(%)]               |                   |                     |                 |
| Subjects with any drug-related serious adverse event     | 3 ( 6.0%)         | 2( 3.9%)            | 5 ( 5.0%)       |
| Maximum CTCAE grade of adverse events [n (%)]            |                   |                     |                 |
| SubjectswithAEs ofamaximumCTCAEgrade I                   | 1 ( 2.0%)         | 0 ( 0.0%)           | 1( 1.0%)        |
| Subjects with AEs ofa maximum CTCAE grade II             | 6 ( 12.0%)        | 8 (15.7%)           | 14 ( 13.9%)     |
| SubjectswithAEsof a maximum CTCAEgradeIII                | 30 ( 60.0%)       | 34 (66.7%)          | 64 (63.4%)      |
| Subjects withAEs ofamaximum CTCAE gradeIV                | 8 ( 16.0%)        | 7 (13.7%)           | 15 ( 14.9%)     |
| Subjects with AEs of a maximum CTCAE grade V             | 3 ( 6.0%)         | 0 ( 0.0%)           | 3 ( 3.0%)       |

Abbreviations:AE=adverse event;CTCAE:CommonTerminologyofAdverseEvents;N=total numberof subjects; n = number of subjects in each category.

<div style=\"page-break-after: always\"></div>

- The incidences of TEAEs related to IMP, were broadly similar in the 2 treatment arms (busulfan: 74.0%, treosulfan: 80.4%). Differences of ≥ 10% between the treatment arms were noted only in a few cases.

More subjects in the busulfan arm than the treosulfan arm reported events in the SOC 'Hepatobiliary disorders', while more subjects in the treosulfan arm than the busulfan arm reported events in the SOC 'Skin and subcutaneous tissue disorders'.

- The incidences of TEAEs of at least CTCAE grade III were broadly similar in the 2 treatment arms (busulfan: 82.0%, treosulfan: 80.4%). Differences of ≥ 10% between the treatment arms were noted only in a few cases.

More subjects in the busulfan arm than the treosulfan arm had events in the SOCs 'Gastrointestinal disorders' and 'Respiratory, thoracic and mediastinal disorders'. At the Term level, more subjects in the busulfan arm than the treosulfan arm reported 'Mucositis oral' and 'Nausea' but more subjects in the treosulfan arm reported diarrhoea and abdominal pain.

- The incidences of TEAEs of at least CTCAE grade III related to IMP were broadly similar in the 2 treatment arms (busulfan: 50.0%, treosulfan: 51.0%).

Differences of ≥ 10% between the treatment arms were noted for the Term 'Mucositis oral' which occurred more frequently in the busulfan arm than the treosulfan arm.

Table 12.2.2.1.A Frequency of subjects with treatiment emergent adverse events by CTCAESystemOrganClass and Term occurringin atleast 5%of subjects in either treatment arm (Safety Analysis Set)

| CTCAE System Organ Class CTCAE Term               | Busulfan (N=50)   | Treosulfan (N=51)   | Total (N=101)   |
|---------------------------------------------------|-------------------|---------------------|-----------------|
| Subjects with any event                           | 48 (96.0%)        | 49 (96.1%)          | 97 (96.0%)      |
| Gastrointestinaldisorders                         |                   |                     |                 |
| Any event                                         | 47 (94.0%)        | 46 (90.2%)          | 93 (92.1%)      |
| Mucositis oral                                    | 40 ( 80.0%)       | 36 (70.6%)          | 76 ( 75.2%)     |
| Vomiting                                          | 32 ( 64.0%)       | 34 (66.7%)          | 66 ( 65.3%)     |
| Diarrhea                                          | 23 (46.0%)        | 30 (58.8%)          | 53 (52.5%)      |
| Abdominal pain                                    | 15 (30.0%)        | 23 (45.1%)          | 38 (37.6%)      |
| Nausea                                            | 19 (38.0%)        | 15 (29.4%)          | 34 (33.7%)      |
| Constipation                                      | 7 ( 14.0%)        | 8 ( 15.7%)          | 15 ( 14.9%)     |
| Gastrointestinal disorders - Other, specify       | 4 ( 8.0%)         | 3 ( 5.9%)           | 7( 6.9%)        |
| Gastritis                                         | 2 ( 4.0%)         | 3 ( 5.9%)           | 5 ( 5.0%)       |
| Stomach pain                                      | 2 ( 4.0%)         | 3 ( 5.9%)           | 5 ( 5.0%)       |
| Analmucositis                                     | 1( 2.0%)          | 3 ( 5.9%)           | 4 ( 4.0%)       |
| General disordersand administrationsiteconditions |                   |                     |                 |
| Any event                                         | 39 ( 78.0%)       | 39 (76.5%)          | 78 ( 77.2%)     |
| Fever                                             | 36 (72.0%)        | 36 (70.6%)          | 72 (71.3%)      |
| Infusionrelatedreaction                           | 6 ( 12.0%)        | 9 (17.6%)           | 15 (14.9%)      |
| Chills                                            | 3 ( 6.0%)         | 7 (13.7%)           | 10 ( 9.9%)      |
| Localized edema                                   | 4( 8.0%)          | 4 ( 7.8%)           | 8 ( 7.9%)       |
| Fatigue                                           | 4 ( 8.0%)         | 3 ( 5.9%)           | 7( 6.9%)        |
| Pain                                              | 3 ( 6.0%)         | 4 ( 7.8%)           | 7( 6.9%)        |
| Infectionsandinfestations                         |                   |                     |                 |
| Any event                                         | 35 (70.0%)        | 31 (60.8%)          | 66 (65.3%)      |
| Infections and infestations - Other, specify      | 21 (42.0%)        | 23 (45.1%)          | 44 (43.6%)      |
| Rhinitis infective                                | 6 ( 12.0%)        | 4 ( 7.8%)           | 10 ( 9.9%)      |
| Sepsis                                            | 5 ( 10.0%)        | 3 ( 5.9%)           | 8 ( 7.9%)       |
| Lung infection                                    | 6 ( 12.0%)        | 1( 2.0%)            | 7( 6.9%)        |
| Catheterrelatedinfection                          | 4 ( 8.0%)         | 2 ( 3.9%)           | (%6's ) 9       |
| Enterocolitis infectious                          | 2 ( 4.0%)         | 3 ( 5.9%)           | 5 ( 5.0%)       |
| Skin infection                                    | 1 ( 2.0%)         | 3 ( 5.9%)           | 4 ( 4.0%)       |

<div style=\"page-break-after: always\"></div>

| CTCAE System Organ Class                                         | Busulfan (N=50)   | Treosulfan (N=51)   | Total (N=101)   |
|------------------------------------------------------------------|-------------------|---------------------|-----------------|
| CICAE Term Hepatobiliarydisorders                                |                   |                     |                 |
| Any event                                                        | 29 (58.0%)        | 27 (52.9%)          | 56 (55.4%)      |
| Hepatobiliary disorders - Other, specify                         | 29 ( 58.0%)       | 26 (51.0%)          | 55 (54.5%)      |
| Skin and subcutaneous tissue disorders                           |                   |                     |                 |
| Any event                                                        | 23 (46.0%)        | 30 (58.8%)          | 53 (52.5%)      |
| Pruritus                                                         | 9 ( 18.0%)        | 14 (27.5%)          | 23 (22.8%)      |
| Skin and subcutaneous tissue disorders - Other, specify          | 9 ( 18.0%)        | 13 (25.5%)          | 22 (21.8%)      |
| Rash maculo-papular                                              | 7 ( 14.0%)        | 13 (25.5%)          | 20 ( 19.8%)     |
| Alopecia                                                         | 6 ( 12.0%)        | 11 (21.6%)          | 17 (16.8%)      |
| Dry skin                                                         | 5 ( 10.0%)        | 0 ( 0.0%)           | 5 ( 5.0%)       |
| Skin hyperpigmentation                                           | 3 ( 6.0%)         | 2 ( 3.9%)           | 5 ( 5.0%)       |
| Urticaria                                                        | 1 ( 2.0%)         | 3 ( 5.9%)           | 4 ( 4.0%)       |
| Hypertrichosis                                                   | 0 ( 0.0%)         | 3 ( 5.9%)           | 3 ( 3.0%)       |
| Respiratory, thoracic and mediastinal disorders                  |                   |                     |                 |
| Any event                                                        | 21(42.0%)         | 22 (43.1%)          | 43 (42.6%)      |
| Cough                                                            | 13 ( 26.0%)       | 10 ( 19.6%)         | 23 (22.8%)      |
| Epistaxis                                                        | 7 ( 14.0%)        | 8 (15.7%)           | 15 ( 14.9%)     |
| Hypoxia                                                          | 3 ( 6.0%)         | 4 ( 7.8%)           | 7( 6.9%)        |
| Sore throat                                                      | 2 ( 4.0%)         | 5 ( 9.8%)           | 7( 6.9%)        |
| Respiratory, thoracic and mediastinal disorders - Other, specify | 3 ( 6.0%)         | 1 ( 2.0%)           | 4 ( 4.0%)       |
| Pharyngeal mucositis                                             | 3 ( 6.0%)         | 0 ( 0.0%)           | 3 ( 3.0%)       |
| Vascular disorders                                               |                   |                     |                 |
| Any event                                                        | 21 (42.0%)        | 21 (41.2%)          | 42 (41.6%)      |
| Hypertension                                                     | 18 (36.0%)        | 19 (37.3%)          | 37 (36.6%)      |
| Hematoma                                                         | 6 ( 12.0%)        | 3 ( 5.9%)           | 9 ( 8.9%)       |
| Hypotension                                                      | 2 ( 4.0%)         | 3 ( 5.9%)           | 5 ( 5.0%)       |
| Capillary leak syndrome                                          | 0 ( 0.0%)         | 3 ( 5.9%)           | 3 ( 3.0%)       |
| Nervous system disorder's                                        |                   |                     |                 |
| Any event                                                        | 14 ( 28.0%)       | 21 (41.2%)          | 35 (34.7%)      |
| Headache                                                         | 12 (24.0%)        | 14 (27.5%)          | 26 (25.7%)      |
| Dizziness                                                        | 6 ( 12.0%)        | 3 ( 5.9%)           |                 |
| CTCAESystem Organ Class CICAE Term                               | Busulfan          | Treosulfan (N=51)   | Total (N=101)   |
| Investigations                                                   | (N=50)            |                     |                 |
| Any event                                                        | 17 (34.0%)        | 16 (31.4%)          | 33 (32.7%)      |
| Alanine aminotransferaseincreased                                | 10 (20.0%)        | 8 ( 15.7%)          | 18 (17.8%)      |
| Investigations - Other, specify                                  | 4( 8.0%)          | 8 (15.7%)           | 12 (11.9%)      |
| Aspartate aminotransferaseincreased                              | 7 ( 14.0%)        | 4 ( 7.8%)           | 11 (10.9%)      |
| GGT increased                                                    | 6 ( 12.0%)        | 2 ( 3.9%)           | 8 ( 7.9%)       |
| Bloodbilirubinincreased                                          | 3 ( 6.0%)         | 3 ( 5.9%)           | 6 ( 5.9%)       |
| Metabolismandnutritiondisorders                                  |                   |                     |                 |
| Any event                                                        | 15 (30.0%)        | 14 (27.5%)          | 29 (28.7%)      |
| Anorexia                                                         | 3 ( 6.0%)         | 3 ( 5.9%)           | 6 ( 5.9%)       |
| Iron overload                                                    | 3 ( 6.0%)         | 3 ( 5.9%)           | 6 ( 5.9%)       |
| Hyperkalemia                                                     | 2 ( 4.0%)         | 3 ( 5.9%)           | 5 ( 5.0%)       |
| Hypokalemia                                                      | 2 ( 4.0%)         | 3 ( 5.9%)           | 5 ( 5.0%)       |
| Musculoskeletalandconnectivetissuedisorder's                     |                   |                     |                 |
| Any event                                                        | 11 (22.0%)        | 14 (27.5%)          | 25 (24.8%)      |
| Pain in extremity                                                | 6 ( 12.0%)        | 9 (17.6%)           | 15 ( 14.9%)     |
| Back pain                                                        | 2 ( 4.0%)         | 3 ( 5.9%)           | 5 ( 5.0%)       |
| Renalandurinary disorder's                                       |                   |                     |                 |
| Any event                                                        | 11 (22.0%)        | 14 (27.5%)          | 25 (24.8%)      |
| Hematuria                                                        | 5 ( 10.0%)        | 5 ( 9.8%)           | 10 ( 9.9%)      |
| Urinary frequency                                                | 1( 2.0%)          | 4 ( 7.8%)           | 5 ( 5.0%)       |
| Cardiac disorders                                                |                   |                     |                 |
| Any event                                                        | 9 ( 18.0%)        | 8 (15.7%)           | 17 (16.8%)      |
| Sinus tachycardia                                                | 7 (14.0%)         | 5 ( 9.8%)           | 12 (11.9%)      |
| Sinus bradycardia                                                | 4 ( 8.0%)         | 1( 2.0%)            | 5 ( 5.0%)       |
| Blood and lymphatic system disorders                             |                   |                     |                 |
| Anyevent                                                         | 5 ( 10.0%)        | 10 (19.6%)          | 15 ( 14.9%)     |
| Blood and lymphatic system disorders -Other, specify             | 3 ( 6.0%)         | 2 ( 3.9%)           | 5 ( 5.0%)       |
| Febrile neutropenia                                              | 0 ( 0.0%)         | 4 ( 7.8%)           | 4 ( 4.0%)       |
| Hemolysis                                                        | 1 ( 2.0%)         | 3 ( 5.9%)           |                 |

<div style=\"page-break-after: always\"></div>

| CTCAE System Organ Class CICAE Term           | Busulfan (N=50)   | Treosulfan (N=51)   | Total (N=101)   |
|-----------------------------------------------|-------------------|---------------------|-----------------|
| Eye disorder's                                |                   |                     |                 |
| Any event                                     | 7 (14.0%)         | 5 ( 9.8%)           | 12 (11.9%)      |
| Eye disorders -Other, specify                 | 3 ( 6.0%)         | 1 ( 2.0%)           | 4 ( 4.0%)       |
| Reproductivesystemandbreastdisorders          |                   |                     |                 |
| Anyevent                                      | 5 ( 10.0%)        | 2 ( 3.9%)           | 7 ( 6.9%)       |
| Injury,poisoning and procedural complications |                   |                     |                 |
| Any event                                     | 2 ( 4.0%)         | 3 ( 5.9%)           | (%0's ) s       |
| Endocrine disorders                           |                   |                     |                 |
| Any event                                     | 1( 2.0%)          | 3 ( 5.9%)           | 4 ( 4.0%)       |
| Immunesystemdisorders                         |                   |                     |                 |
| Any event                                     | 0 ( 0.0%)         | 3 ( 5.9%)           | 3 ( 3.0%)       |
| Psychiatricdisorders                          |                   |                     |                 |
| Any event                                     | 3 ( 6.0%)         | 0 ( 0.0%)           | 3 ( 3.0%)       |

Source:Table14.3.1C

Note: Absolute and relative frequencies of subjects with event relative to the total number of subjects (N)  (4 of 4) Abbreviations: CTCAE: Common Terminology of Adverse Events; N = number of subjects.

Table12.2.2.1.B Frequencyofsubjectswithtreatmentemergentadverseeventsofat least CTCAE grade III by CTCAE System Organ Class and Term occurringinatleast5%ofsubjectsineithertreatmentarm (Safety Analysis Set)

| CTCAE System Organ Class CTCAE Term             | Busulfan (N=50)   | Treosulfan (N=51)   | Total (N=101)   |
|-------------------------------------------------|-------------------|---------------------|-----------------|
| Subjects with any event                         | 41 ( 82.0%)       | 41 ( 80.4%)         | 82 (81.2%)      |
| Gastrointestinal disorders                      |                   |                     |                 |
| Any event                                       | 30 (60.0%)        | 25 (49.0%)          | 55 (54.5%)      |
| Mucositis oral                                  | 24 ( 48.0%)       | 14 (27.5%)          | 38 (37.6%)      |
| Diarrhea                                        | 7 (14.0%)         | 7 (13.7%)           | 14 ( 13.9%)     |
| Nausea                                          | 9 ( 18.0%)        | 3 ( 5.9%)           | 12 (11.9%)      |
| Vomiting                                        | 7 (14.0%)         | 4 ( 7.8%)           | 11 (10.9%)      |
| Infections and infestations                     |                   |                     |                 |
| Any event                                       | 17 (34.0%)        | 20 (39.2%)          | 37 (36.6%)      |
| Infections and infestations - Other, specify    | 4 ( 8.0%)         | 14 (27.5%)          | 18 (17.8%)      |
| Sepsis                                          | 5 (10.0%)         | 3 ( 5.9%)           | 8 ( 7.9%)       |
| Catheter related infection                      | 4 ( 8.0%)         | 2 ( 3.9%)           | (%6's )9        |
| Lung infection                                  | 5 (10.0%)         | 1 ( 2.0%)           | 6( 5.9%)        |
| Vascular disorders                              |                   |                     |                 |
| Any event                                       | 6 (12.0%)         | 10 ( 19.6%)         | 16 (15.8%)      |
| Hypertension                                    | 6 (12.0%)         | 8 (15.7%)           | 14 ( 13.9%)     |
| Investigations                                  |                   |                     |                 |
| Any event                                       | 6 ( 12.0%)        | 7 (13.7%)           | 13 ( 12.9%)     |
| Alanineaminotransferaseincreased                | 4 ( 8.0%)         | 4 ( 7.8%)           | 8 ( 7.9%)       |
| Aspartate aminotransferase increased            | 2 ( 4.0%)         | 3 ( 5.9%)           | 5 ( 5.0%)       |
| Investigations - Other, specify                 | 2 ( 4.0%)         | 3 ( 5.9%)           | 5 ( 5.0%)       |
| Respiratory,thoracicandmediastinaldisorders     |                   |                     |                 |
| Any event                                       | 9 ( 18.0%)        | 4 ( 7.8%)           | 13 (12.9%)      |
| Hypoxia                                         | 2( 4.0%)          | 3 ( 5.9%)           | 5 ( 5.0%)       |
| Bloodandlynphaticsystemdisorders                |                   |                     |                 |
| Any event                                       | 4 ( 8.0%)         | 7 (13.7%)           | 11 (10.9%)      |
| Febrile neutropenia                             | (%00 )0           | 4 ( 7.8%)           | 4 ( 4.0%)       |
| Generaldisordersandadninistrationsiteconditions |                   |                     |                 |
| Any event                                       | 7 (14.0%)         | 4 ( 7.8%)           | 11 (10.9%)      |
| Fever                                           | 1 ( 2.0%)         | 3 ( 5.9%)           | 4 ( 4.0%)       |
| Metabolismandnutritiondisorders                 |                   |                     |                 |
| Any event                                       | 6 ( 12.0%)        | 3 ( 5.9%)           | 9 ( 8.9%)       |
| CTCAE System Organ Class CTCAE Term             | Busulfan (N=50)   | Treosulfan (N=51)   | Total (N=101)   |
| Renalandurinarydisorders                        |                   |                     |                 |
| Any event                                       | 3 ( 6.0%)         | 3 ( 5.9%)           | 6 ( 5.9%)       |
| Hematuria                                       | 3 ( 6.0%)         | 1 ( 2.0%)           | 4 ( 4.0%)       |
| Skinand subcutaneoustissue disorders            |                   |                     |                 |
| Any event                                       | 1 ( 2.0%)         | 3 ( 5.9%)           | 4 ( 4.0%)       |

Note: Absolute and relative frequencies of subjects with event relative to the total number of subjects (N)  (2 of2) Abbreviations:CTCAE:CommonTerminologyof AdverseEvents;N=number of subjects.

Source:Table 14.3.1E

<div style=\"page-break-after: always\"></div>

Table 12.2.2.1.C Frequencyofsubjectswithtreatmentemergentdrug-relatedadverse eventsbyCTCAESystemOrganClassandTermoccurringinatleast 5%of subjects in either treatmentarm(SafetyAnalysisSet)

| CTCAE System Organ Class CTCAE Term                     | Busulfan (N=50)   | Treosulfan (N=51)   | Total (N=101)   |
|---------------------------------------------------------|-------------------|---------------------|-----------------|
| Subjects with any event                                 | 37 ( 74.0%)       | 41 ( 80.4%)         | 78 ( 77.2%)     |
| Gastrointestinal disorders                              |                   |                     |                 |
| Any event                                               | 34 ( 68.0%)       | 36 ( 70.6%)         | 70 ( 69.3%)     |
| Mucositis oral                                          | 29 ( 58.0%)       | 32 (62.7%)          | 61 ( 60.4%)     |
| Vomiting                                                | 19 (38.0%)        | 22 ( 43.1%)         | 41 ( 40.6%)     |
| Diarrhea                                                | 11 (22.0%)        | 20 (39.2%)          | 31 (30.7%)      |
| Nausea                                                  | 15 (30.0%)        | 9 (17.6%)           | 24 (23.8%)      |
| Abdominal pain                                          | 6 (12.0%)         | 12 (23.5%)          | 18 (17.8%)      |
| Anal mucositis                                          | 1 ( 2.0%)         | 3 ( 5.9%)           | 4 ( 4.0%)       |
| Hepatobiliary disorders                                 |                   |                     |                 |
| Any event                                               | 23 ( 46.0%)       | 17 (33.3%)          | 40 (39.6%)      |
| Hepatobiliary disorders - Other, specify                | 23 (46.0%)        | 16 (31.4%)          | 39 (38.6%)      |
| Skin andsubcutaneoustissuedisorders                     |                   |                     |                 |
| Any event                                               | 11 (22.0%)        | 18 (35.3%)          | 29 (28.7%)      |
| Alopecia                                                | 6 (12.0%)         | 11 (21.6%)          | 17 ( 16.8%)     |
| Pruritus                                                | 2 ( 4.0%)         | 8 (15.7%)           | 10 ( 9.9%)      |
| Skin and subcutaneous tissue disorders - Other, specify | 3 ( 6.0%)         | 6 (11.8%)           | 9 ( 8.9%)       |
| Rash maculo-papular                                     | 2 ( 4.0%)         | 4 ( 7.8%)           | 6 ( 5.9%)       |
| Dry skin                                                | 4 ( 8.0%)         | 0 ( 0.0%)           | 4 ( 4.0%)       |
| Investigations                                          |                   |                     |                 |
| Any event                                               | 11 (22.0%)        | 11 (21.6%)          | 22 (21.8%)      |
| Alanine aminotransferase increased                      | 6 ( 12.0%)        | 6 (11.8%)           | 12 ( 11.9%)     |
| Aspartateaminotransferaseincreased                      | 3 ( 6.0%)         | 3 ( 5.9%)           | (%6's ) 9       |
| Blood bilirubin increased                               | 2 ( 4.0%)         | 3 ( 5.9%)           | 5 ( 5.0%)       |
| GGT increased                                           | 4 ( 8.0%)         | 1 ( 2.0%)           | 5( 5.0%)        |
| Investigations - Other, specify                         | 2 ( 4.0%)         | 3 ( 5.9%)           | 5 ( 5.0%)       |
| Generaldisordersandadninistrationsiteconditions         |                   |                     |                 |
| Any event                                               | 9 (18.0%)         | 7 (13.7%)           | 16 (15.8%)      |
| Fever                                                   | 8 (16.0%)         | 5 ( 9.8%)           | 13 ( 12.9%)     |
| CTCAE System Organ Class CTCAE Term                     | Busulfan (N=50)   | Treosulfan (N=51)   | Total (N=101)   |
| Respiratory,thoracicandmediastinaldisorders             |                   |                     |                 |
| Any event                                               | 8 (16.0%)         | 6 (11.8%)           | 14 ( 13.9%)     |
| Epistaxis                                               | 2 ( 4.0%)         | 3 ( 5.9%)           | 5( 5.0%)        |
| Sore throat                                             | 2 ( 4.0%)         | 3 ( 5.9%)           | 5 ( 5.0%)       |
| Cough                                                   | 3 ( 6.0%)         | 1 ( 2.0%)           | 4 ( 4.0%)       |
| Infections andinfestations                              |                   |                     |                 |
| Any event                                               | 5 (10.0%)         | 6 (11.8%)           | 11 (10.9%)      |
| Infections and infestations - Other, specify            | 3 ( 6.0%)         | 5 ( 9.8%)           | 8 ( 7.9%)       |
| Metabolismand nutritiondisorders                        |                   |                     |                 |
| Any event                                               | 5 (10.0%)         | 1 ( 2.0%)           | 6 ( 5.9%)       |
| Nervoussystemdisorders                                  |                   |                     |                 |
| Any event                                               | 3 ( 6.0%)         | 3 ( 5.9%)           | (%6's )9        |

Source:Table 14.3.1G

Note: Absolute and relative frequencies of subjects with event relative to the total number of subjects (N)(2 of2) Abbreviations:CTCAE:CommonTerminology ofAdverseEvents;N=number of subjects.

<div style=\"page-break-after: always\"></div>

Table 12.2.2.1.D events ofatleast CTCAE grade III byCTCAE System Organ Class and

Frequencyofsubjectswithtreatmentemergentdrug-relatedadverse Termoccurringin at least 5%of subjectsineither treatment arm (Safety Analysis Set)

| CTCAESystem Organ Class CTCAE Term            | Busulfan (N=50)   | Treosulfan (N=51)   | Total (N=101)   |
|-----------------------------------------------|-------------------|---------------------|-----------------|
| Subjects with any event                       | 25 (50.0%)        | 26 (51.0%)          | 51 ( 50.5%)     |
| Gastrointestinal disorders                    |                   |                     |                 |
| Any event                                     | 22 (44.0%)        | 19 (37.3%)          | 41 ( 40.6%)     |
| Mucositis oral                                | 18 (36.0%)        | 13 (25.5%)          | 31 (30.7%)      |
| Nausea                                        | 7 (14.0%)         | 3 ( 5.9%)           | 10 ( 9.9%)      |
| Diarrhea                                      | 3 ( 6.0%)         | 6 (11.8%)           | 9 ( 8.9%)       |
| Vomiting                                      | 4 ( 8.0%)         | 1 ( 2.0%)           | 5 ( 5.0%)       |
| Investigations                                |                   |                     |                 |
| Any event                                     | 1 ( 2.0%)         | 6 (11.8%)           | 7 ( 6.9%)       |
| Alanine aminotransferase increased            | 1( 2.0%)          | 3 ( 5.9%)           | 4 ( 4.0%)       |
| Respiratory,thoracic andmediastinal disorders |                   |                     |                 |
| Any event                                     | 4( 8.0%)          | 1 ( 2.0%)           | 5 ( 5.0%)       |
| Infectionsandinfestations                     |                   |                     |                 |
| Any event                                     | 3 ( 6.0%)         | 1 ( 2.0%)           | 4 ( 4.0%)       |
| Metabolismandnutritiondisorders               |                   |                     |                 |
| Any event                                     | 3 ( 6.0%)         | 0 ( 0.0%)           | 3 ( 3.0%)       |

Source: Table 14.3.11

Note: Absolute and relative frequencies of subjects with event relative to the total number of subjects (N)

Abbreviations:CTCAE:CommonTerminology of AdverseEvents;N=numberof subjects.

- The  incidence  of  aGvHD  grade  I-IV  was  similar  in  the  2  treatment  arms  (busulfan:  42.0%, treosulfan:  54.9%,  p=0.0889)  as  was  the  incidence  of  aGvHD  Grade  II-IV  (busulfan:  26.0%, treosulfan: 27.5%, p=0.6407), and Grade III-IV (busulfan: 8.0%, treosulfan: 13.7%, p=0.4598).

Table12.2.2.2.A Summary results of grade I-IV aGvHD (Full Analysis Set)

|                                                     | Busulfan (N=50)          | Treosulfan (N=51)        |
|-----------------------------------------------------|--------------------------|--------------------------|
| Subjects with event                                 | 21 (42.0%)               | 28 (54.9%)               |
| Subjectswithout event(censored)orwithcompetingevent | 29 (58.0%)               | 23 (45.1%)               |
| Censored                                            | 24 (48.0%)               | 19 (37.3%)               |
| Deatha                                              | 3 (6.0%)                 | 0 (0.0%)                 |
| Primary graft failured                              | 2 (4.0%)                 | 2 (3.9%)                 |
| Secondary graft failure?                            | 0 (0.0%)                 | 2 (3.9%)                 |
| Cumulative incidence at 14 days [%] (90% CI)        | 2.0 (0.0, 5.3)           | 13.7 (5.8, 21.7)         |
| Cumulative incidence at 28 days [%] (90% CI)        | 30.0 (19.3, 40.7)        | 37.3 (26.1, 48.4)        |
| Cumulative incidence at 100 days [%] (90%C1)        | 42.0 (30.5, 53.5)        | 54.9 (43.4, 66.4)        |
| Hazard Ratio (Treosulfan/Busulfan)(90%CI) p-valueb  | 1.65 (1.02, 2.67) 0.0889 | 1.65 (1.02, 2.67) 0.0889 |
| Unadjusted p-valuec                                 | 0.1641                   |                          |

Abbreviations: aGvHD = acute graft-versus-host disease; CI = confidence interval; N= total number of subjects.

<div style=\"page-break-after: always\"></div>

Figure 12.2.2.2.A Cumulative incidence of grade I-IV aGvHD (Full Analysis Set)

<!-- image -->

[aladjusted forThiotepa and discase asfactorsusingFineand Gray model

Source:Figure14.3.5.1A

Abbreviations:aGvHD=acute graft-versus-host disease;CI=confidence interval;Max=maximum; Min = minimum; NA = not applicable.

Table 12.2.2.2.B Summary results of gradeII-IV aGvHD (Full AnalysisSet)

|                                                          | Busulfan (N=50)   | Treosulfan (N=51)   |
|----------------------------------------------------------|-------------------|---------------------|
| Subjects with event                                      | 13 (26.0%)        | 14 (27.5%)          |
| Subjects without event(censored) or with competing event | 37 (74.0%)        | 37 (72.5%)          |
| Censored                                                 | 32 (64.0%)        | 33 (64.7%)          |
| Deatha                                                   | 3 (6.0%)          | 0 (0.0%)            |
| Primary graft failurea                                   | 2 (4.0%)          | 2 (3.9%)            |
| Secondary graft failured                                 | (%00) 0           | 2 (3.9%)            |
| Cumulative incidence at 14 days [%] (90% CI)             | 2.0 (0.0, 5.3)    | 9.8 (3.0, 16.7)     |
| Cumulative incidence at 28 days [%] (90% CI)             | 18.0 (9.1, 26.9)  | 13.7 (5.8, 21.7)    |
| Cumulative incidence at 100 days [%] (90% CI)            | 26.0 (15.8, 36.2) | 27.5 (17.2, 37.7)   |
| Hazard Ratio(Treosulfan/Busulfan)b(90%CI) p-valueb       | 1.21 (0.62, 2.34) | 1.21 (0.62, 2.34)   |
|                                                          | 0.6407            | 0.6407              |
| Unadjusted p-valuec                                      | 0.8745            | 0.8745              |

Abbreviations: aGvHD = acute graft-versus-host disease; CI= confidence interval; N = total number of subjects.

<div style=\"page-break-after: always\"></div>

Figure 12.2.2.2.B Cumulative incidence of gradeII-IV aGvHD (Full Analysis Set)

<!-- image -->

[a]adjusted foThiotepa and discase asfactors usingFineand Gray model

Source:Figure14.3.5.2A

Abbreviations:aGvHD ）=acute graft-versus-host disease;CI=confidence interval;Max=maximum; Min = minimum; NA = not applicable.

Table12.2.2.2.C Summary results of grade III-IV aGvHD (Full Analysis Set)

|                                                          | Busulfan (N=50)   | Treosulfan (N=51)   |
|----------------------------------------------------------|-------------------|---------------------|
| Subjects with event                                      | 4 (8.0%)          | 7 (13.7%)           |
| Subjects without event(censored) or with competing event | 46 (92.0%)        | 44 (86.3%)          |
| Censored                                                 | 41 (82.0%)        | 40 (78.4%)          |
| Death*                                                   | 3 (6.0%)          | 0 (0.0%)            |
| Primary graft failured                                   | 2 (4.0%)          | 2 (3.9%)            |
| Secondary graft failure                                  | 0 (0.0%)          | 2 (3.9%)            |
| Cumulative incidence at 14 days [%] (90% CI)             | 2.0 (0.0, 5.3)    | 2.0 (0.0, 5.2)      |
| Cumulative incidence at 28 days [%] (90% C1)             | 4.0 (0.0, 8.6)    | 2.0 (0.0, 5.2)      |
| Cumulative incidence at 100 days [%] (90% CI)            | 8.0 (1.7, 14.3)   | 13.7 (5.8, 21.7)    |
| Hazard Ratio (Treosulfan/Busulfan) (90% CI)              | 1.63 (0.55,4.81)  | 1.63 (0.55,4.81)    |
| p-valueb                                                 | 0.4598            | 0.4598              |
| Unadjusted p-valuec                                      | 0.3734            | 0.3734              |

Abbreviations: aGvHD= acute graft-versus-host disease; CI=confidence interval; N=total number of subjects.

<div style=\"page-break-after: always\"></div>

Figure 12.2.2.2.C Cumulative incidence of grade III-IV aGvHD (Full Analysis Set)

<!-- image -->

Source:Figure 14.3.5.3A

Abbreviations:aGvHD =acute graft-versus-host disease;CI =confidence interval;Max=maximum; Min = minimum; NA =not applicable.

Results from exploratory subgroup analyses (100-day rates of aGvHD by disease, donor type, thiotepa, serotherapy, CTP age group, and ICH age group) are presented. A forest plot for 100-day rates of grade I-IV  aGvHD by subgroups is given in Figure 11.4.1.1.A. The results of the subgroup analyses were consistent with the main analysis.

<div style=\"page-break-after: always\"></div>

<!-- image -->

N =Number of subjects, n = Number of events

[al not adjusted, all other HRs are adjusted for Thiotepa and disease as factor using Fine and Gray model

Source:Figure 14.3.5.1B

- The incidence of overall cGvHD was significantly higher in the busulfan arm than the treosulfan arm (busulfan: 38.6%, treosulfan: 12.8%, p=0.0168). There was an advantage in favour of treosulfan for moderate / severe cGvHD (busulfan: 22.7%, treosulfan: 10.6%, p=0.1611).

Table 12.2.2.2.D Summaryresults ofoverall cGvHD (Full AnalysisSet)

|                                                                        | Busulfan (N=50)                 | Treosulfan (N=51)               |
|------------------------------------------------------------------------|---------------------------------|---------------------------------|
| Subjects at risk                                                       | 44                              | 47                              |
| Subjects with event                                                    | 17 (38.6%)                      | 6 (12.8%)                       |
| Subjects without event (censored) or with competing event              | 27 (61.4%)                      | 41 (87.2%)                      |
| Censored                                                               | 27 (61.4%)                      | 34 (72.3%)                      |
| Deathb                                                                 | 0 (0.0%)                        | 0 (0.0%)                        |
| Primary graft failureb                                                 | 0 (0.0%)                        | 0 (0.0%)                        |
| Secondary graft failureb                                               | 0 (0.0%)                        | 7 (14.9%)                       |
| Cumulative incidence at 12 months [%] (90% CI)                         | 38.6 (26.6, 50.7)               | 12.8 (4.8, 20.8)                |
| Cumulative incidence at 24 months [%] (90% CI)                         | 38.6 (26.6, 50.7)               | 12.8 (4.8, 20.8)                |
| Cumulative incidence at 36months[%] (90%CI)                            | 38.6 (26.6, 50.7)               | 12.8 (4.8, 20.8)                |
| Hazard Ratio (Treosulfan/Busulfan)(90%CI) p-valuec Unadjusted p-valued | 0.31 (0.14, 0.69) 0.0168 0.0059 | 0.31 (0.14, 0.69) 0.0168 0.0059 |

Abbreviations:cGvHD=chronic graft-versus-host disease;CI=confidence interval; N=total number of subjects.

<div style=\"page-break-after: always\"></div>

Figure 12.2.2.2.E Cumulative incidence ofoverall cGvHD (Full AnalysisSet)

<!-- image -->

Source: Figure 14.3.5.4A

Results  from  exploratory  subgroup  analyses  (overall  cGvHD  by  disease,  donor  type,  thiotepa, serotherapy, CTP age group, and ICH age group) are presented. A forest plot for 12-month rates of overall cGvHD by subgroups is given below. The results of the subgroup analyses were consistent with the main analysis.

<div style=\"page-break-after: always\"></div>

<!-- image -->

N = Number of subjects, n = Number of events [al not adjusted, all other HRs are adjusted for Thiotepa and disease as factor using Fine and Gray model

Source: Figure 14.3.5.4B

- Overall, 9 of 101 subjects (8.9%) died until data cut-off, 7 of 50 subjects (14.0%) in the busulfan arm and 2 of 51 subjects (3.9%) in the treosulfan arm. All deaths were transplantation-related. Most common cause of death was infection in the busulfan arm and GvHD associated with multiple organ failure in the treosulfan arm.

| Table12.3.1.1.A                                  | Overviewandcauseofdeaths(SafetyAnalysisSet)   | Overviewandcauseofdeaths(SafetyAnalysisSet)   | Overviewandcauseofdeaths(SafetyAnalysisSet)   |
|--------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                                  | Busulfan (N=50)                               | Treosulfan (N=51)                             | Total (N=101)                                 |
| Suvival status at trialternination [n(%)]        |                                               |                                               |                                               |
| Alivea                                           | 43 (86.0%)                                    | 49 (96.1%)                                    | 92 (91.1%)                                    |
| Dead                                             | 7 ( 14.0%)                                    | 2 ( 3.9%)                                     | 9 ( 8.9%)                                     |
| -If dead, cause of death [n (%o)]                |                                               |                                               |                                               |
| Transplantationrelated                           | 7( 14.0%)                                     | 2 ( 3.9%)                                     | (%68 )6                                       |
| -If dead,timefromtransplantationtodeath [months] |                                               |                                               |                                               |
| n                                                | 7                                             | 2                                             | 9                                             |
| Mean (SD)                                        | 6.44 (8.44)                                   | 5.73 (2.49)                                   | 6.29 (7.37)                                   |
| Median (Q1, Q3)                                  | 2.96 (2.27, 6.64)                             | 5.73 (3.98, 7.49)                             | 3.22 (2.60, 6.64)                             |
| Min, Max                                         | 2.2, 25.3                                     | 4.0, 7.5                                      | 2.2, 25.3                                     |

Source:Table14.3.2.1A

The status'alive'isdisplayedfor all subjectswhodid not terminate the trial duetodeath.

Abbreviations:Max=maximum;Min=minimum;N=total number of subjects;n=number of subjects in each category;Q1=firstquartile;Q3=third quartile;SD=standarddeviation.

<div style=\"page-break-after: always\"></div>

Table12.3.1.1.B Summaryof detailed causes of deaths(SafetyAnalysisSet)

Source:Table 14.3.2.1B

|                                               | Busulfan (N=50)   | Treosulfan (N=51)   | Total (N=101)   |
|-----------------------------------------------|-------------------|---------------------|-----------------|
| Survival status at trial termination [n (%o)] |                   |                     |                 |
| Alive                                         | 43 (86.0%)        | 49 (96.1%)          | 92 (91.1%)      |
| Dead                                          | 7 ( 14.0%)        | 2 ( 3.9%)           | 9 ( 8.9%)       |
| -If dead, cause of death [n (%)]b             |                   |                     |                 |
| Transplantation relatede                      | 7 (14.0%)         | 2 ( 3.9%)           | 9 ( 8.9%)       |
| GvHD                                          | 2 ( 4.0%)         | 2 ( 3.9%)           | 4 ( 4.0%)       |
| Pulmonary toxicity                            | 1 ( 2.0%)         | (%0'0 )0            | 1 ( 1.0%)       |
| Haemorrhage                                   | 1 ( 2.0%)         | (%0'0 )0            | 1 ( 1.0%)       |
| Renal failure                                 | (%00 )0           | 1 ( 2.0%)           | 1 ( 1.0%)       |
| Multiple organ failure                        | 1 ( 2.0%)         | 2 ( 3.9%)           | 3 ( 3.0%)       |
| Infection                                     | 5 (10.0%)         | 1( 2.0%)            | 6 ( 5.9%)       |
| Bacterial                                     | 2 ( 4.0%)         | 1( 2.0%)            | 3 ( 3.0%)       |
| Viral                                         | 2 ( 4.0%)         | 0 ( 0.0%)           | 2 ( 2.0%)       |
| Fungal                                        | 1 ( 2.0%)         | (%00 ) 0            | 1( 1.0%)        |
| Unspecified                                   | (%0'0 ) 0         | 1 ( 2.0%)           | 1 ( 1.0%)       |
| Interstitial pneumonitis                      | 1 ( 2.0%)         | 0( 0.0%)            | 1 ( 1.0%)       |
| EBV proliferative disease                     | (%00 )0           | 1 ( 2.0%)           | 1 ( 1.0%)       |
| Gastrointestinal toxicity                     | 0 ( 0.0%)         | 1 ( 2.0%)           | 1 ( 1.0%)       |
| Other transplantrelated cause                 | 1 ( 2.0%)         | 0 ( 0.0%)           | 1 ( 1.0%)       |

The status'alive'is displayedfor allsubjectswhodidnot terminate the trial due todeath.

*Multiple transplantation related causes per subject possible b Causes answered 'Unknown' are not counted. Please refer to data listing.

Abbreviations:EBV=Epstein-Barr virus;GvHD=graft-versus-host disease;N=total mumber of subjects;n = number of subjects in each category.

- The incidence of TESAEs was also similar in the 2 treatment arms (busulfan: 32.0%, treosulfan: 35.3%). TESAEs were most commonly reported in the SOCs 'Infections and infestations', 'General disorders and administration site conditions, and ' Blood and lymphatic system disorders ' .

Differences of ≥ 5% between the treatment arms were noted only in a few cases. More subjects in the busulfan arm than the treosulfan arm had events in the SOCs 'Blood and lymphatic system disorders' and 'Respiratory, thoracic and mediastinal disorders', while more subjects in the treosulfan arm than the  busulfan  arm  had  events  in  the  SOC  'Infections  and  infestations'  and  'General  disorders  and administration site conditions'.

At the Term level, more subjects in the busulfan arm than the treosulfan arm had 'Lung infection', while more subjects in the treosulfan arm than the busulfan arm had 'Infections and infestations - Other' and 'Fever'.

<div style=\"page-break-after: always\"></div>

Table 12.3.1.2.A Frequencyofsubjectswithtreatmentemergent-seriousadverseevents by CTCAE System Organ Class and Term (SafetyAnalysisSet)

| CTCAE System Organ Class CTCAE Term                           | Busufan (N=50)   | Treosulfan (N=51)   | Total (N=101)   |
|---------------------------------------------------------------|------------------|---------------------|-----------------|
| Subjects with any event                                       | 16 (32.0%)       | 18 (35.3%)          | 34 (33.7%)      |
| Infectionsandinfestations                                     |                  |                     |                 |
| Any event                                                     | 7 (14.0%)        | 12 (23.5%)          | 19 (18.8%)      |
| Infections andinfestations Other, specify                     | 0( 0.0%)         | 5 ( 9.8%)           | 5 ( 5.0%)       |
| Sepsis                                                        | 2 ( 4.0%)        | 2 ( 3.9%)           | 4 ( 4.0%)       |
| Lung infection                                                | 3 ( 6.0%)        | 0 ( 0.0%)           | 3 ( 3.0%)       |
| Catheter related infection                                    | 1 ( 2.0%)        | 1 ( 2.0%)           | 2 ( 2.0%)       |
| Enterocolitis infectious                                      | 1 ( 2.0%)        | 1 ( 2.0%)           | 2 ( 2.0%)       |
| Bronchial infection                                           | (%00 ) 0         | 1 ( 2.0%)           | 1( 1.0%)        |
| Encephalitis infection                                        | (%00 ) 0         | 1 ( 2.0%)           | 1 ( 1.0%)       |
| Upper respiratory infection                                   | 0 ( 0.0%)        | 1 ( 2.0%)           | 1 ( 1.0%)       |
| General disordersand adninistrationsiteconditions             |                  |                     |                 |
| Any event                                                     | 1( 2.0%)         | 6 (11.8%)           | 7 ( 6.9%)       |
| Fever                                                         | (%00 )0          | 6 (11.8%)           | 6 ( 5.9%)       |
| Multi-organ failure                                           | 1 ( 2.0%)        | (%00 ) 0            | 1( 1.0%)        |
| Bloodandlymphaticsystemdisorders                              |                  |                     |                 |
| Any event                                                     | 4 ( 8.0%)        | 1 ( 2.0%)           | 5 ( 5.0%)       |
| Blood and lymphatic system disorders - Other, specify         | 2 ( 4.0%)        | 1 ( 2.0%)           | 3 ( 3.0%)       |
| Anemia                                                        | 2 ( 4.0%)        | (%00 ) 0            | 2 ( 2.0%)       |
| Respiratory,thoracic andmediastinal disorders                 |                  |                     |                 |
| Any event                                                     | 4 ( 8.0%)        | 0 ( 0.0%)           | 4 ( 4.0%)       |
| Bronchopulmonary hemonhage                                    | 1( 2.0%)         | 0 ( 0.0%)           | 1 ( 1.0%)       |
| Pneumonitis                                                   | 1( 2.0%)         | 0 ( 0.0%)           | 1 ( 1.0%)       |
| Pneumothorax                                                  | 1 ( 2.0%)        | (%00 ) 0            | 1( 1.0%)        |
| Respiratory,thoracic andmediastinal disorders -Other,specify  | 1 ( 2.0%)        | 0 ( 0.0%)           | 1( 1.0%)        |
| Hepatobiliarydisorders                                        |                  |                     |                 |
| Any event                                                     | 2 ( 4.0%)        | (%00 ) 0            | 2 ( 2.0%)       |
| Hepatobiliary disorders - Other, specify                      | 2 ( 4.0%)        | 0 ( 0.0%)           | 2 ( 2.0%)       |
| Nervoussystemdisorders                                        |                  |                     |                 |
| Any event                                                     | 1 ( 2.0%)        | 1 ( 2.0%)           | 2 ( 2.0%)       |
| Encephalopathy                                                | 1 ( 2.0%)        | 1 ( 2.0%)           | 2 ( 2.0%)       |
| CTCAE System Organ Class CTCAE Term                           | Busulfan (N=50)  | Treosulfan (N=51)   | Total (N=101)   |
| Gastrointestinal disorders                                    |                  |                     |                 |
| Any event                                                     | (%00 )0          | 1 ( 2.0%)           | 1 ( 1.0%)       |
| Vomiting                                                      | (%00 )0          | 1 ( 2.0%)           | 1( 1.0%)        |
| Immune system disorders                                       |                  |                     |                 |
| Any event                                                     | 0 ( 0.0%)        | 1 ( 2.0%)           | 1 ( 1.0%)       |
| Immune system disorders - Other, specify                      | (%00 )0          | 1 ( 2.0%)           | 1 ( 1.0%)       |
| Injury,poisoning andprocedural complications                  |                  |                     |                 |
| Any event                                                     | (%00 )0          | 1 ( 2.0%)           | 1( 1.0%)        |
| Injury, poisoning and procedural complications -Other,specify | (%00 )0          | 1 ( 2.0%)           | 1 ( 1.0%)       |
| Investigations                                                |                  |                     |                 |
| Any event                                                     | (%00 ) 0         | 1 ( 2.0%)           | 1 ( 1.0%)       |
| Investigations - Other, specify                               | (%00 )0          | 1 ( 2.0%)           | 1 ( 1.0%)       |
| Neoplasms benign, malignant and unspecified (incl cysts and   |                  |                     |                 |
| polyps)                                                       |                  |                     |                 |
| Any event                                                     | (%00 )0          | 1 ( 2.0%)           | 1 ( 1.0%)       |
| Myelodysplastic syndrome                                      | (%00 ) 0         | 1 ( 2.0%)           | 1 ( 1.0%)       |

Note: Absolute and relative frequencies of subjects with event relative to the total number of subjects (N)  (2 of 2) Abbreviations; CTCAE: Common Terminology of Adverse Events; N = total number of subjects.

Source:Table 14.3.2.2A

- In the busulfan arm, 5 TESAEs had a fatal outcome while no fatal TESAE was reported for the treosulfan arm. None of the fatal TESAEs was assessed to be IMP-related.
- The incidence of TESAEs related to the IMP was also similar in the 2 treatment arms (busulfan: 6.0%, treosulfan: 3.9%).

<div style=\"page-break-after: always\"></div>

Table 12.3.1.2.B Frequencyofsubjectswithtreatmentemergentdrug-relatedserious adverse events by CTCAE System Organ Class and Term (Safety Analysis Set)

| CTCAE System Organ Class CTCAE Term                                 | Busulfan (N=50)   | Treosulfan (N=51)   | Total (N=101)   |
|---------------------------------------------------------------------|-------------------|---------------------|-----------------|
| Subjects with any event                                             | 3 ( 6.0%)         | 2 ( 3.9%)           | 5 ( 5.0%)       |
| Hepatobiliarydisorders                                              |                   |                     |                 |
| Any event                                                           | 2 ( 4.0%)         | 0 ( 0.0%)           | 2 ( 2.0%)       |
| Hepatobiliary disorders - Other, specify                            | 2 ( 4.0%)         | (%00 ) 0            | 2 ( 2.0%)       |
| Blood and lymphatic system disorders                                |                   |                     |                 |
| Any event                                                           | 1 ( 2.0%)         | 0 ( 0.0%)           | 1 ( 1.0%)       |
| Blood and lymphatic system disorders - Other, specify               | 1 ( 2.0%)         | 0 ( 0.0%)           | 1 ( 1.0%)       |
| Injury,poisoningandproceduralcomplications                          |                   |                     |                 |
| Any event                                                           | 0 ( 0.0%)         | 1 ( 2.0%)           | 1 ( 1.0%)       |
| Injury, poisoning and procedural complications - Other, specify     | (%00 )0           | 1 ( 2.0%)           | 1 ( 1.0%)       |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                   |                     |                 |
| Any event                                                           | 0 ( 0.0%)         | 1 ( 2.0%)           | 1 ( 1.0%)       |
| Myelodysplastic syndrome                                            | 0 ( 0.0%)         | 1 ( 2.0%)           | 1 ( 1.0%)       |
| Respiratory,thoracicandmediastinal disorders                        |                   |                     |                 |
| Any event                                                           | 1 ( 2.0%)         | 0 ( 0.0%)           | 1 ( 1.0%)       |
| Bronchopulmonaryhemorrhage                                          | 1 ( 2.0%)         | 0 ( 0.0%)           | 1 ( 1.0%)       |

Sources: Table 14.3.2.2B

Note:Absolute and relative frequencies of subjects with event relative to the total number of subjects (N)

Abbreviations:CTCAE:CommonTerminologyofAdverseEvents,N=totalnumberofsubjects.

- The incidences of significant AEs were similar in the 2 treatment arms: 'Early toxicity' (busulfan: 96.0%,  treosulfan:  94.1%,  p=1.000),  'Hepatic  toxicity'  (busulfan:  54.0%,  treosulfan:  51.0%, p=0.8429),  and  'Infections'  (busulfan:  70.0%,  treosulfan:  60.8%,  p=0.4044).  However,  the incidence  of  'HSOS'  was  slightly  higher  in  the  busulfan  arm  (all  grades:  busulfan:  10.0%, treosulfan: 2.0%, p=0.1120; ≥ grade  III  according  to  Jones:  busulfan  4.0%,  treosulfan  0.0%, p=0.2426). No case of 'Lung toxicity' (CTCAE Term 'Pulmonary Fibrosis') was recorded.

Table 12.3.1.3.A Incidence of alltreatment emergentsignificantadverse events (Safety Analysis Set)

|                                                   | Busulfan (N=50)   | Treosulfan (N=51)   |
|---------------------------------------------------|-------------------|---------------------|
| HSOS according to Jones (1987)                    |                   |                     |
| Subjects with HSOS                                | 5 ( 10.0%)        | 1 ( 2.0%)           |
| Subjects without HSOS                             | 45 (90.0%)        | 50 ( 98.0%)         |
| Incidence of HSOS [%]                             | 10.0              | 2.0                 |
| ID %06                                            | (4.0, 19.9)       | (0.1, 9.0)          |
| ID%56                                             | (3.3, 21.8)       | (0.0, 10.4)         |
| p-valuea                                          | 0.1120            | 0.1120              |
| Earlytoxicity definedasanyAEoccurringuntil day+28 |                   |                     |
| Subjects with Early toxicity                      | 48 (96.0%)        | 48 ( 94.1%)         |
| Subjects without Early toxicity                   | 2 ( 4.0%)         | 3 ( 5.9%)           |
| Incidence of Early toxicity [%]                   | 96.0              | 94.1                |
| ID %06                                            | (87.9, 99.3)      | (85.5, 98.4)        |
| ID %56                                            | (86.3, 99.5)      | (83.8, 98.8)        |
| p-valuea                                          | 1.0000            | 1.0000              |
| HepatictoxicityaccordingtoBearman(1988)           |                   |                     |
| SubjectswithHepatic toxicity                      | 27 ( 54.0%)       | 26 (51.0%)          |
| Subjects without Hepatic toxicity                 | 23 (46.0%)        | 25 ( 49.0%)         |
| Incidence of Hepatic toxicity [%]                 | 54.0              | 51.0                |
| ID %06                                            | (41.5, 66.2)      | (38.7, 63.2)        |
| ID%S6                                             | (39.3, 68.2)      | (36.6, 65.2)        |
| p-valued                                          | 0.8429            | 0.8429              |
| Lung toxicity (CTCAE term\"Pulmonary fibrosis\")    |                   |                     |
| Subjects with Lung toxicity                       | (%00 ) 0          | 0 ( 0.0%)           |
| Subjects without Lung toxicity                    | 50 (100.0%)       | 51 (100.0%)         |
| Incidence of Lung toxicity [%]                    | 0.0               | 0.0                 |
| ID %06                                            | (0.0, 5.8)        | (0.0, 5.7)          |
| I0 %56                                            | (0.0, 7.1)        | (0.0, 7.0)          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Table12.3.1.3.A                            | Incidence of all treatment emergent significant adverseevents (Safety AnalysisSet)   |              |              |
|--------------------------------------------|--------------------------------------------------------------------------------------|--------------|--------------|
| Infections(SoC\"Infectionsandinfestations\") |                                                                                      |              |              |
| SubjectswithInfections                     |                                                                                      | 35 (70.0%)   | 31 ( 60.8%)  |
| SubjectswithoutInfections                  |                                                                                      | 15 (30.0%)   | 20 (39.2%)   |
| Incidence of Infections [%]                |                                                                                      | 70.0         | 60.8         |
| ID%06                                      |                                                                                      | (57.6, 80.5) | (48.3, 72.3) |
| ID %S6                                     |                                                                                      | (55.4, 82.1) | (46.1, 74.2) |
| p-value                                    |                                                                                      | 0.4044       | 0.4044       |
| Source:Table14.3.2.3A                      |                                                                                      |              |              |
| Fisher's exact test                        |                                                                                      |              | (2of2)       |

- No unknown risks were identified.
- Laboratory parameters were largely comparable for the 2 treatment arms throughout the trial. The durations of leukopenia and neutropenia were significantly longer in the treosulfan arm than the busulfan arm.
- Vital signs were largely comparable for the 2 treatment arms throughout the trial.
- The median KPS following transplantation and clinically relevant exploratory endpoints 'time to deterioration of KPS by at least 20 points' as well as 'deterioration of the KPS to less than 60 points' were comparable for the 2 treatment arms.

Sources:Figure 14.3.6.6F

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure12.4.2.3.B Kaplan-MeierestimatesfortimetoKarnofsky/LanskyPerformance Score less than 60points (Safety Analysis Set)

<!-- image -->

Note:Months aremonthsfrombaseline visit tofi-stpost-haseline value&lt;60points [a]adjusted forThiotepa anddisease asfactors usingCoxregression model

Source:Figure14.3.6.6G

Abbreviations:CI=confidenceinterval;KPS=KarmofskyPerformance Score;LPS=LanskyPerformance Score.

MC-FludT.17/M

## Criteria for Evaluation:

## Safety:

Adverse events (AEs): All AEs (serious and non serious) occurring between day -7 and day +100 were recorded continuously. After day +100, only serious AEs with suspected relatedness (SAR) to the IP were documented up to visit 12 months after the HSCT. SARs were continuously assessed during the longer term follow up phase and results were reported.

Acute (a) and chronic (c) GvHD: aGvHD was classified as GvHD up until 100 days after HSCT. Time to cGvHD was defined as the time between 100 days after end of HSCT and the first episode of cGvHD and evaluated up to visit 12 months after HSCT. cGvHD episodes were continuously assessed during the longer term follow up phase and results were reported.

Clinical laboratory tests: The subject's viral status was characterised by HIV, cytomegalovirus, Epstein Barr virus (EBV), hepatitis A, B, C, and herpes tests within 3 weeks prior to day -7. Pregnancy was assessed routinely in the subject's urine or serum within 3 weeks prior to day -7, in any female who had experienced menarche. The standard laboratory parameters (total blood count, differential blood count, blood chemistry, and the computed GFR) were documented once within 3 weeks prior to Day -7 and until visit Day +28, and on visit Day +100, if applicable.

Vital signs, physical examinations: Blood pressure, pulse, height, weight, and body temperature were assessed between day -10 and day -8, and on visit Day 0, +28, +100, and on visit Month 6, 9, and 12. Lansky Performance Score (LPS), or Karnofsky Performance Score (KPS) were assessed within 3 weeks prior to Day -7, and at visit Day 0, visit Day +28, visit Day +100, visit Month 6, 9, and 12.

<div style=\"page-break-after: always\"></div>

## Results

## SAFETY:

1. The incidences of total Treatment-emergent adverse events (TEAEs) were reported by 97.1% of subjects, of these 90% of subjects reported drug-related TEAEs. This could be expected with an intensive treatment procedure as alloHSCT.

Table 12.2.1.A Overallsummaryoftreatiment-emergentadverseevents(Safety Analysis Set)

|                                                            | Treosulfan (N=70)   |
|------------------------------------------------------------|---------------------|
| Any adverse event [n (%)]                                  |                     |
| Subjects with any adverse event                            | 68 (97.1)           |
| Subjects with AEs of at least CTCAE grade III              | 53 (75.7)           |
| Drug-related adverse events [n (%)]                        |                     |
| Subjects with any drug-related adverse event               | 63 (90.0)           |
| Subjects with drug-related AEs of at least CTCAE grade III | 34 (48.6)           |
| Serious adverse events [n (%)]                             |                     |
| Subjectswith anyserious adverse event                      | 23 (32.9)           |
| - Results in death                                         | 1 (1.4)             |
| - Life-threatening                                         | 6 (8.6)             |
| - Hospitalization of prolongation of hospitalization       | 20 (28.6)           |
| - Disability/incapacity                                    | 1(1.4)              |
| - Congenital anomaly or birth defect                       | 0 (0.0)             |
| Drug-related serious adverse events [n(%)]                 |                     |
| Subjects with any drug-related serious adverse event       | 1 (1.4)             |
| Maximum CTCAE grade of adverse events [n(%)]               |                     |
| SubjectswithAEsofamaximumCTCAEgradeI                       | 3 (4.3)             |
| Subjects withAEs of a maximumCTCAE grade II                | 12 (17.1)           |
| SubjectswithAEs ofa maximum CTCAEgrade III                 | 42 (60.0)           |
| Subjects with AEs of a maximum CTCAE grade IV              | 11 (15.7)           |
| Subjects with AEs of a maximum CTCAE grade V               | 0 (0.0)             |

Sources: Table 14.3.1.A, Listing 16.2.7A, Listing 16.2.7B

Abbreviations:AE = adverse event;CTCAE=Common Terminology Criteria forAdverse Events;N=number of subjects; n = number of subjects in category.

TEAEs were most commonly reported in the System Organ Classes (SOCs) 'Gastrointestinal disorders', 'General disorder and administration site conditions', and 'Infections and infestations' (TEAEs reported by 92.9%, 78.6%, and 71.4% of subjects, respectively). The most frequently reported AEs by preferred term (PT) were 'Mucositis oral' (77.1%), 'Fever' (72.9%), 'Vomiting (68.6%), and Diarrhoea' (65.7%), as expected considering the nature of the drug. However, the frequent use of the intensified conditioning regimen (65 out of 70 subjects received additional treatment with Thiotepa) might have negatively affected this result.

<div style=\"page-break-after: always\"></div>

Table12.2.2.1.A Frequencyofsubjectswithtreatment-emergentadverseeventsby CICAE System Organ Class and Term occurringin at least 5% of subjects (Safety Analysis Set)

Sources:Table14.3.1B,Table14.3.1C,Listing 16.2.7A,Listing16.2.7B

| CTCAE SystemOrgan Class CTCAE Term                           | Treosulfan (N=70)   |
|--------------------------------------------------------------|---------------------|
| Subjects with any event [n (%)]                              | 68 (97.1)           |
| Gastrointestinal disorders [n (%)]                           |                     |
| Any event                                                    | 65 (92.9)           |
| Mucositis oral                                               | 54 (77.1)           |
| Vomiting                                                     | 48 (68.6)           |
| Diarhoea                                                     | 46 (65.7)           |
| Nausea                                                       | 32 (45.7)           |
| Abdominal pain                                               | 22 (31.4)           |
| Constipation                                                 | 8 (11.4)            |
| Oral pain                                                    | 5 (7.1)             |
| Dyspepsia                                                    | 4 (5.7)             |
| General disorders and adininistration site conditions [n(%)] |                     |
| Any event                                                    | 55 (78.6)           |
| Fever                                                        | 51 (72.9)           |
| Fatigue                                                      | 6 (8.6)             |
| Oedema face                                                  | 5 (7.1)             |
| Infusion related reaction                                    | 5 (7.1)             |
| Chills                                                       | 4 (5.7)             |
| Oedema limbs                                                 | 4 (5.7)             |
| Pain                                                         | 4 (5.7)             |
| Infections and infestations [n (%o)]                         |                     |
| Any event                                                    | 50 (71.4)           |
| Infections and infestations - Other, specify                 | 43 (61.4)           |
| Catheter related infection                                   | 7 (10.0)            |
| Urinary tract infection                                      | 6 (8.6)             |
| Upper respiratory infection                                  | 5 (7.1)             |
| Sepsis                                                       | 4 (5.7)             |
| Skin and subcutaneous tissue disorders [n (%)]               |                     |
| Any event                                                    | 41 (58.6)           |
| Rash maculo-papular                                          | 20 (28.6)           |
| Pruritus                                                     | 13 (18.6)           |

<div style=\"page-break-after: always\"></div>

| CTCAE System Organ Class                                | Treosulfan        |
|---------------------------------------------------------|-------------------|
| CTCAE Term                                              | (N=70)            |
| Skin and subcutaneous tissue disorders - Other, specify | 11 (15.7)         |
| Erythemamultiforme                                      | 8 (11.4)          |
| Pain of skin                                            | 8 (11.4)          |
| Respiratory,thoracic and mediastinal disorders [n (%)]  |                   |
| Any event                                               | 28 (40.0)         |
| Cough                                                   | 13 (18.6)         |
| Nasal congestion                                        | 7 (10.0)          |
| Dyspnoea                                                | 5 (7.1)           |
| Pneumonitis                                             | 4 (5.7)           |
| Sore throat                                             | 4 (5.7)           |
| Vascular disorders [n (%)]                              |                   |
| Any event                                               | 26 (37.1)         |
| Hypertension                                            | 21 (30.0)         |
| Hematoma                                                | 7 (10.0)          |
| Hypotension                                             | 4 (5.7)           |
| Hepatobiliary disorders [n (%)]                         |                   |
| Any event                                               | 25 (35.7)         |
| Hepatobiliary disorders - Other, specify                | 25 (35.7)         |
| Nervous system disorders [n (%)]                        |                   |
| Any event                                               | 24 (34.3)         |
| Headache                                                | 19 (27.1)         |
| Lethargy                                                | 4 (5.7)           |
| Tremor                                                  | 4 (5.7)           |
| Musculoskeletal and connective tissue disorders [n (%)] |                   |
| Any event                                               | 23 (32.9)         |
| Pain in extremity                                       | 13 (18.6)         |
| Bone pain                                               | 7 (10.0)          |
| Back pain                                               | 6 (8.6)           |
| Investigations [n (%)]                                  |                   |
| Any event                                               | 21 (30.0)         |
| Blood bilirubin increased                               | 9 (12.9)          |
| Alanine aminotransferase increased                      | 8 (11.4)          |
| Aspartate aminotransferaseincreased                     | 8 (11.4)          |
| Investigations - Other, specify                         | 4 (5.7)           |
| Metabolism and nutrition disorders [n (%)]              |                   |
| Any event                                               | 21 (30.0)         |
| CTCAE System Organ Class                                | Treosulfan        |
| CTCAE Term                                              | (N=70)            |
| Hypokalemia Hypomagnesemia                              | 11 (15.7) 4 (5.7) |
| Renal and urinary disorders [n (%)]                     |                   |
| Any event                                               | 14 (20.0)         |
| Acute kidney injury                                     | 4 (5.7)           |
| Haematuria                                              | 4 (5.7)           |
| Urinary tract pain                                      | 4 (5.7)           |
| Immune system disorders [n (%)]                         |                   |
| Any event                                               | 12 (17.1)         |
| Allergic reaction                                       | 12 (17.1)         |
| Eye disorders [n (%)]                                   |                   |
| Any event                                               | 11 (15.7)         |
| Blurred vision                                          | 4 (5.7)           |
| Eye pain Blood and lynphatic system disorders [n (%)]   | 4 (5.7)           |
| Anyevent                                                | 10 (14.3)         |
| Febrile neutropenia                                     | 5 (7.1)           |
| Cardiac disorders [n (%)]                               |                   |
| Any event                                               | 9 (12.9)          |
| Sinus tachycardia                                       | 8 (11.4)          |
| Reproductive system and breast disorders [n (%)]        |                   |
| Anyevent                                                | 7 (10.0)          |
| Injury, poisoning and procedural complications [n (%)]  | 6 (8.6)           |
| Psychiatric disorders [n (%)]                           |                   |
| Any event                                               |                   |
| Any event                                               | 5 (7.1)           |

- TEAEs of at least CTCAE grade III were reported by 75.5% of subjects, and most commonly reported in  the  SOCs  'Gastrointestinal  disorders',  'Infections  and  infestations',  and  'Metabolism  and nutrition disorders' (TEAEs reported by 55.7%, 41.4%, and 24.3% of subjects, respectively).

<div style=\"page-break-after: always\"></div>

Table 12.2.2.1.B Frequencyofsubjectswithtreatment-emergentadverseeventsofat leastCTCAEGradeIIIbyCTCAESystemOrganClassandTerm occurringinat least5%of subjects(SafetyAnalysisSet)

Sources:Table14.3.1D,Table 14.3.1E,Listing 16.2.7A,Listing 16.2.7B

| CTCAE System Organ Class CTCAE Term            | Treosulfan (N=70)   |
|------------------------------------------------|---------------------|
| Subjects with any event [n (%)]                | 53 (75.7)           |
| Gastrointestinal disorders [n (%)]             |                     |
| Any event                                      | 39 (55.7)           |
| Mucositis oral                                 | 29 (41.4)           |
| Nausea                                         | 12 (17.1)           |
| Vomiting                                       | 11 (15.7)           |
| Diarrhoea                                      | 10 (14.3)           |
| Infections and infestations [n (%)]            |                     |
| Any event                                      | 29 (41.4)           |
| Infections and infestations - Other, specify   | 20 (28.6)           |
| Catheter related infection                     | 6 (8.6)             |
| Sepsis                                         | 4 (5.7)             |
| Metabolism and nutrition disorders [n (%)]     |                     |
| Any event                                      | 17 (24.3)           |
| Hypokalemia                                    | 10 (14.3)           |
| Investigations [n (%)]                         |                     |
| Any event                                      | 8 (11.4)            |
| Bloodbilirubin increased                       | 5 (7.1)             |
| Skin and subcutaneous tissue disorders [n (%)] |                     |
| Any event                                      | 8 (11.4)            |
| Rash maculo-papular                            | 5 (7.1)             |
| Blood and lymphatic system disorders [n (%)]   |                     |
| Any event                                      | 7 (10.0)            |
| Febrile neutropenia                            | 5 (7.1)             |
| Vascular disorders [n (%)]                     |                     |
| Any event                                      | 7 (10.0)            |
| Hypertension                                   | 5 (7.1)             |
| Nervous system disorders [n (%)]               |                     |
| Any event                                      | 5 (7.1)             |
| Renal and urinary disorders [n (%)]            |                     |
| Anyevent                                       | 5 (7.1)             |

- TEAEs related to IP were reported by 90.0% of subjects. Such TEAEs were most commonly reported in the SOCs of 'Gastrointestinal disorder', 'Hepatobiliary disorders', and 'Skin and subcutaneous tissue  disorders'  (TEAEs  reported  by  80.0%  and  24.3%  of  subjects  each  for  'Hepatobiliary disorders' and 'Skin and subcutaneous tissue disorders'). The most commonly reported TEAEs by PT  were  'Mucositis  oral'  (68.6%),  'Vomiting'  (41.4%),  'Nausea'  (32.9%),  and  'Diarrhoea' (28.6%).

<div style=\"page-break-after: always\"></div>

Table 12.2.2.1.C Frequency of subjectswithdrug-related adverse events byCTCAE SystemOrganClassandTermoccurringinatleast5%ofsubjects (Safety Analysis Set)

| CTCAE System Organ Class CTCAE Term                           | Treosulfan (N=70)   |
|---------------------------------------------------------------|---------------------|
| Subjects with any event [n (%)]                               | 63 (90.0)           |
| Gastrointestinal disorders [n (%)]                            |                     |
| Any event                                                     | 56 (80.0)           |
| Mucositis oral                                                | 48 (68.6)           |
| Vomiting                                                      | 29 (41.4)           |
| Nausea                                                        | 23 (32.9)           |
| Diarrhoea                                                     | 20 (28.6)           |
| Abdominal pain                                                | 8 (11.4)            |
| Hepatobiliary disorders [n (%)]                               |                     |
| Any event                                                     | 17 (24.3)           |
| Hepatobiliary disorders - Other, specify                      | 17 (24.3)           |
| Skin and subcutaneous tissue disorders [n(%)]                 |                     |
| Any event                                                     | 17 (24.3)           |
| Pruritus                                                      | 5 (7.1)             |
| Rash maculo-papular                                           | 5 (7.1)             |
| Skin and subcutaneous tissue disorders - Other, specify       | 5 (7.1)             |
| General disorders and adininistration site conditions [n (%)] |                     |
| Any event                                                     | 12 (17.1)           |
| Fever                                                         | 11 (15.7)           |
| Investigations [n (%)]                                        |                     |
| Any event                                                     | 12 (17.1)           |
| Alanine aminotransferaseincreased                             | 7 (10.0)            |
| Aspartate aminotransferase increased                          | 5 (7.1)             |
| Blood bilirubin increased                                     | 5 (7.1)             |
| Infections and infestations [n (%o)]                          |                     |
| Any event                                                     | 8 (11.4)            |
| Infections and infestations - Other, specify                  | 6 (8.6)             |
| Respiratory, thoracic and mediastinal disorders [n (%)]       |                     |
| Anyevent                                                      | 4 (5.7)             |

Sources: Table 14.3.1F, Table 14.3.1G, Listing 16.2.7A, Listing 16.2.7B.

- TEAEs of at least CTCAE Grade III related to IP were reported by 48.6% of subjects. Such events were only reported by &gt; 5% of subjects for 4 SOCs: 'Gastrointestinal disorders' (42.9% of subjects),  'Infections  and  infestations'  (7.1%),  'Skin  and  subcutaneous  tissue  disorders' (7.1%), and 'Investigations' (5.7%) with 'Mucositis oral' and 'Nausea' as the most common Terms. The frequent use of the intensified conditioning regimen B (65 out of 70 subjects received additional  treatment  with  Thiotepa)  might  have  negatively  affected  this  result.  In  paediatric population,  'Mucosal  inflammation'  and  'Nausea'  are  very  common  ARs  considered  at  least possibly related to Thiotepa.

Table12.2.2.1.D Frequencyofsubjectswithdrug-relatedadverseeventsofatleast CTCAEGradeIIIbyCTCAESystemOrganClassandTerm occurring in at least 5% of subjects (Safety Analysis Set)

| CTCAE System Organ Class CTCAE Term            | Treosulfan (N=70)   |
|------------------------------------------------|---------------------|
| Subjects with any event [n (%)]                | 34 (48.6)           |
| Gastrointestinal disorders [n (%)]             |                     |
| Any event                                      | 30 (42.9)           |
| Mucositis oral                                 | 26 (37.1)           |
| Nausea                                         | 7 (10.0)            |
| Vomiting                                       | 4 (5.7)             |
| Infections and infestations [n (%)]            |                     |
| Any event                                      | 5 (7.1)             |
| Infections and infestations - Other, specify   | 5 (7.1)             |
| Skin and subcutaneous tissue disorders [n (%)] |                     |
| Any event                                      | 5 (7.1)             |
| Investigations [n (%)]                         |                     |
| Any event                                      | 4 (5.7)             |

Sources:Table14.3.1H,Tab1e14.3.11,Listing 16.2.7A,Listing 16.2.7B

Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events; N= number of subjects.

<div style=\"page-break-after: always\"></div>

- The incidence of Treatment-emergent serious adverse events (TESAEs) were reported by 32.9% of subjects (n=23), of these only 1 subject (1.4%) reported any drug-related serious adverse event (SAE) (Grade III 'Mucositis oral'). TESAEs were reported by &gt; 2 subjects for only 3 CTCAE Terms; 'Infections  and  infestations-Other'  (6  subjects),  'Upper  respiratory  infection'  (3  subjects),  and 'Febrile neutropenia' (3 subjects).

Table12.3.1.2.A Frequencyofsubjectswithtreatment-emergentserious adverseevents by CTCAE System Organ Class and Term (Safety Analysis Set)

Sources:Table 14.3.2.2A,Listing 14.3.2.2F

| CTCAE System Organ Class CTCAE Term                           | Treosulfan (N=70)   |
|---------------------------------------------------------------|---------------------|
| Subjects with any event [n (%)]                               | 23 (32.9)           |
| Infections and infestations [n (%)]                           |                     |
| Any event                                                     | 15 (21.4)           |
| Infections and infestations - Other, specify                  | 6 (8.6)             |
| Upper respiratory infection                                   | 3 (4.3)             |
| Sepsis                                                        | 2 (2.9)             |
| Catheter related infection                                    | 1(1.4)              |
| Encephalitis infection                                        | 1(1.4)              |
| Hepatitis viral                                               | 1(1.4)              |
| Sinusitis                                                     | 1(1.4)              |
| Skin infection                                                | 1(1.4)              |
| Blood and lymphatic system disorders [n (%)]                  |                     |
| Any event                                                     | 3 (4.3)             |
| Febrile neutropenia                                           | 3 (4.3)             |
| Gastrointestinal disorders [n (%)]                            |                     |
| Any event                                                     | 3 (4.3)             |
| Enterocolitis                                                 | 1(1.4)              |
| Mucositis oral                                                | 1(1.4)              |
| Upper gastrointestinal hemorrhage                             | 1(1.4)              |
| General disorders and adininistration site conditions [n (%)] |                     |
| Any event                                                     | 2 (2.9)             |
| Fever                                                         | 2 (2.9)             |
| Nervous system disorders [n (%)]                              |                     |
| Any event                                                     | 2 (2.9)             |
| Encephalopathy                                                | 1(1.4)              |
| Tremor                                                        | 1(1.4)              |
| Respiratory, thoracic and mediastinal disorders [n (%)]       |                     |
| Anyevent                                                      | 2 (2.9)             |
| Laryngeal haemorrhage                                         | 1(1.4)              |
| Pulmonary oedema                                              | 1 (1.4)             |
| Sources:Table 14.3.2.2A,Listing 14.3.2.2F                     |                     |
| CTCAESystem Organ Class CTCAE Term                            | Treosulfan (N=70)   |
| Immune system disorders [n (%)]                               |                     |
| Any event                                                     | 1(1.4)              |
| Allergic reaction                                             | 1(1.4)              |
| Metabolism and nutrition disorders [n (%)]                    |                     |
| Any event                                                     | 1(1.4)              |
| Dehydration                                                   | 1(1.4)              |
| Renal and urinary disorders [n (%)]                           |                     |
| Any event                                                     | 1(1.4)              |
| Acute kidney injury                                           | 1 (1.4)             |

Note:Absolute and relativefrequencies of subjects with event relative to the total number of subjects (N) Abbreviations:CTCAE=CommonTerminologyCriteriaforAdverseEvents;N=numberofsubjects (2of2)

Table 12.3.1.2.B Frequencyofsubjectswithdrug-relatedtreatment-emergentserious adverse events by CTCAE System Organ Class and Term (Safety Analysis Set)

| CTCAE System Organ Class CICAE Term   | Treosulfan (N=70)   |
|---------------------------------------|---------------------|
| Subjects with any event [n (%)]       | 1 (1.4)             |
| Gastrointestinal disorders [n (%)]    |                     |
| Any event                             | 1(1.4)              |
| Mucositis oral                        | 1 (1.4)             |

Note: Absolute and relative frequencies of subjects with event relative to the total number of subjects Abbreviations:CTCAE=CommonTerminologyCriteria forAdverseEvents;N=number of subjects,n=number of subjects in category.

Sources:Table 14.3.2.2B,Listing 14.3.2.2E,Listing 14.3.2.2F

<div style=\"page-break-after: always\"></div>

- No unknown risks were identified in the trial. No suspected unexpected serious adverse reactions (SUSARs) occurred during the trial.
- At the end of the trial, 14 subjects out of the 70 registered subjects terminated the trial prematurely. Death was the predominant reason for premature termination for a total of 12 subjects (17.1%). The causes  of  these  deaths  were  relapse  /  progression  (8  subjects)  and  transplantation-related  (4 subjects). Seven subjects (10.0%) died within 12 months after HSCT. Furthermore, 1 subject was lost to follow-up and 1 subject (1.4%) withdrew his/her consent from participating in the trial. The mean (standard deviation [SD]) time from transplantation to death was 14.97 (12.35) months.

| Table12.3.1.1.A                                   | Overview and detailed causes of deaths (Safety Analysis Set)   |
|---------------------------------------------------|----------------------------------------------------------------|
|                                                   | Treosulfan (N=70)                                              |
| Survival status at trialtermination [n(%)]        |                                                                |
| Alive\"                                            | 58 (82.9)                                                      |
| Dead                                              | 12 (17.1)                                                      |
| -If dead, cause of death [n (%)]b                 |                                                                |
| Relapse/progression                               | 8 (11.4)                                                       |
| Transplantation related                           | 4 (5.7)                                                        |
| -If dead,timefromtransplantation to death[months] |                                                                |
| n                                                 | 12                                                             |
| Mean (SD)                                         | 14.97 (12.35)                                                  |
| Median (Q1, Q3)                                   | 11.01 (7.82, 19.25)                                            |
| Min, Max                                          | 0.5, 46.7                                                      |
| - If dead, cause of death [n (%)]b                |                                                                |
| Relapse/progression                               | 8 (11.4)                                                       |
| Transplantation related?                          | 4 (5.7)                                                        |
| GvHD                                              | 1(1.4)                                                         |
| Pulmonary toxicity                                | 1(1.4)                                                         |
| Haemomhage                                        | 1(1.4)                                                         |
| Multiple organ failure                            | 2 (2.9)                                                        |
| Infection                                         | 3 (4.3)                                                        |
| Bacterial                                         | 2 (2.9)                                                        |
| Unspecified                                       | 1(1.4)                                                         |
| Interstitial pneumonitis                          | 2 (2.9)                                                        |

Sources:Table 14.3.2.1A,Table 14.3.2.1B,Listing 14.3.2.1C

Causes answered 'Unknown' are not counted. Please refer to data listing.

The status 'alive' is displayed for all subjects who did not terminate the trial due to death.

° Multiple transplantation related causes per subject possible.

n=number of subjects in category;Q1 =first quartile;Q3= third quartile; SD= standard deviation.

Abbreviations:GvHD=graft-versus-host disease;Max=maximum;Min =minimum;N=number of subjects;

- The  vital  signs  did  not  change  substantially  during  the  trial  with  an  exception  of  diastolic  blood pressure. The median diastolic blood pressure at baseline was 59.0 mmHg (Q1 [25%-percentile] 55.0, Q3 [75%-percentile] 67.0) with considerable variability (range from 43 to 81). At visit Month 12, median change from baseline was 5.0 (Q1 2.0, Q3 11) mmHg (range from -23 to 34).
- A total of 7 subjects (12.1%) deteriorated to less than 60 points in the LPS and 2 subjects (16.7%) deteriorated to less than 60 points in the KPS.
- None of the subjects reported any lung toxicity ('Pulmonary Fibrosis') during the trial. Only 1 subject reported an AE of HSOS Grade II (according to Jones et al). Hepatic toxicity of any grade (according to Bearmann) was reported by 34.3% of subjects. Infections of any CTCAE grade belonging to SOC 'Infections and Infestations' were reported by 71.4% of subjects.

<div style=\"page-break-after: always\"></div>

Table 12.3.1.3.A Incidenceofalltreatment-emergentsignificantadverseevents (Safety Analysis Set)

|                                                                                   | Treosulfan (N=70)   |
|-----------------------------------------------------------------------------------|---------------------|
| HSOS according toJones (1987)                                                     |                     |
| Subjects with HSOS according to Jones (1987) [n (%)]                              | 1 (1.4)             |
| Subjects without HSOS according to Jones (1987) [n (%)]                           | 69 (98.6)           |
| Incidence of HSOS according to Jones (1987) (%)                                   | 1.4                 |
| I0%06                                                                             | (0.1, 6.6)          |
| Early toxicity defined as anyAE occurring until day +28                           |                     |
| Subjects withEarly toxicity defined as any AEoccurringuntil day+28[n(%)]          | 68 (97.1)           |
| Subjects without Early toxicity defined as any AE occurring until day +28 [n (%)] | 2 (2.9)             |
| Incidence of Early toxicity defined as any AE occurring until day +28 (%)         | 97.1                |
| I%06                                                                              | (91.3, 99.5)        |
| Hepatic toxicity according toBearman(1988)                                        |                     |
| Subjects with Hepatic toxicity according to Bearman (1988) [n (%)]                | 24 (34.3)           |
| Subjects without Hepatic toxicity according toBearman(1988)[n(%)]                 | 46 (65.7)           |
| Incidence ofHepatic toxicity according toBearman(1988) (%)                        | 34.3                |
| I0%06                                                                             | (24.9, 44.7)        |
| Lung toxicity(CTCAE term\"Pulmonary fibrosis\")                                     |                     |
| Subjects with Lung toxicity (CTCAE term \"Pulmonary fibrosis\") [n (%)]             | 0 (0.0)             |
| Subjects without Lung toxicity (CTCAE term\"Pulmonary fibrosis\") [n (%)]           | 70 (100.0)          |
| Incidence of Lung toxicity (CTCAE term \"Pulmonary fibrosis\") (%)                  | 0.0                 |
| I0%06                                                                             | (0.0, 4.2)          |
| Infections(SoC\"Infections andinfestations\")                                       |                     |
| Subjects with Infections (SOC \"Infections and infestations\")[n (%)]               | 50 (71.4)           |
| Subjects without Infections (SOC \"Infections and infestations\") [n (%)]           | 20 (28.6)           |
| Incidence of Infections (SOC \"Infections and infestations\") (%)                   | 71.4                |
| I%06                                                                              | (61.2, 80.2)        |

Abbreviations: AE = adverse event; CI = confidence interval; CTCAE = Common Terminology Criteria for Adverse Events; N = number of subjects; n = number of subjects in category, SOC = System Organ Class.

Sources:Table 14.3.2.3A,Listing 16.2.7C

- Acute GvHD Grade I-IV was reported by 42.9% of subjects (n=30), with a cumulative incidence at 100 days of 43.5% (90% CI: 33.7, 53.3), and overall chronic GvHD by 25.4% subjects (n=17), with a cumulative incidence of chronic GvHD at 12 months was 23.9% (90% CI: 15.3,32.4), reached a plateau before 24 months and was subsequently maintained at 36 months with 25.4% (90% CI: 16.6, 34.1).  Acute GvHD Grade III-IV was reported by 8.6% of subjects, with a cumulative incidence at 100 days of 8.7% (90% CI: 3.1, 14.3). A total of 19.4% of subjects (n=13) experienced moderate / severe chronic GvHD. The cumulative incidence of moderate / severe chronic GvHD at 12 months was 17.9% (90% CI: 10.2, 25.6), reached a plateau at 24 months and was subsequently maintained at 36 months with 19.4% (90% CI: 11.5, 27.4).

<div style=\"page-break-after: always\"></div>

Table12.2.2.2.A Summary tableofaGvHD(FullAnalysisSet)

|                                                           | Treosulfan (N=70)   |
|-----------------------------------------------------------|---------------------|
| Grade I-IV                                                |                     |
| Subjects with event [n (%)]                               | 30 (42.9)           |
| Subjects without event (censored) or with competing event | 40 (57.1)           |
| Censored                                                  | 38 (54.3)           |
| Death*                                                    | 1 (1.4)             |
| Relapse/Progression*                                      | 1(1.4)              |
| Primary graft failure                                     | 0 (0.0)             |
| Secondary graft failure                                   | 0 (0.0)             |
| Cumulative incidence of acute GvHD at 100 days (%)        | 43.5                |
| 10 %06                                                    | (33.7, 53.3)        |
| Grade II-IV                                               |                     |
| Subjects with event [n (%)]                               | 18 (25.7)           |
| Subjectswithout event(censored) orwith competing event    | 52 (74.3)           |
| Censored                                                  | 49 (70.0)           |
| Death*                                                    | 1(1.4)              |
| Relapse/Progression*                                      | 2 (2.9)             |
| Primary graft failure                                     | 0 (0.0)             |
| Secondary graft failure*                                  | 0 (0.0)             |
| Cumulative incidence of acute GvHD at 100 days (%)        | 26.1                |
| I0%06                                                     | (17.4, 34.8)        |
| Grade III-IV                                              |                     |
| Subjects with event [n (%)]                               | 6 (8.6)             |
| Subjects without event (censored) or with competing event | 64 (91.4)           |
| Censored                                                  | 61 (87.1)           |
| Death*                                                    | 1 (1.4)             |
| Relapse/Progression*                                      | 2 (2.9)             |
| Primary graft failure                                     | 0 (0.0)             |
| Secondary graft failure                                   | 0 (0.0)             |
| Cumulative incidence of acute GvHD at100 days(%)          | 8.7                 |
| I%06                                                      | (3.1, 14.3)         |

Only ifthis event occurred first.

Sources:Table 14.3.5A, Tab1e 14.3.5B,Listing 16.2.7G

Abbreviations:CI=confidence interval; aGvHD= acute graft-versus-host disease;N=number of subjects; n = number of subjects in category.

Table 12.2.2.2.B Summary tableofcGvHD(FullAnalysisSet)

|                                                                   | Treosulfan (N=70)   |
|-------------------------------------------------------------------|---------------------|
| Orerall                                                           |                     |
| Subjects at riska                                                 | 67                  |
| Subjects with event [n (%)]                                       | 17 (25.4)           |
| Subjects without event (censored) or with competing event [n (%)] | 50 (74.6)           |
| Censored                                                          | 37 (55.2)           |
| Deathb                                                            | 1 (1.5)             |
| Relapse/Progression                                               | 11 (16.4)           |
| Primary graft failure                                             | 0 (0.0)             |
| Secondary graft failure                                           | 1 (1.5)             |
| Cumulative incidence of chronic GvHD at 12 months(%)              | 23.9                |
| ID %06                                                            | (15.3, 32.4)        |
| Cumulative incidence of chronic GvHD at 24 months(%)              | 25.4                |
| I%06                                                              | (16.6, 34.1)        |
| Cumulative incidence of chronic GvHD at 36 months (%)             | 25.4                |
| ID %06                                                            | (16.6, 34.1)        |
| Moderate/severe                                                   |                     |
| Subjects at risk                                                  | 67                  |
| Subjects with event [n (%)]                                       | 13 (19.4)           |
| Subjects without event (censored) or with competing event [n (%)] | 54 (80.6)           |
| Censored                                                          | 40 (59.7)           |
| Deathb                                                            | 1 (1.5)             |
| Relapse/Progressiona                                              | 12 (17.9)           |
| Primary graft failureb                                            | 0 (0.0)             |
| Secondary graft failureb                                          | 1 (1.5)             |
| Cumulative incidence of chronic GvHD at 12 months(%)              | 17.9                |
| I%06                                                              | (10.2, 25.6)        |
| Cumulative incidence of chronic GvHD at 24 months(%)              | 19.4                |
| I0%06                                                             | (11.5, 27.4)        |
| Cumulative incidence of chronic GvHD at 36 months (%)             | 19.4                |
| I0%06                                                             | (11.5, 27.4)        |

Sources:Table14.3.5ZA,Table 14.3.5ZB,Listing16.2.7G

<div style=\"page-break-after: always\"></div>

## Safety in special populations

## Age of patients

Age- and BSA-dependent pharmacokinetics of TREO in children was investigated in the PK sub-study of trials MC-FludT.16/NM and MC-FludT.17/M [Venn Life Sciences 2020]. With respect to the shape of the mean plasma concentration-time profiles of TREO and its monoepoxide metabolite, no major differences were observed between the age groups or BSA groups. However, a covariate analysis revealed that BSA was the only clinically relevant covariate for clearance and volumes of distribution. Therefore, patients with a BSA of &lt; 1 m² received a lower dose of TREO in the clinical trials (≤ 0.5 m²: 10 g/m²; &gt; 0.5 to 1 m²: 12 g/m²; &gt; 1 m²: full dose of 14 g/m²) to reach a similar exposure.

A general trend to higher incidence of TEAEs was observed in patients receiving the highest dose group of TREO (14 g/m²) which refers also to the older patient group. Seizures were observed only in the 10 g/m² dose group (n = 2 [8.7%]), i.e. the lowest age group (both children received the transplant for non-malignant diseases). Furthermore, there is a trend of higher incidence of severe TEAEs with higher doses of TREO and older age of the patients, especially with respect to blood and lymphatic system disorders (e.g. febrile neutropenia) and gastrointestinal disorders (e.g. stomatitis, nausea/vomiting).

Age-dependent frequency of drug-related TEAEs was lower in the youngest age group. Influence of age on several toxicity parameters were also explored in paediatric patients within a registry study performed by the EBMT [Peters 2011].

No significant correlation between age groups and the rate of grade III/IV aGvHD and extensive cGvHD, hyperbilirubinemia,  diarrhoea,  vomiting,  CNS  toxicity  or  peripheral  neurological  toxicity  was  found. However, considering all AE grades, more CNS toxicity was seen in the youngest age group. There was a significant increase of stomatitis and AST elevation grade III/IV with age. There was a significant association  between  age  and  respiratory  toxicity.  Children  below  the  age  of  one  year  (mainly  nonmalignant diseases) experienced more respiratory grade III/IV toxicity. However, this could be explained by the fact that it is likely that these small children underwent HSCT for immunodeficiencies which are often associated with severe pulmonary infections even before HSCT.

## Gender of patients

TEAEs were more frequently observed in female patients with only a few AEs being more frequently observed in male patients (CMV infection, cough, chills, and peripheral oedema). The same is observed for the incidence of severe (≥ grade III) TEAEs which was slightly higher in female patients, especially with respect to blood and lymphatic system disorders (17.1% vs. 10.0%), nervous system disorders (12.2% vs. 2.5%), gastrointestinal disorders (56.1% vs. 50.0%), and investigations (26.8% vs. 12.5%).

With  respect  to  drug-related  TEAEs,  more  (&gt; 5%  difference)  female  patients  experienced  vomiting (female vs. male: 48.8% vs. 38.8%), nausea (31.7% vs. 26.3%), abdominal pain (22.0% vs. 13.8%), hepatobiliary disorders (31.7% vs. 26.3%), increased ALT (14.6% vs. 8.8%), and increased AST (12.2% vs. 3.8%), whereas more male patients experienced infections (male vs. female: 15.0% vs. 4.9%), anal inflammation (5.0% vs. 0%), and general disorders (17.5% vs. 9.8%).

## Concomitant use of thiotepa in paediatric patients

The majority of paediatric patients received the intensified regimen with thiotepa, which is associated with a trend of more TEAEs; however, the number of patients not receiving thiotepa is too small to draw final conclusions. TEAEs which have only been recorded in the thiotepa group (only those AEs considered with a frequency ≥ 5%) include viremia (n = 15 [13.9%]), EBV infection (10 [9.3%]), device -related infection  (10  [9.3]%),  adenovirus  infection  (8  [7.4%]),  sepsis  (7  [6.5%]),  febrile  neutropenia  (9

<div style=\"page-break-after: always\"></div>

[8.3%]), iron overload (6 [5.6%]), tremor (6 [5.6%]), eye disorders (15 [13.9%]), haematoma (10 [9.3%]),  hypotension  (7  [6.5%]),  epistaxis  (10  [9.3%]),  oropharyngeal  pain  (9  [8.3%]),  nasal congestion (7 [6.5%]), dyspnoea (6 [5.6%]), constipation (16 [14.8%]), oral pain (6 [5.6%]), pruritus (27 [25.0%]), pain of skin (10 [9.3%]), erythema (11 [10.2%]) and erythema multiforme (9 [8.3%]), pain in extremity (22 [20.4%]), back pain (9 [8.3%]), bone pain (7 [6.5%]), haematuria (9 [8.3%], reproductive system and breast disorders (11 [10.2%]), face oedema (7 [6.5%]), and blood bilirubin increased (12 [11.1%]).

## Safety related to drug-drug interactions and other interactions

As per the SmPC, no interaction of treosulfan was observed in high dose chemotherapy. Moreover, detailed  in  vitro  studies  did  not  completely  exclude  potential  interactions  between  high  plasma concentrations of treosulfan and CYP3A4, CYP2C19, or P-gp substrates. Therefore, medicinal products with a narrow therapeutic index (e.g. digoxin) that are substrates for CYP3A4, CYP2C19 or P-gp should avoided during treatment with treosulfan.

The effect of treosulfan on the pharmacokinetics of fludarabine is not known.

No studies of specific drug-drug interactions were performed because TREO is given for three days only. No specific drug interaction could be identified within the clinical development programme.

## Gonadal toxicity

Gonadal impairment is an important late effect with a significant impact on quality of life of transplanted patients.  Faraci  et  al.  [Faraci  2019]  compared  gonadal  function  after  BU-based  or  TREO-based conditioning regimens in pre- and postpubertal children. This retrospective, multicentre study included children  transplanted  in  paediatric  EBMT  centres  between  1992  and  2012  who  did  not  receive gonadotoxic chemoradiotherapy before the transplant. 137 patients transplanted in 25 paediatric EBMT centres were evaluated. Median age at transplant was 11.04 years (range, 5 to 18); 89 patients were boys and 48 girls. Eighty-nine patients were prepubertal at transplant and 48 postpubertal. One hundred eighteen  children  received  BU  and  19  TREO.  A  higher  proportion  of  girls  treated  with  TREO  in  the prepubertal  stage  reached  spontaneous  puberty  compared  with  those  treated  with  BU  (P = 0.02). Spontaneous menarche was more frequent after TREO than after BU (P &lt; 0.001). Postpubertal boys and girls  treated  with  TREO  had  significantly  lower  luteinizing  hormone  levels  (P = 0.03  and  P = 0.04, respectively) compared with the BU group. This study suggests that the frequency of gonadal damage associated with TREO is significantly lower than that observed after BU.

Although this is a small study where very few TREO-based treated patients were included (19) versus BU-based treated patients (118), this observation is corroborated by data from a more recent study [Leiper  2020]  where  the  fertility  in  121  survivors  of  all  ages  of  myeloid  leukaemia  and  other haematological and immunodeficiency disorders who have undergone HSCT after three chemotherapyconditioning  regimens  of  different  intensity  which  included  TREO-based  (25  males  and 16  females), BU/cyclophosphamide (BU/Cy) (32 males and 23 females) and Fludarabine/melphalan (Flu-Mel) (13 males and 12 females) containing regimens was assessed by measuring serum concentrations of AntiMüllerian hormone (AMH) and Inhibin B. Normal age-matched control data were used to convert the measurements  of  AMH  and  lnhibin  B  to  standard  deviation  scores  (SDS).  The  AMH  data  obtained suggested less ovarian reserve impairment after TREO and Flu-Mel than after Bu-Cy and the mean serum AMH concentration was significantly better with treosulfan (&gt;1.0 μg/l) than with Flu -Mel or Bu-Cy. The same more favourable trend for TREO-based conditioning regimen is seen in males regarding Inhibin B data with the Flu-Mel group suffering greatest impairment. These authors reach the same conclusion,

<div style=\"page-break-after: always\"></div>

that a TREO-based regimen confers a more favourable gonadal compromise than Flu-Mel or Bu-Cy in both sexes.

Gonadal toxicity was investigated in one pre-clinical study [Levi 2018] that concludes that treosulfan induces  distinctive  gonadal  toxicity  compared  with  busulfan.  The  rationale  for  this  study  was  the knowledge that busulfan is considered highly gonadotoxic but the gonadal toxicity profile of treosulfan was not yet clear. In this pre-clinical study, pubertal and prepubertal male and female mice were injected with treosulfan or busulfan and sacrificed one week, one month or six months later. The assessment of testicular  and  ovarian  functions  indicated  that  treosulfan  testicular  toxicity  was  milder  than  that  of busulfan toxicity and the ovarian toxicity of both treosulfan and busulfan was severe and permanent.

In the RMP, impaired fertility (male/female) is recognized as not yet reported in clinical studies and therefore classified within the safety concerns list as a missing information with the need for long-term follow up data after TREO-based conditioning (especially in paediatric patients)..

## Discontinuation due to adverse events

There were no events that led to a substantial intervention (premature discontinuation of study drug, dose reduction, or substantial additional concomitant therapy) in both studies.

## Post marketing experience

Not applicable

## 2.5.1. Discussion on clinical safety

All seven trials also provide important safety data for the use of TREO. In total, the submitted data package includes safety data from 613 adult patients and 121 paediatric patients who have been treated with TREO-based conditioning.

Considering  the  aim  of  the  current  variation  the  discussion  of  clinical  safety  is  focused  in  the  two paediatric clinical trials MC-FludT.16/NM and MC-FludT.17/M .

The  most  commonly  reported  undesirable  effects  of  TREO  are  myelosuppression  (leukocytopenia, thrombocytopenia, anaemia) and gastrointestinal complaints (nausea, vomiting). They are usually mild and resolve after treatment.

Bone  marrow  suppression  (neutropenia,  leukocytopenia,  thrombocytopenia,  anaemia)  is  the  doselimiting side effect of TREO. However, it is this toxicity that supported the development of TREO for conditioning treatment prior to HSCT, especially in the allogenic setting. For this indication, TREO is always combined with FLU. Most paediatric patients receive additionally thiotepa (TT). This conditioning regimen is followed by infusion of haematopoietic stem cells.

Bone  marrow  depression  and  immunosuppression  are  therefore  desired  therapeutic  effects  of  the conditioning  regimen  and  consequently  cannot  be  considered  as  undesirable  effects.  Therefore,  any changes in blood counts and differential blood counts occurring between Day -6 and Day +28 were not documented as AEs. Especially during the time of bone marrow aplasia induced by the conditioning regimen, infections may develop and are a major source of morbidity and mortality of patients.

Facing the above, the adverse events (AEs) and adverse reactions (ARs) observed with TREO-based conditioning  followed  by  alloHSCT  are  not only  due  to  TREO  alone  but  relate  to  the  whole  complex treatment procedure of alloHSCT.

<div style=\"page-break-after: always\"></div>

A total 121 paediatric patients have been treated with TREO-based conditioning, including 51 patients with non-malignant diseases (primary immunodeficiency, haemoglobinopathy, inborn error of metabolism and bone marrow failure syndromes) and 70 patients with malignant diseases (AML, ALL, MDS, and JMML).

The study in non-malignant diseases (MC-FludT.16/NM) also included an active-control group with 50 evaluable patients treated with the reference conditioning regimen BU/FLU ± TT.

This safety data set is supplemented by safety data derived from two registry studies of the EBMT [Peters 201193; Peters 2017] which included a total  of  1  521  paediatric  patients  with  malignant  and  nonmalignant diseases who had been treated with TREO-based conditioning. Therefore, available safety data cover all paediatric patients which are currently treated with alloHSCT.

Two comparisons can be made based on the safety data submitted: a) a comparison of the safety between treosulfan - and busulfan -based conditioning regimens prior HSCT in paediatric patients with non-malignant diseases as gathered within the MC-FludT.16/NM trial;  b)  and  a  comparison  of  the safety of the treosulfan-based conditioning regime prior HSCT between paediatric patients with nonmalignant diseases (from MC-FludT.16/NM ) and with malignant diseases as gathered within the MC-FludT.17/M .

- a) From the data gathered in patients with non-malignant diseases it is possible to observe that frequency of TEAEs, including TEAEs with at least CTCAE grade III TEAEs, was broadly similar in the 2 treatment arms with some exceptions. The TREO group showed higher frequency of TEAEs including drugrelated TEAEs, with differences ≥ 10%, for diarrhoea, abdominal pain, maculo -papular rash and pruritus but lower frequency for lung infection, dry skin, oral mucositis, nausea and hepatobiliary disorders; Higher frequency, with differences ≥ 5%, was observed with TREO for  infections,  febrile  neutropenia  and  vascular  events  but  lower  frequency  for  vomiting  and respiratory disorders. The frequency of gonadal damage and HSOS associated with TREO was lower than that observed after BU.

Frequency of SAEs was also comparable in both groups of trial MC-FludT.16/NM however the TREO group of subjects experienced less life-threatening SAEs and SAEs resulting in death as well as drug-related SAEs than the BU group but more SAEs, such as infections and more general disorders (fever) and conditions that required hospitalisation or prolongation of hospitalisation. This was confirmed by data from EBMT registry. The most common causes of death after HSCT for non-malignant diseases were infection, graft versus host disease, the original disease and transplant associated organ complications.

Cumulative incidence of aGvHD of all grades as well as of grade III/IV was higher for the TREO group up to Day +100 of the HSCT but on the contrary the cumulative incidence of cGvHD was higher in the BU arm

Laboratory parameters were largely comparable for the 2 treatment arms throughout the trial. The durations of leukopenia and neutropenia were significantly longer in the treosulfan arm than the busulfan arm.  In  trial  MC-FludT.16/NM,  the  median  level  of  WBCs  at  baseline,  incidence  of  increased bilirubin/ALT/AST and median change levels from baseline of electrolytes (sodium, potassium) had no significant differences between both treatment groups. The same is largely verified for vital signs. The Kaplan Meier estimate at 12 months for subjects showing a deterioration to less than 60 points was slightly more favourable for the TREO group (8.3%) than for the BU group (12.7%).

- b) When comparing the use of TREO prior HSCT in paediatric patients with malignant and nonmalignant diseases similar rate of AEs of any CTCAE grade and drug-related ADRs of at least CTCAE Grade III was seen although the rate of AEs of at least CTCAE Grade III was somewhat lower (difference &lt;5%) and the drug-related ADRS of any CTCAE grade (difference &gt;5%) higher

<div style=\"page-break-after: always\"></div>

in the case of patients with malignant diseases. Patients with at least one SAE were comparable between the two classes of diseases when treated with TREO, with life-threatening AEs slightly more associated with the treatment of malignant diseases (difference &lt;5%). Subjects with nonmalignant disease also presented slightly higher drug-related SAE (3.9% vs 1.4%).

It is possible to see that more patients (&gt; 5% difference) with malignant diseases experienced viremia, device-related infection, hypersensitivity reactions, hypokalaemia, psychiatric disorders, nausea, bone pain,  positive  viral  test,  and  increased  blood  bilirubin  while  epistaxis,  abdominal  pain,  hepatoxicity, puritus, alopecia, increased CRP and infusion-related reactions were found in patients transplanted for non-malignant diseases.

Number of death cases were considerable higher in the trial MC-FludT.17/M (17.1%, n=12) than in the TREO arm of the MC-FludT.16/NM (3.9%, n=2) being largely due to relapse/progression in the case of the former trial. However, the mean time from transplantation to death was longer for the patients with malignant diseases treated with TREO than for the patients with non-malignant (14.97 months vs 5.75 months). Incidences of hepatic toxicity and infections were higher (but no significant) for the patients with malignant diseases than for patients with non-malignant diseases. Results were comparable in both trials regarding the frequency of SAEs.

Incidences of aGvHD were slightly higher in patients with non-malignant diseases (54.9%) than with malignant diseases (43.5%). However, for malignant diseases, there was a borderline significant impact of age-group on the incidence of aGvHD of any grade (P = 0.045). Mainly in non-malignant diseases children below the age of one year experienced more respiratory grade III/IV toxicity, which could be explained by the fact that it is likely these small children usually underwent HSCT for immunodeficiencies, that are often associated with severe pulmonary infections even before HSCT. Also, for non-malignant diseases, EBMT registry studies data indicate that there is no significant association between grade III/IV toxicity and dose-group in the subgroups of patients according to donor type, and diagnoses [Peters 2011]. Cumulative incidence of cGvHD is maintained over time for patients with both malignant and nonmalignant diseases and was considerably higher (difference &gt;10%) when TREO is used in the patients with malignant diseases. The same (although with a difference &gt;5%) was observed for the cumulative incidence  of  moderate/severe  cGvHD.  The  overall  Kaplan  Meier  estimate  at  12  months  for  subjects showing a deterioration to less than 60 points was higher for patients with malignant diseases (13.6%) than with non-malignant diseases (8.3%). Acute GvHD Grade III-IV was reported in less than 9% of the subjects and was maintained at 100 days. Also, for chronic GvHD cumulative incidence did not change up to the end of the duration of the trial's follow-up, i.e. 36 months.

The MAH proposes to amend an existing warning on section 4.4 of the SmPC and corresponding section of PL on skin toxicity based on new literature data. In a recent publication from Even-Or et al. 2020  1 regarding  skin  toxicities  following  TREO-thiotepa-FLU-based  conditioning  regimen  in  non-malignant paediatric  patients,  an  increase  of  skin  disorders  was  observed  when  patients  received  sodium bicarbonate-containing hydration in the course of TREO infusion. The MAH postulated that this effect could be due to the acceleration of the pH-dependent formation of alkylating epoxides. The effect may be prevented by keeping the skin clean and dry on days of treosulfan infusion. Rash and dermatitis are given as examples of such skin toxicities. The MAH specified the exact ADRs and their severity (see SmPC sections 4.4 and 4.8).

With the responses to the second request for supplementary information comparative results on graft failures in line with the final Clinical Trial Report of the MCFludT.16/NM trial were reintroduced in section 5.1 of the SmPC.

<div style=\"page-break-after: always\"></div>

## 2.5.2. Conclusions on clinical safety

As expected considering the target indication of intensive treatment conditioning-based treatment in paediatric population with malignant diseases prior alloHSCT and confirming the previous safety data almost all subjects treated with treosulfan in this disease setting presented TEAEs (68/70). Likewise, the combination treatment with Thiotepa in the majority of the subjects (65/70) also explains the frequency of TEAEs and TEAEs of at least CTCAE grade III related or not with the drug. These adverse events are already included in section 4.8 of the SmPC related with paediatric population. Among the TESAEs, upper respiratory infection and febrile neutropenia are reported, the former is not clearly included in SmPC and the  latter  is  included  with  unknown  frequency.  No  unknown  risks  were  identified  and  there  was  no occurrence of any SUSARs. At the end of the trial where treosulfan was included in the conditioning regime for patients with malignant diseases, 20% subjects (n=14) terminated the trial prematurely, being  death  from  relapse/progression  and  transplantation-related  the  main  cause  in  17.1%  of  the subjects (n=12). Laboratory parameters and vital signs did not change and performance scores were as expected.

Overall, safety data gathered from the MU-FludT.17/M trial is in line with the adverse reactions listed for adults and paediatric patients already included in the approved PI and can be explained by the intensive treatment prior alloHSCT of treosulfan on top of standardized fludarabine, and in the majority of the cases also with thiotepa, as well due to the underlying malignant disease (ALL, AML, MDS, and JMML) and transplantation-procedure per se. The safety profile is comparable to those reported for treosulfan in other trials and comparable or even favourable to those reported for BU- or TBI-based conditioning regimens.

No unknown risks were identified in the trial and there was no occurrence of any SUSARs. Comparable incidences of aGvHD were observed between the treatment arms however a significantly and clinically meaningful lower incidence of overall cGvHD was found with treosulfan. More deaths occurred in the busulfan arm than the treosulfan arm. Overall, safety results favour the treatment with treosulfan in comparison with busulfan in for conditioning prior to alloHSCT in paediatric patients with non-malignant diseases.

An existing warning on section 4.4 of the SmPC and corresponding section of PL on skin toxicity (e.g. rash, dermatitis) was revised based on new literature data.

Further safety data will be provided as the MAH agreed to a CHMP recommendation to submit the final study report of study MC-FludT.16/NM when available.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted/was requested to submit an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 1.4 is acceptable.

<div style=\"page-break-after: always\"></div>

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 1.4 with the following content:

## Safety concerns

## Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns                                    |
|------------------------------|---------------------------------------------------------------|
| Important identified risks   | - Treatment-related second malignancy                         |
| Important potential risks    | - Seizures in small infants*                                  |
| Missing information          | - Effect on fertility* - Use in patients with prior alloHSCT* |

## Pharmacovigilance plan

No pharmacovigilance studies are planned, on-going or have been completed by medac GmbH.

Routine pharmacovigilance activities beyond ADR reporting and signal detection:

Specific adverse reaction follow-up questionnaires: None

Other forms of routine pharmacovigilance activities: None

No additional pharmacovigilance activities are performed or planned for TREO.

## Risk minimisation measures

## Description of routine risk minimisation measures by safety concern

| Safety concern                         | Routine risk minimisation activities                                                                                                                                                                                                                                                                                                                                                                                                                |
|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks             | Important identified risks                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Treatment-related secondary malignancy | Trecondi 1 g / 5 g powder for solution for infusion Routine risk communication: SmPC sections 4.4, and 4.8; PL sections 2, and 4 Routine risk minimisation activities recommending specific clinical measures to address the risk: SmPC section 4.4: The possible risk of a second malignancy should be explained to the patient. Other routine risk minimisation measures beyond the product information: Legal status: prescription only medicine |
| Treatment-related secondary malignancy | Treosulfan Powder for Solution for Infusion Treosulfan 250 mg Capsule, Hard Routine risk communication: SmPC sections 4.8; PL section 4 Routine risk minimisation activities recommending specific clinical measures to address the risk: None                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Safety concern                       | Routine risk minimisation activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                      | Other routine risk minimisation measures beyond the product information: Legal status: prescription only medicine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Important potential risks            | Important potential risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Seizures in small infants*           | Routine risk communication: SmPC section 4.4, and 4.8; PL sections 2, and 4 Routine risk minimisation activities recommending specific clinical measures to address the risk: SmPC section 4.4: Children should be monitored for signs of neurological side effects. The use of clonazepam prophylaxis for children younger than 1 year might be considered. Other routine risk minimisation measures beyond the product information: Legal status: prescription only medicine                                                                                                                                                                                                                                      |
| Missing information                  | Missing information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Effect on fertility*                 | Routine risk communication: SmPC sections 4.4, and 4.6; PL section 2 Routine risk minimisation activities recommending specific clinical measures to address the risk: SmPC section 4.4: Men are advised not to father a child during and up to 6 months after treatment and to seek advice on cryo-conservation of sperm prior to treatment because of the possibility of irreversible infertility. Women are informed on ovarian suppression and amenorrhoea. SmPC section 4.6: Advice on cryo-conservation of sperm prior to treatment because of the possibility of irreversible infertility. Other routine risk minimisation measures beyond the product information: Legal status: prescription only medicine |
| Use in patients with prior alloHSCT* | Routine risk communication: None Routine risk minimisation activities recommending specific clinical measures to address the risk: None Other routine risk minimisation measures beyond the product information: Legal status: prescription only medicine                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

-this new indication does not introduce any major amendments to the Package Leaflet which affects the readability and requires to conduct a new user test. The introduced changes are the new indication, the amendment of an existing warning on skin toxicity based on new literature data and the update of side effects, being the majority of the changes related to rearrangements in terms of frequency, only a few

<div style=\"page-break-after: always\"></div>

new effects were introduced. This does not impact the readability already tested for this PL.

-The package leaflet included in this submission is in general, identical to the previously readability tested package leaflet. During the initial marketing authorisation application, the MAH has performed a full user testing that has successfully demonstrated the comprehensibility and usability of the PL. This conclusion can be extended to the PL submitted as part of this proposed extension of the therapeutic indication.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) to treat paediatric patients older than one month with malignant and non-malignant diseases.

Treosulfan is approved for the conditioning treatment prior to alloHSCT in malignant and non-malignant diseases  in  adult  and  in  malignant  diseases  in  paediatric  patients.  The  MAH  intends  to  extend  the approved indication also to paediatric patients with non-malignant indications.

## 3.1.2. Available therapies and unmet medical need

AlloHSCT is the only potentially curative treatment option for many patients especially with AML and MDS, relapsed patients with various other haematological malignancies, as well as some non-malignant disorders (NMD) such as primary immunodeficiencies (PID), inborn errors of metabolism, haemoglobinopathies or bone marrow failure syndromes. The most common indications for an alloHSCT are AML (40.8%), followed by MDS/MPS (15.7%), and ALL (15.4%) and NMD (13.2%). Main indications for alloHSCT in children are ALL, AML and NMD [Passweg 2021].

An increasing number of children with non-malignant diseases can be cured by alloHSCT. There is a number  of  conditioning  regimens  that  can  be  used  in  this  treatment.  Treosulfan  (TREO)-based conditioning regimens is  one of them [Slatter 2015; Peters 201794], although the use is not approved in the EU being the target of the application for the extension of indication under assessment.

The various conditioning regimens prior alloHSCT used in clinical practice today differ in their intensity and are currently divided into three categories: myeloablative conditioning (MAC), reduced intensity conditioning  (RIC)  and  non-myeloablative  conditioning  (NMA).  Myeloablative  conditioning  regimens cause  irreversible  cytopenia  and  Haematopoietic  stem  cells  (HSC)  support  is  mandatory.  Nonmyeloablative  conditioning  regimens  cause  minimal  cytopenia  and  can  be  given  also  without  HSC support. Reduced intensity conditioning regimens do not fit criteria for MAC or NMA regimens. They cause cytopenia of variable duration and should be given with stem cell support, although cytopenia may not be irreversible [Bacigalupo 2009]. The most frequently used medicinal products used for conditioning treatment  include  oral  or  preferably  intravenous  Busulfan  (BU),  Cyclophosphamide  (CY),  Melphalan (MEL),  Thiotepa  (TT),  Fludarabine  (FLU),  cytarabine,  amsacrine,  and  increasingly  TREO.  Total  body

<div style=\"page-break-after: always\"></div>

irradiation (TBI) has been included in some of the regimens to further reduce relapse incidence; however, it causes substantial toxicity.

In paediatric patients, various conditioning regimens are used depending on the disease (malignant or non-malignant), disease status, as well as institute-specific preferences. Reduced intensity conditioning regimens  are  much  less  frequently  used  than  in  adults  because  children  less  frequently  have comorbidities which do not allow using a MAC regimen. In addition, children with non-malignant diseases like  haemoglobinopathies  or  metabolic  disorders  require  an  intensive,  myeloablative  conditioning treatment  to  ensure  a  successful  engraftment.  In  recent  years,  thiotepa  has  been  increasingly incorporated into conditioning regimens for malignant as well as non-malignant diseases [Peters 2017].

Transplant-related morbidity/mortality limits the use of alloHSCT for many patients. The mortality rate at 100 days post alloHSCT ranges between 7% for patients with acute leukaemia in remission undergoing matched related donor (MRD) HSCT and 27% for patients with refractory acute leukaemia undergoing matched unrelated donor (MUD) HSCT [Pasquini 2014].

There is a high unmet medical need for new conditioning regimens with low treatment-related toxicities but no increased risk for relapse to improve the OS and ensure a good quality of life for the patients. Such a regimen should offer sufficient stem cell toxicity, immunosuppressive potential and high antitumour activity (in case of malignant disorders), but reduced organ toxicity (especially with respect to the liver, kidneys, lung, and the nervous system) and predictive pharmacokinetics. With the current application, treosulfan in meant to replace busulfan in the conditioning prior alloHSCT in patients with non-malignant diseases with similar clinical results and less toxicity as in adults.

## 3.1.3. Main clinical studies

Treosulfan-based conditioning regimens followed by alloHSCT have been investigated by the MAH in a total of 613 adult and 121 paediatric patients within seven clinical trials. According to the Paediatric Investigation  Plan  (PIP),  two  clinical  transplantation  studies  with  TREO-based  conditioning  were conducted in paediatric patient populations [Table 3].

Table3Listingofclinicalstudiesinpaediatricpatients

| Study ID        | Study title                                                                                                                                                              | Objectives                                                                                                                                                                                                 |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MC-FludT.16/ NM | ClinicalphaseIItrialtocompare TREO-based conditioning therapy with BU-based conditioning prior to alloHSCT in paediatric patients with non-malignantdiseases             | Todescribethesafetyandefficacyof TREOcompared to theconventional doseBU(control),each administered as part of a standardised FLU-containing conditioning regimen and to contribute toapharmacokineticmodel |
| MC-FludT.17/M   | Clinical phase II trial to describe the safety and efficacy of TREO-based conditioning therapyprior toalloHSCT in paediatric patients with haematologi- cal malignancies | Todescribethesafety andefficacyof TREO as part of a standardised FLU- containing conditioning and to contri- bute to a pharmacokinetic model                                                               |

The final clinical study report (CSR) of MC-FludT.17/M (Version 2, dated 24-Mar-2020) includes longerterm follow-up results until 36 months after transplant. The CSR of study MC-FludT.16/NM focusses on completed 12 month follow-up data for all subjects, but also contains follow-up data available as of the data cut-off on 07-Jun-2021. Longer-term follow-up data will be collected until the last recruited subject has completed visit Month 36 and presented in an updated version of the CSR expected in 2023. Both studies are based on an approved PIP, incl. four agreed modifications.

<div style=\"page-break-after: always\"></div>

## 3.2. Favourable effects

In paediatric patients, a conditioning regimen consisting of 10-14 g/m²/d × 3 TREO (Day -6/-5/-4) plus fludarabine  (FT10-14)  proved  to  be  very  effective  and  well  tolerated  in  MC-FludT.17/M  and  MCFludT.16/NM clinical trials that included a total of 121 patients with, respectively, malignant or nonmalignant  disorders.  In  the  latter  clinical  trial,  a  comparison  of  the  TREO/FLU/±TT  regime  with  a BU/FLU/±TT regime is performed after randomisation of 1:1 of 101 patients (51:50). Most of the patients (89%) received a regimen of FT10-14 combined with thiotepa (FT10-14/TT).

Furthermore, data of TREO-based conditioning are available from the EBMT registry for a total of 1 416 patients  which  confirm  its  efficacy  and  safety  for  malignant  as  well  as  non-malignant  transplant indications [Peters 2011/2017].

The main favourable effects of the use of TREO and in particularly when comparing with BU are:

- High cumulative engraftment rate, with a maximum conditional cumulative incidence of neutrophil engraftment of 97.3% in paediatric patients with non-malignant diseases (study 16/NM) and 100% in paediatric patients with malignant diseases (study MC-FludT.17/M). This is also concordant with the higher (3.9% for TREO and 4.0% for BU) primary graft failure rates observed for in patients with non-malignant diseases when compared with patients with malignant diseases (0) and higher secondary graft failure for the TREO arm of the study 16/NM (18.4%). According to the 2017 EBMT meta-analysis in paediatric patients with non-malignant diseases, neutrophil engraftment at Day 100 after alloHSCT was superior with the TREO/FLU/TT combination versus BU/FLU/TT (96.1% vs. 83.5%) [Peters 201794].
- Lower freedom from transplant (treatment) related mortality until Day +100 after HSCT: both TREO and BU give good results but the treosulfan behaves better with 100% (.16/NM; 90% CI: 94.3, 100) or 98.6% subjects (MC-FludT.17/M; 90% CI: 93.4, 99.9) without an event for treosulfan vs 90% for busulfan /90% CI: 80.1, 96.0)(unadjusted p-value 0.0267; adjusted p-value 0.0528).
- Lower transplant-related mortality: TREO-based conditioning was at 1 year very low in patients with both non-malignant (3.9%; 90% CI: 1.2, 12.0) as well as malignant diseases (1.4%; 90% CI: 0.3, 7.2%) and lower than with BU in no-malignant diseases (12.0%; 90% CI: 6.3, 22.1) (HR (TREO/BU) 0.29 (90% CI 0.0, 1.09); p value 0.1244). This was also seen in the EBMT registry analysis with no influence  of  age  or  dose  of  treosulfan  and  significantly  lower  TRM  for  TREO/FLU/TT  than  for BU/FLU/TT conditioning [Peters 2017]. In both treatments for non-malignant diseases the TRM was maintained over time (only a slight increase between 2 and 3 years for BU arm) however after to 2 years in malignant disease with treosulfan. TRM after TREO-based conditioning was also very low in the EBMT registry analysis. TREO dosing in the paediatric studies aimed to reach TREO plasma levels in the range observed with the 14 g/m² dose in adults. The data from both studies suggest that paediatric patients tolerate TREO-based conditioning better than adult patients and justify that there was no need to reduce the TREO dose in this patient population.
- Higher disease-free survival in patients with non-malignant diseases: Disease-free survival (DFS) at one year in paediatric patients with non-malignant diseases was highest with the TREO/FLU/TT regimen (86%). This was significantly higher than the 77.3% DFS rate observed with the BU/FLU/TT regimen (P = 0.002) [Peters 2017]. However, event-free survival was lower for TREO arm in study 16/NM  than  for  BU  at  all  time  points  but  comparable  between  non-malignant  and  malignant diseases.
- Higher overall survival rate in patients with non-malignant diseases: In study 16/NM OS rate at 1 year after TREO-based conditioning was 96.1% (90% CI: 88.0, 98.8%), higher than for BU with an OS value of 88.0% (90% CI:77.9,93.7) than for malignant diseases with an OS of 91.4% (90% CI: 83.9, 95.5). This OS rate was maintained at 3 years for TREO in non-malignant diseases, decreased

<div style=\"page-break-after: always\"></div>

to 84.0% (90% CI: 71.4, 91.4) for BU and for TREO in malignant diseases to 84.3% (90% CI: 75.5, 90.1). These data are confirmed by data from the EBMT registry.

- Low relapse rate: The conditional cumulative incidence of relapse/progression in the 70 patients treated with TREO-based conditioning in trial MC-FludT.17/M was 15.7% at 12 months and 23.0% at 24/36 months with 15.7% (n=11) of these patients requiring rescue therapy mainly of donor lymphocyte  infusion  (DLI)  or  stem  cell  boost.  According  to  the  EBMT  registry  [Peters  2017], incidence of disease relapse at 1 year after transplant is also very low in patients with non-malignant diseases  and  ranged  from  6.1-6.8%  with  TREO-based  conditioning  to  7.2-9%  with  BU-based conditioning. The no difference regarding rescue therapies between TREO and BU is confirmed in the 16/NM trial. However, in study 16/NM, patients with non-malignant diseases required more rescue  therapies  (41.2%;  especially  transfusions  for  RBCs  [33%]  and  platelets  [27.5%])  than patients with malignant diseases in study MC-FludT.17/M.
- Lower gonadal toxicity: Results from two clinical [Faraci 2019; Leiper 2020] and one preclinical study [Levi 2018] suggest that the gonadal toxicity is lower with TREO compared to BU.

Good engraftment with lower freedom from transplant (treatment) related mortality until Day +100 after HSCT, lower transplant-related mortality, better overall survival as compared to busulfan.

Based on the engraftment and chimerism data approaching 100% and &gt; 90%, respectively, efficacy parameters like EFS, OS, and GvHD-free and relapse-free survival confirm the effectiveness of this conditioning treatment not only in preparing for alloHSCT paediatric patients with malignant diseases but also in intended extension of the indication, i.e. non-malignant diseases as for adults.

## 3.3. Uncertainties and limitations about favourable effects

Long term data on efficacy will be provided as the final study report of study MC-FludT.16/NM will be submitted when available. This is of interest as allo-HSCT  will  be  applied in the  treatment  for  nonmalignant diseases with the expectation of long-term treatment benefit.

## 3.4. Unfavourable effects

The  most  commonly  reported  undesirable  effects  of  TREO  are  myelosuppression  (leukocytopenia, thrombocytopenia, anaemia), immunosuppression, and gastrointestinal complaints (nausea, vomiting). They  are  usually  mild  and  resolve  after  treatment.  In  fact,  it  is  this  toxicity  that  supported  the development of TREO for conditioning treatment prior to HSCT, especially in the allogenic setting. Bone marrow  depression  and  immunosuppression  are  therefore  the  desired  therapeutic  effects  of  a conditioning regimen.

The study in non-malignant diseases (MC-FludT.16/NM) also included an active-control group with 50 evaluable patients treated with the reference conditioning regimen BU/FLU ± TT.

This safety data set is supplemented by safety data derived from two registry studies of the EBMT [Peters 201193; Peters 2017] which included a total  of  1  521  paediatric  patients  with  malignant  and  nonmalignant diseases who had been treated with TREO-based conditioning. Therefore, available safety data cover all paediatric patients which are currently treated with alloHSCT.

Two comparisons can be made based on the unfavourable effects based on the data submitted: a) a comparison between the effects with treosulfan - and busulfan -based conditioning regimens prior HSCT in paediatric patients with non-malignant diseases as gathered within the MC-FludT.16/NM trial; b)

<div style=\"page-break-after: always\"></div>

and  a  comparison  of  the  effects  of  the  treosulfan-based  conditioning  regime  prior  HSCT  between paediatric  patients  with non-malignant  diseases (from MC-FludT.16/NM )  and  with malignant diseases as gathered within the MC-FludT.17/M .

The most common causes of death after HSCT for non-malignant diseases were infection, graft versus host disease, the original disease and transplant associated organ complications.

From  the  data  gathered  in  patients  with non-malignant  diseases it  is  possible  to  observe  that frequency of TEAEs, including TEAEs with at least CTCAE grade III TEAEs, and frequency of SAEs was broadly  similar  in  the  two  treatment  arms  with  the  exceptions  depicted  below.  Also,  laboratory parameters  were  largely  comparable  for  the  2  treatment  arms  throughout  the  trial.  In  trial  MCFludT.16/NM, the median level of WBCs at baseline, incidence of increased bilirubin/ALT/AST and median change levels from baseline of electrolytes (sodium, potassium) had no significant differences between both treatment groups. The same is largely verified for vital signs.

Higher rate of unfavourable effects is seen with TREO-based conditioning treatment prior allo-HSCT in non-malignant diseases when comparing with BU-based treatment: The TREO group showed higher frequency of TEAEs including drug-related TEAEs, with differences ≥ 10%, for diarrhoea, abdominal pain, maculo-papular rash and pruritus; Higher frequency, with differences ≥ 5%, was observed with TREO  for  infections,  febrile  neutropenia  and  vascular  events  but  lower  frequency  for  vomiting  and respiratory disorders. The TREO group of subjects experienced more SAEs, such as infections and more general disorders (fever) and conditions that required hospitalisation or prolongation of hospitalisation than the BU group. Cumulative incidence of aGvHD of all grades as well as of grade III/IV was higher for the TREO group up to Day +100 of the HSCT. The durations of leukopenia and neutropenia were significantly  longer  in  the  TREO  arm  than  the  BU  arm  but  the  MAH  clarified  the  potential  factors associated with these events (see above Section 8.3).

Lower rate of unfavourable effects is seen with TREO-based conditioning treatment prior allo-HSCT in non-malignant  diseases  when  comparing  with  BU-based  treatment:  The  TREO  group  showed  lower frequency of TEAEs including drug-related TEAEs, with differences ≥ 10%, for lung infection, dry skin, oral mucositis, nausea and hepatobiliary disorders. The TREO group of subjects experienced less lifethreatening  SAEs  and  SAEs  resulting  in  death  as  well  as  drug-related  SAEs  than  the  BU  group. Cumulative incidence of cGvHD was higher in the BU arm. The Kaplan Meier estimate at 12 months for subjects showing a deterioration to less than 60 points was slightly more favourable for the TREO group (8.3%) than for the BU group (12.7%).

When comparing the use of TREO prior HSCT in paediatric patients with malignant and non-malignant diseases similar rate of AEs of any CTCAE grade and drug-related ADRs of at least CTCAE Grade III was seen. Results were comparable in both trials when treated with TREO regarding the frequency of SAEs and the % of patients with at least one SAE. Some exceptions are listed below:

Higher rate of unfavourable effects is seen with TREO-based conditioning treatment prior alloHSCT in non-malignant diseases when comparing malignant diseases: the rate of AEs of at least CTCAE Grade III  was  somewhat higher  (difference  &lt;5%)  when  comparing  with  patients  with  malignant  diseases. Subjects with non-malignant disease also presented slightly higher drug-related SAE (3.9% vs 1.4%). The mean time from transplantation to death was shorter for the patients with non-malignant diseases treated with TREO than for the patients with malignant (5.75 months vs 14.97 months). Incidences of aGvHD  were  slightly  higher  in  patients  with  non-malignant  diseases  (54.9%)  than  with  malignant diseases (43.5%). In non-malignant diseases children below the age of one year experienced more respiratory grade III/IV toxicity

Lower rate of unfavourable effects is seen with TREO-based conditioning treatment prior alloHSCT in non-malignant diseases when comparing malignant diseases: the drug-related ADRS of any CTCAE grade

<div style=\"page-break-after: always\"></div>

(difference &gt;5%) was lower than in the case of patients with malignant diseases. Life-threatening AEs slightly more associated with the treatment of malignant diseases (difference &lt;5%). More patients (&gt; 5% difference) with malignant diseases experienced viremia, device-related infection, hypersensitivity reactions,  hypokalaemia, psychiatric  disorders,  nausea,  bone  pain,  positive  viral  test,  and  increased blood  bilirubin  while  epistaxis,  abdominal  pain,  hepatoxicity,  puritus,  alopecia,  increased  CRP  and infusion-related reactions were found in patients transplanted for non-malignant diseases. Number of death cases were considerable higher in the trial MC-FludT.17/M (17.1%, n=12) than in the TREO arm of the MC-FludT.16/NM (3.9%, n=2) being largely due to relapse/progression in the case of the former trial. Incidences of hepatic toxicity and infections were lower (but no significant) for the patients with non-malignant diseases than for patients with malignant diseases. Cumulative incidence of cGvHD is maintained over time for patients with both malignant and non-malignant diseases but was considerably higher  (difference  &gt;10%)  when  TREO  is  used  in  the  patients  with  malignant  diseases.  The  same (although with a difference &gt;5%) was observed for the cumulative incidence of moderate/severe cGvHD. The overall Kaplan Meier estimate at 12 months for subjects showing a deterioration to less than 60 points was lower for patients with non-malignant diseases (8.3%) than with non-malignant diseases (13.6%).

Based on new literature data (Even-Or et al. 2020  1 ), the MAH proposes to amend an existing warning on section 4.4 of the SmPC and corresponding section of PL on skin toxicity following TREO-thiotepaFLU-based conditioning regimen in non-malignant paediatric patients, when patients received sodium bicarbonate-containing hydration in the course of TREO infusion. In the response provided to the first request for supplementary information, the MAH reevaluated the issue on skin toxicity to specify the exact related ADRs and their severity. From the literature consulted no clear relation between skin toxicity and sodium bicarbonate-containing hydration could be found and only reports from clinical practice support the proposed change to the SmPC. Without being able to obtain detailed information the MAH concluded that further investigation is needed so that this issue can be detailed in the SmPC. As such, the MAH proposes to withdraw the proposed amendment to the existing warning on section 4.4 of the SmPC and corresponding PL and leave the texts has previously approved. This is acceptable, especially considering the commitment of the MAH to collect additional information within signal management to allow a proper evaluation of the issue of skin toxicity and the submission of a future variation if applicable.

## 3.5. Uncertainties and limitations about unfavourable effects

The MAH proposes to amend an existing warning on skin toxicity based on new literature data. Rash and dermatitis are given as examples of such skin toxicities. In the first round of the assessment the MAH was asked to specify the exact ADRs and their severity and if applicable to update the Product Information accordingly. From the literature consulted no clear relation between skin toxicity and sodium bicarbonate-containing hydration could be found and only reports from clinical practice support the proposed change. Without being able to obtain detailed information the MAH concluded that further investigation is needed so that this issue can be detailed in the SmPC.

Long term data on safety in the treatment for non-malignant diseases -with the expectation of longterm treatment benefit - will be provided as the MAH agreed to a CHMP recommendation to submit the final study report of study MC-FludT.16/NM when available.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 2. Effects Table for Trecondi (conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in paediatric patients older than one month with nonmalignant)(data cut-off: MC-FludT.16/NM trial 07-Jun-2021)

| Effect                                                      | Short description                                                                                            | Unit   | TREO (n=51)   | BU (n=50)   | Uncertainties / Strength of evidence   | References                 |
|-------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|--------|---------------|-------------|----------------------------------------|----------------------------|
| Favourable Effects                                          | Favourable Effects                                                                                           |        |               |             |                                        |                            |
| Freedom from transplantation (treatment)- related mortality | Incidence Freedom from transplantation (treatment)- related mortality until day +100                         | %      | 100.0         | 90.0        | p a <0.0528 OR<0.0001                  | Table 11.4.1.1.A CSR (FAS) |
| TRM                                                         | Primary endpoint Transplantation- related Mortality at 1 year Secondary endpoint                             | %      | 3.9           | 12.0        | p a <0.1244 HR 0.29 (0.08, 1.09)       | Table 11.4.1.2.A CSR (FAS) |
| OS                                                          | Overall survival at 1 year Secondary endpoint                                                                | %      | 96.1          | 88.0        | p a <0.0718 HR 0.29 (0.08, 1.09)       | Table 11.4.1.3.A CSR (FAS) |
| Graft failure                                               | Rates of primary graft failures Secondary endpoints                                                          | %      | 3.9           | 4.0         |                                        | Table 11.4.1.4.A CSR (FAS) |
| Graft failure                                               | Rates of secondary graft failures Secondary endpoints                                                        | %      | 18.4          | 0.0         |                                        | Table 11.4.1.4.A CSR (FAS) |
| Graft failure                                               | Cumulative incidences of graft failure at 12 months Primary and secondary graft failures Secondary endpoints | %      | 15.8          | 4.0         | p a < 0.0366 HR 5.48 (1.44, 20.91)     | Table 11.4.1.4.B CSR (FAS) |
| Engraftment Granulopoiesis                                  | Maximum conditional cumulative incidence reached Reconstitution of granulopoiesis Secondary endpoint         | %      | 97.3          | 100.0       | P b < 0.0521                           | Table 11.4.1.5.A CSR (FAS) |
| Neutropenia                                                 | Mean (SD) Duration of neutropenia d                                                                          | days   | 19.9 (7.7)    | 15.9 (7.3)  | P c < 0.0108                           | Table 11.4.1.5.B CSR (FAS) |
| Engraftment Leukopoiesis                                    | Maximum conditional cumulative                                                                               | %      | 96.8          | 100.0       | P b < 0.2469                           | Table 11.4.1.5.A CSR (FAS) |

<div style=\"page-break-after: always\"></div>

| Effect                                   | Short description                                                                                                     | Unit   | TREO (n=51)   | BU (n=50)   | Uncertainties / Strength of evidence   | References                  |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|--------|---------------|-------------|----------------------------------------|-----------------------------|
|                                          | incidence reached Reconstitution of leukopoiesis Secondary endpoint                                                   |        |               |             |                                        |                             |
| Leukopenia                               | Mean (SD) Duration of leukopenia d                                                                                    | days   | 19.0 (5.7)    | 16.3 (7.3)  | P c < 0.0087                           | Table 11.4.1.5.B CSR (FAS)  |
| Engraftment Thrombopoiesis > 20 x10 9 /L | Maximum conditional cumulative incidence reached Reconstitution of thrombopoiesis > 20 x10 9 /L Secondary endpoint    | %      | 100.0         | 96.8        | P b <0.8595                            | Table 11.4.1.5.A CSR (FAS)  |
| Engraftment Thrombopoiesis > 50 x10 9 /L | Maximum conditional cumulative incidence reached Reconstitution of thrombopoiesis > 50 x10 9 /L Secondary endpoint    | %      | 94.8          | 97.1        | P b < 0.3635                           | Table 11.4.1.5.A CSR (FAS)  |
| Donor Type Chimerism                     | Incidence of complete donor type chimerism until Month 12 visit Subjects at risk at Day +100 visit Secondary endpoint | %      | 66.7          | 84.8        | p a < 0.1196 OR 0.3972                 | Table 11.4.1.6.A CSR (FAS)  |
| EFS                                      | Event-free Survival at 1 year Secondary endpoint                                                                      | %      | 80.3          | 86.0        | p a <0.3343 HR 1.54 (0.74, 3.22)       | Table 11.4.1.7.A CSR (FAS)  |
| GvHD-free Survival                       | GvHD-free survival at 1 year Secondary endpoint                                                                       | %      | 82.9          | 69.4        | p a <0.2178 HR 0.58 (0.28, 1.20)       | Table 11.4.1.8.A CSR (FAS)  |
| Chronic GvHD- free Survival              | Chronic GvHD-free Survival at 1 year Secondary endpoint                                                               | %      | 89.3          | 69.4        | p a <0.0308 HR 0.32 (0.14, 0.76)       | Table 11.4.1.9.A CSR (FAS)  |
| Rescue Therapies                         | Incidence of Any Rescue Therapies Secondary endpoints                                                                 | %      | 41.2          | 42.0        | p a <0.5264 OR 0.7592                  | Table 11.4.1.10.A CSR (FAS) |
| Unfavourable Effects                     | Unfavourable Effects                                                                                                  |        |               |             |                                        |                             |
| TEAE                                     | Any Adverse event                                                                                                     | n (%)  | 49 (96.1)     | 48 (96.0)   |                                        | Table 12.2.1.A CSR (FAS)    |
| TRAE                                     | Any Drug-related adverse events                                                                                       | n (%)  | 41 (80.4)     | 37 (74.0)   |                                        | Table 12.2.1.A              |

<div style=\"page-break-after: always\"></div>

| Effect                      | Short description                                  | Unit   | TREO (n=51)      | BU (n=50)        | Uncertainties / Strength of evidence   | References                 |
|-----------------------------|----------------------------------------------------|--------|------------------|------------------|----------------------------------------|----------------------------|
|                             |                                                    |        |                  |                  |                                        | CSR (FAS)                  |
| SAE                         | Any serious adverse event                          | n (%)  | 18 (35.3)        | 16 (32.0)        |                                        | Table 12.2.1.A CSR (FAS)   |
| SAE                         | Death/Life- threatening Results in death           | n (%)  | 0 (0.0)/ 3 (5.9) | 4 (8.0)/ 4 (8.0) |                                        | Table 12.2.1.A CSR (FAS)   |
| SAE                         | Hospitalization or prolongation of hospitalization | n (%)  | 16 (31.4)        | 8 (16.0)         |                                        | Table 12.2.1.A CSR (FAS)   |
| STRAE                       | Drug-related serious adverse events                | n (%)  | 2 (3.9)          | 3 (6.0)          |                                        | Table 12.2.1.A CSR (FAS)   |
| AE                          | Maximum CTCAE grade of adverse events Grade III    | n (%)  | 34 (66.7)        | 30 (60.0)        |                                        | Table 12.2.1.A CSR (FAS)   |
| cGvHD                       | Overall cGvHD Cumulative incidence at 1 year       | %      | 12.8             | 38.6             | p a <0.0168 HR 0.31 (0.14, 0.69)       | Table 12.2.2.2.D CSR (FAS) |
| Infections and infestations | Any event                                          | n (%)  | 12 (23.5)        | 7 (14.0)         |                                        | Table 12.3.1.2.A CSR (FAS) |

Table 3. Effects Table for Trecondi (conditioning treatment prior to allogeneic haematopoietic stem  cell  transplantation  (alloHSCT)  in  paediatric  patients  older  than  one  month  with malignant and)(data cut-off: MC-FludT.17/NM trial Date last subject completed - longer-term follow-up visit: 30-Sep-2019 )

| Effect                                                      | Short description                                                                                     | Unit               | TREO (n=70)        | Uncertainties / Strength of evidence   | References                 |
|-------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|--------------------|--------------------|----------------------------------------|----------------------------|
| Favourable Effects                                          | Favourable Effects                                                                                    | Favourable Effects | Favourable Effects | Favourable Effects                     | Favourable Effects         |
| Freedom from transplantation (treatment)- related mortality | Incidence Freedom from transplantation (treatment)- related mortality until day +100 Primary endpoint | % (90% CI)         | 98.6% (93.4, 99.9) |                                        | CSR (FAS)                  |
| TRM                                                         | Transplantation- related Mortality at 1 year Secondary endpoint e                                     | % (90% CI)         | 1.4 (0.3, 7.2)     |                                        | Table 11.4.1.2.A CSR (FAS) |
| OS                                                          | Overall survival at 1 year Secondary endpoint e                                                       | % (90% CI)         | 91.4 (83.9, 95.5)  |                                        | Table 11.4.1.3.A CSR (FAS) |
| Relapse / Progression                                       | Relapse / Progression Incidence after HSCT                                                            | % (90% CI)         | 15.7 (8.6, 22.9)   |                                        | Table 11.4.1.4.A CSR (FAS) |

<div style=\"page-break-after: always\"></div>

| Effect                                   | Short description                                                                                                  | Unit             | TREO (n=70)              | Uncertainties / Strength of evidence   | References                 |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------|------------------|--------------------------|----------------------------------------|----------------------------|
| RFS / PFS                                | Relapse-free / Progression-free Survival at 1 year e                                                               | % (90% CI)       | 82.9 90% CI (73.9, 89.0) |                                        | Table 11.4.1.5.A CSR (FAS) |
| Graft failure                            | Rates of primary graft failures Secondary endpoints                                                                | n/N (%) (90% CI) | 0/70 (0.0) (0.0, 4.2)    |                                        | Table 11.4.1.6.A CSR (FAS) |
| Graft failure                            | Rates of secondary graft failures Secondary endpoints                                                              | n/N (%) (90% CI) | 1/69 (1.4) (0.1, 6.7)    |                                        | Table 11.4.1.6.A CSR (FAS) |
| NRM                                      | Non-relapse Mortality after HSCT at 1 year                                                                         | % (90% CI)       | 1.4 (0.0, 3.8)           |                                        | Table 11.4.1.7.A CSR (FAS) |
| Engraftment Granulopoiesis               | Maximum conditional cumulative incidence reached Reconstitution of granulopoiesis Secondary endpoint               | % (90% CI)       | 100.0 (97.7, 100.0)      |                                        | Table 11.4.1.8.A CSR (FAS) |
| Neutropenia                              | Mean (SD) Duration of neutropenia d                                                                                | days             | 22.3 (7.7)               |                                        | Table 11.4.1.8.B CSR (FAS) |
| Engraftment Leukopoiesis                 | Maximum conditional cumulative incidence reached Reconstitution of leukopoiesis Secondary endpoint                 | % (90% CI)       | 100.0 (97.7, 100.0)      |                                        | Table 11.4.1.8.C CSR (FAS) |
| Leukopenia                               | Mean (SD) Duration of leukopenia d                                                                                 | days             | 20.5 (6.1)               |                                        | Table 11.4.1.8.D CSR (FAS) |
| Engraftment Thrombopoiesis > 20 x10 9 /L | Maximum conditional cumulative incidence reached Reconstitution of thrombopoiesis > 20 x10 9 /L Secondary endpoint | % (90% CI)       | 94.1 (88.4, 99.9)        |                                        | Table 11.4.1.8.E CSR (FAS) |
| Engraftment Thrombopoiesis > 50 x10 9 /L | Maximum conditional cumulative incidence reached Reconstitution of thrombopoiesis > 50 x10 9 /L Secondary          | % (90% CI)       | 91.9 (84.9, 98.8)        |                                        | Table 11.4.1.8.F CSR (FAS) |
| Donor Type Chimerism                     | Incidence of complete donor                                                                                        | % (90% CI)       | 91.3 (83.6, 96.1)        |                                        | Table 11.4.1.9.A           |

<div style=\"page-break-after: always\"></div>

| Effect                           | Short description                                                                           | Unit                 | TREO (n=70)          | Uncertainties / Strength of evidence   | References                  |
|----------------------------------|---------------------------------------------------------------------------------------------|----------------------|----------------------|----------------------------------------|-----------------------------|
|                                  | type chimerism Subjects at risk at Day +100 visit Secondary endpoint                        |                      |                      |                                        | CSR (FAS)                   |
| EFS                              | Event-free Survival at 1 year Secondary endpoint                                            | % (90% CI)           | 81.4 (72.3, 87.8)    |                                        | Table 11.4.1.10.A CSR (FAS) |
| GvHD-free and RFS / PFS (GRFS)   | GvHD-free Relapse-free / Progression-free Survival at 1 year Secondary                      | % (90% CI)           | 65.7 (55.5, 74.1)    |                                        | Table 11.4.1.11.A CSR (FAS) |
| Chronic GvHD- free and RFS / PFS | Chronic GvHD-free and Relapse-free / Progression-free Survival at 1 yeat Secondary endpoint | % (90% CI)           | 67.1 (57.0, 75.4)    |                                        | Table 11.4.1.12.A CSR (FAS) |
| Rescue Therapies                 | Incidence of Any Rescue Therapies Secondary endpoints                                       | n (%)                | 58 (82.9)            | p a <0.5264 OR 0.7592                  | Table 11.4.1.13.A CSR (FAS) |
| Unfavourable Effects             | Unfavourable Effects                                                                        | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                   | Unfavourable Effects        |
| TEAE                             | Any Adverse event                                                                           | n (%)                | 68 (97.1)            |                                        | Table 12.2.1.A CSR (FAS)    |
| TRAE                             | Any Drug-related adverse events                                                             | n (%)                | 63 (90.0)            |                                        | Table 12.2.1.A CSR (FAS)    |
| SAE                              | Any serious adverse event                                                                   | n (%)                | 23 (32.9)            |                                        | Table 12.2.1.A CSR (FAS)    |
| SAE                              | Death/Life- threatening Results in death                                                    | n (%)                | 1 (1.4)/ 6 (8.6)     |                                        | Table 12.2.1.A CSR (FAS)    |
| SAE                              | Hospitalization or prolongation of hospitalization                                          | n (%)                | 20 (28.6)            |                                        | Table 12.2.1.A CSR (FAS)    |
| STRAE                            | Drug-related serious adverse events                                                         | n (%)                | 1 (1.4)              |                                        | Table 12.2.1.A CSR (FAS)    |
| AE                               | Maximum CTCAE grade of adverse events Grade III                                             | n (%)                | 42 (60.0)            |                                        | Table 12.2.1.A CSR (FAS)    |
| cGvHD                            | Overall cGvHD Cumulative incidence at 1 year                                                | % (90% CI)           | 23.9 (15.3, 32.4)    |                                        | Table 12.2.2.2.B CSR (FAS)  |
| Infections and infestations      | Any event                                                                                   | n (%)                | 15 (21.4)            |                                        | Table 12.3.1.2.A CSR (FAS)  |

Abbreviations: TREO - treosulfan; BU - busulfan; OR - Odd ratio; HR - Hazard Ratio; TEAE - treatment emergent

<div style=\"page-break-after: always\"></div>

adverse events; TRAE - drug-related adverse events; STRAE - serious drug-related adverse events

Notes:  a p-value is adjusted for thiotepa and disease using the stratified Cochran-Mantel-Haenszel test (freedom from TRM, Donor Type Chimerism, rescue therapies), Cox regression Model (TRM, OS, EFS, GvHD-free survival, Chronic GvHD-free Survival), Fine and Gray model (graft failure, cGvHD);  b  Based on the Pepe-Mori test;  c  Wilcoxon-MannWhitney test;  d  First date with neutropenia until date of engraftment (subjects at risk = subjects with neutropenia and neutrophilic granulopoiesis);  e  Based on Kaplan-Meier estimates

Hazard Ratio (Treosulfan/Busulfan) (90% CI); OS - The median duration of follow-up was 25.4 months (11.7 - 63.3 months) in the BU arm and 25.6 months (10.7 - 60.9 months) in the TREO arm.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Overall the efficacy results of the first randomised Phase II alloHSCT trial (MC-FludT.16/NM) in paediatric patients with non-malignant diseases demonstrated a benefit for the treosulfan conditioning regimen over busulfan conditioning regimen in the selected subject population regarding Freedom from transplant (treatment) related mortality until day +100 after HSCT, TRM, OS, GvHD-free and cGvHD-free survival and EFS despite a higher rate of secondary graft failures and lower complete donor-type chimerism. Therefore, in children with non-malignant diseases indicated for alloHSCT the risk of graft failure must be carefully weighed against the risk of TRM, especially when an unrelated (MUD) or partly matched alloHSCT is proposed and treosulfan is part of their preparative regimen for alloHSCT.

As per the final CTR of the MCFludT.16/NM trial, the Transplant-related mortality (TRM) after treosulfan is lower than after busulfan which translates into an OS of treosulfan-treated patients at least comparable to the one of busulfan-treated patients which is reassuring.

When comparing the two treatment arms - treosulfan and busulfan - form the MC-FludT.16/NM trial were conditioning prior HSCT was tested in patients with non-malignant diseases, it is possible to observe that the rate of TEAEs, TESAEs and significant TEAEs was similar in the 2 treatment arms with only small differences on the CTCAE SOC and Term level. No unknown risks were identified in the trial and there was  no  occurrence  of  any  SUSARs.  Comparable  incidences  of  aGvHD  were  observed  between  the treatment arms, however, a significantly and clinically meaningful lower incidence of overall cGvHD was found with treosulfan. More deaths occurred in the busulfan arm than the treosulfan arm. Overall, safety results favour the treatment with treosulfan in comparison with busulfan in for conditioning prior to alloHSCT in paediatric patients with non-malignant diseases.

The second Phase II trial in paediatric patients with malignant haematological disease (MC-FludT.17/M) has shown that a BSA-adapted i.v. dose of 10 g/m 2 , 12 g/m 2 , or 14 g/m 2  Treosulfan given on Days -6, -5, and 4 can be successfully used as conditioning treatment before alloHSCT in the selected paediatric population. However, the selected BSA-adapted dosing required further justification/clarification. The newly proposed regime (10 g/m 2  for BSA &lt;0.4 m 2 , 12 g/m 2  for 0.4 ≤ BSA&lt;0.9 m 2  and 14 g/m 2  for BSA ≥ 0.9 m 2 ) resulted in an increase in the % of values &gt;3600 mg*h/L in all groups. Also, for the BSA levels of 0.4, 0.5, 0.9, and 1.0 m2 max AUC values of 4361, 4719, 4209 and 4147 mg*h/L were simulated. The proposed final BSA-categories for dose calculation seem adequate.

Based on the engraftment and chimerism data approaching 100% and &gt; 90%, respectively, efficacy parameters like  EFS,  OS,  and  GvHD-free  and  relapse-free  survival  confirm  the  effectiveness  of  this conditioning treatment.

<div style=\"page-break-after: always\"></div>

The adverse events presented were already included in section 4.8 of the SmPC related with paediatric population. Among the TESAEs, upper respiratory infection and febrile neutropenia are reported, the former is not clearly included in SmPC and the latter is included with unknown frequency. No unknown risks were identified and there was no occurrence of any SUSARs. At the end of the trial where treosulfan was included in the conditioning regime for patients with malignant diseases, 20% subjects (n=14) terminated the trial prematurely, being death from relapse/progression and transplantation-related the main cause in 17.1% of the subjects (n=12). Laboratory parameters and vital signs did not change and performance scores were as expected.

Acute GvHD Grade III-IV was reported in less than 9% of the subjects and was maintained at 100 days. Also, for chronic GvHD cumulative incidence did not change up to the end of the duration of the trial's follow-up, i.e. 36 months.

Overall, safety data gathered from the MU-FludT.17/M trial is in line with the adverse reactions listed for adults and paediatric patients already included in the approved PI and can be explained by the intensive treatment prior alloHSCT of treosulfan on top of standardized fludarabine, and in the majority of the cases also with thiotepa, as well due to the underlying malignant disease (ALL, AML, MDS, and JMML) and transplantation-procedure per se. Safety are comparable to those reported for treosulfan in other trials and comparable or even favourable to those reported for BU- or TBI-based conditioning regimens.

## 3.7.2. Balance of benefits and risks

Overall, the reported efficacy and safety results of these two Phase II allo-HSCT trials resulted in a positive benefit judgement for the Treosulfan-based conditioning regimen used in paediatric patients with selected malignant diseases and non-malignant diseases, with an expected and manageable safety profile confirming the approved indication in paediatric patients with malignant diseases as well as in paediatric patients with selected non-malignant diseases. The efficacy and safety results obtained from the MU-FludT.16/NM also support the benefit of using treosulfan instead of a Busulfan-based condition regimen in paediatric patients with non-malignant diseases facing a comparable safety profile and thus allow to support the request for an extension of the use of Treosulfan to this population.

## 3.7.3. Additional considerations on the benefit-risk balance

Furthermore, summarised results of TREO-based conditioning are available from four EBMT registry analyses [Nagler 2017; Shimoni 2015/2021; Peters 2011/2017].

A conditioning regimen consisting of 14 g/m²/d × 3 TREO Day -6/-5/-4 plus FLU (FT10 14) and preferably combined with TT resulted in a very high disease-free and overall survival rate in paediatric patients with malignant as well as non-malignant disorders. The efficacy of this regimen is supported by data from the EBMT registry that included a total of 1 416 patients with malignant or non-malignant diseases. Furthermore, a large number of published trials of other study groups support the use of TREO-based conditioning in these patients. Meanwhile, two European guidelines recommend the use of TREO-based conditioning in patients with MDS as well as primary immunodeficiencies. Paediatric patients seem to tolerate higher doses of TREO compared to adults since most safety parameters were comparable to results obtained with the FT10 regimen used in adult patients.

The data strongly suggest that TREO-based conditioning is an effective and safe treatment for paediatric patients with malignant as well as non-malignant diseases.

<div style=\"page-break-after: always\"></div>

## 3.8. Conclusions

The overall B/R of Trecondi is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include additional non-malignant transplant indications (non-malignant diseases in the paediatric population) for Trecondi 1 g/5 g powder for solution for infusion based on final 12-months follow-up results of study MC-FludT.16/NM; a randomised phase II interventional study aimed to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with non-malignant diseases.

Further, the MAH proposes to amend an existing warning on skin toxicity based on new literature data. Moreover, the MAH proposes to introduce a slightly modified dosing regimen according to the patient's body surface based on long-term follow-up data of paediatric study MC-FludT.17/M, a Phase II trial to describe the safety and efficacy of Treosulfan based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haematological malignancies, as well as a final analysis of the population pharmacokinetics of treosulfan in paediatric patients. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.4 of the RMP has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I and IIIB and to the Risk Management Plan are recommended.

## Paediatric data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan P/0346/2020 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

<div style=\"page-break-after: always\"></div>

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Trecondi-H-C-004751/II/0014'